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Abstract
Abstract
Transforming growth factor-P (TGF-p) plays a crucial anti-atherogenic role. TGF-p 
classically signals through the Smad pathway but is known to activate other signalling 
pathways such as the mitogen-activated protein kinase (MAPK) cascades. Foam cell 
formation is inhibited by TGF-p through the regulation of expression o f genes 
involved in macrophage cholesterol homeostasis. However, the molecular 
mechanisms underlying this regulation are yet to be fully elucidated. Studying such 
mechanisms may lead to identification of novel avenues for treatment of this disease 
and was therefore the main focus of these studies. TGF-p regulates the stability of 
atherosclerotic plaques through the regulation of expression of genes encoding 
proteins involved in the turnover of the extracellular matrix (ECM). The ADAMTS 
proteases cleave proteoglycans within the ECM and have recently been hypothesised 
to have roles in atherosclerosis. Cytokine regulation o f these proteases and 
elucidation of the molecular mechanisms behind this regulation may enhance 
understanding of the roles these proteases play in atherosclerosis with a view to 
identifying novel avenues for treatment of this disease and was therefore an additional 
focus of these studies.
RT-qPCR and Western blot analysis demonstrated that TGF-p inhibited the 
expression o f key genes involved in cholesterol uptake (LPL, SR-A, SR-B1 and 
CD36) and induced the expression of key genes involved in cholesterol efflux (ApoE, 
ABCA-1, ABCG-1) in the THP-1 cell line and identified an optimal time point for 
their regulation. Western blotting revealed that the Smad pathway was active in 
macrophages through the increased levels of phospho-Smad-2 and phospho-Smad-3 
in response to TGF-P treatment. Small interfering RNA (siRNA) knockdown of 
Smad-2, Smad-3 and Smad-2 and -3 revealed crucial roles for the Smad pathway in 
the TGF-P-regulation of LPL, SR-A, SR-B1, CD36, ApoE, ABCA-1, and ABCG-1. 
Roles for the Smad pathway in the constitutive expression o f SR-B1 and CD36 were 
also identified. Western blotting and non-radioactive kinase activity assays 
demonstrated that ERK, JNK and p38 kinase levels were induced by TGF-p in 
macrophages and this led to an increase in kinase activity. Individual knockdown of 
ERK 1/2, c-Jun and p38 kinase expression using siRNA revealed crucial roles for c- 
Jun and p38 kinase in the TGF-P-regulated expression of LPL, SR-A, SR-B1, CD36, 
ABCA-1, and ABCG-1 and a role for ERK 1/2 in the expression of CD36, ABCA-1 
and ABCG-1. No discemable role for p38 kinase, c-Jun or ERK 1/2 in the expression 
of ApoE was identified.
Inhibition o f ADAMTS-4 expression by TGF-p was observed using RT-qPCR and 
Western blot analysis. Knockdown of Smad and MAPK pathway components using 
siRNA revealed roles for the Smad pathway and for c-Jun and p38 kinase in this 
regulation. Transient transfection of a full length ADAMTS-4 promoter construct 
demonstrated that TGF-p down-regulated ADAMTS-4 promoter activity. 
Transfection of promoter deletion constructs located the minimal regulatory region for 
TGF-P action within the -506/-396 region of the ADAMTS-4 promoter and EMSA 
analysis demonstrated increased protein binding to this region. These studies have 
identified crucial roles for the Smad and MAPK pathways in the TGF-P regulation of 
expression of key genes involved in macrophage cholesterol homeostasis and have 
characterised the regulation o f ADAMTS-4 by TGF-p.
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CHAPTER 1: Introduction
CHAPTER I 
Introduction
1.1 Heart disease and atherosclerosis
Atherosclerosis is the primary cause of coronary heart disease. Coronary heart 
disease is the main cause o f death in the UK and accounts for almost 94,000 deaths 
per year, making up almost half of all deaths from cardiovascular disease (Allender et 
al. 2010). The British Heart Foundation describes coronary heart disease as the 
narrowing of the coronary arteries that supply the heart with blood and oxygen. This 
process, known as atherosclerosis, is caused by a build up of fatty material (atheroma) 
within the walls of the arteries. Coronary heart disease often presents with angina or 
severe chest pains (British Heart Foundation 2006).
1.2 Atherosclerosis
Atherosclerosis was originally considered to be a lipid storage disease but it is now 
recognised as a form of chronic inflammation (Libby et al. 2010; Libby et al. 2002). 
Atherosclerosis begins as an immune response to vascular injury initiated by the 
accumulation of lipoproteins and other lipid aggregates in the intima of the arterial 
wall leading to the development o f atherosclerotic lesions (Ross 1999). This widely 
accepted model for the disease is known as the ‘response to injury’ hypothesis and 
was first proposed by Russell Ross (Ross 1999).
Early lesions are known as fatty streaks and are made up of lipid-rich macrophage- 
derived foam cells (Lusis et al. 2004). Intermediate lesions are characterized by 
layers of foam cells, smooth muscle cells and T-lymphocytes (Ross 1999). Formation 
of more complex lesions, known as early atheroma, follows migration of smooth
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muscle cells into the innermost layer of the artery, known as the intima (Hansson and 
Libby 2006; Singh and Ramji 2006). More advanced lesions are surrounded by a 
fibrous cap containing extracellular matrix proteins synthesized by smooth muscle 
cells present within the lesion. The lipid-rich core forms from the debris of foam cells 
that have undergone apoptosis (Lusis et al. 2004). Progression of atherosclerosis is 
summarised in Figure 1.1 and further described in Sections 1.2.2 to 1.6.
Although plaques can become large enough to block blood flow through the artery, 
the most clinically important complication o f atherosclerosis is the formation o f a 
blood clot (thrombus). This occurs on rupture or erosion of the plaque and it is this 
that can lead to myocardial infarction (Lusis et al. 2004). If  atherosclerosis affects the 
arteries that supply the brain with blood and oxygen, it can cause an ischaemic stroke 
(Hansson and Libby 2006).
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Adventia
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Figure 1.1 Progression of atherosclerosis. Regions of arterial damage attract 
monocytes and other inflammatory cells. Accumulation of cholesterol produces foam 
cells and leads to fatty streak formation. Migration of smooth muscle cells into the 
intima and production of a fibrous cap characterises development of more advanced 
lesions that become prone to rupture. For more details refer to text. Figure taken 
from Lusis et al. 2004.
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1.2.1 Risk factors for atherosclerosis
Atherosclerosis is a multifactorial disease with both genetic and environmental risk 
factors. However, many single risk factors for atherosclerosis can be managed in 
conjunction with exercise and a well-balanced diet (Glass and Witztum 2001). Major 
risk factors for atherosclerosis include but are not limited to, hypertension, high 
cholesterol levels, obesity and diabetes (Lusis et al. 2004). Physical inactivity, age, 
stress and smoking can also be risk factors for the disease (Harvey and Ramji 2005).
1.2.1.1 Genetic risk factors
Only a limited number of genetic risk factors for the disease have been identified. It 
is known that mutations in genes encoding lipoprotein lipase (LPL), the low density 
lipoprotein receptor (LDLR), apolipoprotein E (ApoE), the ATP-binding cassette 
transporter ABCA-1, and lipoprotein(a) confer significantly increased risk for 
cardiovascular disease (Doevendans et al. 2001; Puddu et al. 2005).
1.2.1.2 High cholesterol levels
Of the environmental factors, high levels of low-density lipoprotein (LDL) 
cholesterol, known as ‘bad cholesterol’ is unique as the one risk factor that can drive 
the development of the disease even if no other risk factors are present (Glass and 
Witztum 2001). Conversely, low levels of ‘good cholesterol’ high-density lipoprotein 
(HDL) cholesterol also confers a higher risk of atherosclerosis. Low levels of HDL 
have been associated with obesity, smoking and physical inactivity. High LDL 
cholesterol levels cause damage to the endothelium, triggering an inflammatory 
response (Singh and Ramji 2006).
1.2.1.3 Obesity
Many of the risk factors for atherosclerosis and stroke can be related to lipoprotein 
metabolism. While the link between obesity and an increased risk of cardiovascular 
disease is clear, the mechanisms explaining this link remain poorly understood 
(Stocker and Keaney 2004). Obesity is known to predispose other risk factors for 
atherosclerosis, including diabetes. Studies suggest that high levels of fatty acids can 
stimulate the synthesis o f very low-density lipoprotein (VLDL) by hepatocytes. This
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in turn causes a reduction in HDL by exchange through the cholesterol ester transfer 
protein (Libby et al. 2002). Low plasma levels of HDL-cholesterol are also linked 
with smoking and lack of exercise (Doevendans et al. 2001).
1.2.1.4 Diabetes
The risk o f atherosclerosis is 3-5 fold higher in diabetic patients (Stocker and Keaney 
2004). Non-insulin dependent diabetes is caused by insufficient levels of insulin or 
defects in insulin signalling and results in hyperglycaemia. This can cause proteins to 
become modified leading to the production o f advanced glycation end products. 
These modified proteins can then elicit the production of pro-inflammatory cytokines. 
In addition to this, the modified proteins can react with reactive oxygen species 
causing damage to the arterial wall and accelerating the development of 
atherosclerosis (Libby et al. 2002; Lusis et al. 2004).
1.2.1.5 Hypertension
Hypertension is a known risk factor for atherosclerosis and is defined as a diastolic 
blood pressure above 90mmHg or a systolic blood pressure above 140mmHg (Stocker 
and Keaney 2004). Genetic factors contributing to hypertension remain unclear, 
although some linkage studies have shown a role for the angiotensin II gene in 
Caucasian and African-Caribbean populations. The gene encoding the angiotensin 
converting enzyme has also been linked with coronary heart disease; however, this 
has no effects on blood pressure. The renin-angiotensin pathway may play a role in 
mediating the effects of high blood pressure on atherosclerosis (Lusis et al. 2004).
1.2.1.6 Infections
Both intravascular and chronic extravascular infections such as gingivitis and 
bronchitis may accelerate the development of atherosclerotic plaques through 
stimulation of inflammatory cytokines. Bacterial infections such as Chlamydia 
pneumoniae are also linked to atherosclerosis. The presence of bacteria and 
subsequent release of heat shock proteins and endotoxins such as lipopolysaccharide 
(LPS) stimulate the production of pro-inflammatory mediators (Libby et al. 2002).
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1.2.2 Initiation of atherosclerosis
Damage to the endothelial wall from risk factors is thought to be mediated through 
oxidative stress, leading to changes in the permeability of the endothelium (Preiss and 
Sattar 2007). Under physiological conditions, pro-atherogenic factors in the vascular 
wall are balanced by the production of nitric oxide (NO) by endothelial cells (Preiss 
and Sattar 2007). NO has anti-atherogenic actions including vasodilation and 
inhibition o f monocyte adhesion. However, in atherosclerosis decreased NO 
production, due to the damage to the vascular endothelium, may allow pro- 
inflammatory sites to develop (Preiss and Sattar 2007).
Fatty streaks, typically seen at the earliest stages o f atherosclerosis, form through the 
recruitment of monocytes and other inflammatory cells to sites of damage in the 
arterial wall (Ross 1993). On activation by stimuli (risk factors and oxidative stress), 
endothelial cells produce adhesion molecules that recruit leukocytes, o f which blood 
monocytes are the most numerous inflammatory cells (Libby et al. 2010). On 
adherence o f monocytes to the endothelium, pro-inflammatory chemokines induce 
their uptake into the intima. Monocytes differentiate into macrophages which 
proliferate inside the intima and release growth factors and cytokines to enhance the 
inflammatory process and proteases to breakdown the extracellular matrix (ECM) 
(Libby et al. 2010). Macrophages also take up modified LDL such as oxidised LDL 
(oxLDL) which accumulates in atherosclerosis. This transforms them into lipid-laden 
foam cells, which are characteristic of early-stage atherosclerotic lesions (Glass and 
Witztum 2001).
1.2.3 Monocyte recruitment and migration
Recruitment of monocytes to lesions in the arterial wall occurs initially to remove 
cytotoxic molecules from the site of inflammation (Glass and Witztum 2001). This is 
regulated by cell adhesion molecules on the surface o f endothelial cells (Lusis et al. 
2004). Under normal conditions the endothelium does not bind white blood cells; 
however, in atherosclerosis endothelial cells express adhesion molecules on their 
surface that are able to bind leukocytes (Bobryshev 2006). Adhesion molecules are 
often expressed in areas within the artery prone to the development of atherosclerosis. 
Areas of the artery prone to the development of atherosclerosis are often branch points
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where there is disturbed flow (Bobryshev 2006). Levels of adhesion molecules may 
be indicative of the severity of atherosclerosis and can be correlated with risk factors 
including smoking and hypertension (Bobryshev 2006; Libby et al. 2002).
In response to pro-inflammatory cytokines, endothelial cells not only express 
adhesion molecules but also increase the permeability o f the endothelium (Hansson et 
al. 2002). The selective permeability o f the endothelium can also be affected by fluid 
shear stress, disrupting its role in the regulation o f inflammation (Lusis et al. 2004). 
Stress to the arterial wall may also induce proteoglycan production, increasing the 
inflammatory response through the binding of modified lipoproteins (Libby et al. 
2002).
Adhesion of monocytes begins with a rolling interaction mediated by selectins 
including L-selectin expressed on monocytes and E-selectin expressed on the 
endothelial surface. P-selectin is mainly expressed on platelets but also on endothelial 
cells (Bobryshev 2006). The three selectins share a conserved glycoprotein structure 
and interact with highly fucosylated ligands but also with glycoprotein ligands. Both 
E- and P-selectins are activated at the transcriptional level by cytokines. Nuclear 
factor kappa B (NFkB) seems to be important for this induction (Preiss and Sattar 
2007).
The rolling interaction is followed by a firm attachment to the endothelium, mediated 
by integrins (Li and Glass 2002). Integrins are transmembrane glycoproteins that exist 
in low-affinity conformations. Signals, possibly arising from changes in cellular 
activity, cause conformational changes to allow high affinity interactions with ligands, 
pi and p2 integrins on monocytes interact with ligands of the immunoglobulin 
superfamily, namely the adhesion molecules intracellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Preiss and Sattar 2007).
VCAM-1 is expressed by smooth muscle cells and endothelial cells and is present in 
fatty streaks (Preiss and Sattar 2007). In addition, the expression of VCAM-1 is up- 
regulated in response to oxLDL (Li and Glass 2002) while VCAM-1 deficient mice 
display reduced atherosclerosis (Ramji et al. 2006). Mice deficient in endothelial 
selectin and platelet selectins also develop less severe atherosclerosis. Endothelial
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expression of VCAM-1 is followed by smooth muscle cell expression of this adhesion 
molecule (Hansson and Libby 2006). Inflammatory cells move across the 
endothelium by diapedesis after binding to adhesion molecules (Preiss and Sattar 
2007).
1.2.3.1 Roles ofchemokines in monocytes migration 
Chemotactic factors (or chemokines) as well as adhesion molecules mediate the entry 
of monocytes into the intima and can be stimulated by oxLDL (Li and Glass 2002). 
Chemokines are low molecular weight proteins, typically 8-10kDa (Burke-Gaffhey et 
al. 2002). There are approximately 50 human chemokines (or chemotactic cytokines). 
These can be divided into 3 families based on the spacing of conserved cysteine 
residues (Bobryshev 2006). Chemotactic factors include monocyte chemoattractant 
protein 1 (MCP-1), macrophage colony stimulating factor (M-CSF), migratory 
inflammatory protein 1 (MIP-1), transforming growth factor-P (TGF-P) and tumour 
necrosis factor-a (TNF-a) (Bobryshev 2006). The largest group is the CC 
chemokines, of which MCP-1 is a member. Other members o f this group include 
MIP-1 a and MIP-1 p. These chemokines are often found at sites of inflammation and 
attract mononuclear cells (Charo and Taubman 2004).
In response to chemoattractant signals, adherent leukocytes migrate into the intima. 
Chemokines such as MCP-1 may be involved in this process (Hansson et al. 2002). 
Chemokines are able to bind to proteoglycans in addition to binding to their cognate 
receptors (over 20 o f which have been identified). The ability to bind to 
proteoglycans may facilitate the recruitment of monocytes by allowing the formation 
of chemokine gradients across the endothelium. Some chemokines contribute to 
angiogenesis and smooth muscle cell migration in atherosclerosis in addition to 
promoting monocyte recruitment (Burke-Gaffhey et al. 2002).
MCP-1 is the most extensively studied member o f the CC chemokines due to its role 
in atherosclerosis. MCP-1 and its receptor CCR2 are expressed in atherosclerotic 
plaques and also independently by endothelial and smooth muscle cells (Burke- 
Gaffiiey et al. 2002; Charo and Taubman 2004). MCP-1 is likely to play a key role in 
recruiting monocytes to atherosclerotic lesions and its expression may be induced
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through interactions between monocytes and endothelial cells (Burke-Gaffney et al. 
2002; Charo and Taubman 2004). Expression of MCP-1 has been shown to be 
induced by oxLDL while knockout of this gene in apoE-deficient or LDL receptor 
(LDLR)-deficient mice results in reduced development of atherosclerosis (Glass and 
Witztum 2001). MCP-1 is able to attract leukocytes through a CCR-2 receptor 
(Hansson et al. 2002) and absence of CCR2 can inhibit atherosclerosis by restricting 
the entry o f monocytes into the intima (Hansson and Libby 2006). MCP-1 may also 
play a role in the development of thrombosis in more advanced plaques through the 
activation o f tissue factor. Studies using bone marrow transplantation have shown 
that overexpression of MCP-1 in vessel wall macrophages results in increased foam 
cell formation while mice deficient in both LDLR and MCP-1 show reduced 
macrophage recruitment (Burke-Gaffney et al. 2002; Charo and Taubman 2004).
1.3 Foam cell formation-Cholesterol uptake
Once at the site of lesion formation, monocytes differentiate into macrophages (Libby 
et al. 2002). M-CSF is produced by both endothelial and smooth muscle cells and can 
mediate differentiation of these cells (Hansson and Libby 2006). Differentiation leads 
to the up-regulation of scavenger receptor expression on the surface of macrophages. 
Normally, scavenger receptors function to recognise pathogens and apoptotic cells for 
phagocytosis by macrophages. However, in atherosclerosis macrophages are able to 
take up cholesterol ester-rich lipoproteins through these receptors through receptor- 
mediated endocytosis (Rader and Pure 2005). This process is unregulated. Once 
internalised, lipoproteins are targeted to the lysosome where the cholesterol esters are 
hydrolysed to unesterified cholesterol to be delivered to the endoplasmic reticulum to 
be stored in lipid droplets following conversion back to cholesterol esters by acyl- 
CoA: cholesterol acyltransferase-1 (ACAT-1). Accumulation of these droplets is 
responsible for the soap bubble-like appearance o f foam cells (Rader and Pure 2005). 
The physiological functions of key scavenger receptors and their pathophysiological 
roles in atherosclerosis are detailed in Section 1.3.3.
In addition to scavenger receptors, macrophages also express toll-like receptors (TLR) 
on their cell surface to mediate phagocytosis and host defence (Rader and Pure 2005).
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These pattem-recognition receptors are expressed by macrophages in atherosclerotic 
plaques and may link innate immunity and atherosclerosis. TLRs can be activated by 
bacterial molecules such as LPS and also by modified lipoproteins such as minimally 
modified LDL (mmLDL). TLR signalling can promote pro-inflammatory gene 
expression through activation of NFkB and promote lipid accumulation through 
interaction with peroxisome proliferator-activated receptors (PPARs) and liver-X- 
receptors (LXRs) (Rader and Pure 2005). Macrophages therefore have critical roles 
in the initiation and progression of atherosclerosis. The importance of macrophages is 
demonstrated by their presence in lesions. Approximately 40% of cells present in 
atherosclerotic plaques express macrophage markers (Hansson and Libby 2006). The 
shoulder region of the plaque and the interface between the lipid rich core and the 
fibrous cap are particularly abundant in macrophages (Hansson and Libby 2006).
Quantity o f circulating LDL is a well-known risk factor for cardiovascular disease 
(Glass and Witzum 2001). Mechanisms behind the entry of dietary cholesterol into 
the body, including absorption from the diet, are major causes o f variation in 
cholesterol homeostasis. Under normal physiological conditions dietary cholesterol is 
packaged into chylomicrons and put into circulation where they accept 
apolipoproteins ApoC2 and ApoE from HDL to form mature chylomicrons (Daniels 
et al. 2009). This activates an enzyme known as lipoprotein lipase (LPL) to catalyse 
the hydrolysis of triglycerides to distribute fatty acids to tissues. As triglycerides and 
ApoC2 are lost from chylomicrons, ApoE is enriched; targeting the chylomicron 
remnants to the liver where lipids are hydrolysed into free fatty acids and free 
cholesterol for synthesis of very low-density lipoprotein (VLDL). VLDLs are 
processed in the same way as chylomicrons and mature into LDL (Daniels et al. 
2009). Cholesterol-carrying lipoproteins are taken up through the LDL receptor into 
the liver/other cells or tissues (Daniels et al. 2009). Cholesterol synthesis also 
contributes to levels of cholesterol homeostasis. Cholesterol is synthesised in a series 
of steps that convert mevalonic acid into cholesterol using enzymes to catalyse each 
step. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) is synthesised from 
acetyl-CoA and converted to mevalonic acid by HMG-CoA reductase as the first and 
rate-limiting step of cholesterol synthesis. Transcription o f the HMG-CoA reductase 
gene is regulated by sterol-response element binding proteins (SREBPs) in response
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to cholesterol levels in the cell providing a feedback mechanism for this pathway 
(Buhaescu and Izzedine 2007).
In atherosclerosis, the accumulation o f cholesterol within macrophages and 
subsequent formation of foam cells can be enhanced by high levels of circulating 
LDL. LDL enters the intima by diffusion through endothelial cell junctions and it is 
retained through interactions between the apoB component of the lipoprotein and 
matrix proteoglycans (Lusis et al. 2004). Hydrolysis of lipoproteins by LPL 
contributes to the uptake of cholesterol by macrophages. The physiological function 
of LPL and its role in atherosclerosis is discussed in Section 1.3.2.
1.3.1 Oxidation of LDL
Modification o f accumulated LDL through oxidation is a key step in its conversion to 
an atherogenic molecule (Ross 1993). Initial oxidation of LDL produces minimally 
modified LDL (mmLDL) that is still recognised by its native receptor. mmLDL 
stimulates the production and secretion of MCP-1 by smooth muscle cells and 
endothelial cells to promote monocyte recruitment. Immunolocalisation studies with 
antibodies to oxLDL demonstrate that oxLDL colocalises with macrophages in 
atherosclerotic lesions (Rader and Pure 2005; Stocker and Keaney 2004). Oxidation 
of LDL is promoted by oxygen free radicals from surrounding vascular cells and also 
by enzymes expressed by macrophages including myleoperoxidase, inducible nitric 
oxide synthase (iNOS), lipoxygenases and NADPH oxidases (Ohashi et al. 2004; 
Stocker and Keaney 2004). Most LDL filters through the endothelium by transcytosis 
but can be prevented by hydrodynamic resistance and thickness of the ECM 
explaining why areas of high shear stress are prone to atherosclerosis development 
(Newby 2000).
OxLDL is itself pro-inflammatory (Rader and Pure 2005). Oxidation of LDL 
generates cytotoxic by-products that can damage the vascular wall and oxLDL itself 
may also cause damage by initiating immune reactions as an autoantigen. Oxidative 
modifications to apoB can also elicit an immune response so contributing to 
atherogenesis (Stocker and Keaney 2004). Oxidation of LDL promotes foam cell 
formation by facilitating the recruitment of monocytes into the intima and enhancing
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the rate of lipoprotein uptake, possibly through its own aggregation. The lipoprotein 
is also chemotactic for macrophages, preventing them leaving the intimal layer and 
further contributing to foam cell formation. It can also induce the expression of 
scavenger receptors and a number of pro-inflammatory genes in macrophages. The 
transcription factor peroxisome proliferator activated receptor-y (PPAR-y) may be 
involved in this regulation (Stocker and Keaney 2004). The importance of oxLDL in 
the initial events of atherosclerosis may explain why trials with antioxidants have 
been successful when administered at the outset o f atherosclerosis in animal models 
but less successful in human trials where antioxidant treatment was given at later 
stages in the disease (Tedgui and Mallat 2006).
1.3.2 Lipoprotein lipase
The lipase family, comprising lipoprotein lipase, hepatic lipase and endothelial lipase 
are involved in the hydrolysis and regulation of lipid metabolism. LPL was the first 
of the lipases to be discovered and is consequently well studied. The gene for LPL 
resides on chromosome 8p22 and is 30kb in size, containing 10 exons or coding 
regions encoding a protein 473 amino acids in size (Hasham and Pillarisetti 2006; 
Merkel et al. 2002). LPL is synthesised mainly by the heart, adipose tissue and 
skeletal muscle and is secreted and attached to the endothelium by heparin sulphate 
proteoglycans (Hasham and Pillarisetti 2006; Merkel et al. 2002).
LPL hydrolyses VLDL and chylomicrons to produce free fatty acids and 
monoacylglycerols to be utilised by tissues (Hasham and Pillarisetti 2006). In 
addition to its catalytic action in lipid metabolism, LPL also has non-catalytic 
functions, in particular the enzyme can act as a molecular bridge between cell-surface 
receptors and other proteins to enhance lipoprotein uptake following hydrolysis. This 
was first discovered in 1975 when it was found that the enzyme remained associated 
with chylomicrons after their hydrolysis (Mead et al. 2002; Mead and Ramji 2002). 
Further studies confirmed that LPL was able to associate with a range of lipoproteins 
and receptors to enhance lipoprotein uptake and was also a ligand for the LDL 
receptor-related protein (LRP) (Mead et al. 2002; Mead and Ramji 2002).
1.3.2.1 LPL and atherosclerosis
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The roles of LPL in lipid metabolism implicate the enzyme in atherosclerosis, where 
deregulation and retention of lipids and lipoproteins in the arterial wall can initiate 
inflammation and development of atherosclerotic plaques. High levels of LPL have 
also been observed in hypercholesterolemia and diabetes and mRNA and protein 
expression of the enzyme is also increased following damage to the arterial wall and 
upon monocyte-macrophage differentiation (Hasham and Pillarisetti 2006; Mead et al. 
2002; Mead and Ramji 2002). Macrophages and smooth muscle cells are primary 
sources o f LPL within atherosclerotic lesions (Mead and Ramji 2002; Stein and Stein 
2003).
LPL was first hypothesised to be pro-atherogenic by Donald Zilversmit in 1973 who 
suggested that the action of the enzyme on circulating lipoproteins (chylomicrons and 
VLDL) would lead to high concentrations of cholesterol remnants that could 
contribute to development of atherosclerosis through their uptake into the arterial wall 
(Mead et al. 2002; Mead and Ramji 2002). This hypothesis proved correct. 
Accumulation o f cholesterol esters and hydrolysis of VLDL to LDL undoubtedly 
contributes to atherosclerotic lesions as LDL undergoes oxidation by free radicals 
within the intima allowing uptake of both chylomicron remnants and oxLDL into 
macrophages through scavenger receptors, leading to enhanced foam cell formation 
(Mead et al. 2002; Mead and Ramji 2002).
Subsequently, Zilversmit showed that development of atherosclerotic lesions in 
rabbits fed a high cholesterol diet was associated with increased activity of LPL 
(Hasham and Pillarisetti 2006). Studies in mice confirmed that the association was 
due to raised levels o f macrophage LPL. Mice overexpressing macrophage lipase 
showed accelerated atherosclerosis while mice deficient in lipases were shown to be 
resistant to the (high cholesterol diet-induced) disease (Hasham and Pillarisetti 2006). 
The hydrolysis of VLDL and chylomicrons by LPL produces smaller, cholesterol rich 
remnants that can be taken up by macrophages. This accumulation of cholesterol 
esters within macrophages is a key step in the formation of foam cells while 
hydrolysis of VLDL to LDL undoubtedly contributes to atherosclerotic lesions as they 
become oxidised by free radicals present in the intima of the artery. This modification 
increases the uptake of LDL by macrophage scavenger receptors to enhance foam cell 
development (Mead and Ramji 2002).
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Interestingly, expression of macrophage LPL is associated with atherosclerosis 
development whilst plasma LPL has been demonstrated to exert anti-atherogenic 
actions suggesting that the enzyme has dual roles in atherosclerosis (Stein and Stein 
2003). Significant reductions in lesion area and atherosclerosis incidence have been 
observed in transgenic mice and rabbits overexpressing human LPL and this is 
associated with lowered levels of plasma cholesterol and triglycerides (Stein and Stein 
2003). Overexpression of LPL in wild-type mice also reduces atherosclerosis and can 
normalise the lipoprotein profiles of apoE ~ mice with atherogenic profiles. 
Cholesterol-lowering drugs such as statins and fibrates have also been shown to 
increase LPL expression in heart and adipose tissue (Mead and Ramji 2002).
In contrast to this, apoE_/' mice expressing human macrophage LPL showed 
significant increases in atherosclerotic lesion size and studies using mice deficient in 
macrophage LPL have demonstrated that atherogenic actions o f LPL predominate 
during the early stages of the disease (Mead and Ramji 2002; Stein and Stein 2003). 
In addition to promoting foam cell formation through hydrolysis of VLDL and 
chylomicrons, LPL is also able to increase the production of smooth muscle cells to 
further disturb the endothelium and contribute to the development of the plaque. The 
capacity of LPL to act as a molecular bridge to aid binding o f lipoproteins to cell 
surface receptors and heparan sulphate also promotes the migration of lipoproteins 
into the intima to promote foam cell formation (Hasham and Pillarisetti 2006; Stein 
and Stein 2003). The enzyme has been demonstrated to contribute to cholesterol ester 
uptake by vascular cells by acting as a cholesterol ester transferase and this may 
promote plaque formation by enhancing cholesterol uptake by vascular smooth 
muscle cells (VSMCs) (Stein and Stein 2003).
1.3.3 Macrophage scavenger receptors
Scavenger receptors were first identified by Brown and Goldstein in 1979; who 
described a binding site for acetylated LDL (AcLDL) on macrophages that mediates 
its uptake and degradation (de Winther et al. 2000). The general function of these 
receptors in clearing or ‘scavenging’ a broad range of ligands including apoptotic 
cells, anionic phospholipids, (3-amyloid and pathogens such as Staphylococcus aureas
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and Mycoplasma pneumoniae explains their naming as scavenger receptors (Bottalico 
et al. 1991; Greaves and Gordon 2009; Moore and Freeman 2006). Scavenger 
receptors are pattern recognition receptors which recognise pathogens through 
conserved pathogen associated molecular patterns. This allows the innate immune 
system to differentiate between ‘self and infectious ‘non-self (Kunjathoor et al. 
2002; Moore and Freeman 2006). Scavenger receptors are found in organisms with 
both simple and complex immune systems. This conservation supports a critical role 
in the response to pathogens and in normal homeostasis (Febbraio and Silverstein 
2007). Currently 8 classes of scavenger receptor have been identified as shown in 
Table 1.1 (Moore and Freeman 2006; Pliiddemann and Neyen 2007).
Table 1.1 Scavenger receptor classification
Classification Scavenger Receptors
Class A SR-AI
SR-AII
SR-AIII
MARCO (macrophage receptor with 
collagenous structure)
SR with C-type lectin
Class B CD36
SR-B1
SR-BII
Lysosomal integral membrane protein II
Class C Drosophila dSR-C (no human homologue 
identified)
Class D CD68
Macrosialin (mouse homologue of CD68)
Class E LOX-1 (lectin-like oxidised LDL 
receptor)
Class F SREC-1 (Scavenger receptor expressed 
by endothelial cells)
SREC-II
Class G SR-PSOX (SR-phosphotidylserine and 
oxidised lipoproteins)
Class H FEEL1 (fasciclin, epidermal growth
factor (EGF)-like, laminin-type 
EGF-like, and link domain- 
containing scavenger receptor)
FEEL2
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In atherosclerosis, scavenger receptors promote atherogenesis by binding modified 
LDL that is not taken up by the classical LDL receptor (Greaves and Gordon 2009). 
Under normal physiological conditions LDL is taken up into cells through the LDLR 
in a process regulated by negative feedback. Uptake through scavenger receptors is 
unregulated. This results in foam cell formation leading to further development and 
progression of atherosclerosis. Of the group o f scavenger receptors shown in Table 
1.1, only a few have been found to be expressed in the arterial intima and have the 
ability to take up modified LDL. These include SR-A, CD36, CD68, lectin-like 
oxidised LDL receptor (LOX-1) and scavenger receptor for phosphatidylserine and 
oxidised lipoprotein (SR-PSOX). Of these, SR-A and CD36 have been demonstrated 
to be the principal players in atherogenesis (Moore and Freeman 2006).
Mice lacking both SR-A and CD36 demonstrate that these receptors are responsible 
for 75-90% of AcLDL and oxLDL uptake and degradation. Foam cell formation is 
also not evident in this knockout model. Further studies using knockouts crossed onto 
a hypercholesterolemic (ApoE deficient) background also show reduced formation of 
atherosclerotic lesions (de Villiers and Smart 1999; Kunjathoor et al. 2002; Moore 
and Freeman 2006; Pluddemann and Neyen 2007). It is thought that SR-A and CD36 
are responsible for the uptake of different forms of modified LDL. In support of this, 
AcLDL and oxLDL have been shown to be trafficked to different intracellular 
compartments. AcLDL uptake is thought to be primarily driven by SR-A whilst 
oxLDL uptake is mediated through CD36. It is interesting to note that the 
contribution of SR-A to the uptake of oxLDL is determined by the extent of 
oxidation; the more oxidation, the greater the contribution o f SR-A to its uptake (de 
Villiers and Smart 1999; Kunjathoor et al. 2002; Moore and Freeman 2006; 
Pluddemann and Neyen 2007).
In addition to the uptake of lipoproteins, scavenger receptors may contribute to the 
chronic inflammation of atherosclerosis through the promotion of pro-inflammatory 
signalling and macrophage activation and may have roles in macrophage retention and 
adhesion at sites of inflammation (Moore and Freeman 2006; Peiser and Gordon 
2001). The role of scavenger receptors in the clearance of macrophages that have 
undergone apoptosis may also contribute to the development of atherosclerotic 
plaques (Moore and Freeman 2006; Peiser and Gordon 2001). The structure and
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function of three principal scavenger receptors SR-A, SR-B1 and CD36 in 
atherosclerosis is outlined below.
1.3.3.1 SR-A
SR-A was the first scavenger receptor to be isolated and cloned in 1990. It has 
subsequently been shown to be present in human atherosclerotic plaques and is 
expressed in macrophages, vascular smooth muscle cells, endothelial cells and foam 
cells of lesions (Moore and Freeman 2006; Peiser and Gordon 2001). The gene for 
SR-A is located on chromosome 8 in humans and spans ~80kb. Three variants can be 
generated by alternative splicing of the same gene, SR-AI, II and HI (de Winther et al.
2000). Analysis of the protein structure of SR-A has shown that the receptor consists 
of 6 domains. SR-A binds to LDL through its collagenous domain through 
recognition of the apoB protein component of the lipoprotein (Greaves and Gordon 
2009; Moore and Freeman 2006; Peiser and Gordon 2001).
Studies using SR-A knockout mice in atherosclerosis susceptible backgrounds, (ApoE 
or LDLR deficient) showed reductions (60% and 20% respectively) in lesion size, 
suggesting a pro-atherosclerotic role for SR-A (Moore and Freeman 2006). A number 
of other studies using knockout mice models however have had varying results, with 
some studies showing increases in lesion area in SR-A knockout models. For 
example, SR-A deficient mice crossed onto an APOE3 Leiden background (where 
mice carry a variant of the ApoE gene that results in sensitivity to diet-induced 
atherosclerosis and also hypercholesterolemia) showed increased lesion area 
following SR-A knockout. These conflicting sets of data are likely to be due to 
differences in the mouse models used. Interestingly, peritoneal macrophages from 
SR-A deficient mice have reduced levels of AcLDL and oxLDL degradation (80% 
and 30% respectively) but show no change in the in vivo clearance of modified LDL 
(de Winther et al. 2000; Moore and Freeman 2006; Peiser and Gordon 2001).
A number of roles for SR-A in macrophages have been identified. The clearance of 
apoptotic cells is an important function of macrophages in the inflammatory response 
and has been demonstrated to involve SR-A. A study using a monoclonal antibody 
against SR-A showed a 50% reduction in the uptake of thymocytes by macrophages in
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the presence of the antibody. Macrophages from SR-A knockout mice also show a 
reduced capacity for apoptotic cell removal, however, in vivo studies with SR-A 
knockouts have not shown any change in apoptotic cell removal. This may be due to 
functional redundancy between scavenger receptors (de Winther et al. 2000; Moore 
and Freeman 2006; Peiser and Gordon 2001; Pluddemann and Neyen 2007). SR-A 
may also play a role in the retention and adhesion of macrophages at atherosclerotic 
lesions. In 1993, Fraser et al isolated an antibody that inhibited adhesion of 
RAW264.7 macrophages to tissue culture plastic. This antibody was subsequently 
identified as directed against SR-A and other studies demonstrated that it could also 
block adhesion of macrophages to various tissue sections (de Winther et al. 2000). 
SR-A may also play a role in adhesion of macrophages to the extracellular matrix of 
smooth muscle cells as biglycan and decorin have been identified as ligands for the 
receptor (Pluddemann and Neyen 2007). In addition, SR-A can modulate cytokine 
production as demonstrated by the high levels of pro-inflammatory cytokines in the 
myocardium of SR-A knockout mice as compared with wildtype mice, leading to 
impaired healing following myocardial infarction and lower survival rates (de 
Winther et al. 2000; Greaves and Gordon 2009). In summary, roles in the adherence 
of macrophages, binding and uptake of modified lipoproteins into macrophages and 
modification of macrophage activation suggest SR-A has a multi-functional role in 
atherosclerosis with some pro-atherogenic and some anti-atherogenic actions.
1.3.3.2 CD36
CD36 was first described as platelet glycoprotein IV in 1989 and subsequently 
identified as a receptor for oxLDL in 1993. The gene for CD36 encodes a protein of 
471 amino acids, 88kDa in size, and is located on chromosome 7, spanning 28kb. 
CD36 is made up of a large extracellular domain (containing binding sites for fatty 
acids and oxLDL) and two transmembrane domains (Febbraio and Silverstein 2007). 
The receptor is expressed by a number of cell types including 
monocytes/macrophages, platelets, microvascular endothelial cells, cardiac and 
skeletal muscle and adipocytes (Febbraio and Silverstein 2007; Han et al. 1997; 
Moore and Freeman 2006; Nicholson et al. 2001). The receptor is able to bind to a 
broad range of ligands similar to SR-A but unlike SR-A it can interact with the native 
lipoproteins VLDL, LDL and HDL and also to fatty acids. Interestingly both SR-A
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and CD36 are also able to bind the (3-amyloid fibrils that characterise the plaques of 
Alzheimer’s disease. (3-amyloid fibrils have been detected in human atherosclerotic 
plaques and the increase in lipoprotein oxidation seen in atherosclerosis has also been 
observed in Alzheimer’s disease (Pluddemann and Neyen 2007).
CD36 has been identified as the primary receptor for oxLDL. The role of macrophage 
CD36 in the uptake of oxLDL is pro-atherogenic and significantly contributes to foam 
cell formation (Febbraio and Silverstein 2007; Moore and Freeman 2006). Binding 
and degradation of oxLDL is increased 4-fold in CD36-transfected cells compared to 
vector-transfected controls and this binding occurs in a saturable manner (Nicholson 
et al. 2001). Antibodies against CD36 can inhibit binding o f oxLDL by human 
monocyte-derived macrophages and macrophages from patients with a genetic 
polymorphism in the CD36 gene accumulate less cholesterol ester and bind -40% less 
oxLDL than macrophages from normal control patients (Nicholson 2004; Nicholson 
et al. 2001). Unlike SR-A which binds to the apoprotein component of modified 
LDL, CD36 binds to the lipid moiety of the lipoprotein. This is evidenced by the 
observations that delipidated oxLDL will not bind to CD36 and binding of CD36 to 
oxLDL can be inhibited by anionic phospholipids. The binding o f CD36 to oxLDL is 
mediated by oxidised phospholipids that associate with both parts of oxLDL 
(Nicholson 2004; Nicholson et al. 2001).
Knockout mice models have helped define the role of CD36 as a receptor for oxLDL. 
CD36 deficient mice show significantly less atherosclerosis than wildtype and show 
no foam cell formation in response to oxLDL. Mice deficient in macrophage CD36 
also appear to be protected against lesion development (Febbraio and Silverstein 
2007; Silverstein 2009). CD36‘/'ApoE'/* double knockout mice have 70% less lesions 
and also show reductions in lesion size. Re-introduction of CD36 into these mice 
results in lesion formation due to foam cell formation (Febbraio and Silverstein 2007; 
Nicholson 2004; Nicholson et al. 2001). In addition to this, CD36‘/’ApoE‘/‘ mice and 
CDSb^'LDLR ^  mice also present with significantly less macrophages in lesions. 
Treatment of ApoE knockout mice with a CD36 ligand (EP 80317) also showed 
decreased atherosclerosis. Macrophages isolated from these mice showed reduced 
uptake of modified LDL and up-regulation of expression of genes implicated in 
cholesterol efflux including ABCA1 and LXRa (Febbraio and Silverstein 2007).
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Inactivation o f CD36 in LDLR deficient mice fed a high cholesterol diet also show 
reductions in atherosclerotic lesion size. Interestingly, these mice also show higher 
levels o f inflammation and oxidant stress and pro-inflammatory cytokine expression 
suggesting that in addition to hypercholesterolemia, a pro-inflammatory state also 
contributes to CD36-mediated atherogenesis (Kennedy et al. 2009).
Expression o f CD36 can be up-regulated by oxLDL. This was first demonstrated by 
studies using the murine J774.2 macrophage cell line that showed that CD36 mRNA 
and protein expression could be up-regulated by lipoproteins, with the largest 
induction observed in response to oxLDL exposure. Treatment of cells with 
actinomycin D (an inhibitor of transcription) had no effects on mRNA decay 
suggesting that this effect was regulated at the transcriptional level (Nicholson 2004; 
Nicholson et al. 2001). The expression of CD36 in macrophages is regulated by 
oxLDL in a feed-forward loop where oxLDL increases CD36 expression which in 
turn stimulates the uptake of oxLDL resulting in foam cell formation (Nicholson et al.
2001). This loop is mediated through the transcription factor PPARy. Studies have 
demonstrated that cells transfected with a PPARy-response element attached to a 
reporter gene were able to increase reporter gene expression on exposure to oxLDL 
(Nicholson et al. 2001). On oxidation of LDL, oxidised fatty acids such as 9- 
hydroxyoctadecadienoic acid (HODE) and 12-HODE are formed. These are oxidised 
metabolites of linoleic acid and are ligands for PPARy. PPARy regulates the 
expression of a range of target genes involved in lipid metabolism and adipogenesis 
including CD36, by heterodimerising with the retinoid X receptor (RXR) (Nicholson 
et al. 2001; Silverstein 2009).
Interestingly studies using PPARy agonists in ApoE- ' or LDLR'7' mice showed that 
despite increased CD36 expression, atherosclerosis development was inhibited 
(Nicholson 2004). Treatment of human macrophages with PPARy agonists also does 
not result in increased foam cell formation. This may be due to the negative effects of 
PPARy ligands/agonists on macrophage activation or through the effects of PPARy 
ligands on cholesterol efflux (Nicholson 2004). Cholesterol uptake is countered by 
the induction in expression of genes involved in cholesterol efflux, such as the ATP- 
binding cassette transporter ABCA-1, through a liver X receptor (LXR) dependent 
pathway. PPARy ligands are able to induce the expression of ABCA-1 by increasing
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the expression of the oxysterol activated receptor LXRa, resulting in enhanced 
cholesterol efflux (Nicholson 2004).
The original identification of CD36 as a platelet receptor for thrombospondin-1 (TSP- 
1) still has relevance to cardiovascular biology. The interaction between CD36 and 
TSP-1 is likely to contribute to the role o f the receptor in atherosclerosis and CD36 is 
abundantly expressed on platelets. The ability o f oxLDL, but not LDL, to bind to 
platelets may play a role in atherosclerotic plaque thrombosis (Silverstein 2009). 
Exposure to oxLDL renders platelets more susceptible to platelet agonists such as 
collagen and thrombin and results in platelet activation and hence plaque 
development. Binding of oxLDL to platelets is CD3 6-dependent and can be blocked 
by an antibody to the receptor. Platelets from CD3 6-deficient mice also show no 
binding of oxLDL (Silverstein 2009). The interaction of CD36 with TSP-1 may also 
contribute to apoptotic cell phagocytosis, angiogenesis and the retention of 
macrophages at sites of vascular injury. Binding of TSP-1 by CD36 inhibits 
angiogenesis and causes endothelial cell apoptosis. Initial interaction of TSP-1 with 
CD36 is o f low affinity but results in the release o f phosphatases which de- 
phosphorylate CD36 to allow high affinity binding with TSP-1 (Draud and Lorenz 
2001; Febbraio and Silverstein 2007; Pluddemann and Neyen 2007).
Absence of CD36 has been shown to have effects on fatty acid uptake by a number of 
tissues including the heart (Febbraio and Silverstein 2007). Under normal 
physiological conditions the heart uses fatty acids as a source of energy. During 
myocardial infarction however, the heart uses glucose as an energy source. 
Interestingly, this is also the case in the absence of CD36 (Febbraio and Silverstein
2007). CD3 6-deficient mice show higher glucose uptake and oxidation and reduced 
storage, and glucose has been shown to enhance CD36 expression in the J774 cell 
line. Insulin is also able to up-regulate CD36 suggesting a role for the receptor in 
insulin resistance/diabetes (Febbraio and Silverstein 2007). CD36-deficient mice do 
not show diabetes but are resistant to hepatic insulin while macrophages from diabetic 
ApoE'7' mice demonstrate increased uptake and accumulation of oxLDL cholesterol 
(Febbraio and Silverstein 2007).
1.3.3.3SR-B1
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SR-B1 (also known as CLA-1) was discovered in a study of scavenger receptor 
activity in CHO cells. The gene for SR-B1 is located on chromosome 12 in humans 
and encodes a 509 amino acid protein that contains two membrane spanning domains 
linked by a large extracellular region containing multiple sites for N-glycosylation. 
SR-B1 is expressed as an 82kDa protein with a similar structure to and sharing -30%  
sequence homology with CD36. SR-B1 is expressed in the liver, steroidogenic tissues 
(such as the adrenal glands), tissue macrophages, monocyte-derived macrophages and 
a number o f other cell types (de Villiers and Smart 1999; Gillotte-Taylor et al. 2001; 
Moore and Freeman 2006; Peiser and Gordon 2001).
In addition to being classed as a scavenger receptor SR-B1 is a HDL receptor 
(Gillotte-Taylor et al. 2001). HDL levels are inversely correlated with atherosclerosis 
risk and HDL is recognised to have a protective role in the disease through its roles in 
reverse cholesterol transport, endothelial cell signalling and protection against 
oxidative damage. Reverse cholesterol transport involves the efflux of unesterified 
(‘free’) cholesterol from tissues (such as macrophages) to the liver for excretion or 
recycling (see Section 1.4 for more detail). The major physiological role of SR-B1 is 
as a HDL receptor that mediates this binding and movement of cholesterol between 
HDL and cells. The exact mechanisms by which SR-B1 mediates uptake of lipids 
from lipoproteins and efflux of cholesterol from cells to lipoproteins are unclear (de 
Villiers and Smart 1999; Gillotte-Taylor et al. 2001; Moore and Freeman 2006). SR- 
B1 binds to HDL with high affinity through its protein component, apolipoproteins 
ApoE, ApoA-I and ApoC-I-ApoCIII of which ApoA-I is the most abundant. The 
amphipathic a-helices of ApoA-I, which are also present in the other HDL 
apolipoproteins, have been shown to be the recognition motif for SR-B1 binding 
(Moore and Freeman 2006; Pluddemann and Neyen 2007). Studies using purified 
SR-B1 have demonstrated that the receptor can mediate binding of HDL and lipid 
uptake essentially by itself with no requirement for other proteins (Trigatti et al. 
2003). Deletion of SR-B1 in mice models results in increased levels of HDL and 
reduced cholesterol secretion by the liver leading to hypercholesterolemia, whilst 
overexpression of SR-B1 correlates with decreases in HDL levels (Moore and 
Freeman 2006).
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SR-B1 mRNA has been found to be expressed in atherosclerotic plaques in both 
murine models and in humans. Expression is up-regulated following differentiation in 
macrophage cultures and is also expressed at significant levels in THP-1 macrophages 
(de Villiers and Smart 1999; Gillotte-Taylor et al. 2001; Moore and Freeman 2006; 
Zhang et al. 2003). SR-B1 is expressed by foam cells o f atherosclerotic lesions and is 
likely to influence development of lesions through its roles in lipoprotein uptake and 
efflux. Macrophage SR-B1 appears to promote fatty streak formation but reduce the 
development of advanced plaques suggesting that SR-B1 may act in a pro- or anti- 
atherosclerotic way depending on context (Moore and Freeman 2006).
Studies in gene-targeted mice have demonstrated an anti-atherogenic role for both 
hepatic and macrophage SR-B1. This is thought to be mainly due to its role in uptake 
and secretion of HDL cholesterol and in reverse cholesterol transport (Trigatti et al. 
2003). SR-B1 knockout mice develop significantly more atherosclerosis at the aortic 
sinus than wildtype mice and show impaired secretion o f biliary cholesterol and 
accumulation of abnormally large HDL particles (Moore and Freeman 2006; Trigatti 
et al. 2004; Zhang et al. 2003). Other studies using SR-B1 knockout mice have 
observed a 2-fold increase in plasma cholesterol, reduced lipid storage in 
steroidogenic tissues and increased ratios of unesterified/esterified cholesterol in HDL 
in the absence of SR-B1. This is consistent with a role for the receptor in the removal 
of unesterified cholesterol from HDL (Trigatti et al. 2004).
Double knockout (SR-B I'7', ApoE'7") mice die prematurely due to development of 
hypercholesterolemia, accelerated coronary atherosclerosis and myocardial infarction. 
Deletion of SR-B1 in the LDLR'7' mouse model also results in a 6-fold increase in 
atherosclerotic lesion development. Hepatic overexpression of SR-B 1 in the LDLR'7' 
mouse model suppresses atherosclerosis (Moore and Freeman 2006; Trigatti et al. 
2004; Zhang et al. 2003). Taken together, these data suggests that hepatic SR-B1 has 
a protective (anti-atherogenic) role in atherosclerosis through its involvement in 
reverse cholesterol transport. Knockout o f macrophage SR-B1 in an apoE knockout 
mouse model results in a 2-fold increase in lesion area compared to single apoE 
knockouts but show no changes in lipid or lipoprotein profiles (Zhang et al. 2003). 
This suggests that macrophage SR-B1 also plays a protective role in atherosclerosis.
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A role for SR-B1 in atherosclerosis may be due to actions other than the role of the 
receptor in HDL cholesterol transport. Roles for SR-B1 in the clearance of LDL and 
ApoB-containing lipoproteins have been suggested by studies in transgenic mice 
(Trigatti et al. 2004). SR-B1 overexpression results in reduced LDL and VLDL 
cholesterol while attenuation of SR-B1 expression in LDLR" ' mice results in 
increased levels of LDL and ApoB (Trigatti et al. 2004). Cell culture studies have 
suggested a role for the receptor in preventing oxidative damage. Overexpression of 
SR-B1 increases uptake of a-tocopherol (a form of vitamin E) from HDL suggesting 
that the receptor may be important for uptake of this and protection against oxidative 
damage. A role in mediating HDL-dependent synthesis o f nitric oxide in vascular 
endothelial cells has also been suggested as an anti-atherogenic action of SR-B1 
(Trigatti et al. 2003; Zhang et al. 2003).
Alternative roles for SR-B1 may be of particular relevance in macrophages. Some of 
these actions may contribute to atherosclerosis development and progression. Much 
of the focus on SR-B1 research has been on its role as a HDL receptor, however SR- 
B1 deficiency does not lead to increases in ABCA-1 expression and AcLDL-loaded 
macrophages show no change in cholesterol efflux to HDL in the absence of SR-B1. 
This suggests that a role for macrophage SR-B1 in atherosclerosis does not involve 
cholesterol efflux (Trigatti et al. 2003; Zhang et al. 2003). Interestingly, SR-B1 
deficiency can induce the expression of a number o f genes involved in the adhesion 
and migration of monocytes in the arterial wall, suggesting there may be an enhanced 
inflammatory response in the absence of SR-B 1 (Zhang et al. 2003).
SR-B1 is likely to have important roles as a true scavenger receptor, especially in 
macrophages. Similar to CD36, SR-B1 has a broad specificity for ligands including 
modified forms of LDL (acetylated and oxidised), native LDL, VLDL and HDL 
lipoproteins and anionic phospholipids (Gillotte-Taylor et al. 2001). Its similar 
structure to CD36, a principal player in cholesterol uptake in macrophages is 
suggestive of a similar role. SR-B1 has been demonstrated to be involved in the 
clearance of apoptotic cells and is able to bind oxLDL with high affinity (Gillotte- 
Taylor et al. 2001). Studies have shown that oxLDL associates with SR-B1 
transfected Chinese hamster ovary (CHO) cells with a higher affinity than HDL. This 
binding could be competed out by oxidised LDL and to a lesser extent by oxidised
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lipoproteins (Gillotte-Taylor et al. 2001). It has been suggested that SR-B1 has 
multiple binding sites and that both the oxidised lipid moieties and the protein 
moieties of oxLDL are important for its recognition by SR-B1. The oxLDL is 
internalised and degraded through an endocytic pathway and the ratio of binding to 
degradation was similar to that seen with SR-A (Gillotte-Taylor et al. 2001). Despite 
this finding, the exact contribution of SR-B 1 to foam cell formation in macrophages 
remains unclear.
1.4 Foam cell formation-Cholesterol efflux
Foam cell formation in atherosclerosis can be prevented by the process of cholesterol 
efflux or RCT from macrophages. Reverse cholesterol transport is the process of 
moving cholesterol from macrophages and other cells to the liver or to other tissues 
(Daniels et al. 2009; Tall 2008). RCT can be grouped into three stages; firstly, 
cholesterol moves out of tissues, it is then transported in the plasma to the liver and it 
can then be excreted into the bile (Daniels et al. 2009; Tall 2008). The efficiency of 
RCT is determined by levels of HDL which stimulates the process (Ohashi et al.
2005).
HDL, like other lipoproteins is a spherical particle made up o f a core of cholesterol 
and triglyceride surrounded by a monolayer of phospholipids punctuated by 
apolipoproteins; predominantly ApoA-I but also ApoC-I, ApoC-II, ApoC-III and 
ApoE (Daniels et al. 2009; Tabat and Rye 2009). Recycling o f ApoA-I is important 
for HDL metabolism. Production of ApoA-I by the liver and its interaction with 
phospholipids and unesterified cholesterol forms discoidal HDL particles (Ohashi et 
al. 2005; Tall 2008). Discoidal HDL triggers cholesterol efflux from macrophages 
and other cells. Cholesterol from these cells is absorbed by the discoidal HDL and 
esterified by lecithin:cholesterol acyltransferase (LCAT) (Ohashi et al. 2005; Tall
2008). Accumulation of cholesterol esters inside HDL transforms them into larger, 
spherical HDL particles, normally observed in the plasma. This process requires the 
phospholipid transfer protein (PTP) (Tabat and Rye 2009). HDL enriched with 
triglyceride are processed by hepatic lipase while HDL enriched with cholesterol 
esters is processed by the cholesterol ester transport protein (CETP) which exchanges
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cholesterol esters for triglycerides from other lipoproteins (VLDL and chylomicrons). 
Remnants are then taken up into the liver through the LDL receptor or through 
proteoglycans. Cholesterol in the liver can be utilised for a number of purposes or can 
be excreted into the bile via ABCG5 and ABCG8 transporters (Daniels et al. 2009; 
Ohashi et al. 2005; Tall 2008).
Key molecules involved in reverse cholesterol transport from macrophages include 
ABCA-1, ABCG-1 and ApoE. These proteins and their roles in atherosclerosis are 
discussed in detail in Sections 1.4.1 and 1.4.2 Whilst ABCA-1 promotes efflux of 
cholesterol to lipid-poor apoA-I and HDL formation in the liver, ABCG-1 promotes 
cholesterol efflux to HDL particles where it is esterified by LCAT without influencing 
overall levels of HDL (Tall 2008). Both ABCA-1 and ABCG-1 are targets of LXR, a 
transcription factor activated in response to accumulation of oxysterols in cells, 
suggesting a feedback mechanism for RCT. The exact mechanism of RCT and the 
relationships between key factors involved in RCT is currently unclear (Ohashi et al. 
2005; Tall 2008).
In addition to its role in RCT, HDL has been demonstrated to have anti-inflammatory, 
anti-thrombotic and anti-apoptotic effects that are likely to contribute to its anti­
atherogenic nature. A number of studies have demonstrated that HDL inhibits 
monocyte recruitment into the intima by inhibiting the pro-inflammatory cytokine- 
induced expression of adhesion molecules by endothelial cells and the expression of 
MCP-1 (Tabat and Rye 2009; Tall 2008). Oxidation of LDL and oxLDL-induced 
macrophage apoptosis is also inhibited by HDL. This action may be mediated 
through an inhibition of ROS production and restoration of vascular endothelial 
function by increasing endothelial NOS to increase NO availability, so inhibiting 
VSMC proliferation and monocyte adhesion to the endothelium (Tabat and Rye 2009; 
Tall 2008).
1.4.1 Apolipoprotein E
ApoE was first described in the 1970s by Shore and Shore. On its discovery it was 
found to be a component of VLDL, however, it has now been recognised as a 
component of a range of lipoproteins including chylomicrons and HDL (Greenow et
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al. 2005; Horejsi and Ceska 2000). ApoE is a glycoprotein of 299 amino acids. It 
contains two domains linked by a protease sensitive loop and has recognition sites for 
the LDLR and the LRP. Binding sites in the N terminal region have been identified 
for heparin sulphate proteoglycans (HSPGs) and SR-B1 while the C terminal region 
of the protein is important for binding to lipids and has an a  helical structure 
conserved throughout lipid binding apolipoproteins (Greenow et al. 2005; Mahley and 
Rail 2000).
The ApoE gene is located on chromosome 19 and encodes a 34kDa protein. 
Regulation of gene expression is complex with tissue specific regulation observed. 
The expression of the protein can be enhanced by factors including TGF-0, TNF-a 
and also by the differentiation of monocytes into macrophages. The cytokines IL-1 
and IFN-y both down-regulate ApoE expression (Greenow et al. 2005; Harvey and 
Ramji 2005; Kockx et al. 2008). Three common isoforms of apoE, derived from a 
single gene locus, exist and are known as apoE2, apoE3 and apoE4. The three allele 
products differ by a single amino acid substitution. The products o f three alleles 
produce six phenotypes overall and the most common o f these is the apoE3/3 
phenotype. The isoforms show specificity in binding ability to both lipids and 
receptors. ApoE2 binds with only very low affinity to the LDL receptor while ApoE3 
and ApoE4 bind with higher affinity. ApoE4 has high affinity for VLDL, a 
lipoprotein rich in triglyceride, while ApoE2 and ApoE3 preferentially bind to 
phospholipid rich HDL (Greenow et al. 2005; Horejsi and Ceska 2000; Mahley and 
Rail 2000). ApoE4 is linked with increased risk of cardiovascular disease (Kockx et 
al. 2008).
The main site of ApoE synthesis is the liver, however it is also synthesised by 
extrahepatic tissues including brain, lung, kidney and muscles (Greenow et al. 2005; 
Mahley and Rail 2000). In the vasculature apoE is secreted by smooth muscle cells 
and by macrophages. ApoE can undergo repeated cycles of secretion from and 
internalisation into macrophages, hepatocytes and a number of other cell types and 
this recycling is promoted by apoAI and HDL. Currently the importance of this 
recycling is unclear (Kockx et al. 2008).
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ApoE derived from extra-hepatic sources makes up 20-40% of total plasma protein. 
The protein has roles in the hepatic uptake of lipoproteins and therefore also in 
cholesterol homeostasis, and is involved in the regulation of immune and 
inflammatory responses. The uptake and degradation of lipoproteins is regulated by 
ApoE through binding to the LDLR (Greenow et al. 2005; Mahley and Rail 2000). 
ApoE is a potent ligand for this receptor. The HSPG/LRP pathway functions in the 
liver to metabolise remnants of lipoproteins including chylomicrons. ApoE also 
stimulates RCT and the production of VLDL and triglycerides. Lipids are directed by 
delivery to either the liver (via VLDL) or the small intestine (via chylomicron 
remnants) (Greenow et al. 2005; Mahley and Rail 2000).
1.4.1.1 ApoE and atherosclerosis 
Deficiency of apoE leads to the development of atherosclerosis and 
hypercholesterolemia and apoE-deficient mice are often used as a model for the 
disease. The protein is not expressed in normal vessel walls but is synthesised at high 
levels by macrophages present within atherosclerotic plaques. Reduced expression of 
the protein in atherosclerosis is associated with a pro-atherogenic lipoprotein profile 
whilst re-expression of apoE has been demonstrated to reduce the extent of 
atherosclerosis (Mahley and Rail 2000; Puddu et al. 2005).
The major anti-atherogenic property of apoE is the stimulation of cholesterol efflux 
from foam cells. It has been demonstrated that apoE can act as an acceptor of both 
cholesterol and phospholipids released from macrophages via ABCA-1 and is able to 
interact with ABCA-1, at least in vitro (Greenow et al. 2005).
ApoE can also exert anti-atherogenic actions that are independent of effects on 
cholesterol metabolism. For example, macrophage apoE can inhibit the expression of 
key proteins through binding to the apoE receptor 2 and causing the activation of 
nitric oxide synthase (NOS). Oxidation of LDL, proliferation of T-lymphocytes and 
smooth muscle cells, aggregation of platelets and production of the adhesion molecule 
VCAM-1 by endothelial cells are all inhibited by apoE and contribute to the anti­
atherogenic nature of the protein (Greenow et al. 2005; Harvey and Ramji 2005).
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1.4.2 ABCA-1 and ABCG-1
ABCA-1 and ABCG-1 are part o f the ABC superfamily (Attie 2007). ABC 
transporters use ATP to facilitate the movement of lipids and metabolites across 
membranes and there are 49 human ABC transporters grouped into seven classes, A- 
G. Members of the ABC family are transmembranous transporters and have one of 
two structures. Whole transporters have a two domain structure that is joined by 
covalent bonds while half transporters are composed of single units that form homo- 
or hetero-dimers to become active (Oram and Heinecke 2005; Oram and Vaughan
2006).
1.4.2.1 ABCA-1
Of the ABC transporters, ABCA-1 is the best characterised and studied. The ABCA- 
1 gene has been mapped to chromosome 9q31 and encodes a whole transporter, 2216 
amino acids in size (Cavelier et al. 2006). The protein is widely expressed with high 
mRNA levels in liver, small intestine and lung and has a broad substrate specificity 
(Oram and Heinecke 2005; Oram and Vaughan 2006). ABCA-1 is composed of 2 
nucleotide binding folds exposed to the cytoplasm and 2 a  helical transmembrane 
domains. Walker A and Walker B motifs present within the nucleotide binding folds 
are characteristic of ABC proteins (Attie 2007).
The primary role of ABCA-1 is the transport of cholesterol and phospholipids from 
cells to apolipoproteins in the bloodstream. This efflux of free cholesterol and 
phospholipids to lipid-poor apolipoproteins via ABCA-1 is the initial step in the 
formation o f HDL (Wang and Tall 2003). In the intestine, cholesterol is moved out of 
epithelial cells into the bloodstream via ABCA-1 and this leads to over one third of 
HDL production (Attie 2007). ABCA-1 knockout mice present with HDL deficiency 
and reduced cholesterol efflux. Selective knockout of hepatic ABCA-1 also 
demonstrates a key role for the transporter in HDL production (Cavelier et al. 2006).
The central role of ABCA-1 in cholesterol efflux involves interaction with ApoAl, 
the protein component of HDL. It is thought that ApoAl binds to ABCA-1 directly 
and the complex formed is essential for efflux of cholesterol. Cross linking studies 
have demonstrated that ABCA-1 associates with ApoAl (Attie 2007; Fitzgerald et al.
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2010; Wang and Tall 2003). However, it has also been suggested that the ApoAl 
may not interact directly with ABCA-1 but that ApoAl may dock at the plasma 
membrane following a local redistribution of lipids within the membrane, induced by 
the expression of ABCA-1. The formation of this complex stimulates lipid transfer 
from ABCA-1 to ApoAl although how these two events are related remains to be 
clarified (Attie 2007; Fitzgerald et al. 2010; Wang and Tall 2003).
ABCA-1 targets specific regions of the membrane that are cholesterol-rich or 
sensitive to cholesterol accumulation, for secretion of lipids (Oram and Heinecke 
2005). This may work through the targeting of excess cholesterol in transport vesicles 
to regions of the membrane where ABCA-1 is present or through the endocytosis of 
vesicles containing ABCA-1 and apolipoproteins to lipid rich deposits. It has been 
shown that ABCA-1 moves between endosomes and the plasma membrane and this 
may be involved in its regulation (Oram and Heinecke 2005).
The expression of the transporter is highly regulated and has a rapid turnover rate. 
This is likely to be due to the need to balance the beneficial cholesterol efflux and 
prevention of cytotoxicity effects, with the detrimental effects of altered membrane 
structure in the absence of cholesterol loading, seen on overexpression of ABCA-1 
(Oram and Heinecke 2005; Wang and Tall 2003).
Levels o f the transporter are increased in response to both ApoAl and ApoE (Wang 
and Tall 2003). Studies in human THP-1 macrophages have demonstrated that 
endogenous synthesis of cholesterol up-regulates gene expression of ABCA-1 and 
other LXR-regulated genes involved in cholesterol efflux including ApoE and 
ABCG1 (Beyea et al. 2007). LXR is itself activated by cholesterol metabolites and is 
involved in ‘sensing’ cholesterol levels so activates ABCA-1 in cholesterol-loaded 
cells. Accumulation of modified lipoproteins and cholesterol in macrophages during 
atherosclerosis will therefore induce the expression of ABCA-1 in these cells (Oram 
and Vaughan 2006; Wang and Tall 2003).
OxLDL has also been demonstrated to up-regulate the expression of ABCA-1 at 
transcriptional and protein levels in vitro (Tang et al. 2004). Levels of ABCA-1 can 
be down-regulated by a decrease in LXR/RXR activation in response to cholesterol
30
CHAPTER 1: Introduction
efflux (Wang and Tall 2003). Interestingly, statins have also been shown to down- 
regulate the expression of ABCA-1 in human and mouse macrophage cell lines (Sone 
et al. 2004).
1.4.2.2ABCG1
The human ABCG-1 gene has been mapped to chromosome 21q22.3. Unlike ABCA- 
1, ABCG-1 is a half-transporter. The protein is widely expressed but present at high 
levels in macrophage-rich tissues, macrophages, endothelial cells and lymphocytes 
(Ni et al. 2007). The mRNA expression of ABCG-1 is increased on transformation of 
macrophages into foam cells using acetylated or oxidised LDL and also on incubation 
of macrophages with cholesterol derivatives. Similar to ABCA-1, expression of 
ABCG-1 can be up-regulated by LXR, RXR, PPARy and reduced by statins and 
cholesterol depletion (Ni et al. 2007).
The first evidence of ABCG1 activity was observed by Schmitz and colleagues in 
2000 when they showed that the expression of ABCG1 was up-regulated by 
cholesterol in human macrophages. Studies using siRNA against ABCG-1 or 
overexpression of the protein have demonstrated that ABCG-1 stimulates cholesterol 
efflux to HDL but not to apoA-I (Fitzgerald et al. 2010; Ni et al. 2007). Further 
studies have indicated that ABCG-1 mediates cholesterol efflux to major HDL 
fractions to improve HDL efficiency. In addition to this, ABCG-1 also increases 
cholesterol levels in plasma membranes and this may control the availability of 
cholesterol to lipoprotein acceptors. These acceptors may in turn induce ABCG-1 - 
mediated cholesterol efflux based on their phospholipid content (Ni et al. 2007).
1.4.2.3 ABCA-1, ABCG-1 and atherosclerosis 
ABCA-1 is an anti-atherogenic protein. Deficiency of macrophage ABCA-1 in mice 
leads to accelerated atherosclerosis with excess accumulation of cholesterol 
independent of HDL levels, while overexpression reduces atherosclerosis (Cavelier et 
al. 2006; Oram and Vaughan 2006). ABCG-1 null mice exhibit increased 
accumulation of cholesterol and triglycerides in hepatocytes and macrophages when 
fed a high fat diet and overexpression of human ABCG-1 reduced accumulation in
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these tissues. However, loss of ABCG-1 has not been linked with accelerated 
atherosclerosis (Cavelier et al. 2006; Fitzgerald et al. 2010; Ni et al. 2007).
The preventative role of ABCA-1 in atherosclerosis is also demonstrated by the 
association between ABCA-1 mutations and premature atherosclerosis observed in 
diseases including Tangier disease and Familial hypoalphalipoproteinemia (Attie 
2007). For example, mutations in ABCA-1 in Tangier disease prevent cells moving 
cholesterol and phospholipids onto ApoAl and this transfer is the rate-limiting step of 
HDL biogenesis. Tangier patients have very low levels of circulating HDL but no 
changes in LDL cholesterol levels and are prone to foam cell formation and 
atherosclerosis due to accumulation of cholesterol esters in the liver, intestine and in 
macrophages (Attie 2007; Fitzgerald et al. 2010; Oram and Vaughan 2006; Wang and 
Tall 2003).
The function of ABCA-1 and ABCG-1 as removers o f excess cholesterol from 
macrophages is responsible for their anti-atherogenic properties. In addition to 
negative feedback control of cholesterol synthesis, cholesterol levels can be regulated 
by a heterodimers of LXR and RXR transcription factors. Macrophages express high 
levels of ABCA-1 and ABCG-1 in response to the transcription factors, LXR, RXR 
and PPAR which can activate the ABC transporters (Attie 2007; Ni et al. 2007). The 
most likely ligand for this is 27-hydroxycholesterol which correlates with cellular 
cholesterol levels and may therefore provide a positive feedforward mechanism for 
ABCA-1-mediated cholesterol efflux (Beyea et al. 2007; Cavelier et al. 2006).
1.5 Development of lesions and plaque formation
Fatty streaks can be present in young individuals and rarely cause symptoms with 
most disappearing with time (Hansson and Libby 2006). Although fatty streaks are 
not always clinically significant, in the presence of risk factors for atherosclerosis 
such as hypertension or hyperlipidemia, they can develop into more advanced lesions. 
The migration of smooth muscle cells from the medial layer of the artery into the 
intima accompanies the progression of atherosclerotic lesions from fatty streaks to 
more complex plaques. Once inside, smooth muscle cells proliferate and take up
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modified lipoproteins enhancing foam cell formation and further contributing to the 
necrotic core of the lesion. Smooth muscle cells also synthesise ECM proteins that 
form the fibrous cap often seen with in complex lesions (Glass and Witztum 2001; Li 
and Glass 2002).
1.5.1 The ECM
The ECM is composed of three different elements; elastins form elastic fibres to 
accommodate changes in blood flow; collagens provide tensile strength to the 
vascular wall; and proteoglycans interact with vascular cells and ECM components 
such as hyaluronan to form complexes that regulate permeability and structure 
(Raines 2000). Degradation and remodelling o f the ECM by activated proteases is 
essential for processes such as growth and development but also has a role in a 
number of pathological processes. In atherosclerosis, degradation of the ECM that 
normally surrounds VSMCs results in the migration of VSMCs from the arterial 
media to the intima to form intermediate fibrofatty lesions composed of dense layers 
of VSMCs, macrophages and T-lymphocytes around a necrotic core. These lesions 
develop into plaques (or atheroma) which are characterised by the formation of a 
fibrous cap comprised of collagen, proteoglycans and fibrous elements (Libby et al. 
2010).
1.5.2 Proteases and the atherosclerotic plaque
In atherosclerosis, macrophages (and monocytes) are known to secrete proteolytic 
enzymes at all stages of atherosclerosis to influence the development and/or stability 
of the plaque (Worley et al. 2003). Differentiation of monocytes to macrophages is 
accompanied by an increase in the expression of matrix-degrading proteinases 
(Whatling et al. 2004; Worley et al. 2003). In the later stages of atherosclerosis, high 
levels of proteases and correspondingly high levels of matrix degrading activity are 
seen in the vulnerable shoulder region of atherosclerotic plaques and macrophage- 
produced proteases have been demonstrated to induce the breakdown of collagen in 
the fibrous cap (Galis et al. 1995; Raines 2000).
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Two important groups of ECM proteases are the matrix metalloproteinases (MMPs) 
and the ADAMTSs. MMPs are zinc-dependent endopeptidases that play a major role 
in ECM remodelling in a number of physiological and pathophysiological processes 
such as angiogenesis, wound healing, inflammation, arthritis and atherosclerosis. The 
MMP family is made up of 28 members divided into 4 classes based on their enzyme 
action. They are the interstitial collagenases, stromelysins, gelatinases and the 
membrane-type metalloproteinases. They are regulated by their endogenous 
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). ADAMTS proteases 
are secreted enzymes that are able to cleave proteoglycans such as aggrecan and 
versican. The structure and function of the ADAMTS proteases and their roles in 
atherosclerosis are described in detail in Chapter 6 o f this thesis.
1.5.2.1 MMPs and atherosclerosis 
Changes in the degradation of extracellular matrix by MMPs have been associated 
with a number of pathological conditions including rheumatoid arthritis and 
atherosclerosis (Galis and Khatri 2002; Galis et al. 1994; Malemud 2006; Wight
2005). This shift in the balance of synthesis and degradation is often driven by 
inflammation, injury and oxidative stress (Galis and Khatri 2002). Both MMPs and 
their endogenous inhibitors, the TIMPs are found in the heart and of the MMPs, 
MMP-2 is constitutively expressed in the heart and is found within human arteries 
(Chow et al. 2007). Matrix-degrading proteases are also constitutively expressed by 
foam cells of atherosclerotic plaques (Galis et al. 1995).
Investigation of normal and diseased human arteries showed that MMP-2 is 
constitutively expressed in both, however in normal arteries MMP-2 is associated 
with its endogenous inhibitor TIMP-2 and is inactive (Galis and Khatri 2002; Galis et 
al. 1994). MMP-1 and MMP-3 are also expressed by vascular smooth muscle cells 
and their expression can be induced by the pro-inflammatory cytokines TNF-a and 
IL-1 (Galis et al. 1994). MMP-9 expression can be induced by pro-inflammatory 
cytokines due to the presence of an activator protein-1 (AP-1) binding site and a 
nuclear factor-icB (NFkB) binding site in the promoter, and is associated with 
leukocytes and macrophages (Chow et al. 2007). Mice deficient in MMP-9 show
34
CHAPTER 1: Introduction
decreased intimal hyperplasia. This model supports a role for metalloproteinases in 
the promotion of VSMC migration and proliferation (Jonsson-Rylander et al. 2005).
Secretion of cytokines by activated macrophages results in the up-regulation of MMPs 
(Galis and Khatri 2002). Accumulation of lipids as seen in atherosclerosis can cause 
an increase in MMP expression while changes in oxidative stress associated with 
foam cell accumulation can also increase activation of latent MMPs in vascular cells 
(Galis and Khatri 2002). Increases in MMP production/activity have been associated 
with migration of smooth muscle cells and with the recruitment of inflammatory cells 
via interaction with adhesion molecules such as VCAM-1 (Galis and Khatri 2002).
1.5.3 T cells and plaque development
Inflammation and immune response continue to contribute to atherosclerosis 
development during plaque formation. T cells can be stimulated by the same 
adhesion molecules and chemokines as macrophages and can make up approximately 
10-20% of advanced plaques (Hansson et al. 2002). CD4+ T cells are observed in 
human atherosclerosis and deletion of CD4+ and CD8+ T cells can reduce fatty streak 
formation in C57BL/6 mice. CD8+ T cells may contribute to disease progression by 
contributing to apoptosis within lesions however; CD4+ T cells are likely to play a 
larger role in development of the disease (Ohashi et al. 2004). Once activated, T cells 
can produce pro-inflammatory cytokines including the CD40 ligand, ligation of which 
promotes production of MMPs and the procoagulant tissue factor (TF) which initiates 
the coagulation cascade (Libby et al. 2010).
T cells present in atherosclerotic plaques are characterised according to the cytokines 
they secrete. Thl cells are responsible for cell-mediated immunity, can activate 
macrophages and secrete pro-inflammatory cytokines including interferon-y (IFN-y). 
Th2 cells are involved in the production of antibodies by B cells and reduce 
macrophage activity through the secretion of anti-inflammatory cytokines such as IL- 
10 and TGF-P (Ohashi et al. 2004). Thl type cytokines make up the highest 
proportion of cytokines in both mouse and human atherosclerotic plaques. These 
include IFN-y, TNF-a and IL-12, -15 and -18. Studies have demonstrated a 
pathogenic role for Thl cytokines in atherosclerosis. Hypercholesterolemic mice
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deficient in any of these cytokines show reduced atherosclerosis (Hansson and Libby 
2006; Tedgui and Mallat 2006). Th2 cytokines, such as IL-10 and TGF-p, inhibit the 
action of Thl cytokines. The anti-inflammatory cytokines, IL-10 and TGF-P are 
atheroprotective. For example, mice overexpressing IL-10 under the control of the 
IL-2 promoter have reduced production o f the pro-atherogenic cytokine, IFN-y 
(Hansson and Libby 2006; Tedgui and Mallat 2006). Despite this, many studies 
suggest that balance of Thl/Th2 responses is not straightforward. IL-10 is not 
specific to Th2 cells and has been shown to inhibit the Th2 response while deficiency 
of the Th2 cytokine IL-4 has also been linked to reduced formation of atherosclerosis 
(Tedgui and Mallat 2006).
In addition to T helper cells, regulatory T (Treg) cells exist in two types. Natural Treg 
cells are characterised by expression of CD4, CD25 and the transcription factor 
FOXP3 and regulate immune responses to self-antigens to prevent autoimmunity 
(Taleb et al., 2010; Nilsson et al., 2009). Induced Treg cells are generated by the anti­
inflammatory cytokines TGF-P or IL-10 during an immune response. Cells generated 
in response to TGF-P (Th3 cells) or IL-10 (Trl cells) mediate suppressor function 
through production of these two cytokines (Taleb et al., 2010). Both natural and 
induced Treg cells are therefore atheroprotective (Taleb et al., 2010; Nilsson et al., 
2009). Roles for autoimmune responses in atherosclerosis were first suggested by the 
discovery of activated T cells and MHC class II antigens in atherosclerotic plaques 
(Nilsson et al., 2009). Deletion of T cells or their receptors is associated with 
enhanced progression of the disease and this is associated with depleted levels of Treg 
cells and enhanced inflammation (Nilsson et al., 2009). Low levels of Treg cells are 
observed in ApoE 7' mice and in human arterial lesions compared to normal arterial 
tissue (Nilsson et al., 2009). Co-culture of murine macrophages with Treg cells can 
reduce lipid accumulation (and therefore foam cell formation) through cell-cell 
contact and production of TGF-P and IL-10 associated with reduced expression of 
scavenger receptors CD36 and SR-A (Lin et al., 2010).
A recently identified T cell lineage is T h l7 cells which have physiological roles in 
defence against bacterial and fungal infections (Taleb et al., 2010). Differentiation in 
vitro is mediated by TGF-P and IL-6. Roles for T hl7 cells in autoimmune disease 
including rheumatoid arthritis have also been identified (Taleb et al., 2010). Their
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role in atherosclerosis is currently unclear although a number of studies have 
suggested a pro-inflammatory role for IL-17 (Taleb et al., 2010). The cytokine can 
activate NFkB which is associated with the induction of pro-inflammatory factors 
including TNFa and IL-1. Cells expressing both IL-17 and IFNy are present in 
atherosclerosis patients and enhance inflammation however; induction of IL-17 in the 
presence o f TGF-P and IL-6 can have anti-inflammatory effects (Taleb et al., 2010).
1.6 Plaque rupture and Thrombosis
The composition and vulnerability of the atherosclerotic plaque determines 
development of thrombosis and subsequent acute coronary events. Plaques that are 
vulnerable to rupture have high numbers of inflammatory cells and a thin fibrous cap 
(Glass and Witztum 2001; Lusis et al. 2004). The fibrous cap is maintained through a 
balance o f collagen and matrix production and degradation mediated by cytokines 
produced by inflammatory cells. In addition to thinning of the fibrous cap through 
breakdown of the ECM, other factors that may contribute to plaque stability include 
apoptosis which is promoted by the balance of cytokines and pro- and anti-apoptotic 
proteins within the arterial wall. Angiogenesis and calcification of lesions may also 
have effects on plaque stability (Glass and Witztum 2001; Lusis et al. 2004).
As the size of the atherosclerotic lesion increases, it initially expands outwards 
resulting in remodelling of the arterial wall. When the lesion becomes large enough, 
it extends inwards leading to narrowing of the artery and angina (Li and Glass 2002). 
Arterial thrombosis arising from disruption to the plaque can lead to myocardial 
infarction or stroke (Libby et al. 2002). This is the culmination of atherosclerosis.
1.7 Cytokines and atherosclerosis
In the context of disease or pathophysiology, cytokines are often grouped according to 
their pro-or anti-inflammatory actions. High levels o f pro-inflammatory cytokines are 
observed in atherosclerotic lesions (Harvey and Ramji 2005). Pro-inflammatory 
cytokines include TNF-a, IFN-y, IL-1 and IL-12 amongst others. Anti-inflammatory
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cytokines include IL-10, IL-4 and TGF-p. Macrophages are the main source o f 
cytokines in the atherosclerotic lesion alongside other vascular cells and platelets 
(Dinarello 2000; Tedgui and Mallat 2006). Cytokines mediate the development of the 
atherosclerotic lesion at all stages of the disease and have central roles in endothelial 
permeability, expression of adhesion molecules and scavenger receptors, migration of 
smooth muscle cells and induction of apoptosis (Tedgui and Mallat 2006).
1.7.1 Pro-inflammatory cytokines
Pro-inflammatory cytokines are expressed at high levels in the initial stages of 
atherosclerosis and can promote the expression of growth factors including vascular 
endothelial growth factor (VEGF), involved in plaque progression and stability, and 
platelet-derived growth factor (PDGF), involved in the proliferation and migration of 
smooth muscle cells (Tedgui and Mallat 2006). The most studied pro-inflammatory 
cytokine is IFN-y which is a type II interferon. The main sites of IFN-y synthesis are 
natural killer cells and T-lymphocytes (Thl cells) but it is also synthesised by 
monocytes/macrophages. IFN-y is important in the recruitment of immune cells to 
lesions in atherosclerosis. Expression of chemokines including MCP-1 and MIP-1 is 
induced by this cytokine (Harvey and Ramji 2005). Expression of adhesion 
molecules important for monocyte recruitment such as VCAM-1 is also increased by 
IFN-y (Harvey and Ramji 2005). The cytokine can promote differentiation of 
monocytes into macrophages and can contribute to cholesterol accumulation by 
inhibiting the expression of key genes involved in cholesterol efflux (Harvey and 
Ramji 2005). Roles for IFN-y in apoptosis of vascular smooth muscle cells and in 
plaque destabilisation have also been reported (Harvey and Ramji 2005).
1.7.2 Anti-inflammatory cytokines
Anti-inflammatory cytokines serve to limit inflammatory responses often through 
their ability to suppress the expression of pro-inflammatory cytokines. They also 
have effects on macrophage and T cell function. Major anti-inflammatory cytokines 
include IL-4, IL-10 and TGF-P (Dinarello 2000; Opal and DePalo 2000). TGF-P is 
the most studied anti-inflammatory cytokine. Knockout of TGF-pi in mice results in 
uncontrolled inflammatory reactions, supporting its role as an anti-inflammatory
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cytokine (Mallat et al. 2001). The cytokine has key roles in the regulation of cell 
proliferation and differentiation and can inhibit proliferation of B cells and T cells. 
Similar to IL-10, TGF-P can inhibit the production of pro-inflammatory cytokines 
TNF-a and IFN-y by monocytes/ macrophages but these effects are less potent than 
those observed with IL-10 (Opal and DePalo 2000). TGF-P is discussed in detail in 
Section 1.9.
The balance between pro- and anti-inflammatory cytokines is important in the 
development and progression of atherosclerosis. For example, IFN-y is known to 
inhibit the expression of apoE and ABCA-1, two proteins involved in reverse 
cholesterol transport whilst the anti-inflammatory cytokine TGF-P up-regulates their 
expression (Tedgui and Mallat 2006). Synthesis and degradation of ECM is important 
in the vulnerability of atherosclerotic plaques to rupture. This is likely to be mediated 
by the balance between pro- and anti-inflammatory cytokines. TGF-P and IL-10 
inhibit the expression of MMPs which break down the ECM. TGF-p also induces 
synthesis of collagen to promote a stable plaque structure. In contrast, IFN- y inhibits 
collagen synthesis while other pro-inflammatory cytokines, IL-1 and TNF-a induce 
the expression of MMPs (Dinarello 2000; Opal and DePalo 2000; Tedgui and Mallat
2006).
1.8 TGF-p
The TGF-p superfamily comprises 3 TGF-P isoforms, 4 activin p chains, the protein 
Nodal, 10 bone morphogenetic proteins and 11 growth and differentiation factors 
(Schmierer and Hill 2007). The three isoforms of TGF-p share between 64 and 82% 
homology in their amino acid sequence but are coded for by separate genes and have 
distinct patterns of expression. Whilst all three isoforms are expressed in the vascular 
wall, TGF-pl is expressed at sites of inflammation and injury and is therefore most 
studied in relation to atherosclerosis (Ashcroft 1999). In the vasculature, the cytokine 
is expressed by endothelial cells, smooth muscle cells and macrophages and TGF-P 
mRNA is constitutively expressed by monocytes (Ashcroft 1999; Bobik 2006).
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1.8.1 TGF-P synthesis
TGF-p is synthesised as a 24kDa dimeric precursor which is cleaved to become 
active. The cytokine is initially rendered inactive through association with the latency 
associated peptide (LAP), a 75kDa protein (Goumans et al. 2009). This complex is 
known as the small latent complex (SLC). The signal peptide is cleaved from the 
pre-pro-TGF-p on movement from the site o f synthesis to the rough endoplasmic 
reticulum (RER) (ten Dijke and Arthur 2007). TGF-p has a cysteine knot motif in the 
mature protein formed by six conserved cysteine residues linked by three disulphide 
bonds, a structure conserved throughout the TGF-P superfamily (Schmierer and Hill 
2007; Singh and Ramji 2006). Two monomers, 12-15kDa in size, of TGF-P dimerise 
through disulphide bridges and then undergo cleavage by furin-like proprotein 
convertases inside the cell. This cleavage produces the C-terminal mature TGF-p 
peptide and an N-terminal LAP, which remain attached through non-covalent bonds 
(Singh and Ramji 2006; ten Dijke and Arthur 2007).
The SLC can then covalently bond with a latent TGF-P binding protein (LTBP) to 
form the large latent complex (LLC) which can then be secreted. Four LTBPs have 
been identified and contain domains rich in cysteine residues and epidermal-growth 
factor-like repeats that allow interaction with components o f the ECM (Singh and 
Ramji 2006; ten Dijke and Arthur 2007). The C-terminal o f the LTBP interacts with 
microfibrils, possibly to stabilise TGF-p. Following secretion, the N-terminal of the 
LTBP interacts with components of the ECM, possibly to allow TGF-P to be targeted 
to specific sites and to regulate its activity. For TGF-P to become active and 
subsequently bind to TGF-P receptors to initiate signalling, the LLC must be released 
from interaction with microfibrils and ECM components. The exact mechanism that 
regulates this is unclear. The binding of Thrombospondin-1 to the LAP has been 
suggested to have a role in this by disrupting the bonds between TGF-p and the LAP. 
Binding of integrins to the LAP or the action of proteases on the LTBP may also have 
a role in this regulation (Singh and Ramji 2006; ten Dijke and Arthur 2007).
1.8.2 TGF-p receptors
TGF-P signals through its endogenous receptors also known as activin receptor-like 
kinases (ALKs). There are five type I receptors (TGFpRI) and seven type II receptors
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(TGFpRII) in mammals (Goumans et al. 2009). TGF-P binds to a receptor complex 
made up of type I and type II receptors. The exact structure of the receptor complex 
is not known but is thought to be a heterotetramer consisting of two type I and two 
type II receptors. In the absence of TGF-p, the receptors exist as homodimers but 
studies using mutated receptors have suggested that at least two type I receptors are 
required in the signalling complex (ten Dijke and Hill 2004). The two receptor types 
are similar in structure and are the only known transmembranous, serine-threonine 
kinases. The receptors contain a small cysteine-rich extracellular domain, a single 
membrane spanning region and an intracellular kinase domain (ten Dijke and Arthur
2007). The kinase domain of the type II receptor is constitutively active and requires 
autophosphorylation of Ser213 and Ser409 for full kinase activity (Goumans et al. 
2009). The receptor can also autophosphorylate specific tyrosine residues (259, 336 
and 424) which may regulate its activity (Wrighton et al. 2009). Type I receptors act 
downstream of type II receptors and are phosphorylated by the type II receptors on 
specific serine and threonine residues within an intracellular region known as the GS 
domain as it is rich in glycine and serine residues (Bobik 2006; Goumans et al. 2009). 
This phosphorylation results in a conformational change which makes the L45 loop of 
the type I receptor accessible for binding of Smad proteins (Runyan et al. 2006). Two 
types of type I receptor exist- activin-like kinase-5 (ALK5) and ALK1 and these can 
often have opposing roles (see Section 1.9.3).
Proteins that interact with TGF-p receptors can positively or negatively regulate TGF- 
P signalling. The TGF-P receptor interacting protein (TRIP-1) binds to and becomes 
phosphorylated by the type II TGF-P receptor to inhibit TGF-p signalling (Wrighton 
et al. 2009). The TGF-p-related protein (TRAP-1) negatively regulates TGF-p 
receptor activation by binding to inactive type I receptors before being released upon 
receptor activation. Similar to this, the immunophilin FKBP12 binds to the type I 
receptor within the GS domain and is released on activation of type II TGF-P 
receptors. Disruption of FKBP12 and receptor interaction results in activation of 
receptors in the absence of ligand suggesting that the protein may safeguard against 
this (Runyan et al. 2006; Wrighton et al. 2009). In addition to receptor binding 
proteins, ligand binding proteins such as the type III TGF-P receptors endoglin and 
betaglycan can also regulate access to TGF-P receptors. These are abundant, 
transmembrane proteins that bind TGF-P with low affinity to facilitate signalling.
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Endoglin only interacts with TGF-(3 when it is complexed with the TGF-p receptor 
but binds the BMPs directly. Betaglycan will interact with TGF-P before it is 
presented to the TGF-P receptor complex (Goumans et al. 2009; ten Dijke and Arthur
2007).
1.8.3 Endocytosis of TGF-p receptors
Like the majority of cell surface receptors, activated TGF-P receptors are internalized 
through clathrin-dependent endocytosis. Clathrin-coated vesicles contain a number of 
positive regulators of TGF-p signalling including the Smad anchor for receptor 
activation (SARA) (Schmierer and Hill 2007; ten Dijke and Hill 2004). 
Internalisation receptors, gathered around clathrin coated pits on the cytoplasmic side 
of the plasma membrane, recognise a di-leucine-like internalization signal (Ile218, 
Ile219, Leu220) found within the TGF-P receptors and conserved amongst most cell 
surface receptors (Chen 2009). The pits undergo invagination and pinch off from the 
membrane to move to the early endosomes where the clathrin coat is shed and 
vesicles fuse with the endosome to release the TGF-p receptors. Receptors are 
recycled back to the surface in the absence of the ligand (Chen 2009).
Following TGF-p signalling, TGF-P and its receptors can be internalized through 
clathrin-independent endocytosis. Cholesterol and sphingolipid enriched lipid rafts 
are found in the plasma membrane and associate with calveolin which is able to 
interact with type I TGF-P receptors to disrupt their interaction with Smads (Chen
2009). Endocytosis through lipid rafts attenuates TGF-P signalling as the lipid rafts 
contain Smad-7, Smurfs 1 and 2 and E3 ubiquitin ligases to promote receptor 
degradation as explained in more detail in Section 1.11.4 (Lonn et al. 2009). The 
factors that determine how TGF-p receptors are internalised remains unclear.
1.8.4 Roles of TGF-P
TGF-P has roles in numerous cellular processes including inflammation, fibrosis, 
wound healing and cell growth which are discussed briefly below.
1.8.4.1 The role of TGF-/3 in immune and inflammatory responses
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The cytokine is recognised as a crucial negative regulator of the immune response and 
can control the threshold of activation for immune responses. The inhibitory role of 
TGF-P in the immune response was first recognised in the 1990s when mice deficient 
in the cytokine were found to display uncontrolled and widespread inflammation 
(Tedgui and Mallat 2006). Blockage of TGF-p signalling in T-lymphocytes using a 
dominant-negative form of the TGF-P type II receptor also results in inflammation 
spread across many organs (Li et al. 2006; Lutgens and Daemen 2001; Tedgui and 
Mallat 2006). Expression of MHC class II molecules by macrophages is down- 
regulated by the cytokine (Li et al. 2006). Inhibition of the co-stimulatory molecule 
CD40 by the cytokine is likely to impair the antigen presenting function of 
macrophages (Li et al. 2006). This would contribute to regulation of the immune 
response and may reduce secondary stimulation at sites of infection (Li et al. 2006). 
TGF-p can also inhibit the in vitro expression of LPS-induced inflammatory 
mediators including TNF-a, MMP-12 and the chemokines M IP-la and MIP-2. 
Down-regulation of nitric oxide expression and inhibition of nitric oxide synthase by 
the cytokine has important implications for resolving inflammation and preventing 
immunopathology (Li et al. 2006).
TGF-P also plays important roles in other cell types including B lymphocytes, T cells 
and platelets. The cytokine affects the survival and inhibits proliferation of both T 
cells and B lymphocytes and also has regulatory roles in activated leukocytes (Singh 
and Ramji 2006; Grainger 2007). The cytokine inhibits the development of CD4 and 
CD8 T cells into mature T cells and can inhibit the proliferation of T cells via a 
number of pathways including inhibition of interleukin-2 or the c-myc transcription 
factor (Li et al. 2006; Singh and Ramji 2006). The cytokine also inhibits the 
differentiation of T cells to inhibit the acquisition of Th cell functions and also 
inhibits T cell activation of cytotoxic T cells and induces activation of regulatory T 
cells which function to suppress immune responses (Li et al. 2006). The extensive 
roles of TGF-p in immune and inflammatory mechanisms is beyond the scope of this 
thesis but is excellently reviewed by Li et al, 2006.
1.8.4.2 TGF-p and fibrosis
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Overexpression of TGF-p under an organ specific promoter results in high levels of 
fibrosis in the target organ (Ghosh et al. 2005). TGF-p is the one of the most potent 
fibrogenic cytokines and excessive signalling via Smad-3 is thought to promote 
fibrogenesis (Ghosh et al. 2005). TGF-p promotes fibrosis through regulation of key 
components of the ECM. The cytokine can increase the synthesis of ECM proteins 
such as collagens, proteoglycans and fibronectin in a wide range of cell types (Ruiz- 
Ortega et al. 2007). The stimulation of TIMP expression and inhibition of collagenase 
production also contributes to the potent effects o f TGF-p on matrix accumulation and 
fibrosis (Ruiz-Ortega et al. 2007). The pro-fibrotic effects of the cytokine have linked 
it with pulmonary fibrosis. This disease is characterised by impaired lung function 
and respiratory failure, caused by chronic scar formation and deposition of 
extracellular matrix (Ghosh et al. 2005).
1.8.4.3 Role of TGF-p in wound healing
The actions of the cytokine on endothelial cells are important for its role in wound 
healing. The cytokine inhibits migration and cell cycle progression of endothelial 
cells (Kim et al. 2005). It is also an inducer of apoptosis (Kim et al. 2005). At low 
concentrations the cytokine is associated with the invasion of endothelial cells. This 
may be critical in the migration of cells associated with wound healing. Higher 
concentrations of the cytokine cause an inhibitory effect on endothelial cells and may 
facilitate movement of vascular smooth muscle cells to sites o f injury (Kim et al.
2005).
1.8.4.4 TGF-p and cellular growth and proliferation
TGF-p is a central mediator of growth inhibition in a range of cell types. Downstream 
targets of TGF-p signalling at the transcriptional level include the cyclin-dependent 
kinase inhibitor, p21cn>1, which prevents progression through the cell cycle (Kim et al.
2005). The cytokine can induce anti-proliferative responses during the cell cycle 
through down-regulation of c-myc or cdk responses. Overexpression of c-Myc can 
cause cells to become resistant to growth suppression mediated by the cytokine (Kim 
et al. 2005; Massague et al. 2000). The TGF-P signalling pathway is now recognized 
to have effects as a tumour suppressor pathway. Inactivation of type I or type II 
receptors underlies a wide range of pathologies including carcinogenesis (Kim et al.
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2005). In human colon and gastric cancers mutation of TGF-p type II receptors 
results in cells becoming resistant to TGF-p-mediated growth inhibition (Kim et al. 
2005; Massague et al. 2000). However, these cancers often have high levels of TGF- 
p secretion which may contribute to pathogenesis through local immuno-suppression 
of immune responses or through induction of new blood vessel growth (angiogenesis). 
The cytokine potently induces angiogenesis by increasing expression of VEGF and 
up-regulation of MMP-2 and MMP-9 expression resulting in an increase in 
degradation of extracellular matrix to promote endothelial cell invasion and migration 
(Kim et al. 2005; Massague et al. 2000).
1.9 TGF-p and atherosclerosis
1.9.1 Links between TGF-p and atherosclerosis
Evidence for the role of TGF-P in vascular biology was first proposed after studies in 
the balloon injured rat carotid artery, a model for neointima formation (Singh and 
Ramji 2006). Studies showed that levels of the cytokine were increased after the 
procedure and that overexpression or inhibition of the cytokine not only had effects on 
neointima formation but also on smooth muscle cell proliferation and extracellular 
matrix deposition (Singh and Ramji 2006). TGF-P is highly expressed in vascular 
cells of early stage fatty lesions and in more advanced atheroma and has been shown 
to have effects on all cell types present within lesions (Bobik 2006). Expression of 
the cytokine is higher in asymptomatic plaques (at both the mRNA and protein levels) 
and the cytokine accumulates in the shoulder regions of the plaque, in particular 
within macrophages and smooth muscle cells (Mallat et al. 2001; Singh and Ramji
2006).
Expression of TGF-P type I and type II receptors is higher in fatty streaks and 
decreases in more advanced lesions (Ramji et al. 2006; Singh and Ramji 2006). 
Expression profiles of TGF-p in lesions have revealed that lesional cells express type 
I TGF-p receptor at high levels whereas in the normal vessel wall, type II TGF-P 
receptors dominate (Grainger 2004; Lutgens and Daemon 2001). In vitro, type I
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expressing VSMCs show increased production of extracellular matrix in response to 
the cytokine while typell expressing VSMCs show no change in ECM production 
(Grainger 2004; Ghosh et al. 2005). It is therefore possible that excess levels of TGF- 
(3 maintain high levels of type II receptors allowing the vessel wall to retain normal 
differentiation and produce very little ECM. Changes in the expression of TGF-P can 
alter the ratio of type I and type II receptors. Inhibition of TGF-p in response to 
external factors switches the expression of receptors from type II to type I. This is 
accompanied by the increased proliferation, differentiation and migration of VSMCs 
into the intima, promoting lesion formation (Grainger 2004; Singh and Ramji 2006). 
Increases in endoglin and decorin accessory receptor have been associated with the 
disease but as these can act as positive or negative regulators of TGF-P signalling 
through either sequestering TGF-P into inactive pools or by facilitating formation of 
the active receptor complex it is difficult to interpret the meaning of these 
observations (Grainger 2007).
As detailed in Table 1.2, in vivo and in vitro studies have demonstrated the 
importance of TGF-P 1 in regulation of vascular cell proliferation, plaque stability, 
differentiation and roles in immune and inflammatory mechanisms, with many studies 
pointing to a protective role for the cytokine in atherosclerosis (Kim et al. 2005). In 
the early 1990s it was proposed that TGF-P helped to maintain the normal structure of 
the arterial wall thereby protecting against the development of atherosclerosis. This 
was termed the protective cytokine hypothesis (Grainger 2004).
Studies in human and animal models support a primarily anti-atherogenic role for 
TGF-p. Serum levels of the cytokine correlate inversely with the development of 
atherosclerosis, with low serum levels seen in more advanced cases of the disease 
(Grainger 2004). Low levels of the cytokine are also linked to advanced 
atherosclerosis in angina patients (Kim et al. 2005). Regions of the aorta prone to 
development of lesions (sites with low shear stress) display low levels of TGF-P 
expression and levels of the cytokine are reduced in leukocytes following myocardial 
infarction (Grainger 2007; Redondo et al. 2007). High levels of active TGF-p 1 have 
also been observed in patients with hypertension who have renal failure, end organ 
damage or obesity (Ghosh et al. 2005). The cytokine is thought to increase blood 
pressure by increasing peripheral resistance in the vascular wall through changes in
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the levels of vaso-active mediators such as nitric oxide and endothelin-1 (a 
vasoconstrictor) (Ghosh et al. 2005; Lutgens and Daemon 2001). An arginine 
polymorphism in the TGF-p 1 gene which causes increased production of the cytokine 
is associated with higher systolic blood pressure while other polymorphisms within 
the TGF-P 1 gene have also been associated with cardiovascular disease (Ghosh et al. 
2005; Kim et al. 2005). In contrast to these studies, the expression of TGF-P has also 
been demonstrated to be induced in vitro by shear stress and oxidised cholesterol and 
increased TGF-P expression is observed in clinical samples suggesting that the actions 
of TGF-P may be dependent on its bioavailability (Redondo et al. 2007). In support of 
this, human advanced atherosclerosis patients show increased levels of latent TGF-P 
and reduced levels of active TGF-P (Grainger 2007). Factors that may trigger 
suppression of TGF-p expression in the vessel wall remain poorly understood. One 
factor that is thought to contribute is the lipoprotein particle, Lp(a). Lp(a) is made up 
of two apolipoproteins, apo(a) and apoB, covalently bound to each other. Lp(a) can 
inhibit TGF-P activation in vitro and in vivo. Apo(a) has also been found to 
accumulate in regions where TGF-P activation is already suppressed forming a 
positive feedback loop at these sites (Grainger 2004).
TGF-P+/' mice fed a high cholesterol diet show higher levels of lipid retention and 
endothelial activation than controls and overexpression of TGF-p reduces 
atherosclerosis development (Grainger 2007). Targeted deletions of type I and II 
TGF-P receptors have demonstrated that loss of TGF-P signalling leads to abnormal 
vessel wall integrity and vascular structure; Embryos lacking these components die 
during gestation due to impaired vascular development (Goumans et al. 2009). Mice 
deficient in Smad-1, -2 or -4 present with pre-angiogenesis lethality and mice lacking 
Smad-3 die of impaired immunity (Goumans et al. 2009). Disruption of TGF-P 
signalling, using dominant negative forms of the receptor or neutralising antibodies to 
the cytokine, results in accelerated lesion formation, vascular inflammation and a 
tendency towards unstable plaques (Grainger 2007). Studies linking TGF-P with 
atherosclerosis are detailed in Table 1.2
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Table 1.2 Studies on TGF-p and atherosclerosis
Aspect of atherosclerosis Cell type or in vivo model Key findings Reference(s)
Atherosclerosis risk Atherosclerosis patients Serum levels of TGF-p are reduced in 
patients with advanced atherosclerosis.
Increased serum levels of TGF-P in 
atherosclerosis patients
Grainger et al. 1995 
Blann et al. 1996
Adhesion of monocytes to 
vascular endothelium
Porcine peripheral blood 
mononuclear cells
Human coronary artery 
endothelial cells
THP-1 monocytes and human 
blood monocytes
TGF-p decreases adhesiveness of the 
endothelium for monocytes.
TGF-P expression is decreased in response 
to oxLDL and this reduces expression of 
adhesion molecules.
TGF-p induced gene product (betaig- 
h3/TGFBIp integrin) is a chemoattractant 
for monocytes
Cai et al. 1991 
Chen et al. 2001
Kim and Kim 2008
Monocyte migration Differentiated U937 cells and 
human blood monocytes
Mouse RAW.264 macrophages
TGF-P inhibits the expression of the 
CD 11 b leukocyte integrin and its activator 
Rapl and their activation by chemokines 
reducing the migration of monocytes 
across a layer of endothelial cells.
Short-term exposure to TGF-p increases 
macrophage migration whilst long-term 
exposure inhibits macrophage migration. 
This change is mediated through inhibition 
of RhoA expression and through increases 
in expression of chemokines such as MIP- 
1 and MCP-1.
Basoni et al. 2005 
Kim et al. 2006
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Foam cell formation- 
Cholesterol uptake
Vascular cells and ApoE'^mice Cholesterol reduces the responsiveness of 
TGF-P in all vascular cells by increasing 
the accumulation of receptors in lipid rafts 
or caveolae and increasing degradation of 
TGF-p.
Chen et al. 2007
Vascular cells and ApoE ’7' mice Cholesterol reduces binding of TGF-P to 
its receptors to reduce TGF-P 
responsiveness
Chen et al. 2008
Foam cell formation- 
Cholesterol efflux
Human plasma TGF-p associates with and has higher 
levels of expression and bioactivity in 
high-density lipoproteins.
Tesseur et al. 2009
J774 murine macrophages TGF-p inhibits macrophage uptake of 
oxLDL to prevent accumulation of 
cholesterol esters and triglycerides. TGF- 
P also enhances cholesterol efflux through 
ABCA-1 and ABCG-1.
Argmann et al. 2001
Immune responses ApoE'^ mice Disrupted TGF-p signalling in T cells 
leads to accelerated atherosclerosis and 
increased activation of T cells.
Robertson et al. 2003
LDLR'7' mice Blockade of TGF-p signalling in T cells 
results in lesions that are smaller in size 
and have high levels of infiltrating T cells 
and MHC class II expression.
Gojova et al. 2003
ApoE'7' mice Elevated expression of TGF-p inhibits T 
cell responses and macrophage activation.
Zhou et al. 2009
Migration and proliferation of 
vascular smooth muscle cells
Rats with carotid balloon injury 
and vascular smooth muscle cells
Elevated expression of Smad-3 results in 
stimulation of VSMC proliferation by
Tsai et al. 2009
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TGF-p.
PAC-1 smooth muscle cells TGF-p induces the expression of SMC 
differentiation marker genes and this 
requires activation of p38 kinase and the 
RhoA-PKN pathway.
Deaton et al. 2005
Mouse VSMCs
TGF-p causes growth inhibition and 
inhibits proliferation of VSMCs and this 
requires activation of the p38 kinase 
pathway.
Seay et al. 2005
Human arterial vascular smooth 
muscle cells
TGF-p stimulates the production of 
proteoglycans by VSMCs.
Chen et al. 1987
Cultured rabbit aortic smooth 
muscle cells
TGF-P inhibits proliferation of SMCs 
during the G0/G1 stage of the cell cycle.
Morisaki et al. 1991
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Plaque stability ApoE'7' mice Overexpression of TGF-f3 reduces 
expression of pro-inflammatory cytokines 
and MMPs and limits plaque growth to 
increase plaque stability.
Frutkin et al. 2009
ApoE'7' mice Inhibition of TGF-P results in accelerated 
atherosclerosis development and plaques 
with reduced collagen content and higher 
inflammatory content which are 
characteristically unstable.
Mallat et al. 2001
Human carotid atherosclerotic 
plaques
TGF-p signalling is active in 
atherosclerotic plaques. Higher levels of 
endoglin and early growth factor-1 
correlate with increased smooth muscle 
cell and collagen expression associated 
with a stable plaque phenotype.
Bot et al. 2009
Human atherosclerotic plaques Levels of TGF-p are higher in 
asymptomatic plaques and is associated 
with a increase in collagen content.
Cipollone et al. 2004
ApoE'7' mice Inhibition of TGF-p signalling using 
recombinant soluble TGF-p receptor II 
resulted in decreased size of plaques with 
decreased fibrosis and increased 
inflammatory and lipid content.
Lutgens et al. 2002
Human coronary artery 
atherosclerotic plaques
Immunohistochemical staining shows that 
TGF-P is expressed at higher levels in 
stable plaques whilst expression of MMP- 
9 is higher in unstable plaques.
Jiang et al. 2004
51
CHAPTER I: Introduction
Human aortic vascular smooth PPARdelta regulates ECM turnover Kim et al. 2009
muscle cells through increased expression of collagen
and inhibition of VSMC apoptosis in
response to oxLDL. This is mediated
through TGF-p and Smad-3.
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1.9.2 Actions of TGF-p on monocytes/macrophages in atherosclerosis
TGF-p has opposing stimulatory and inhibitory effects on monocytes and 
macrophages. A pro-inflammatory role for TGF-P in monocytes is supported by 
several studies. The cytokine is a potent chemoattractant for monocytes to facilitate 
their recruitment to the site of injury and inflammation (Ghosh et al. 2005; Li et al.
2006). The cytokine enhances the expression of integrins such as lymphocyte 
function-associated antigen-1 (LFA-1) and the fibronectin receptor to assist with 
monocyte attachment to the endothelial wall by interacting with ICAM-1 which 
mediates binding to fibronectin and collagen (Ashcroft 1999). Migration of 
monocytes is enhanced by the cytokine through the induction of MMP-2 and MMP-9 
expression (Ashcroft 1999; Ghosh et al. 2005).
On monocyte-macrophage differentiation the expression of TGF-P is down-regulated 
and exhibits anti-inflammatory actions including the inhibition of pro-inflammatory 
genes including IL-1, IL-6, MCP-1 and MIP-1 and induction of anti-inflammatory 
cytokine IL-10 expression (Ashcroft 1999). The cytokine protects macrophages from 
apoptosis by stimulating ERK and attenuates macrophage activation by reducing 
iNOS expression through Smad3 (Werner et al. 2000). Macrophages produce 
inflammatory mediators and present antigens to T cells as part o f the adaptive immune 
response. They also function to clear apoptotic cells and microbes by phagocytosis. 
It has been reported that phagocytosis of apototic cells can induce the secretion of 
TGF-P resulting in inhibition of expression of chemokines and pro-inflammatory 
cytokines (Li et al. 2006).
Many of the actions of TGF-p on macrophages inhibit foam cell formation (Mallat et 
al. 2001; Singh and Ramji 2006). Foam cell formation can be viewed as an imbalance 
between cholesterol uptake and efflux leading to cholesterol accumulation by 
macrophages (Sections 1.3 and 1.4). TGF-p reduces levels of cholesterol esters and 
triglycerides in macrophages by several mechanisms. Reduced uptake of lipoproteins 
is associated with decreased expression and activity of both LPL and the LDL 
receptor while uptake o f oxidised lipoproteins can be reduced via inhibition of 
scavenger receptor expression (Mallat et al. 2001; Singh and Ramji 2006). In addition
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to inhibiting the expression of genes implicated in cholesterol uptake, the cytokine 
induces the expression of genes involved in macrophage cholesterol efflux including 
apoE and ABCA-1 (Table 3.1). The actions of TGF-P on genes involved in 
cholesterol uptake and efflux and implications on foam cell formation are discussed in 
more detail in Chapter 3 of this thesis. This reduction in foam cell formation has been 
demonstrated in cultured macrophages and in apoE'7' mice where the presence of the 
cytokine prevents deposition of lipids within the intima (Grainger 2004).
1.9.3 Actions of TGF-P on VSMCs and endothelial cells in atherosclerosis
Formation of advanced atherosclerotic plaques is characterised by the migration and 
proliferation of smooth muscle cells and their subsequent production of extracellular 
matrix. TGF-p is a potent enhancer of both matrix deposition and collagen synthesis 
and inhibits the migration and proliferation of smooth muscle cells (Grainger 2004; 
Singh and Ramji 2006; Yokote et al. 2006). This contribution to fibrous cap 
formation and reduction of inflammation in the plaque promotes a stable plaque 
phenotype and the cytokine therefore has an important protective role in the 
development of atherosclerosis (Kim et al. 2005; Mallat et al. 2001).
In VSMCs TGF-P can attenuate activation by opposing the effects of pro- 
inflammatory cytokines and mitogenic growth factors as well as the expression of 
genes involved in vascular remodeling (Goumans et al. 2009). Activation of the 
expression of a2 type I collagen and inhibitor of metalloproteinase-1 is Smad-3 
dependent (Bobik 2006). Signalling through Smad3 also prevents activation of SMCs 
by cytokines by binding to the CCAT/enhancer binding protein-P (Bobik 2006; 
Feinberg et al. 2004). Synthesis of VEGF is regulated through interactions which lead 
to p38MAPK activation (Bobik 2006). Differentiation of VSMCs is promoted by 
TGF-P by inducing a set of differentiation marker genes. At least one of these genes 
(the induction of SM22a actin) is known to be mediated through Smad-3 (Bobik
2006). The cytokine also inhibits growth of VSMCs through a Smad-3 and p38 
kinase dependent mechanism (Feinberg et al. 2004; Goumans et al. 2009). Migration 
of VSMCs is also inhibited but through a Smad-independent pathway by up- 
regulation of cysteine-rich protein 2 expression through the recruitment of the 
transcription factor ATF-2 (Lin et al. 2008). SMCs within fibrous plaques also
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express Smads which are not present in fatty lesions suggesting that TGF-P-mediated 
increase in collagen is only present in more advanced plaques. In ApoE- ' mice, a 
TGF-P neutralising antibody reduces collagen content by 50% and this is associated 
with reduced Smad-2 activation and increased lesion size, supporting a role for TGF-p 
in collagen production in lesions (Kalinina et al. 2004).
The cytokine regulates interaction between VSMCs and ECs. On interaction, 
production of TGF-P by ECs promotes differentiation of VSMCs while TGF-P 
produced by VSMCs stimulates VEGF to promote EC growth and differentiation 
(Bobik 2006; Goumans et al. 2009; ten Dijke and Arthur 2007; ten Dijke and Hill 
2004). In endothelial cells, TGF-P can have contrasting actions depending on the 
receptor pathways used for signalling. For example, signalling through ALK5 inhibits 
migration and proliferation of ECs and also induces PAI-1 which contributes to the 
inhibition o f EC migration. Signalling through ALK1 stimulates migration and 
proliferation of ECs through association with caveolin (a membrane protein involved 
in endocytosis). The two pathways can interact in ECs to regulate EC function. 
ALK5 is required for recruitment of ALK1 to the receptor complex whilst ALK1 is 
able to antagonise ALK5 signalling (Bobik 2006; Goumans et al. 2009; ten Dijke and 
Arthur 2007; ten Dijke and Hill 2004).
1.10 TGF-p-Smad signalling
1.10.1 The Smad signalling pathway
Smads are named after orthologs in C. elegans and Drosophila, known as Sma and 
Mad respectively. There are 8 Smad proteins, 42-60kDa in size (Heldin et al. 1997). 
Smads 1, 2, 3, 5 and 8 are receptor-regulated Smads (R-Smads) that interact with the 
TGF-P receptor complex. Smad-4 is a common mediator Smad (Co-Smad-4) that 
facilitates transport of Smads to the nucleus and Smads-6 and -7 are inhibitory Smads 
which negatively regulate TGF-P signalling. Smad proteins have a conserved 
structure consisting of two Mad-homology domains; an MH1 domain linked to an 
MH2 domain by a less conserved, proline-rich linker region (Bobik 2006; Ross and
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Hill 2008; Schmierer and Hill 2007). The MH2 domain of Smad-2 has been analysed 
by crystallography and is made up of anti-parallel (3-sheets capped at one end by three 
a-helices and at the other end by a loop/helix region consisting of three loops and an a 
helix (Heldin et al. 1997).
R-Smads are recruited to and phosphorylated by the TGF-P type I receptor. ALK4, 5 
and 7 activate Smad-2 and -3 in response to TGF-P stimulation while ALK1, 2, 3 and 
6 mediate activation of Smads -1, -5 and -8 in response to BMPs (Bobik 2006; 
Goumans et al. 2009). The type I receptor phosphorylates the R-Smad on two serine 
residues in the C-terminus. A positively charged pocket within the L3 loop of the 
MH2 domain of the R-Smad is essential for docking to the activated TGFpRI and is 
also required for binding to other Smad subunits (Ross and Hill 2008; ten Dijke and 
Arthur 2007; ten Dijke and Hill 2004). Binding of R-Smads to the type I receptor is 
facilitated by SARA. SARA contains a Smad binding domain that interacts with the 
pi strand of the MH2 domain of Smad proteins to control the location of Smads 
following TGF-P stimulation. The C-terminal domain o f SARA interacts with the 
TGF-P receptor to aid the receptor-Smad interaction (Runyan et al. 2006; ten Dijke 
and Hill 2004; Wrighton et al. 2009). The TRAP-1-like protein (TLP) is another 
positive regulator of TGF-p-Smad signalling. TLP is able to associate with active and 
inactive receptors (predominantly type II receptors) and in response to TGF-p is able 
to interact with Smad-4. Overexpression of the protein disrupts Smad complex 
formation (Runyan et al. 2006; Wrighton et al. 2009). TLP may differentially 
regulate Smad-2 and Smad-3 responses as overexpression of the protein blocks Smad- 
3 responses and potentiates Smad-2-mediated responses (Felici et al. 2003). Other 
receptor-interacting proteins that may be involved in the positive regulation of Smad 
signalling include the chaperone protein Hsp90 which stabilises TGF-p receptors and 
prevents them from becoming targeted for degradation (Wrighton et al. 2009). The 
Dab2 protein has been demonstrated to associate with Smad-2 and -3 in response to 
TGF-p and expression of this protein in a TGF-P-deficient cell line restores the 
activity of Smad-2 (Runyan et al. 2006).
R-Smads form complexes with co-Smad4 and other Smad subunits to translocate to 
the nucleus to regulate transcription of target genes. Smad complexes are formed 
through the binding of Smads to phosphorylated serines in the SXS motif in the C-
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terminus of adjacent Smads. This also ensures that on complex formation, Smads are 
released from the type I receptor (Goumans et al. 2009; Ross and Hill 2008; ten Dijke 
and Hill 2004). The Smad signalling pathway is summarised in Figure 1.2 Recently, 
it has been demonstrated that some TGF-P responses can be mediated in a Smad-4 
independent manner. Smad-4 deficient murine ES cells show no change in the TGF-P 
induced regulation of a subset of ECM genes and no change in the TGF-P regulated 
growth inhibition of fibroblasts, suggesting that signalling can be mediated through 
complexes lacking Smad-4 or may be Smad-independent (Sirard et al. 2000; ten Dijke 
and Hill 2004).
Type II Type I
Receptor Receptor
Transcription Factor
C o ac tiva to r
Target G enes \-
► Activation 
Or
H Repression
Figure 1.2 The Smad signalling pathway. On activation of the TGF-P receptor 
complex by TGF-P binding, the receptor-regulated Smads become phosphorylated by 
the type I receptor. Active Smads form complexes with Smad-4 to translocate to the 
nucleus where they can regulate gene transcription through binding to Smad binding 
elements within the promoter of target genes or through interaction with other 
transcription factors. For more details refer to text. Figure taken from Liu (2003).
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TGF-P receptors. If the receptors are active Smads are re-phosphorylated and move 
back to the nucleus, if  not low-level de-phosphorylation occurs and Smads move back 
to the cytoplasm. Fluorescence and GFP-fusion Smad proteins have demonstratec 
that in epithelial cells, TGF-P-stimulated nuclear accumulation of Smad-2, -3 and - A  
reaches a maximum 45min after cytokine addition and Smads remain in the nucleuj 
for at least 4-5h after which they slowly return to the cytoplasm at a rate that mirrors 
receptor inactivation (Hill 2009; ten Dijke and Hill 2004).
The exact mechanism of Smad translocation to the nucleus is unclear. Import anc 
export may be determined by each other where monomeric Smads are preferentially 
exported and complexed Smads are preferentially imported (Hill 2009). Similar t( 
this idea, the involvement of retention factors in Smad shuttling has also beer 
suggested where monomeric Smads have a high affinity for cytoplasmic retentioi 
factors such as SARA whilst complexed Smads have a high affinity for nuclea] 
retention factors. Various studies have suggested the involvement of nuclear transpon 
proteins and/or interactions between Smad complexes and nucleoporins of the nucleai 
pore (Hill 2009; ten Dijke and Hill 2004).
Binding sites for nucleoporins have been identified in Smad proteins within the MH2 
domain. Interestingly, these overlap with binding sites for SARA and for the Smad 
interacting m otif (SIM) which suggests that interactions between Smads and cellular 
components may be exclusive and work in a competitive manner to move Smads to 
the nucleus (ten Dijke and Hill 2004). A lysine-rich NLS sequence (KKLKK) in the 
MH1 domain is conserved in all R-Smads and mutation of this sequence prevents 
nuclear accumulation of Smads in response to TGF-p. In Smad-3 the NLS mediates 
nuclear import by binding to importin-pi and importin-a is not used. Smad-4 nuclear 
import uses both importin-a and -pi as its NLS extends into the DNA-binding region
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of the MH1 domain to allow interaction with importin-a. In Smad 2 the NLS motif is 
non-functional due to an insert located close to it which is likely to impair its binding 
to importin (Hill 2009).
Nuclear export of Smads relies on de-phosphorylation. So far, the protease PPM1A 
has been identified as being able to de-phosphorylate the SXS C-terminal motif of 
Smad-2 and -3 to facilitate their export to the cytoplasm. This interaction may 
involve phosphatase and tensin homolog (PTEN). Indeed Smad-2 and -3 
phosphorylation is negatively correlated with the expression levels of both PPM1A 
and PTEN. Overexpression of PPM 1A abolishes Smad-2 and -3 phosphorylation and 
shRNA-mediated knockdown of PPM1A enhances the duration of Smad 
phosphorylation and subsequent TGF-P-mediated responses (Itoh and ten Dijke 2007; 
Wrighton et al. 2009). It is likely that de-phosphorylation results in the dissociation 
of R-Smads from Smad-4 and that the two are exported by different mechanisms. 
Smad-4 contains a nuclear export signal (NES) within its linker region that is required 
for the binding of the nuclear exporter CRM1 (also known as exportin-1). Both of 
these components are required for nuclear export of Smad-4. Export of Smad-2 and - 
3 is independent of CRM1 but is likely to require other transport proteins such as 
exportin-4 which has been demonstrated to be required for export of Smad-3 (Hill 
2009; ten Dijke and Hill 2004).
1.10.3 How Smads control gene transcription
Smad complexes control gene expression in a cell-type and ligand concentration- 
dependent manner. In Smad-3 and -4, direct contact to DNA is made through an 11- 
residue (3-hairpin loop. It contacts the Smad binding element (sequence 5’-AGAC- 
3’). Smad -2 has an additional sequence N-terminal to this loop to prevent direct 
contact with DNA so binds DNA through Smad-4 (ten Dijke and Hill 2004; Wrighton 
and Feng 2008). Smads themselves have a low affinity for binding to DNA. Due to 
this, Smads recruit other factors such as co-activators and co-repressors that are able 
to bind specific sequences within target promoters to signal specificity and facilitate 
the binding of other transcription factors (Schmierer and Hill 2007).
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A large number of Smad interacting proteins have been identified. The first Smad 
interacting transcription factor identified was the FastXl, a member of the Xenopus 
FoxHl transcription factor family. FastXl contains a Smad binding domain in its C- 
terminus and interacts with complexes of Smad-2 and -4 (ten Dijke and Hill 2004). 
The identification of other interacting factors has led to the identification of a 
common Smad interacting motif (SIM) which is rich in proline residues and shares 
similarity to the SBD of SARA and binds to the MH2 domain in the same way. One 
important difference between the two is that the SIM is shorter than the SBD and 
docks away from Smad interaction interfaces meaning that it binds equally well to 
monomeric and complexed Smads whereas the SBD of SARA binds with higher 
affinity to monomeric Smads (ten Dijke and Hill 2004)
Target genes are positively regulated through interaction with histone acetylases 
(HATs) such as CBP/p300. The addition of an acetyl coA to lysine residues in the 
Smad protein is TGF-p dependent. Interestingly, acetylation of Smad-2 is higher than 
Smad-3 suggesting that acetylation functions to improve Smad-DNA binding. 
Interaction between Smads and HATs is also thought to reduce nuclear export. 
CBP/p300 acetylates Smad-2 on lysines 19, 20 and 39 in the MH1 domain of Smad-2 
and lysine 19 in the MH1 domain and lysine 378 in the MH2 domain of Smad-3 (Itoh 
and ten Dijke 2007; Ross and Hill 2008; Wrighton and Feng 2008). Another co­
activator that has been demonstrated to interact with Smad proteins is P/CAF. This 
was discovered through its association with p300/CBP and like p300 has intrinsic 
HAT activity. The co-activator has been associated with the control of differentiation 
and growth inhibition. P/CAF interacts directly with Smad 3 on activation of the type 
I TGF-p receptor, in cultured mammalian cells. The co-activator has also been shown 
to enhance transcriptional responses mediated by the TGF-p/Smad3 pathway. 
p300/CBP further enhances these responses suggesting that the two co-activators may 
work cooperatively (Itoh and ten Dijke 2007).
Negative regulation of Smad target genes occurs through the recruitment of Smad co- 
repressors c-Ski and SnoN. In the absence of TGF-p, these bind to Smad binding 
elements in the promoters of target genes in a Smad-4 dependent manner and inhibit 
the basal expression of target genes through the recruitment of histone deacetylases 
(HDACs). HDACs remove acetyl groups from the lysine residues of histones to
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increase their positive charge and promote high affinity binding with negatively 
charged DNA. TGF-p rapidly induces the degradation of c-Ski and SnoN to allow 
Smad complexes to interact with Smad binding elements. In addition to this, SnoN 
has been demonstrated to block the recruitment of co-activators to Smads and to block 
the formation of Smad complexes (Itoh and ten Dijke 2007; Ross and Hill 2008; 
Schmierer and Hill 2007).
1.10.4 Negative regulation of Smad signalling
Smad signalling is negatively regulated by Smad-6 and -7 also known as the 
inhibitory Smads (I-Smads). Smad-6 and -7 negatively regulate BMP and TGF-p 
signals respectively and of these, Smad-7 is the best studied. Smad-6 and -7 
antagonise TGF-P-Smad signalling by competing with R-Smads for binding to the 
type I receptor and preventing their phosphorylation. The structure of Smad-6 and -7 
is conserved within the MH2 domain, allowing them to bind to the TGF-P receptor, 
but show only limited similarity to other Smads in their MH1 domain (Schmierer and 
Hill 2007; ten Dijke and Hill 2004). The I-Smads are target gene for TGF-P so acts in 
a negative feedback loop to regulate TGF-P signalling. The I-Smads bind to TGF-P 
receptors to mediate their ubiquitination and subsequent targeting for degradation 
(Bobik 2006; Goumans et al. 2009). They can also carry phosphatase enzymes and 
disrupt interactions between Smads and receptors and also between R-Smads and 
Smad-4 to disrupt complex formation. (Lonn et al. 2009) Interaction of I-Smad and 
the type I receptor is stabilised by the serine-threonine kinase receptor associated 
protein (STRAP) (Runyan et al. 2006).
I-Smads recruit E3 ubiquitin ligases known as Smad wbiquitination regulatory factor-1 
and -2 (Smurf-1, and -2) within the nucleus. Smurf-1 binds Smads-1 and -5 whilst 
Smurf-2 has a broader specificity (Itoh and ten Dijke 2007; Ross and Hill 2008; 
Wrighton and Feng 2008). On binding to the TGF-P type I receptor, both the receptor 
and Smad-7 are ubiquitinated by the Smurf and targeted for degradation (Lonn et al. 
2009). Ubiquitin is a 76 amino acid polypeptide that covalently attaches to lysine 
residues of a target protein. Ubiquitination is a three step process. Ubiquitin is 
covalently attached to lysine residues using El ubiquitin activating and E2 ubiquitin 
conjugating enzymes. The formation of ubiquitin chains linked from lysine residues
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to the C-terminal glycine residue of ubiquitin is catalysed by E3 ubiquitin ligases. 
Polyubiquitination can take place as ubiquitin itself contains lysine residues to which 
more ubiquitin molecules can attach. This targets the protein to the 26S proteosome 
for degradation where the Smurf protein is also degraded (Lonn et al. 2009; Ross and 
Hill 2008; Wrighton et al. 2009).
Following TGF-p signalling, levels of Smurf-2 interaction with and ubiquitination of 
Smad-2 are enhanced (Lonn et al. 2009). Ubiquitination and degradation of Smad-2 
requires Smurf-like proteins such as NEDD4-2 (neural precursor cell expressed, 
developmentally down-regulated 4-2)and W WPl/Tiull (WWP domain protein-1) 
which are activated by TGF-p and binds to Smad-2 (Itoh and ten Dijke 2007; 
Wrighton and Feng 2008). Although Smurfs are able to bind to Smad-3, it is not 
directly affected by Smurf interaction. Instead, Smad-7 induces the degradation of the 
co-repressor SnoN which interacts with the Smad-3-Smurf complex to disrupt it 
(Lonn et al. 2009; Wrighton and Feng 2008). Smad-4 can be ubiquitinated but 
requires R-Smads and TGF-p receptors to act as bridging proteins to mediate Smurf 
interaction (Ross and Hill 2008). The MH1 domain of Smad-4 can also become 
modified through the attachment of the small ubiquitin-related modifier (SUMO) to 
lysine residues which alters the transcriptional activity and stability of Smad-4 and 
has also been demonstrated to enhance its retention in the nucleus (Ross 1999; 
Wrighton and Feng 2008).
1.11 Smads and atherosclerosis
Relatively little is known about the roles of Smads in relation to atherosclerosis 
although as classical mediators of the TGF-p response they are likely to be central to 
many of the TGF-P-regulated effects observed in the vasculature during 
atherosclerosis. Smad signalling is reduced by shear stress through increased levels of 
I-Smad expression (Redondo et al. 2007). However, Smads are highly expressed in 
macrophages (and subsequent foam cells) of early lesions and smooth muscle cells of 
more advanced lesions (Kalinina et al. 2004). This expression profile supports the 
influence of TGF-P on macrophage foam cell formation and inflammatory responses. 
Smads are not expressed or are expressed at low levels in the smooth muscle cells of 
early lesions suggesting that enhanced collagen production characteristic in more
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advanced, fibrous plaques, is impaired in early lesions (Kalinina et al. 2004). Smads 
have been implicated in a number of TGF-P-regulated responses in the vasculature 
including the induction of connective tissue growth factor (CTGF) expression, the 
production of ECM by VSMCs (Fu et al. 2003) and the inhibition of MMP-12 and 
iNOS, markers of macrophage activation (Werner et al. 2000). Smads have been 
demonstrated to be involved in the TGF-P-regulated induction of proteoglycan 
synthesis and subsequent binding to LDL in VSMCs (Dadlani et al. 2008). Knockout 
of Smad-3 in C57B1/6 mice suggests a role for Smad-3 in TGF-p-regulated inhibition 
of neointimal VSMC hyperplasia. Loss of Smad-3 demonstrated roles for the protein 
in the induction of a2 type I collagen and suppression of MMPs during the vascular 
response to injury (Kobayashi et al. 2005).
1.12 Non-Smad signalling
Although TGF-P classically signals through the Smad pathway it is able to activate 
other cellular signalling pathways to regulate target gene transcription. Of these the 
mitogen-activated protein kinases (MAPKs) are the best described and activation of 
these pathways by the cytokine has been demonstrated in a number o f cell types.
1.12.1 Mitogen-activated protein kinase signalling pathways
Five distinct groups of mitogen-activated protein kinases (MAPKs) have been 
identified to date; extracellular-signal regulated kinases 1 and 2 (ERK1/2), c-Jun N- 
terminal kinases (JNK)/stress-activated protein kinases (SAPK), p38 kinase isoforms 
(a, p, y, 8), ERK3 and ERK5. The best characterised of these are the vertebrate 
ERK1/2, JNK and p38 kinase pathways (Chang and Karin 2001; Johnson and Lapadat 
2002). Similar to other protein kinases, the MAPKs consist of small N-terminal and 
large C-terminal domains connected by a linker region. Substrates bind at the surface 
while ATP is able to bind in a deep pocket at the interface between the two domains. 
Two phosphorylation sites are located in a surface loop known as the activation loop 
close to the activation site. In the unphosphorylated (inactive) state the substrate 
binding site is partially blocked but on phosphorylation (activation) of the MAPK this 
moves to help form the correct binding surface for the substrate (Cobb 1999).
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MAPKs require phosphorylation on both a threonine and a tyrosine residue to become 
active. All MAPKs share a Thr-Xxx-Tyr phosphorylation motif, (where X is glutamic 
acid, proline, and glycine, for ERK, JNK and p38 respectively) located close to the 
ATP and substrate binding sites of the kinase (Bardwell 2006; Cobb 1999). MAPKs 
are phosphorylated by dual-specificity (serine/threonine-tyrosine) kinases known as 
MAPK kinases (MKKs) and this increases their activity by approximately 5000-fold 
(Cobb 1999). Phosphorylation of MAPKs enhances homodimerisation to produce 
symmetrical dimers of each of the MAPKs. Following activation MAPKs accumulate 
in the nucleus but the exact mechanism of nuclear import and export of MAPKs is 
unclear (Bardwell 2006; Cobb 1999).
Phosphorylation of MAPKs happens in a sequential manner where phosphorylation of 
the tyrosine residue is followed by threonine phosphorylation, with the MKK 
disassociating from the MAPK between each step (Harlaar and Brown, 1999). The 
specificity of the phosphorylation motif allows specific activation of MAPKs by 
particular MKKs. ERK is activated by MKK1, and MKK2, JNK is activated by 
MKK4 and MKK7 while p38 can be activated by MKK3, MKK4 or MKK6 (Bardwell 
2006; Hommes et al. 2003; Johnson and Lapadat 2002).
In turn, the activity of the MKKs is controlled through phosphorylation by MAPK 
kinase kinases (MKKKs). MKKKs phosphorylate MKKs on activation by external 
stimuli. Little is known about the regulation of the MKKKs and they are numerous in 
number, adding both diversity and complexity to MAPK signalling (Hommes et al. 
2003; Johnson and Lapadat 2002). The MAPK cascades are summarised in Figure 
1.3. The MAPK cascades can be regulated by ligands of the receptor tyrosine kinases 
through binding of adaptor molecules (e.g. Grb2 and She) to phosphorylated receptor 
tyrosine kinases. Adaptor molecules interact with the guanine nucleotide exchange 
protein Sos through their SH3 domains and Sos enhances binding of GTP to Ras 
which is then in turn able to bind to Raf and other MKKKs to initiate the MAPK 
cascades (Cobb 1999; Wrighton et al. 2009). Adaptor molecules may also allow 
crosstalk between different signalling pathways.
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Figure 1.3 The MAPK signalling pathways. MAPKs are phosphorylated by 
MKKs which in turn are phosphorylated by MKKKs. Numerous MKKKs can be 
activated by a number of stimuli including cytokines, growth factors and cellular 
stress. For more details refer to text. Figure taken from Waldburger and Firestein 
(2009).
Activation of the MAPKs through this cascade allows the phosphorylation and 
activation of transcription factors and other kinases to regulate the expression of target 
genes (Hommes et al. 2003). MAPKs are serine/threonine proline-directed kinases 
and phosphorylate the serine or threonine residue within a S/T-P motif (also known as 
a phosphoacceptor site). However, this minimal target site is present within over 80% 
of proteins and so is by itself not enough to determine selectivity and specificity. 
Specificity may be enhanced by regions known as docking sites which are present on 
MAPK-interacting proteins and act to bind MAPKs and promote transactions such as 
MAPK-mediated substrate phosphorylation. These docking sites consist of a cluster 
of basic residues followed by a spacer region and several hydrophobic residues. In 
addition to this, scaffold proteins often play a key role in the specificity of MAPK 
signalling by binding to components of the MAPK pathways (Bardwell 2006; Chang 
and Karin 2001).
65
CHAPTER 1: Introduction
MAPKs are inactivated by the removal of one or both phosphates by MAPK 
phosphatases (MKPs) (Chang and Karin 2001; Cobb 1999). These are dual 
specificity phosphatases that also display specificity towards individual MAPKs. 
MKPs are located in the nucleus and blockage of MKP expression enhances the 
duration of MAPK activation. Other phosphatases such as phosphoprotein 
phosphatase 2A (PP2A) are also able to inactivate the MAPKs (Bardwell 2006; 
Chang and Karin 2001; Cobb 1999).
1.12.2 Extracellular signal-regulated kinases
The ERK pathway was the first MAPK pathway to be characterised. The pathway is 
a key regulator in a number of cellular responses such as cell growth, proliferation and 
survival. Although a number of ERK isoforms have been identified, only ERK1 and 
ERK2 are ubiquitously expressed (Hommes et al. 2003). ERK 1 and 2 are activated 
by a number of stimuli including cytokines, growth factors and ligands for G-protein 
coupled receptors. ERK 1 and 2 (or p44/42) are phosphorylated by either MEK1 or 
MEK2 and these are phosphorylated by the Raf proteins including cRafl, B-Raf and 
A-Raf. Interestingly, the Raf proteins can be activated by the protooncogene Ras 
which is activated in many human tumours and induces the proliferation of tumour 
cells, so linking the ERK pathway with cancer (Johnson and Lapadat 2002). The 
duration of ERK activity can be modulated through removal of one or both phosphate 
groups from the MAPK. Transcription factors phosphorylated by ERK include but 
are not limited to Elk-1, c-Jun, c-Fos (AP-1) and ATF-2 (Hommes et al. 2003).
1.12.3 c-Jun N-terminal kinases
The JNKs were characterised as stress-activated protein kinases on the observation 
that they became activated in response to inhibition of protein synthesis. The JNK 
pathway is activated in response to cellular stress and cytokines and is primarily 
involved in the regulation of cell proliferation and apoptosis (Barr and Bogoyevitch 
2001; Hommes et al. 2003). Three isoforms of JNK are formed by three genes JNK- 
1, JNK-2 and JNK-3. Disruption of the three JNK genes in mice results in defective 
stress-induced apoptosis and impaired immune responses. Each JNK is expressed as a
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short form (46kDa) and a long form (55kDa) and of the three isoforms, JNK1 and 
JNK2 are ubiquitously expressed (Barr and Bogoyevitch 2001; Hommes et al. 2003). 
JNK can be activated by the upstream regulators MKK7 which is activated by 
cytokines such as TNF and IL-1 and MKK4 which is activated by stress. Regulation 
of JNK is complex and more than 13 MKKKs are able to activate the kinase 
(Hommes et al. 2003). The duration of strength of JNK activation is dependent on the 
balance between external stimuli and inactivation of the cascade. To date, four 
negative JNK regulatory factors have been identified; namely, MAPK phosphatase 
MKP7, heat shock protein 72, nitric oxide and evil oncoprotein. JNK phosphorylates 
two components of the AP-1 complex, c-Jun and ATF-2 (Hommes et al. 2003). The 
AP-1 transcription complex which regulates the expression of many cytokine genes 
and is activated in response to environmental stress and other factors that also activate 
JNKs (Johnson and Lapadat 2002). c-Jun is post-translationally activated by JNK 
through phosphorylation of Ser63 and Ser73 in the N-terminal domain. JNK also 
activates ATF-2 which heterodimerises with c-Jun to stimulate its expression (Barr 
and Bogoyevitch 2001).
1.12.4 p38 kinases
Like the ERK and JNK pathways, the p38 kinase pathway is associated with 
inflammation, cell growth, differentiation and death. The p38 kinases were first 
discovered during a screen for drugs inhibiting TNF-a-mediated inflammatory 
responses (Hommes et al. 2003; Johnson and Lapadat 2002). The p38 kinases are 
activated by a large number of inflammatory cytokines and growth factors in 
inflammatory cells (including TGF-p, TNF-a, IL-1, and IL-17) in addition to ligands 
for G-protein coupled receptors, hormones, and environmental stresses such as heat 
shock, pathogens, UV and oxygen radicals (Hommes et al. 2003; Johnson and 
Lapadat 2002). p38 was isolated as a 38kDa protein and four isoforms have been 
identified. p38a, P and 5 are ubiquitously expressed while p38y is predominantly 
expressed in skeletal muscle. In inflammatory cells such as macrophages, p38a is the 
major isoform activated. The kinase is activated by MKK6 and MKK3 although it is 
MKK6 that is able to activate all four isoforms whilst MKK3 preferentially activates 
a, y and 5 (Herlaar and Brown 1999; Ono and Han 2000). Downstream kinases such 
as MK2 or transcription factors such as ATF-2 are downstream targets of p38. The
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p38 pathway promotes translation of proteins involved in the inflammatory response 
through AU-rich elements in the 3’-untranslated region of their mRNAs. These are 
often present in mRNAs of cytokines and inflammatory proteins. For example, the 
MAPK is able to regulate production of the TNF-a protein and inhibition of p38 in 
macrophage cell lines significantly reduces protein levels of TNF-a. Other proteins 
whose production is dependent on p38 include IL-1, MCP-1, VEGF and iNOS 
(Saklatvava 2004). p38 activation predominantly results in the production and
activation of inflammatory mediators to initiate leukocyte recruitment (Herlaar and 
Brown 1999; Hommes et al. 2003).
1.12.5 MAPK and TGF-p-mediated responses
TGF-p activation of the ERK pathway was first suggested by studies in rat intestine 
and mink lung epithelial cells which demonstrated rapid activation of p21 (Ras) by the 
cytokine. ERK activation by TGF-p has subsequently been demonstrated in a number 
of cell types (Zhang 2009). One of the mechanisms by which TGF-P is able to induce 
the ERK pathway is through the activation of tyrosine kinase signalling pathways. 
Both the type I and type II receptors for TGF-p are phosphorylated on tyrosine 
residues following ligand stimulation. The type II receptor for TGF-P is 
autophosphorylated on three tyrosine residues (259, 336 and 424) and can also 
become phosphorylated at tyrosine 284 by Src which bridges TGF-P and MAPK 
activation by acting as a docking site for Grb2 and She recruitment. The type I 
receptor can recruit and phosphorylate ShcA to promote the formation of a Grb2/Sos 
complex which can activate Ras and Raf proteins which link receptor tyrosine kinases 
with sequential activation of ERK signalling components. Interestingly, activation of 
Grb2 has also been linked with the induction of TGF-p responses through p38 kinase 
(Lee et al. 2007; Wrighton et al. 2009; Zhang 2009).
TGF-p activation of the ERK pathway is required for TGF-p-induced epithelial to 
mesenchymal transistion which plays a physiological role in embryo development and 
pathophysiological roles in tumour metastasis (Moustakas and Heldin 2005; Zhang 
2009).
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TGF-p can activate the JNK and p38 kinase pathways through MKK3 or MKK6 in a 
number of cell lines and have been shown to be activated independently of the Smad 
pathway but can also act in conjunction with the Smad pathway. TGF-P is able to 
activate the JNK and p38 pathways through direct interaction between the type II 
receptor and the TGF-P-activated kinase 1 (TAK1). This interaction requires 
activation of TAK1 by TRAF6 which may also interact with the activated TGF-P 
receptor complex (Zhang 2009). TGF-P-activation of the JNK and p38 pathways is 
essential for TGF-P-induced apoptosis (Zhang 2009). The involvement of MAPKs in 
TGF-P-mediated apoptotic mechanisms is the most consistently observed role for 
MAPKs in TGF-p-mediated responses. The interaction between the type II receptor 
and a pro-apoptotic adaptor protein Daxx leads to activation of JNK and apoptosis in 
epithelial cells and hepatocytes (Moustakas and Heldin 2005).
1.13 MAPKs and atherosclerosis
MAPKs are expressed in the cardiovascular system and are activated by a number of 
stimuli including LDL, oxLDL, acute hypertension and mechanical stress (Metzler et 
al. 1999). ERK 1/2 has been shown to be activated and overexpressed in 
atherosclerotic lesions and phosphorylation and activation of ERK and JNK in arterial 
walls has been noted after balloon injury in animal models (Li and Xu 2000). 
Activation of MAPKs in response to shear stress has consistently been observed in a 
number o f cell types and is often associated with cell proliferation and apoptosis. For 
example, ERK can be activated by shear stress in endothelial cells and cardiac 
myocytes and by mechanical stress in VSMCs. This activity is associated with AP-1- 
dependent transcription and with VSMC proliferation. Similarly activation of p38 in 
these cells is associated with proliferation and apoptosis (Cheng et al. 2008; Li and Xu 
2000). MAPK activation may be mediated by Ras which is also activated in response 
to shear stress. Other factors that can activate MAPKs include angiotensin II and 
endothelin-1 in VSMCs (Siasos et al. 2007).
The exact roles of each of the MAPKs in atherosclerosis, is currently unclear. The 
pro- or anti-atherogenic nature of each MAPK is likely to be distinct and dependent 
on stimulus, cell-type and physiological context. Knockout studies in ApoE* ' mice
69
CHAPTER 1: Introduction
have demonstrated a pro-atherogenic role for JNK2 (Ricci et al. 2004). JNK2'7' (but 
not JNK I'7) mice showed less atherosclerosis than ApoE"7" counterparts and use o f a 
pharmacological inhibitor against JNK resulted in reduced plaque formation in these 
mice. Macrophage-restricted deletion of JNK2 also resulted in a reduced uptake of 
lipoproteins, reduced foam cell formation and significantly less atherogenesis (Ricci 
et al. 2004).
Deficiency of macrophage p38 MAPK in ApoE’7" mice promotes apoptosis of 
macrophages and necrosis of advanced lesions. This increase in apoptosis was 
accompanied by thinning of the fibrous cap and reduced collagen content of lesions 
suggestive of enhanced lesion progression (Seimon et al. 2009). Pharmacological 
inhibition of p38 in cultured mouse macrophages also resulted in increased ER-stress 
induced apoptosis suggesting a role for p38 in apoptosis and lesion progression 
(Seimon et al. 2009). In contrast to this, models of inflammation have demonstrated a 
pro-inflammatory and possibly pro-atherogenic role for p38. A study in balloon- 
injured rat carotid arteries demonstrated that injury to the artery wall was followed by 
activation of p38 and that treatment with a p3 8-specific inhibitor produced a 
significant decrease in the numbers of proliferating cells implicating the kinase in 
neointimal formation (Ohashi et al. 2000). A role for the kinase in neointimal 
formation has also been suggested by a vascular injury model where inhibition of p38 
expression in smooth muscle cells resulted in decreased neointimal formation (Proctor 
et al. 2008). Inhibition of p38 has been associated with reduced inflammation in 
models o f skin injury and septic shock (Kim et al. 2008; Seimon et al. 2009). The 
kinase also plays a role in the transcriptional regulation of E-selectin and also of 
VCAM-1 in endothelial cells (Herlaar and Brown 1999). Production of TNF-a is 
regulated by p38 and JNK in macrophages and p38 also plays a role in TGF-P 
mediated chemotaxis of monocytes (Herlaar and Brown 1999).
In macrophages, roles for MAPKs in a number of processes have been defined. 
Apoptosis of macrophages in advanced atherosclerotic lesions has been demonstrated 
to require the p38 and JNK pathways. These pathways are activated by the 
accumulation of free cholesterol and engage the scavenger receptor, SR-A to promote 
apoptosis (Devries-Seimon et al. 2005). Inhibitors against p38 and ERK can inhibit 
oxLDL-induced macrophage proliferation suggesting roles for the kinases in this
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process (Senokuchi et al. 2004). Macrophage proliferation in response to oxLDL is 
mediated by an increase in the production of GM-CSF, induced by oxLDL. Inhibitors 
against p38 and ERK can inhibit macrophage proliferation and indicate distinct roles 
for the two kinases in this process. ERK inhibitors can inhibit both production of 
GM-CSF and subsequent macrophage proliferation whilst inhibitors against p38 have 
no effect on GM-CSF mRNA or protein expression but maintain the inhibitory effect 
on macrophage proliferation, suggesting that p38 acts further down the pathway and 
may play a role in cell cycle progression which is negatively regulated by an oxLDL- 
ERK-GM-CSF cascade (Senokuchi et al. 2004).
Roles for the MAPKs in foam cell formation have been demonstrated by studies in 
mouse peritoneal macrophages where treatment of cells with oxLDL results in the 
rapid activation of ERK, p38 and JNK (Muslin 2008). Treatment of macrophages 
from CD367' mice with a JNK inhibitor blocks oxLDL-induced foam cell formation 
and ApoE null mice treated with a JNK inhibitor are also found to develop 
significantly less atherosclerosis than ApoE 7' untreated mice (Muslin 2008). In 
addition, JNK2 null mice crossed with ApoE'7' mice are resistant to atherosclerosis 
development and have reduced oxLDL and AcLDL-induced foam cell formation. 
Levels of phosphorylated SR-A are also reduced in macrophages from JNK2'7' mice 
suggesting that JNK may promote SR-A phosphorylation and therefore foam cell 
formation (Ricci et al. 2004). In J774 murine macrophages oxLDL-induced foam cell 
formation can be blocked with a p38 inhibitor (Muslin 2008). In addition, p38 has 
been demonstrated to be required for oxLDL-stimulated CD36 expression in 
macrophages (Muslin 2008).
1.14 Integration between Smads and other signalling pathways
A number of studies on TGF-p-regulated gene expression have evidenced crosstalk 
between Smad and MAPK pathways although the exact mechanism of crosstalk is 
often unclear. Interaction between signalling pathways can often be cell-type and 
gene specific. For instance, cells of mesangial origin tend to show a synergy between 
ERK and Smad pathways whilst epithelial cells tend to show that this interaction 
inhibits downstream events (Hayashida et al. 2003). Stimulation of collagen I and
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flbronectin production by TGF-p in mesangial cells is mediated by the Smads but can 
be inhibited by blocking the expression of ERK (Hayashida et al. 2003). Interplay 
between signalling pathways has also been observed in relation to atherosclerosis. 
For example, in VSMCs, the ERK and Smad pathways have been implicated in the 
TGF-P-mediated induction of PAI-1 expression (Hong et al. 2006). PAI-1 promotes 
ECM accumulation and fibrosis therefore impacting on vascular remodelling, 
neointimal growth and VSMC migration and proliferation and is used as a biomarker 
for cardiovascular disease-associated mortality. The ERK and Smad pathways are 
required for PAI-1 induction by TGF-p. Activation of ERK by TGF-p is stimulated 
by oxLDL and this modulates the phosphorylation and nuclear accumulation of Smad- 
3 leading to an increase in PAI-1 expression (Hong et al. 2006; Samarakoon and 
Higgins 2008).
The linker region of Smads can be phosphorylated by MAPKs and cyclin-dependent 
kinases (CDKs) and may integrate signals from other pathways to mediate TGF-p 
responses (Schmierer and Hill 2007). Mitogens are able to initiate the ERK-mediated 
phosphorylation of both Smad-2 and Smad-3 at specific serine and threonine residues 
within the linker region (specifically, Ser245, 250, 255 and Thr220 of Smad-2 and 
Ser204, 208 and Thrl79 of Smad-3) (Javelaud and Mauviel 2005). Phosphorylation 
of Smads by MAPKs can affect their ability to move to the nucleus or thereby affect 
transcriptional activity. For instance, ERK phosphorylation of Smad-1, -2 and -3 
reduces the nuclear translocation of Smads following TGF-P stimulation (Javelaud 
and Mauviel 2005). TGF-p activated JNK can also phosphorylate Smad-3 to induce 
its nuclear translocation and activity. MSK1 kinase, a substrate of p38 kinase, can 
modulate the transcriptional activity of Smad-3 by promoting association with the 
p300 co-activator (Moustakas and Heldin 2005). Recently, phosphatases that 
dephosphorylate the linker region of Smads have been identified. SCP phosphatases 
dephosphorylate specific sites in the Smad-2 (Ser245, 250, 255 and Thr8) and Smad-3 
(Ser204, 209, 213 and Thr8) linker region and have no effect on the SXS 
phosphorylation of the protein (Wrighton and Feng 2008; Wrighton et al. 2009).
The interaction of the MAPKs and Smads with transcription factor substrates adds 
another level of complexity to the interaction between signalling pathways. MAPK- 
associated transcription factors can modulate the activity of Smads and conversely
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these transcription factors can be modulated by the Smad pathway. This regulation 
can be positive or negative and often occurs in a cell-type-, gene- and/or MAPK- 
specific manner (Javelaud and Mauviel 2005). The transcription factor AP-1 and 
Smads tend to cooperate to regulate AP-1-driven promoters while they antagonise 
each other on Smad-dependent transcription (Javelaud and Mauviel 2005). Smad-3 
and c-Jun can interact at the transcriptional level through AP-1 sites. Interestingly, 
the c-Jun promoter itself contains both AP-1 and Smad3/4 binding sites and can be 
induced by TGF-P (Javelaud and Mauviel 2005). Repression of the Smad pathway by 
JNK activation in HepG2 cells is mediated by an interaction between Smad-3 and c- 
Jun (Dennler et al. 2000). Overexpression of constitutively active MKK4 and 
MEKK1 inhibited TGF-P-induced transcription and disrupts the c-Jun/Smad-3 
interaction suggesting that this interaction impairs TGF-P-mediated transcription 
(Dennler et al. 2000). The inhibitory effect of c-Jun/Smad interaction is a result of the 
ability of c-Jun to stabilise the interaction of Smad-3 with co-repressors such as Ski 
and TGIF and block interactions with co-activators such as p300/CBP (Pessah et al. 
2002; Pessah et al. 2001). Interaction between Smad and MAPK signalling pathways 
is discussed further in Chapter 5 of this thesis.
1.15 Target gene transcription
Transcription is the process of synthesising RNA that is complementary to the DNA 
sequence using RNA polymerase. A number of accessory proteins (TFIIA, B, D, E, F 
and H), known as general transcription factors, are required for RNA polymerase II- 
mediated transcription and make up the transcriptional machinery required for 
initiation of transcription (Thomas and Chiang 2006). Two models have been 
proposed for transcription initiation, the sequential assembly model and the 
holoenzyme model, reviewed by Thomas and Chiang 2006 and Malik and Roeder 
2005 respectively. Transcription is regulated by trans-acting factors (or transcription 
factors) that are sequence specific and bind to cis-regulatory elements (CREs) within 
the promoter of the gene. Cis-regulatory elements are situated upstream of the 
transcription start site and interact with RNA polymerase and the associated 
transcriptional machinery to regulate transcription. They can act either as activators
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or as repressors o f gene expression dependent on other cofactors recruited to the gene 
promoter (Venters and Pugh 2009).
Transcription begins as a series of abortive initiations before the RNA polymerase 
enzyme reaches the +9 site where stable initiation begins. This transition is known as 
‘promoter clearance’ (Buratowski 2009; Margaritis and Holstege 2003). As 
transcription elongation progresses levels o f phosphorylated serine mediate 
interactions with histone methyltransferases which can then recruit complexes to 
modify chromatin structure and histone acetylation to allow access to the gene 
sequence for transcription to continue (Buratowski 2009; Venters and Pugh 2009). 
Transcription is terminated following the addition of a 5’CAP and 3’ polyA tail 
(Schoenberg and Maquat 2009; Venters and Pugh 2009). The pre-mRNA is also 
spliced to remove introns from its sequence to form the mature mRNA (Bentley 2005; 
Buratowski 2009).
1.15.1 Histone acetylation and Chromatin remodelling
Genes are packaged and compacted within the nucleus in the form of chromatin. 
Chromosomal DNA is structurally similar to beads on a string where each bead is a 
nucleosome consisting of 147bp of DNA wrapped around an octomer of histones 
containing two copies of histones H2A, H2B, H3 and H4 (Cairns 2009; Venters and 
Pugh 2009). Nucleosomes are evenly spaced every 160-200bp throughout the 
genome. The packaging of chromatin can be modulated by ATP-dependent 
chromatin remodelling complexes such as SWI/SNF to regulate gene expression. 
This is achieved through competition between nucleosomes and transcription factors 
for access to cis-regulatory elements. While constitutively-expressed genes favour 
binding of transcription factors through a nucleosome-depleted region containing cis- 
regulatory elements, regulatory-transcribed genes are often covered using nucleosome 
positioning sequences that help position nucleosomes over key transcription factor 
binding sites. This then requires binding of a key transcription factor at an open site 
followed by remodelling of chromatin and modification to expose other sites (Caims 
2009; Venters and Pugh 2009). Chromatin remodelling is often preceded by histone 
acetylation by transcription factors with histone acetyltransferase (HAT) activity, 
known as co-activators. A large number of proteins with HAT activity that are linked
74
CHAPTER 1: Introduction
to transcription have been identified including p300/CBP (CREB (cAMP response 
element binding protein) binding protein), PCAF (p300/CBP associated factor) and 
SRC-1 (steroid receptor coactivator-1) (Gregory et al. 2001). Histone acetylation 
facilitates not only access for RNA polymerase but also binding of additional 
transcription factors to regulate transcription and gene expression. Acetylation occurs 
on specific lysine residues on the N-terminal tails of histone proteins (Gregory et al. 
2001). The following section will focus on co-activators (transcription factors) 
involved in TGF-|3 signalling with a focus on the role of steroid receptor coactivator-1 
(SRC-1).
1.16 Co-activators and TGF-p signalling
TGF-p-mediated changes in gene expression through the Smad and MAPK pathways 
are regulated by co-activators with HAT activity such as p300/CBP and SRC-1 or by 
co-repressors with HD AC activity such as NCoR and HDAC1 which bind to sites 
within the promoter of the target gene and to each other to regulate gene transcription 
(Spencer et al. 1997). Co-activators facilitate the assembly of a stable pre-initiation 
complex (PIC) of transcription machinery to enhance gene transcription while co­
repressors bind to DNA to prevent assembly of the PIC and gene transcription. 
Recruitment of co-activators with intrinsic HAT activity target specific histones on 
the DNA resulting in the unpacking/unwinding of chromatin to facilitate access for 
other transcription factors and the basal transcriptional machinery while deacetylation 
of histones by co-repressors has the opposite effect (Spencer et al. 1997).
Co-activators and co-repressors, unlike general transcription factors are not part of the 
RNA polymerase II complex and interact with enhancer DNA-binding transcription 
factors. As the levels of co-activators within the cell is limiting, changes in their 
expression levels can have dramatic effects on gene expression and can serve to 
integrate signals from multiple pathways (Yuan and Xu 2007). Over 300 co­
regulators of transcription have been identified to date (Lonard and O’Malley 2007). 
Co-activators and co-repressors do not work alone but in protein complexes made up 
of multiple components. These are dynamic in nature with some proteins stably 
bound and some less so (Lonard and O'Malley 2007). Reversible, post-transcriptional 
modifications to co-regulators (such as phosphorylation, acetylation, methylation and
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ubiquitination) also contribute to this dynamic nature. These modifications can have a 
broad effect on gene expression through the interaction of co-regulators with a 
number of other transcription factors (Lonard and O’Malley 2007).
Interaction with co-activators or co-repressors with Smads is dependent on the MH2 
domain of the proteins. The co-activator p300/CBP has been demonstrated to interact 
with the Smad proteins (Pouponnot et al. 1998). The co-activator is able to interact 
directly with the MH2 domain of Smad-2, -3 or -4 through its C-terminal domain to 
positively regulate transcription of target genes through its HAT activity and can 
enhance transcription of the TGF-P-responsi ve reporter plasmid 3TP-Lux (Dennler et 
al. 2005; Itoh et al. 2000; Nishihara et al. 1998). The transcriptional activity of both 
Smad-2 and -3 can also be enhanced by p300/CBP in response to TGF-P through 
acetylation of their MH2 domain (Inoue et al. 2007). Another co-activator 
demonstrated to interact with the Smad proteins is P/CAF, a co-activator associated 
with the control of differentiation, growth inhibition and apoptosis. Similar to 
p300/CBP, the co-activator is able to interact directly with Smad-3 to enhance Smad- 
dependent transcriptional responses following TGF-P stimulation in mammalian cells. 
Interestingly, the N-terminal of P/CAF is able to interact with p300/CBP suggesting 
that both co-activators may be required for some transcriptional responses (Itoh et al.
2000). Both p300/CBP and P/CAF co-activators are also able to regulate the 
expression of ERK in response to stimulation with retinoic acid (Chu et al. 2005).
1.16.1 Steroid receptor coactivator-1
SRC-1 is also thought to be involved in TGF-P signalling. SRC-1 (also known as 
nuclear receptor coactivator-1 (NCoAl)) is part of the pi 60 family of nuclear receptor 
co-activators and was the first of the p i60 co-activators to be cloned. Other members 
of the p i60 SRC family include SRC-2 (also known as NCoA2/transcriptional 
intermediary factor-2- TEF-2/glucocorticoid receptor-interacting protein- GRIP1) and 
SRC-3 (also known as NCoA3/amplified in breast cancer-1- AIB1/ retinoic acid 
interacting protein-3- RAC3/ thyroid hormone receptor-activated molecule-1- 
TRAM1/ p300/CBP-interacting protein- p/CIP). All SRCs are approximately 160kDa 
in size and expressed in a ubiquitous manner (Li and Shang 2007; Xu and Li 2003). 
Members of the family have been demonstrated to interact with nuclear receptors
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(NR) including the oestrogen receptor, glucocorticoid receptor and the retinoid-X- 
receptor. In addition, they interact with several transcription factors including PPAR- 
y, AP-1, NFkB and cAMP regulatory element-binding protein (CREB) (Leo and Chen 
2000; Xu and Li 2003). SRC-1 knockout mice are prone to obesity, linking the co­
activator to energy homeostasis, glycolysis and fatty acid synthesis (Lonard and 
O'Malley 2007; Xu et al. 2009). SRC-1 has also been linked with the vasoprotective 
effect of oestrogen. The co-activator is expressed in endothelial cells and VSMCs of 
normal arteries and in neointimal cells following vascular injury. Knockout mice 
have demonstrated a role in the inhibitory effects of oestrogen on neointimal growth 
and VSMC proliferation (Yuan and Xu 2007).
The SRC family members share a conserved structure. The N terminal domain is 
thought to be involved in intra-/inter-molecular interactions and the C terminal is 
involved in transcriptional activation. Between these domains, the receptor 
interacting domain contains conserved LXXLL (L-leucine, X-any amino acid) 
sequences known as NR boxes. These mediate interactions between the co-activator 
and nuclear receptors/other co-activators including p300/CBP which has been shown 
to interact with SRC-1 (Leo and Chen 2000; Li and Shang 2007; Lonard and 
O'Malley 2007; Xu and Li 2003). The co-activator has weak HAT activity mapped to 
its C-terminal domain and specific for histones H3 and H4 but is likely to require 
other co-activators for transcriptional activation through histone acetylation (Spencer 
et al. 1997).
Studies using the human PAI-1 promoter have demonstrated that like p300/CBP, the 
co-activator SRC-1 is able to enhance TGF-p/Smad transcriptional responses. In 
contrast to p300/CBP, SRC-1 does not bind directly to Smad-3 but instead is thought 
to interact with the p300/CBP co-activator to enhance association with Smad-3 and 
subsequent Smad-3 dependent transcriptional responses (Dennler et al. 2005). Using 
mammalian two-hybrid assays and transfection studies, Dennler and colleagues 
(2005) were able to show that interaction between p300/CBP and Smad-3 was 
enhanced by SRC-1 and inhibition of p300/CBP blocked the action of SRC-1 on 
Smad-3-dependent transcription (Dennler et al. 2005).
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SRC-1 may also interact with MAPK pathways through phosphorylation (Rowan et 
al. 2000). Phosphorylation of SRC-1 is able to modulate its activity and generally 
enhances its transcriptional activity whilst methylation reduces transcriptional activity 
of the co-activator (Rowan et al. 2000). SRC-1 contains 7 serine/threonine 
phosphorylation sites. These contain consensus sites for proline-directed protein 
kinases (Rowan et al. 2000). The co-activator also contains consensus sites for 
MAPK (ERK 1/2) phosphorylation and the co-activator is able to potentiate AP-1 
activity. cAMP/protein kinase A and NFkB pathways are also able to influence SRC- 
1 activity through phosphorylation (Li and Shang 2007).
1.17 Aims of study
Atherosclerosis is recognised as a progressive, inflammatory disorder and the 
underlying cause of cardiovascular disease, one of the leading causes of death in the 
Western world. Cytokines play crucial roles in the regulation of immune and 
inflammatory responses during atherosclerosis development, often mediated through 
the modulation of gene expression profiles associated with the disease. The study of 
the molecular mechanism regulating cytokine-mediated gene expression in 
atherosclerosis is crucial for the identification of novel targets for therapeutic 
intervention. TGF-p, an anti-inflammatory cytokine, acts as a key modulator of gene 
expression to prevent progression of atherosclerosis. TGF-p has been shown to 
modulate the expression of genes implicated in foam cell formation. However, the 
molecular mechanisms behind this regulation are yet to be elucidated. The classical 
Smad pathway plays a pivotal role in TGF-P signalling and in addition to this the 
cytokine can activate other cellular signalling pathways including the MAPK 
cascades. Studies into the TGF-P-regulation of these genes in macrophages, 
particularly through activation of TGF-P signalling pathways is therefore crucial to 
furthering understanding of the molecular basis of foam cell formation and 
atherosclerosis.
In the later stages of atherosclerosis, TGF-P modulates the expression of genes 
involved in turnover of the extracellular matrix to promote plaque stability. Recent 
identification of the ADAMTS family of proteases and their ability to cleave key
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components of the vascular matrix has sparked interest in their role in atherosclerosis. 
Limited research currently exists on the functions of ADAMTS proteases, in 
particular ADAMTS-4 with relation to atherosclerosis. Studies on the cytokine- 
mediated regulation of ADAMTS-4 are therefore an important area for research.
The aims of the work presented in this thesis were therefore to:
• Investigate the regulation of expression o f key genes implicated in cholesterol 
uptake and cholesterol efflux by TGF-p in macrophages (Chapter 3). This was 
to be achieved using RT-qPCR and Western blotting to analyse changes in 
mRNA and protein levels respectively.
• Investigate activation of key TGF-P signalling pathways in macrophages 
(Chapters 4 and 5). This was to be achieved using Western blotting and non­
radioactive kinase activity assays to analyse protein levels of Smads, MAPKs 
and MAPK substrates respectively.
• Investigate the role of the classical Smad pathway in the TGF-p-regulation of 
key genes implicated in macrophage cholesterol homeostasis (Chapter 4). 
This was to be achieved using siRNA technology.
o Following this, the aims were extended to investigate the role of three 
MAPK pathways (ERK, JNK and p38 kinase) using the same 
methodology (Chapter 5).
• Investigate the regulation of macrophage ADAMTS-4 by TGF-P (Chapter 6). 
This was to be achieved using RT-qPCR and Western blotting to analyse 
mRNA and protein levels respectively.
o Following this, the aims were extended to investigate the action of 
TGF-p on ADAMTS-4 promoter activity using transient transfection 
and to characterise the minimal promoter binding region for the TGF-P 
response using transfection and EMSA analysis techniques.
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CHAPTER 2 
Materials and Methods
2.1 Materials
Table 2.1 lists the materials used during the course of this study, along with the 
suppliers from which they were purchased.
Table 2.1 Materials and Suppliers
M aterials Sup pliers
Anti-ADAMTS-4 Affinity Bioreagents, Cambridge, UK
GAPDH negative control siRNA Ambion, Cambridgeshire, UK
Acrylamide: Bisacrylamide (37.5:1) 
Acrylamide: Bisacrylamide (29:1) Anachem, Luton, UK
INTERFERE'M Autogen Bioclear, Wiltshire, UK
Anti-ApoE Biogenesis, Kiddlington, Oxford, UK
PCR grade magnesium chloride 
PCR grade NH4 reaction buffer Bioline, London, UK
Anti-mouse HRP-conjugate 
Anti-JNK 
Anti-phospho JNK 
Anti-phospho p38 kinase 
Anti-phospho p44/42 
Anti-phospho Smad-2 
Anti-phospho Smad-3 
Anti-p44/42 
Anti-p38kinase 
Anti-rabbit HRP-conjugate 
Anti-Smad-2/3
Cell Signaling Technology, New England 
Biolabs, Herts, UK
LB-medium and LB agar capsules DIFCO Laboratories, Surrey, UK
Agarose Eurogentec, Southampton, UK
Cell lines (Hep3B, THP-1, U937) European Collection of Animal Cell Cultures, Salisbury, UK
EDTA
Ethanol
Hydrochloric acid 
Industrial methylated spirits 
Methanol 
Sodium chloride 
Sodium dodecyl sulphate 
Sodium hydroxide 
Tris-Base
Other general chemicals
Fisher Scientific, Loughborough, UK
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ECL Western blotting detection reagents 
Megaprime DNA labelling kit 
Nick columns
Rainbow protein size markers 
Random Hexamers (PdN6)
GE Healthcare, Buckinghamshire, UK
DMEM with GlutaMAX1M 
Foetal Calf Serum 
RPMI-1640 with GlutaMAX™
GIBCO® Invitrogen, Paisley, UK
1ml cryovials
96-well, 24-well and 12-well plates 
50ml and 15ml Falcon polypropylene tubes 
Tissue culture flasks
Greiner, Gloucestershire, UK
Cell scrapers 
0.2pM sterile filters 
6 -well plates
Helena Biosciences, Sunderland, UK
p38 kinase validated siRNA 
Smad-3 validated siRNA Invitrogen, Paisley, UK
Penicillin/Streptomycin Lonza Biologicals, Slough, UK
PVDF membrane
Stericup® and Steritop™ 500ml filter Millipore Ltd., Gloucestershire, UK
DNA molecular weight markers 
p44/42 MAPK kinase assay kit (non-radioactive) 
SAPK/JNK kinase assay kit (non-radioactive) 
Restriction endonucleases
New England Biolabs, Hertfordshire, UK
Anti- ABCA-1 Novus Biologicals, Suffolk, UK
Phosphate buffered saline tablets Oxoid Ltd., Basingstoke, UK
[a-J2P]-dCTP Perkin Elmer, Massachusetts, USA
Micro BCA protein assay kit Pierce, Chester, UK
dNTPs
Luciferase substrate 
M-MLV (5x) buffer 
M-MLV Reverse Transcriptase 
Passive lysis buffer (5x) 
pGL2 promoter vector 
RNasin®
Shrimp alkaline phosphatase 
T4 DNA ligase
Promega, Southampton, UK
c-Jun validated siRNA 
ERK 1/2 validated siRNA 
QIAquick™ gel extraction kit 
QIAquick™ nucleotide removal kit 
Qiagen plasmid plus maxi kit 
QIAprep™ Spin mini kit 
RNeasy™ total RNA isolation mini kit 
Smad-2 validated siRNA 
SRC-1 (NCOA-1) genome-wide siRNA 
SuperFECT™
Qiagen, Crawley, UK
Anti-c-Jun
Anti-LPL
Anti-SR-A
Santa Cruz Biotechnology, California, USA
DNA oligonucleotides Sigma Genosys, Cambridgeshire, UK
Ampicillin
Aprotonin
Benzamidine
Bovine Serum Albumin
Bromophenol blue
Ethidium bromide
Glycerol
Kodak X-OMAT film
Sigma, Poole, UK
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Leupeptin
Molecular biology grade DMSO
PMA
PMSF
Sodium fluoride
Sodium orthovanadate
Sodium pyrophosphate
TBE (lOx)
TEMED
Tissue culture grade DMSO
Triton x-100
Trypsin/EDTA
Tween 2 0
Zinc chloride
2 -mercaptoethanol
Human TGF-P Totam (Tebu-Bio), Peterborough, Cambridgeshire, UK
2.2 Preparation of solutions and glassware
Solutions and glassware were autoclaved for 20-30 min at 121°C (975kPa) as 
necessary.
2.3 Cell culture techniques
2.3.1 Cell lines
23.1.1 THP-1
THP-1 is a human monocytic leukaemia cell line that can be differentiated with 
phorbol esters. Differentiated THP-1 cells display many of the properties and 
characteristics of human monocyte-derived macrophages and are therefore a useful 
model in which to study the properties of macrophages including cell signalling and 
gene expression (Auwerx, 1991).
2.3.1.2 U937
U937 is a human monocyte lymphoma cell line established by Sundstrom and Nilsson 
(1976) that has the characteristics of human monocytes. It is frequently used for 
promoter analysis in relation to monocyte/macrophage gene expression as it is easier 
to transfect with exogenous DNA. Similar to THP-1 cells, U937 is an immature cell
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of the monocyte-macrophage lineage but can be differentiated using phorbol esters to 
induce a mature macrophage phenotype (Abrink et al. 1994; Tsuchiya et al. 1982).
2.3.1.3 Hep3B
Hep3B is a human hepatoma cell line established by Aden et al. (1979) that is often 
used for studies on cytokine-mediated gene expression during liver inflammation 
(acute-phase response). Cells are fully adherent hepatocytes derived from a human 
carcinoma. Hep3B cells show cytokine-mediated responses similar to that observed in 
inflammatory states (Coulouam et al. 2005; Coulouam et al. 2004; Hiron et al. 1992).
2.3.2 Maintenance of cell lines in culture
Both THP-1 and U937 cells were grown in RPMI-1640 with GlutaMAX™ (stabilized 
L-glutamine). Hep3B cells were grown in DMEM with GlutaMAX™. Medium was 
supplemented with 10% (v/v) heat-inactivated (at 56°C for 30min) foetal calf serum 
(HI-FCS) and penicillin (lOOU/ml) and streptomycin (lOOpg/ml) (complete medium). 
Both HI-FCS and penicillin/streptomycin were passed through a 0.2pm sterile filter 
prior to addition to the medium. Cells were maintained in a humidified incubator 
(37°C) with a 5% (v/v) CO2 atmosphere. DMEM complete medium was replaced 
when required. Cells between passages 2 and 8 were used for experiments.
2.3.3 Sub-culturing of cells
2.3.3.1 THP-1 and U937 cells
Suspension cells were subcultured when they reached approximately 70% confluency 
(0.7 x 106 cells/ml). Confluent cells were split by diluting into fresh RPMI-1640 
complete medium. Routinely cells were split in a ratio of 1:4.
2.3.3.2 Hep3B cells
Confluent (70%) Hep3B cells were washed once with DMEM. Cells were then 
trypsinised using 0.25% (v/v) trypsin/EDTA solution to cover the cell monolayer. 
Cells were incubated at 37°C, 5% (v/v) CO2 until cells became visibly detached from 
the flask. DMEM complete medium was added and the cells were pelleted by
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centrifugation at 1 lOxg for 5min. The cell pellet was resuspended into an appropriate 
volume of fresh DMEM and cells were seeded at a ratio of 1:6.
2.3.4 Preserving and storing cells
Cell lines were preserved at -80°C or in liquid nitrogen. Only early passage cells 
(passages 1-3) were used for storage. Prior to freezing, cells were centrifuged at 
llOxg for 5min and resuspended in HI-FCS containing either 10% (v/v) glycerol 
(THP-1) or 10% (v/v) DMSO (U937 and Hep3B). Cells were aliquoted into 1ml 
cryovials and insulated with polystyrene. Cells were frozen at -80 °C for short-term 
storage, or stored at -80°C overnight before being transferred to liquid nitrogen for 
longer-term storage.
2.3.5 Thawing frozen cells
Cells from liquid nitrogen were defrosted by placing in a water bath at 37°C. Cells 
were transferred to a polypropylene tube containing 10ml (v/v) HI-FCS and 
centrifuged at llOxg for 5min. After resuspension into the appropriate complete 
medium, cells were seeded into tissue culture flasks and incubated at 37°C with 5% 
(v/v) C 02.
2.3.6 Counting cells
To count both U937 and THP-1 cells, a haemocytometer (Neubauer chamber) was 
used. After centrifugation (llOxg for 5min), cells were re-suspended in an 
appropriate volume of medium containing 10% (v/v) HI-FCS. The haemocytometer 
was covered with a precision ground coverslip, then 7 pi of cell suspension was used 
and the number of cells in the 5 x 5 grid was counted. The number of cells/ml was 
calculated by multiplying the number of cells in the counting area by 103. The 
appropriate volume of cells was diluted using fresh medium and seeded into tissue 
culture flasks or plates.
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2.3.7 Treatment of cells with PM A and cytokines
THP-1 and U937 cells were differentiated with 0.16pM PMA for 24hr before 
cytokine treatment. Prior to cytokine treatment of Hep3B cells, the medium was 
aspirated and replaced. Cytokines were added directly to the culture medium and 
treated cells were incubated at 37°C with 5% (v/v) CO2 . Routinely TGF-J3 was added 
at a concentration of 30nM.
2.3.8 Human monocyte-derived macrophage cell culture
Ficoll-Hypaque purification was used to isolate human monocyte derived 
macrophages (HMDMs) from buffy coats. Blood was layered over Lymphoprep™ 
(Nycomed Pharmaceuticals) in Accuspin™ tubes (Sigma) and was centrifuged at 
1 lOxg for 30min to allow sedimentation of erythrocytes. Cells were transferred to a 
new centrifuge tube and an equal volume of PBS containing 0.4% (v/v) tri-sodium 
citrate was added before centrifugation (llOxg, 5min). Pelleted cells were 
resuspended in 10ml 0.2% (v/v) saline solution, to lyse the red blood cells. Following 
centrifugation (llOxg, 5min), platelets were removed from the mononuclear cell 
interface by washing several times with PBS containing 0.4% (v/v) tri-sodium citrate 
(with centrifugation (llOxg, 5min) between washes). Monocytes were plated out in 
12-well plates using RPMI-1640 supplemented with 5% (v/v) HI-FCS and penicillin 
(lOOU/ml) and streptomycin (lOOpg/ml). Cells were left to adhere for 7 days to allow 
for macrophage differentiation. Half of the volume of medium was replaced every 2 
days and prior to use, cells were washed and the medium replaced to remove any non­
adherent cells.
2.4 RNA/DNA related techniques
2.4.1 Isolation of Total RNA
Total RNA was isolated from cells using the RNeasy Mini kit (Qiagen). Briefly, the 
medium was aspirated from the cells and the cells washed once with PBS before 
being resuspended in 350-600pl buffer RLT (containing 1 Op 1/ml P-mercaptoethanol), 
provided in the kit. This is a highly denaturing buffer which inactivates RNases to aid
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in the collection of intact RNA. The lysate was homogenised either by passing the 
collected lysate through a QIA shredder column (Qiagen) or several times through a
0 .9 .m  needle attached to a 1ml syringe. At this stage the lysate was stored at -80°C 
until a later date or immediately used for RNA extraction. The rest of the protocol 
was carried out according to the instructions provided by the manufacturer (Qiagen). 
Briefly, silica-based membrane spin columns were used to bind RNA. Addition of 
ethanol precipitated out any DNA to provide optimum binding conditions. 
Contaminants were washed away using the RW1 wash buffer (provided in the kit) 
before the RNA was eluted.
RNA concentration and purity was determined using a NanoDrop ND-1000 
Spectrophotometer (Labtech International) according to the manufacturer’s 
instructions. The integrity of the RNA was analysed by size-fractionating a small 
aliquot on a 1.5% (w/v) agarose gel (Section 2.4.4.1).
2.4.2 RT-PCR
Reverse transcription-polymerase chain reaction consists of two steps.
1. The synthesis of cDNA using reverse transcriptase.
2. PCR using gene-specific primers and optimised conditions to amplify a 
product of interest.
2A.2.1 Reverse Transcription 
RNA (typically lpg or if the yield was low, 0.5pg) was mixed with lp l random 
hexameric primers (200pmol, PdN6) and sterile water to a total volume of 13.5pi. 
Samples were incubated at 70°C for 5min and immediately cooled on ice. The 
following reagents were subsequently added to the reaction:
lp l dNTP mixture (lOmM each of dATP, dCTP, dGTP, dTTP)
4pl 5 x M-MLV (Molony murine leukemia virus) reverse transcriptase buffer 
0.5 pi recombinant RNase inhibitor (RNasin®) (50U/pl)
1 pi M-MLV reverse transcriptase (200U/pl)
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The total mixture was incubated at 37°C for lhr and the reaction terminated at 92°C 
for 2min. Synthesised cDNA was diluted by adding 80pl (or 30pl if 0.5pg RNA was 
used) RNase-free water and stored at -20°C.
2.4.2.2 Polymerase chain reaction 
PCR conditions were specific to the primers used to amplify specific gene products. 
The primer sets used for PCR are shown in Table 2.2 with the product size in base 
pairs (bp) and the reference, if applicable, from which they were obtained. The 
reaction and amplification conditions are shown in Table 2.3 and Table 2.4 
respectively. PCR conditions and cycle numbers were previously optimised in the 
laboratory so that the products were generated during the exponential phase of 
amplification, providing a direct correlation between the amount of product and the 
input cDNA template. PCR reactions were carried out using a Techne Thermal 
Cycler or a Peltier Thermal Cycler (PTC-200).
2.4.3 Real-time quantitative PCR
Real-time quantitative PCR (qRT-PCR) is an accurate method to analyse the amount 
of PCR products during the exponential stage of the amplification without reaching 
the plateau phase where the PCR reaction is not generating template at an exponential 
rate, one problem that can be encountered with endpoint quantification of RT-PCR 
reactions (Ginzinger 2002). qRT-PCR was carried out using the SYBR® Green 
JumpStart™ Taq ReadyMix™ (Sigma) and samples were prepared as 25 pi reactions 
in duplicate using a 96-well plate format. The following reagents were added to 2.2pl 
cDNA:
27.5pi SYBR® Green JumpStart™ Taq ReadyMix™
10.5pi RNase-free H2O 
0.5pl forward primer 
0.5pi reverse primer
Details of specific primers used are detailed in Table 2.5. SYBR Green is a dye that 
intercalates into dsDNA, similar to ethidium bromide used during agarose gel 
electrophoresis. The dye has undetectable fluorescence in its free form but fluoresces
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on binding to dsDNA. SYBR Green can be used with any set of primers and although 
it is able to bind to any dsDNA target, correct amplification conditions can prevent the 
formation of primer dimers and ensure binding to a single product (Giulietti et al.
2001). Previously optimised amplification conditions are set out in Table 2.6 along 
with the reference, if applicable, from which the primer sequence was obtained. A 
melting curve was also constructed to verify correct, single product amplification.
For each transcript a standard curve was constructed using the purified PCR product 
generated for each specific set of primers. To create this, genes were blunt-end 
cloned into the pGEM-T vector (Promega) and correctly transformed colonies were 
identified by blue/white screening and sequenced. Plasmid DNA was prepared using 
the QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer’s instructions 
(Section 2.4.8). Real-time PCR was carried out using a DNA Engine Opticon 2® 
real-time PCR detection system (MJ Research).
The comparative Ct method was used for analysis as described by Livak and 
Schmittgen (2001). The Ct method is a commonly used method for relative 
quantification of qPCR data. The Ct method relies on the number o f cycles/rounds of 
amplification required for the fluorescence of a gene to surpass a pre-set threshold 
level (the Ct value) within the exponential phase of the amplification. This is directly 
proportional to the amount of starting template. The value of this for the gene of 
interest is compared relative to the equivalent Ct value for the control gene to 
normalise the data (Ginzinger 2002; Livak and Schmittgen 2001). The Ct method 
relies on two assumptions, firstly that the expression of the control gene does not vary 
under experimental conditions and secondly, that the PCR efficiencies for each gene 
are similar to each other. This can be assessed from the slope of the standard curve 
produced for each transcript (Ginzinger 2002). The transcript levels of 28SrRNA and 
RPL13A were used for normalisation in the studies presented in this thesis. These 
were used as normalising genes as they displayed stable expression in all samples. 
RPL13A is a ribosomal protein that has previously been shown to be a reliable 
standard in a number of studies analysing gene expression by qRT-qPCR including 
studies of chondrocyte and articular cartilage gene expression (Foldager et al. 2009; 
Pombo-Suarez et al. 2008) and gene expression during pancreatic diseases (Jesnowski 
et al. 2002) while 28S rRNA is an established housekeeping gene widely used for
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analysis o f gene expression, including in our own laboratory (Irvine et al. 2005; Singh 
and Ramji 2006).
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Table 2.2 Sequences of PCR prim ers used for the analysis of gene expression by RT-PCR
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Product
Size
(bp)
Reference
ABCA-1 GCT GCT GAAGCCAGGGCATGG GTGGGGC AGTGGCCAT ACTCC 306 Kaplan et al. 2002
ADAMTS-4 AGGC ACT GGGCT ACT ACT AT GGG AT AGTG ACCAC ATTGTT 241 Amaoutakis 2008
ApoE TTCCTGGCAGGATGCCAGGC GGTC AGTT GTT CCT CC AGTT C 270 Singh and Ramji 2006
(3-2 microglobulin TTT CTGGCCT GG AGGCT AT C CATGTCTCGATCCCACTTAACT 314 Ali 2007
GAPDH CCCTTCATTGACCTCAACT A AGTCTTCT GGGT GGC AGT GAT GG 455 Sabatakos et al. 1998
LPL GAGATTTCTCTGTATGGCACC CTGCAAATGAGACACTTTCTC 276 Irvine et al. 2005
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Table 2.3 Reaction conditions for RT-PCR
Gene Forward
Primer
(lOOpM)
Reverse
Primer
(lOOpM)
dNTPs
(40mM)
MgCI2
(50mM)
lOx
PCR
buffer
lOx
Mg2+
PCR
buffer
DMSO Taq
Polymerase
(5pg/pl)
ddH20 cDNA
28S rRNA 0.50 0.50 1.00 2.00 5.00 - 5.00 0.25 25.75 10.00
ABCA-1 0.50 0.50 0.50 - - 5.00 - 0.25 33.25 10.00
ADAMTS-4 0.50 0.50 0.50 0.50 5.00 - - 0.50 32.50 10.00
ApoE 0.50 0.50 0.50 - - 5.00 2.50 0.25 30.75 10.00
p-2 microglobulin 0.50 0.50 1.00 1.00 5.00 - - 0.50 36.50 5.00
GAPDH 0.50 0.50 0.50 - 2.00 5.00 - - 0.50 31.00 10.00
LPL 0.50 0.50 1.00 2.00 5.00 - - 0.25 30.75 10.00
*A11 units given are pi and all PCR reactions were carried out in a total volume of 50jnl.
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Tabic 2.4 Amplification conditions for RT-PCR
Gene Initial
melting
Annealing Extension Melting Final extension Number of cycles
28S rRNA 94°C 62°C 72°C 94°C 72°C 11
2 min 30 sec 1 min 30 sec 10 min
ABCA-1 95°C 64 °C 72°C 95°C 72°C 20
5 min 1 min 1 min 1 min 10 min
ADAMTS-4 96°C 60°C 72°C 93°C 72°C 30
5 min 1 min 1 min 30 sec 10 min
ApoE 96°C 62°C 72°C 93°C 72°C 27
5 min 1 min 2 min 30 sec 10 min
p-2 microglobulin 95°C 60°C 72°C 95°C 72°C 19
5 min 1 min 2 min 30 sec 8 min
GAPDH 95°C 60°C 72°C 93°C 72°C 19
5 min 1 min 2 min 30 sec 10 min
LPL 96°C 55°C 72°C 93°C 72°C 24
5 min 1 min 2 min 30 sec 10 min
Tabic 2.5 Sequences of PCR prim ers used for the analysis of gene expression by qRT-PCR
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Reference
28S rRNA TTAGACCGTCGTGAGACAGG TTCAATAGATCGCAGCGAGG Gibbs et al. 2002
ABCA-1 GCTGCTGAAGCCAGGGCATGG GTGGGGCAGTGGCCATACTCC Kaplan et al. 2002
ABCG-1 T GC AATCTTGTGCC AT ATTT G A CCAGCCGACTGTTCTGATCA Kaplan et al. 2002
ADAMTS-4 GGG AT AGTG ACC AC ATT GTT AGGC ACTGGGCT ACT ACT AT -
ApoE TTCCTGGCAGGATGCCAGGC GGTCAGTTGTTCCTCCAGTTC Singh and Ramji 2006
CD36 GAGAACTGTTATGGGGCTAT TTCAACTGGAGAGGCAAAGG Draude and Lorenz 2000
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTTGATGGGATTTC -
LPL GAGATTTCTCTGT ATGGCACC CTGCAAATGAGACACTTTCTC Irvine et al. 2005
RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTCAA -
Smad-2 CCCATCAAATTCAGAGAGGTTC TCACTTAGGCACTCAGCAAAAA -
Smad-3 CTCC AAACCT ATCCCCG AAT GGCTCGCAGTAGGTAACTGG -
SR-A CCAGGGACATGGAATGCAA CCAGTGGGACCTCGATCTCC Draude and Lorenz 2000
SR-B1 ACGACACCGTGTCCTTCC CGGGCTGTAGAACTCCAGCGA Eguchi et al. 2006
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Table 2.6 Amplification conditions for qRT-PCR
Gene Initial melting Annealing Extension Melting Number of cycles
28S rRNA 94°C 62°C 72°C 94°C 40
2 min 30 sec 1 min 30 sec
ABCA-1 94°C 65°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
ABCG-1 94°C 65°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
ADAMTS-4 94°C 60°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
ApoE 94°C 62°C 72°C 93°C 40
2 min 1 min 2 min 30 sec
CD36 94°C 58°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
GAPDH 94°C 60°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
LPL 94°C 55°C 72°C 93°C 40
2 min 1 min 2 min 30 sec
RPL13A 94°C 60°C 72°C 95 °C 40
2 min 1 min 1 min 30 sec
Smad-2 94°C 63°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
Smad-3 94°C 63°C 72°C 95°C 40
2 min 1 min 1 min 30 sec
SR-A 94 °C 60°C 72°C 94°C 40
2 min 1 min 1 min 30 sec
SR-B1 94°C 60°C 72°C 95°C 40
2 min 30 sec 1 min 30 sec 40 sec
94
CHAPTER 2: Materials and Methods
2.4.4 Agarose Gel Electrophoresis
For electrophoresis, lOx TBE [0.89M Tris-Borate (pH 8.3), 0.02M EDTA (Sigma)] 
was used to prepare a lxTBE solution with UV-treated, double distilled water 
(ddH20). Gels were made using 1-2% (w/v) agarose in lxTBE with ethidium 
bromide (0.5pg/ml), a dye that fluoresces following intercalation into dsDNA, thereby 
allowing nucleic acids to be visualised. DNA/total RNA was visualised on the gel 
using a 5x loading dye ( lx  TBE, 50% (v/v) glycerol, 2.25% (w/v) bromophenol blue).
2.4.4.1 Resolving RNA on agarose gels
Routinely lpg RNA was resolved on a 1.5% (w/v) agarose gel to examine its 
integrity. RNA samples were prepared with 5pi o f sterile loading dye and RNase-free 
water (Qiagen) to a total volume of 20pl. Electrophoresis was performed in 1 x TBE 
at 50V for 10-15 min using a Fisherbrand horizontal gel unit.
2.4.4.2 Resolving DNA
To resolve DNA, agarose gels were prepared with between 1-2% (w/v) agarose 
depending on the size of the DNA to be fractionated. Size fractionation of PCR 
products was routinely carried out using 1.5% (w/v) agarose gels and fragment size 
compared to standard DNA molecular weight markers (Appendix I). DNA was 
prepared with 5pi of DNA loading dye and electrophoresis was carried out in lx  TBE 
buffer at 100V for lhr using a Fisherbrand horizontal gel unit.
2.4.4.3 Analysis o f RT-PCR amplification products
Nucleic acids were visualised under UV light using a Syngene Gel Documentation 
System. Signals for PCR products were quantified using the Syngene Gene Tools 
computer package (GRI).
2.4.5 Extracting DNA from agarose gels
DNA bands were extracted from ethidium bromide-stained agarose gels using the
T W
QIAquick gel extraction kit (Qiagen) according to the manufacturer’s instructions.
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Efficiency of purification was analysed by electrophoresis using a 1.5% (v/v) agarose 
gel.
2 .4 .6  Bacterial Strains and Vectors
All bacterial culture media (LB-Agar and LB-liquid media) was prepared according to 
manufacturer’s instructions (DIFCO Laboratories). The strains and genotypes of 
Escherichia coli (E. coli) are shown in Table 2.7 below.
Table 2.7 Bacterial Strains and Genotypes
Bacterial Strain Genotype Reference
DH5a
supE44 AIacU169 (080 lacZAM15) 
hsdl7 recAl endAl gyrA96 thi-1 relAl
Hanahan 1983
2.4 .7  Transform ation of Com petent cells
DH5-a competent cells (Invitrogen) were thawed on ice prior to transformation. 
Plasmid DNA (1-5pi) was added to 50pl of competent cells and kept on ice for 30min 
to allow the plasmid DNA to associate with the cell surface. The cells were heat- 
shocked at 42°C for 20sec to cause a temporary increase in membrane permeability 
and placed back on ice for a further 2min. Then, 950pl S.O.C. medium (Invitrogen) 
was added and the cells were incubated at 37°C with shaking (225rpm) for lhr to 
allow the cells to express the newly-introduced gene. To select ampicillin-resistant 
bacterial colonies the cells were spread on LB-agar plates containing lOOpg/ml 
ampicillin. Plates were incubated overnight at 37°C.
2 .4 .8  Sm all-scale preparation o f plasmid DNA (Mini-prep)
LB-medium (5ml) containing ampicillin (lOOpg/ml) was inoculated with a single 
colony of transformed E.coli and incubated overnight at 37°C with shaking (200rpm). 
Preparation of plasmid DNA from the bacterial culture was carried out using the 
QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer’s instructions. 
Briefly, alkaline lysis of cells was carried out, followed by the binding of plasmid
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DNA to the silica membrane o f the QLAprep column using a high-salt buffer. 
Endonucleases, salt and other contaminants were washed through and the DNA was 
eluted using a low-salt buffer.
2.4.9 Large scale preparation of plasmid DNA (Maxi-prep)
LB-medium (10ml) containing ampicillin (lOOpg/ml) was inoculated with a single 
colony of transformed E.coli and incubated for 8hr at 37°C with shaking (200rpm). 
This was then used to inoculate 500ml fresh LB-medium with ampicillin (lOOpg/ml) 
and this was incubated at 37°C with shaking (200rpm) overnight. Plasmid DNA was 
prepared using a QLAprep Spin Maxiprep kit according to the manufacturer’s 
instructions (Qiagen). Briefly, transformed cells were resuspended in buffer PI (a 
Tris-Cl buffer, provided in the kit). Alkaline lysis o f the cells using NaOH and SDS 
(buffer P2, provided in the kit) was carried out before the plasmid DNA was bound to 
an anion-exchange column in the presence o f a high-salt buffer. DNA was eluted 
using alcohol precipitation.
The concentration and purity of DNA was determined by measuring O.D.260 and 
O.D.280 using a U-1800 Hitachi spectrophotometer.
2.4.10 Restriction endonuclease digestion of recombinant plasmid DNA
Single and double restriction enzyme digests were carried out using lpg/pl DNA in a 
20pl reaction and were performed at 37°C for 3hr in the recommended buffer 
provided by the manufacturer (Promega) in the presence o f acetylated BSA (lOpg/pl). 
Typically 0.5pl o f the appropriate restriction enzyme (lOU/pl) was added to lpl DNA. 
Restriction digests were analysed by agarose gel electrophoresis.
2.4.11 Cloning of Oligonucleotides
Oligonucleotides incorporating a 5’-XmaI or Xhol site were designed (Table 2.8) to 
be cloned directly into a restriction enzyme-digested pGL2 promoter vector 
(Appendix II). The vector was cleaved with the aforementioned restriction enzymes 
and subjected to agarose gel electrophoresis alongside lkb DNA markers (Appendix
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I). The product was excised from the gel and the DNA purified (Section 2.4.5). 
Oligonucleotides were prepared by incubating forward and reverse oligonucleotides 
together at 100°C for lOmin. The mixture was then left to cool to room temperature 
to allow annealing to occur. The annealed oligonucleotides were then ligated into the 
cleaved pGL2 promoter vector. This was carried out by preparing a 10pl reaction mix 
containing lpl lOx T4 DNA ligase buffer, lp l T4 DNA ligase, lpl pGL2 promoter 
vector and l-7pl purified fragment. T4 DNA ligase forms phosphodiester bonds 
between the 3’ hydroxyl group of one nucleotide and the 5’ phosphate group of 
another to ligate the oligonucleotides to the pGL2 promoter vector. The reaction mix 
was incubated overnight at 4°C. Transformation of ligated products was carried out 
using E.coli DH5a competent cells (Section 2.4.7).
Table 2.8 Oligonucleotide sequences used for insertion into pGL2 promoter
vector and subsequent promoter analysis
ADAMTS-4
promoter
region
Annealed oligonucleotide inserts
O ligo 1 
(-502 to -463)
5 -CCGGATGCCTCCTTACCTGTTCCCTACCTTCTTTTCTCAGGCA -3’ 
3'- TACGGAGGAATGGACAAGGGATGGAAGAAAAGAGTCCGTAGCT -5
O ligo 2 
(-464  to -439)
5 ’- CCGGCAGCTCACTCAGTCCCCTCAGCCCTGG -3’
3 - GTCGAGTGAGTCAGGGGAGTCGGGACCAGCT -5’
O ligo 3 
( - 4 4 3  to -423)
5 - CCGGCCTGGAAACCAGCCACTAGG -3’ 
3’- GGACCTTTGGTCGG TGATCCAGCT -5 ’
O ligo 4  
(-423 to -390)
5 - CCGGCC AAAGGGC AGC AT G AGGG AGCCTT GAG A AAA -3’ 
3 - GGTTTCCCGTCGTACTCCCTCGGAACTCTTTTAGCT -5’
The ADAMTS-4 promoter sequence is shown in bold text.
2 .4 .12  DNA sequencing
GL1 and GL2 primers that amplified any insert within the pGL2 multiple-cloning site 
were used for sequencing to detect correctly transformed colonies. Sequencing was 
carried out by the Molecular Biology Support Unit of Cardiff University.
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2.5 DNA Transfections
2.5.1 SuperFect™ Transfection
Transfection work was carried out in U937 and Hep3B cell lines using conditions 
previously optimised in the laboratory. Cells were grown in medium containing 10% 
(v/v) HI-FCS. Confluent Hep3B cells were trypsanised and seeded as previously 
described (Section 2.3.3). Cells were plated in 12-well plates 24hr prior to 
transfection and incubated at 37°C with 5% (v/v) CO2 . Medium was replaced with 
fresh DMEM complete medium prior to transfection. Confluent U937 cells were 
harvested by centrifugation (llOxg for 5 min). Cells were resuspended in medium 
supplemented with 3% (v/v) HI-FCS and plated out into 12-well plates at a density of
600,000 cells per well. Cells were incubated at 37°C with 5% (v/v) CO2 for 4hr prior 
to transfection.
Transient transfection was carried out using SuperFect™ according to the 
manufacturer’s instructions (Qiagen) with minor modifications. Briefly, the 
transfection mix was prepared in 50pl medium that contained no antibiotics and no 
HI-FCS. SuperFect™ Reagent and the plasmid DNA of interest (containing the 
promoter o f the gene of interest linked to the firefly-luciferase reporter gene) was 
added in a 3:1 ratio. Plasmids maps and further information on each plasmid can be 
found in Appendix II. SuperFect™ has a dendrimer structure with positively charged 
amino groups that interact with the phosphate backbone o f DNA to form a complex 
that can be taken up into the cell by endocytosis. The total mixture was allowed to 
incubate at room temperature for lOmin before being added to complete medium 
(containing 10% (v/v) HI-FCS). The complete mix was added dropwise to cells. 
Cytokine treatment was carried out 30min following transfection (Hep3B cells). Cells 
were incubated at 37°C with 5% (v/v) CO2 overnight before being harvested using 1 x 
Passive Lysis Buffer (Promega). In the case o f U937 cells, PMA was added 
immediately following transfection and cytokines were added 2hr after transfection. 
Cells were left to differentiate overnight before being harvested using 1 x Passive 
Lysis Buffer (Promega).
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2.5.2 Preparation of cell extracts for determination of reporter gene activity
To prepare cell extracts for analysis, medium was aspirated and replaced with PBS. 
The PBS was then aspirated and 200pl o f 1 x Passive Lysis Buffer (Promega) was 
added directly to the cell monolayer and left to incubate for 15min at room 
temperature. Cells were then scraped into the buffer, transferred to a microcentrifuge 
tube and centrifuged at top speed for 5min. The supernatant was either stored at - 
20°C or used immediately for the measurement of luciferase activity.
2.5.3 Luciferase assay
Luciferase activity o f samples was determined as described by the manufacturer 
(Promega). Firefly luciferase is an enzyme that catalyses the activation of luciferin by 
ATP to produce an anhydride intermediate which then reacts with oxygen to produce 
oxyluciferin, CO2 and light (Reed et al. 2007). Luciferase Substrate (lOOpl) and 
sample were added to disposable plastic cuvettes in a 1:1 ratio. Luciferase activity 
was determined using a Luminometer (TD-20/20, Turner Designs, California, USA) 
set at 70% sensitivity level with a 2sec delay period and a 20sec integrate period. 
Measurements were taken in duplicate and luciferase counts were normalised to the 
protein concentration (pg/pl) of each sample (Section 2.7.4).
2.6 siRNA Transfections
2.6.1 siRNA transfection with Interferin™
siRNA transfections were carried out using validated siRNAs against target mRNAs 
(Table 2.9). Stock solutions were prepared from lyophilised siRNAs according to the 
manufacturer’s instructions (Qiagen and Invitrogen). siRNA transfection was carried 
out in THP-1 cells prior to differentiation with 0.16pM PMA. Confluent THP-1 cells 
were harvested by centrifugation at 1 lOxg for 5min. The cell pellet was resuspended 
in the appropriate volume of complete RPMI-1640 medium with no antibiotics. Cells 
were seeded into 6-well plates and incubated at 37°C with 5% (v/v) CO2 for 4 hr prior 
to transfection. siRNA transfection was carried out according to the manufacturer’s 
instructions (PolyPlus Transfection) with minor modifications.
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The following procedure was carried out for the transfection of cells in one 2cm2 cell 
culture dish. Transfection mix was prepared in lOOpl antibiotic-free and HI-FCS-ffee 
RPMI-1640 medium. Then, 7.5nM siRNA was added to this and the sample was 
briefly centrifuged in a microcentrifuge. Following addition of the transfection 
reagent Interferin™ (18pl), the mixture was again briefly micro-centrifuged and 
allowed to incubate at room temperature for 20min. The complete mixture (lOOpl) 
was then added dropwise to cells. Following transfection (24hr) cells were 
differentiated using 0.16pM PMA for 24hr. Cells were left untreated or stimulated 
with 30nM TGF-p for the requisite time period before being harvested for RNA 
extraction (Section 2.4.1) or protein extraction (Section 2.7.1).
Table 2.8 siRNAs used during the course of this study
Target mRNA transcript NCBI accession 
number(s) of target
SI Reference 
number/Catalogue 
number*
GAPDH NM 002046 *AM4604
Smad-2 NM 001003652 
NM 001135937 
NM 005901
SI02757496
Smad-3 NM 005902.3 *46-1718/46-1719
p38 M APK NM 0001315.1 
NM 139012.1 
NM 139013.1 
NM 139014.1
*46-1471 / 46-1470
c-Jun NM 002228 SI00300580
ERK 1/2 NM 002745 
NM 138957
SI00300755
SRC-1 (NCOA-1) NM 003743 
NM 147223 
NM 147233
SI00055342
2.7 Protein  analysis
2.7 .1  Preparation o f protein extracts using Laemmli buffer
Cells were routinely grown in a 2cm2 well for protein analysis. The cells were 
washed with 1ml PBS. The PBS was then aspirated from the cells and 70pl freshly
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prepared Laemmli buffer (Table 2.10) was added. Cells were scraped into the buffer 
and the collected extracts were micro-centrifuged at top speed for 5min. Lysates were 
stored at -80°C or used immediately for SDS-PAGE followed by western blotting 
(Section 2.7.7).
2.7.2 Preparation of Whole-cell protein extracts
Cells were washed and scraped into an appropriate volume o f PBS before being 
transferred to a polypropylene (Falcon) tube and centrifuged at 1 lOxg for 5min. Cells 
were resuspended in freshly prepared whole cell extracts buffer (lOOpl) (Table 2.10), 
transferred to microcentrifuge tubes and vortexed for 5sec. The extracts were left on 
ice at 4°C for 30min before being micro-centrifuged at 10,000rpm for lOmin, also at 
4°C. The supernatant containing the total cellular protein was removed and stored at - 
80°C. Protein concentration was determined using the Micro Protein Assay Reagent 
Kit (Pierce).
For preparation o f phosphatase-free whole cell extracts, cells were washed twice with 
ice-cold PBS (1ml) containing lOmM NaF and lOOpM sodium ortho vanadate and 
micro-centrifuged (13,00rpm, lmin) between washes. The cell pellet was resuspended 
in whole cell extraction buffer (Table 2.10). Extracts were vortexed for 45sec and 
micro-centrifuged (10,000rpm, lOmin at 4°C). The supernatant containing the total 
cellular protein was stored at -80°C and protein concentration was determined using 
the Micro Protein Assay Reagent Kit (Pierce) as described above.
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Table 2.10 Composition of stock solutions used for protein analysis by SDS-PAGE and W estern Blotting
Solution Composition
Laemmli sample buffer 0.125M Tris-HCl (pH 6.8), 4% (w/v) SDS, 10% (w/v) Glycerol, 
10% (v/v) 2-mercaptoethanol
Phosphatase-free whole-cell extraction buffer lOmM Tris-HCl (pH 7.05), 50mM NaCl, 50mM NaF, 1% (v/v) 
Triton X-100, 30mM Na4 P2 C>7 (sodium pyrophosphate), 5pM 
ZnCH, lOOpM Na3V04 (sodium orthovanadate), ImM DTT, 
2.8pg/ml Aprotonin, 2.5pg/ml Leupeptin, 2.5pg/ml Pepstatin, 
0.5mM Benzamidine, 0.5mM PMSF
Bromophenol blue 0.05% (w/v) bromophenol blue in ddH20
SDS PAGE gel loading buffer 50mM Tris-HCl (pH 6.8), lOOmM DTT, 2% (w/v) SDS, 0.1% 
(w/v) bromophenol blue, 10% (v/v) glycerol
SDS PAGE separating gel buffer 1.5M Tris-HCl (pH 8.8), 10% (w/v) SDS
SDS PAGE stacking gel buffer 1M Tris-HCl (pH 6.8), 10% (w/v) SDS
SDS PAGE running buffer 25mM Tris, 250mM glycine, 0.1% (w/v) SDS
Western blot transfer buffer 25mM Tris, 192mM glycine, 20% (v/v) methanol
lOx Tris buffered saline (TBS) lOmM Tris-HCl, 20mM NaCl, pH 7.4
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2.7.3 Preparation of Nuclear Extracts
Nuclear extracts were prepared using the Active Motif Nuclear Extract Kit according 
to the manufacturer’s instructions (Active Motif) with minor modifications. The 
following procedure was carried out for Hep3B cells grown in one 100mm2 plate. 
Briefly, cells were washed once with 3ml ice-cold PBS/phosphatase inhibitors 
provided in the kit. This was aspirated and replaced with 5ml ice-cold 
PBS/phosphatase inhibitors. Cells were scraped into the solution and transferred to a 
polypropylene (Falcon) tube and pelleted by centrifugation (1 lOxg, 5min at 4°C). The 
supernatant was discarded and the cell pellet was resuspended in 500pi lx  Hypotonic 
buffer (provided in the kit), transferred to a microcentrifuge tube and incubated on ice 
for 15min. Then, 25pi o f detergent was added, and the mixture vortexed (lOsec) and 
micro-centrifuged at 4°C (13,000rpm, lmin). The supernatant containing the 
cytoplasmic fraction was collected and stored at -80 °C. The cell pellet was 
resuspended in 50pl Complete Cell Lysis Buffer (provided in the kit), vortexed 
(lOsec) and incubated on ice (30min, with rocking). After micro-centrifugation 
(13,000rpm for lOmin at 4°C) the supernatant containing the nuclear fraction was 
collected and stored at -80°C. Protein concentration was determined using the Micro 
Protein Assay Reagent Kit (Pierce).
2.7.4 Determination of protein concentration
Protein concentration was determined using the Micro BCA Protein Assay Reagent 
Kit as described by the manufacturer (Pierce). Samples were processed in 96 well 
plates and a standard curve was prepared for each assay using the appropriate buffer. 
Samples were routinely diluted using PBS at a ratio o f 1 in 50 and 1 in 100. Reagents 
A, B and C, provided in the kit, were mixed according to the manufacturer’s 
instructions (Pierce) and added to each well. The plate was covered and left to 
incubate at 37°C for 2.5hr or overnight at room temperature. A Model 680 Microplate 
Reader (Biorad) was used to measure the absorbance o f each sample at a wavelength 
o f 570nm.
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2.7.5 SAPK/JNK Activity Assay
The SAPK/JNK assay was carried out using the SAPK/JNK non-radioactive kinase 
assay kit according to the manufacturer’s instructions (Cell Signaling Technology) 
with minor modifications. Cell extracts were prepared using 1 x Cell Lysis Buffer 
(provided in the kit) supplemented with ImM of the protease inhibitor PMSF. Then, 
200pl of extract was added to 20pl o f c-Jun fusion protein beads (a c-Jun fusion 
protein linked to agarose beads) and incubated at 4°C overnight, with gentle rocking 
to allow binding o f SAPK/JNK to the c-Jun fusion protein. The sample was micro­
centrifuged at 13,000rpm for 2min. The resultant pellet was washed three times with 
500pl 1 x Cell Lysis Buffer (provided in the kit) and micro-centrifuged between 
washes (13,000rpm, lmin) to remove the agarose beads. The pellet was then washed 
three times with 1 x Kinase Buffer (provided in the kit) with micro-centrifugation 
(13,000rpm, lmin) between washes to remove any contaminants. The resulting pellet 
was resuspended in 50pl of 1 x Kinase Buffer (provided in the kit) supplemented with 
200pM ATP and the mixture was incubated at 30°C for 30min to allow for the 
phosphorylation o f c-Jun by SAPK/JNK. The reaction was terminated by addition of 
25jil solubilising solution (SDS-PAGE gel loading buffer) (Table 2.10). The sample 
was boiled for 5min before being loaded onto a 10% (w/v) SDS-PAGE gel. SDS- 
PAGE and Western blotting were carried out as described in Sections 2.7.7 and 2.7.8 
respectively. An antibody specific to this kit, phospho c-Jun (Ser63) was used for 
immuno-detection.
2.7.6 p44/42 MAPK Activity Assay
The p44/42 MAPK assay was carried out using the p44/42 MAPK non-radioactive 
kinase assay kit according to the manufacturer’s instructions (Cell Signaling 
Technology) with minor modifications. Cells were prepared using 1 x cell lysis 
buffer (provided in the kit) supplemented with ImM PMSF. Cell extracts (200pl) 
were added to 15pl Immobilised phospho p44/p42 (Thr202/Tyr204) MAPK mouse 
monoclonal antibody and incubated at 4°C overnight, with gentle rocking to allow the 
antibody to bind the p44/42 MAPK. Cells were pelleted and washed with 1 x cell 
lysis buffer followed by 1 x kinase buffer as described in Section 2.7.5. After the 
final wash, the pellet was resuspended in 50pi 1 x kinase buffer (provided in the kit) 
supplemented with 200pM ATP and 5pg Elk-1 fusion protein. The mixture was
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incubated at 30°C for 30min to allow the active p44/42 MAPK to phosphorylate the 
Elk-1 substrate and then the reaction was terminated by addition of 25pi solubilising 
solution (SDS-PAGE gel loading buffer) (Table 2.10). The sample was boiled for 
5min before being loaded onto a 10% (w/v) SDS-PAGE gel. SDS-PAGE and western 
blotting were carried out as described in Sections 2.7.7 and 2.7.8 respectively. An 
antibody specific to this kit, phospho Elk-1 (Ser383) was used for immuno-detection.
2.7.7 SDS polyacrylamide gel electrophoresis
SDS-PAGE was routinely carried out using gels composed of 10% or 12.5% (w/v) 
acrylamide. Stacking and separating gels were prepared from stock solutions (Table 
2.11) with the composition o f the separating gel determined by the size of the protein 
being fractionated. Electrophoresis was carried out using the Mini-PROTEAN II slab 
electrophoresis cell (Bio-Rad Laboratories). Glass plates were cleaned and prepared 
and the separating gel poured to within 3cm of the upper edge o f the inner glass plate. 
Isopropanol was layered on top to remove any air bubbles and TEMED and APS were 
added to the gel mix to initiate polymerisation of the acrylamide/bisacrylamide gel. 
Once the gel had set, the isopropanol was washed off using ddfLO and the upper 
surface of the plates dried with Whatman 3MM paper. The stacking gel was poured 
to the top o f the plates and a well-forming comb added. Once the gel had set and 
polymerised, the comb was removed and any air bubbles in the wells removed using 
Whatman 3MM paper. The gel was then placed in the electrophoresis tank and the 
inner and outer compartments were filled with lx  running buffer, containing 0.1% 
(w/v) SDS.
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Table 2.11 Composition of stacking and separating gels for SDS-PAGE
Component 5% (w/v) 
stacking gel
7.5% (w/v) 
separating gel
10% (w/v) 
separating gel
12.5% (w/v) 
separating gel
Upper buffer 1.25ml - - -
Lower buffer - 2.5ml 2.5ml 2.5ml
Acrylamide:
Bisacrylamide
(37.5:1)
0.625ml 1.875ml 2.5ml 3.125ml
10% (w/v) APS 50|il lOOpl lOOpl lOOpl
TEMED 5 gl lOpl lOpl lOpl
ddH.O 3.07ml 5.625ml 5 ml 4.26pl
Protein samples were prepared as described previously (Sections 2.7.1 and 2.7.2). 
Laemmli buffer and whole-cell extraction buffer preparation used the reducing agent 
2-mercaptoethanol (Laemmli buffer-prepared extracts) or DTT (whole-cell extraction 
buffer-prepared extracts) to disrupt the disulphide bonds of the protein and cause 
denaturation. Both buffers also contained the detergent SDS which disrupts the non- 
covalent bonds o f the protein. SDS deposits negative charges on the peptide 
backbone of the protein that are proportional to its molecular weight. The large 
negative charge causes electrostatic repulsion leading to the unfolding and denaturing 
of the protein into a rod-like shape that will run smoothly on the gel (Reed et al. 
2007). To whole cell protein extracts, SDS-PAGE gel loading buffer (Table 2.10) 
was added and with the exception of ABCA-1 samples, the extracts were heated at 
100°C for 5min. Laemmli buffer protein extracts (Section 2.7.1) were heated for 
7min at 100°C following addition of bromophenol blue for visualisation of protein 
samples. Appropriate volumes of sample (routinely between 10 and 30pl of Laemmli 
buffer protein extract or 10-30pg whole cell protein extract) were added to wells and 
were size-ffactionated alongside a full-range rainbow protein marker (GE Healthcare) 
(Appendix I). Electrophoresis was carried out at 200V for 45-50min. The gels were 
then used for western blotting.
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2.7.8 Western Blotting
Following electrophoresis, the stacking gel was cut away and the separating gel 
equilibrated in transferring buffer (Table 2.10). PVDF membrane (0.45pm pore size, 
Millipore) was cut to the size o f the gel and activated in methanol before also being 
placed in transferring buffer. The membrane was placed on top o f the gel and both 
were sandwiched between Whatman 3MM paper and sponge pads which had also 
been soaked in transferring buffer and placed in a blotting cassette. Electrophoretic 
transfer of proteins was carried out using a Mini Trans-Blot cell (Bio-Rad 
Laboratories) containing the transfer buffer (Table 2.10). Electro-blotting was carried 
out at 150V for 75min at 4°C or at 15V for 12-18hr at 4°C.
2.7.9 Immuno-detection of proteins
Following blotting, the membrane was removed and placed in 5% (w/v) powdered 
milk for blocking, for lhr with shaking. Proteins in the milk solution bind to spaces 
in the membrane to prevent non-specific binding o f the antibody, ensuring that it can 
only bind to the target protein (Reed et al. 2007). The membrane was washed three 
times for 5-10min with 1 x TBS containing 0.1% (v/v) TWEEN-20 (Table 2.10). The 
membrane was then incubated with the primary antibody, diluted in lx  TBS with 
0.1% (v/v) TWEEN-20 and 5% (w/v) skimmed milk powder or 5% (w/v) bovine 
serum albumin (BSA), for lhr at room temperature or overnight at 4°C (Table 2.12). 
The membrane was washed as described above and incubated with the secondary 
antibody, diluted in lx TBS containing 0.1% (v/v) TWEEN-20 and 5% (w/v) 
skimmed milk powder, for lhr at room temperature (horse-radish peroxidise- 
conjugated, anti-rabbit IgG, anti-mouse IgG or anti-goat IgG diluted 1:2000 to 
1:20,000). The membrane was washed as described above and then used for 
chemiluminescent detection (Section 2.7.10).
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Table 2.12 Antibodies used for the immuno-detection of proteins following
Western blotting
Primary Antibody Dilution 
(in lx  TBS with 0.1% 
(v/v) TWEEN 20)
5% (w/v) 
non-fat milk 
or 5% (w/v) BSA
Protein 
size (kDa)
Anti- ABCA-1 1:1000 Milk 220
Anti- ADAMTS-4 1:1000 BSA 53 and 68
ApoE 1:1000 Milk 34
0-actin 1:10,000 Milk 42
c-Jun 1:1000 BSA 35 and 37
JNK 1:1000 BSA 46 and 54
LPL 1:500 Milk 56
p38 kinase 1:1000 BSA 43
p44/42 MAPK (ERK 1/2) 1:1000 BSA 42 and 44
Phospho c-Jun 1:1000 BSA 35 and 37
Phospho Elk-1 1:1000 BSA 62
Phospho p44/42 MAPK 1:1000 BSA 42 and 44
Phospho JNK 1:1000 BSA 46 and 54
Phospho p38 kinase 1:1000 BSA 43
Phospho Smad-2 1:1000 BSA 60
Phospho Smad-3 1:1000 BSA 60
Smad 2/3 1:1000 BSA 58
Smad 3 1:1000 BSA 58
SR-A 1:1000 Milk 75
SRC-1 1:1000 BSA 180
2.7 .10  D etection of Chem ilum inescence
Chemiluminescent detection was carried out according to the manufacturer’s protocol 
(GE Healthcare). The chemiluminescent reagent is cleaved by the horse-radish 
peroxidise reporter gene present on the secondary antibody. This results in a 
luminescence that is proportional to the amount of protein present and that can be 
detected by photographic film. Membranes were placed in contact with Kodak X-ray 
film in a light proof cassette (Genetic Research Instrumentation, GRI) for varying 
periods of time. The film was developed using an automatic developer (Agfa- 
Gaevert).
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2.8 E lectrophoretic M obility Shift Assay (EMSA)
2.8 .1  Preparation of radiolabelled o ligonucleotide probe
Forward and reverse oligonucleotide sequences were designed to leave 5’ overhangs 
that contained at least one G residue following annealing to allow for the 
complementary binding of [a-32P]-dCTP during radiolabelling (Table 2.13).
Table 2.13 Sequences of oligonucleotides used for EMSA
ADAMTS-4
promoter
region
Annealed Oligonucleotide
O ligo 1 
(-502 to -463)
5*- TTGATGCCTCCTTACCTGTTCCCTACCTTCTTTTCTCAGGCA -3’
3 ’- T ACGG AGG AAT GG AC AAGGG AT GGAAG AAAAG AGT CCGTCG -5 ’
O ligo 2 
(-464  to -439)
5 ’- AGGCAGCTCACTCAGTCCCCTCAGCCCTGG -3’
3 ’- GTCGAGTGAGTC AGGGG AGTCGGG ACCTTTG -5 ’
O ligo 3 
( ^ 4 3  to -423)
5 ’- GCCCT GG A AACC AGCC ACT AGG -3’
3 ’- GGACCTTTGGTCGGTGATCCCGG -5’
O ligo 4  
(-423 to -390)
5 ’- GGGCCAAAGGGCAGCATGAGGGAGCCTTGAGAAAA -3’
3 ’- GGTTT CCCGT CGT ACT CCCT CGG A ACT CTTTT CTCTT CGG -5 ’
2.8.1.1 Annealing o f oligonucleotides
Forward and reverse oligonucleotides were incubated together (100°C, lOmin) in the 
presence of a medium salt buffer (NEB buffer 3). The mixture was left to cool to 
room temperature and either used immediately for radiolabelling or stored at -20°C.
2.8.1.2 Radiolabelling of oligonucleotides
Oligonucleotides were radiolabelled using the reagents supplied in the MegaPrime™ 
Labelling Kit (Amersham). Annealed oligonucleotides (lOpl) were incubated for 
20min at 37°C with lx labelling buffer, Klenow DNA polymerase (2pl) and [a-32P]- 
dCTP (3pl) in a total volume of 50pl. Radiolabelled probe was separated from
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unincorporated nucleotides using a Sephadex G50 nick column. The column was 
equilibrated using lx TE buffer (lOmM Tris-HCl (pH 7.5), ImM EDTA). The 
reaction mixture (50pl) was added to the column and eluted using lx TE buffer 
(350pl). The unlabelled probe was then discarded and the column further eluted using 
400pl lx TE buffer. The eluate (labelled probe) was collected and stored at -20°C.
2.8 .2  DNA-protein binding reactions
Binding of the radiolabelled probe to the nuclear extracts was carried out in a 10pl 
reaction. Nuclear extract (2pg) was added to 2pl 5x binding buffer (Table 2.14), 2pl 
poly-(dl-dC) (lpg/pl) to prevent non-specific binding, and 3pl radio-labelled probe. 
The mixture was incubated at room temperature for 30min before being subjected to 
electrophoresis.
Table 2.14 Composition o f buffers used for EM SA
Buffer Composition
5x Binding buffer
1M Tris-HCl (pH 8), 2.5M KC1, 0.5M 
EDTA, 1M DTT, 62.5% (v/v) glycerol, 
0.5% (v/v) Triton X-100
2.8 .3  C om petition binding studies
For competition binding studies a 250-fold molar excess of unlabelled competitor 
oligonucleotides was added to the protein binding reaction and incubated on ice for 
20min prior to the addition of radiolabelled probe.
2.8 .4  Electrophoresis o f DNA: protein com plexes
A nondenaturing, polyacrylamide gel (6%) was used to resolve DNAiprotein 
complexes, the composition of which is outlined below.
7.5ml acrylamideibisacrylamide (29:1)
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2.5ml lOx TBE 
40ml dH20  
500jj.1 APS (10%w/v)
50jxl TEMED
Electrophoresis was carried out in 0.25% (v/v) TBE buffer at 150V for 3-4hr using 
vertical gel apparatus (Scotlab). Following electrophoresis the gel was transferred to 
Whatman 3MM paper and dried using a gel dryer (Model 583, Bio-Rad) for lhr. The 
gel was exposed to Kodak XAR film (Sigma) in a light proof cassette at -80°C for 
varying time periods (12-72hr). Film was developed using an automatic developer 
(Agfa-Gevaert).
2.9 Densitometric analysis of data
The density o f bands from agarose gel images, immunoblots and EMSA films was 
analysed using the GeneTools software (Syngene).
2.10 Statistical analysis of data
Data was analysed using a standard Student’s T test with P<0.05 taken as statistically 
significant (Appendix III).
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CHAPTER 3 
TGF-p-regulated expression of key genes 
implicated in the control o f macrophage 
cholesterol homeostasis
3.1 Introduction
3.1.1 Macrophage cholesterol homeostasis
The studies presented in this chapter focus on the regulation o f expression of key 
genes implicated in macrophage cholesterol homeostasis by TGF-p. As detailed in 
Sections 1.3 and 1.4, the differentiation of macrophages into lipid-laden foam cells is 
a critical early event in atherosclerosis. Foam cell formation is caused by an 
imbalance between the uptake of modified LDL into cells and the efflux of cholesterol 
from these cells. Macrophages take up cholesterol through the scavenger receptors, 
SR-A, CD36 and SR-PSOX which normally serve to remove pathogens and cell 
debris but in atherosclerosis take up oxLDL. The enzyme lipoprotein lipase also 
contributes to the uptake of cholesterol by hydrolysing lipids into smaller cholesterol- 
rich remnants that can be easily taken up by macrophages. Cholesterol is removed 
from cells by reverse cholesterol transport; the movement o f cholesterol from cells to 
HDL via ATP binding cassette transporters. This requires two apolipoproteins o f 
HDL, ApoAI and ApoE that act as cholesterol acceptors and subsequently bind to 
lipoprotein receptors to enhance the degradation and clearance of cholesterol.
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The expression o f key genes involved in this balance between cholesterol uptake and 
efflux can be influenced by cytokines produced by macrophages. TGF-p negatively 
regulates foam cell formation and this is thought to be mediated through the inhibition 
o f expression of genes implicated in cholesterol uptake and stimulation of expression 
of genes thought to be involved in cholesterol efflux (Ramji et al. 2006). For 
example, the cytokine inhibits cholesterol accumulation induced by VLDL remnants 
in the mouse macrophage J774.2 cell line and increases cholesterol efflux from 
macrophage-derived foam cells from ApoE-deficient mice (Argmann et al. 2001; 
Panousis et al. 2001). The studies presented in this chapter investigate the regulation 
of expression o f a number of key genes implicated in the control o f macrophage 
cholesterol homeostasis by the cytokine TGF-P, using the THP-1 macrophage cell line 
as a human model system. The genes selected for study have been employed in our 
laboratory as model genes which have well-defined and distinct roles in foam cell 
formation and atherosclerosis. The structure and function o f these genes is detailed in 
Sections 1.3.1, 1.3.2, 1.4.1 and 1.4.2. The regulation o f the expression of these genes 
by TGF-P has been reported but the majority o f studies have been carried out using in 
vivo models or murine macrophage cell lines. The current knowledge regarding their 
regulation is outlined below.
3.1.2 Lipoprotein lipase (LPL)
A large number o f studies have established that macrophage LPL is pro-atherogenic. 
Cholesterol-rich remnants produced by hydrolysis are readily taken up by 
macrophages and the ability o f the enzyme to act as a molecular bridge promotes 
uptake of lipoproteins into the arterial intima as explained in more detail in Section
1.3.2 (Mead et al. 2002; Mead and Ramji 2002). Macrophages and smooth muscle 
cells are major sources of LPL in atherosclerotic plaques and the expression and 
activity of LPL is upregulated following monocyte-macrophage differentiation (Mead 
and Ramji 2002; Stein and Stein 2003).
Our laboratory has previously shown that TGF-p inhibits the mRNA and protein 
expression o f LPL in mouse J774.2 macrophages and primary cultures of human 
monocyte-derived macrophages (HMDMs) and that this corresponds to a decrease in 
LPL activity (Irvine et al. 2005). LPL promoter-luciferase DNA constructs identified
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the -31/+187 promoter region as containing the minimal TGF-p responsive elements 
and bioinformatic analysis o f this region identified three Spl/Sp3 binding sites (at 
positions +44, +62 and +65) that are crucial for inhibition of LPL gene transcription. 
Spl and Sp3 are widely expressed zinc finger transcriptional regulators that are 
involved in regulating constitutive gene transcription and cytokine-induced gene 
transcription. While Spl acts as a transcriptional activator, Sp3 contains a 
transcriptionally repressive domain allowing it to act as either a repressor or activator 
of transcription depending on cellular and promoter context (Black et al. 2001; Irvine 
et al. 2005). Mutation o f these sites abolished the TGF-P response and DNA 
constructs containing multimers o f the Spl/Sp3 sites linked to the SV40 promoter of 
the pGL2 promoter vector showed that the sites were able to confer the TGF-p 
response to a heterologous promoter (Irvine et al. 2005). The absence of any change 
in the binding or expression of Spl/Sp3 in macrophages suggested that TGF-P 
modulated LPL expression through the suppression o f Spl/Sp3 transactivation 
potential as opposed to having effects on Spl/Sp3 ratio (Irvine et al. 2005; Ramji et al. 
2006). Despite this work, the signalling pathways underlying the regulation of LPL 
gene transcription by TGF-P, along with how this cytokine modulates the 
transactivation potential of Spl/Sp3 remains uncharacterised. Due to the critical role 
of this enzyme in cholesterol uptake and foam cell formation, further studies into the 
molecular mechanisms underlying its regulation will enhance our understanding of 
the molecular basis o f atherosclerosis.
3.1.3 Scavenger receptor A (SR-A)
SR-A is expressed in both macrophages and foam cells of human atherosclerotic 
lesions where it plays a pro-atherogenic role through the uptake o f acetylated and 
oxidised LDL (Moore and Freeman 2006; Peiser and Gordon 2001). Gene-targeted 
knockout o f SR-A in ApoE‘~ and LDLR'' murine models results in significantly 
reduced atherosclerotic lesion size (de Winther et al. 2000; Moore and Freeman 2006; 
Peiser and Gordon 2001). SR-A expression and activity is upregulated following 
monocyte-macrophage differentiation and is often used as a marker for differentiation 
(Argmann et al. 2001). TGF-p inhibits the expression of SR-A in both THP-1 
monocytes, macrophages and human monocyte-derived macrophages through a 
reduction of mRNA levels causing a decrease in cell-surface receptor number
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(Bottalico et al. 1991; Draude and Lorenz 2000). In a functional context, this leads to 
reduced uptake of both acetylated and oxidised LDL (Argmann, 2001). Interestingly, 
pravastatin is able to down-regulate SR-A expression in a TGF-P-dependent manner 
in THP-1 macrophages (Baccante et al. 2004).
3.1.4 Scavenger receptor-Bl (SR-B1)
SR-B1 is expressed in cultured macrophages and immunohistochemical analysis has 
demonstrated that it is expressed in foam cells o f human atherosclerotic lesions. Like 
SR-A, its expression is up-regulated following differentiation of monocytes into 
macrophages (de Villiers and Smart 1999; Gillotte-Taylor et al. 2001; Hirano et al. 
1999; Moore and Freeman 2006; Zhang et al. 2003). The role of SR-B1 in 
atherosclerosis is complex with the receptor having two opposing functions. The 
primary and most well-studied function of SR-B1 as a receptor for HDL suggests an 
anti-atherogenic role. SR-B1 knockout mice present with hypercholesterolemia, 
accumulation o f HDL and significantly more atherosclerosis than wild-type 
counterparts (Moore and Freeman 2006; Trigatti et al. 2004; Zhang et al. 2003). 
However, SR-B1 can also function as a classical scavenger receptor and this function 
may be more significant in macrophages. Indeed, knockout of macrophage SR-B1 in 
ApoE-deficient mice results in a 2-fold increase in atherosclerotic lesion area 
suggesting a pro-atherosclerotic role for the receptor (Zhang et al. 2003). Expression 
of SR-B1 at the mRNA and protein levels has been shown to be both induced and 
inhibited by oxLDL and it is likely that this effect is dependent on the differentiation 
state of macrophages with oxLDL decreasing SR-B1 expression in fully differentiated 
macrophages and increasing its expression in differentiating monocytes/macrophages 
(Han et al. 2001; Hirano et al. 1999). The levels of SR-B1 mRNA in macrophages are 
generally lower than that of CD36 (Zuckerman et al. 2001). TGF-P inhibits SR-B1 
mRNA expression in mouse peritoneal macrophages and in macrophage-derived foam 
cells from ApoE‘~ and LDLR " mice and this correlates with a decrease in HDL- 
macrophage interactions (Zuckerman et al. 2001).
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3.1.5 CD36
CD36 acts in a pro-atherogenic manner as it stimulates the uptake of oxLDL and 
significantly contributes to foam cell formation (Febbraio and Silverstein 2007; 
Moore and Freeman 2006). CD36-deficient mice show significantly less
atherosclerosis than wildtypes while CD36'/'ApoE'/* double knockout mice have 70% 
less lesions and reduced lesion size compared to wildtype counterparts (Febbraio and 
Silverstein 2007; Nicholson 2004; Nicholson et al. 2001). The expression of CD36 is 
up-regulated following differentiation o f monocytes into macrophages. The 
expression o f CD36 is inhibited by both TGF- p and IL-10 (Febbraio and Silverstein 
2007; Nicholson 2004). Down-regulation o f CD36 expression by TGF-P has been 
shown in THP-1 macrophages, primary cultures o f human macrophages and 
macrophages from ApoE‘~ and LDLR’’ mice (Draude and Lorenz 2000; Han et al. 
2000; Zuckerman et al. 2001).
Han et al. (2000) have demonstrated that TGF-p can inhibit the expression of CD36 at 
the mRNA and protein level in THP-1 macrophages. In addition to this, the cytokine 
inhibits CD36 expression induced in response to oxLDL and ligands of PPARy. As 
detailed in Section 3.4, PPARy is a nuclear receptor with important roles in 
inflammation and in the regulation of expression of genes involved in fatty acid 
metabolism and cholesterol homeostasis (Han et al. 1997; Han et al. 2000). The TGF- 
P-regulated inhibition of CD36 is accompanied by an increase in the phosphorylation 
of PPARy and the p44/42 MAPK isoforms, and inhibitors o f p44/42 MAPK reverse 
the TGF-P-mediated suppression o f CD36. This suggested that TGF-p down- 
regulates CD36 expression via a mechanism involving cytokine activation of MAPK 
and subsequent inactivation of PPARy through phosphorylation (Argmann et al. 2001; 
Han et al. 1997; Han et al. 2000; Nicholson et al. 2001). Interestingly, HDL inhibits 
the expression of CD36 by the same mechanism (Nicholson 2004). Down-regulation 
o f CD36 expression by TGF-P is associated with a reduction in the uptake of oxLDL 
by macrophages, consistent with the role of CD36 as the primary receptor for oxLDL 
(Draude and Lorenz 2000).
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3.1.6 Apolipoprotein E (ApoE)
ApoE stimulates cholesterol efflux from foam cells and can act as an acceptor for both 
cholesterol and phospholipids released from macrophages through ABCA-1 
(Greenow et al. 2005; Mahley and Rail 2000). ApoE-deficient mice are widely used 
as a model for atherosclerosis as they are hypercholesterolemic and develop 
atherosclerosis even when placed on a low-fat diet. Reduced expression of the protein 
in atherosclerosis is associated with a pro-atherogenic lipoprotein profile (Greenow et 
al. 2005; Mahley and Rail 2000; Ramji et al. 2006).
ApoE is not expressed in normal vessel walls but is synthesised at high levels by 
macrophages present within atherosclerotic plaques. In monocytes and macrophages, 
ApoE expression is enhanced by differentiation and also by cholesterol loading of 
macrophage cultures. Pro-inflammatory cytokines IFNy and IL-1 inhibit the 
expression o f the protein (Greenow et al. 2005). TGF-p induces the mRNA 
expression o f ApoE and its secretion from mouse peritoneal macrophages 
(Zuckerman et al. 1992). Our laboratory has demonstrated that TGF-P induces the 
expression o f ApoE at the mRNA and protein levels in both THP-1 monocytes and 
macrophages (Ramji et al. 2006; Singh and Ramji 2006). Pharmacological inhibitors 
against JNK, p38 kinase and protein kinase CK2 attenuated the TGF-p-mediated 
induction of ApoE, identifying roles for these kinases in the ApoE response. The 
activity and/or expression of protein kinase CK2, p38 kinase, JNK and its downstream 
target c-Jun were induced by TGF-P in THP-1 monocytes and dominant-negative 
DNA constructs o f these inhibited ApoE mRNA expression by this cytokine (Singh 
and Ramji 2006). EMSA analysis showed that the signals converge on the AP-1 
binding site present within the ApoE promoter (Singh and Ramji 2006).
3.1.7 ATP-binding cassette transporters-Al and -G1 (ABCA-1 and ABCG-1)
The primary role of ABCA-1 is the transport o f cholesterol and phospholipids from 
cells to apolipoproteins in the bloodstream (Wang and Tall 2003). ABCA-1 is an 
anti-atherogenic protein. Deficiency of macrophage ABCA-1 in mice leads to 
increased atherosclerosis while overexpression reduces atherosclerosis (Oram and 
Vaughan 2006). The preventative role of ABCA-1 in atherosclerosis is also
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demonstrated by the association between ABCA-1 mutations and premature 
atherosclerosis observed in Tangier disease (Attie 2007).
The function o f ABCA-1 and ABCG-1 as removers of excess cholesterol from 
macrophages is responsible for their anti-atherogenic properties. Macrophages express 
high levels o f ABCA-1 in response to the transcription factor, LXRa which is itself 
activated by cholesterol metabolites derived from excessive uptake of oxLDL by 
cells. LXRa upregulates ABCA-1 and ABCG-1 expression in various sources of 
cholesterol-loaded macrophages, including THP-1 macrophages, primary human 
macrophages and lipid-laden foam cells (Oram and Vaughan 2006; Wang and Tall 
2003). Both ABCA-1 and ABCG1 expression is increased during monocyte- 
macrophage differentiation (Schmitz et al. 2001). TGF-p treatment o f mouse 
peritoneal macrophages from ApoE'7' mice increases ABCA-1 expression and 
cholesterol efflux (Panousis et al. 2001). TGF-p enhances both ABCA-1 and ABCG- 
1 expression in THP-1 macrophages and this corresponds to an increased level of 
cholesterol efflux to apoA-I or HDL. The cytokine also increases levels of ABCA-1 
and cholesterol efflux from macrophage-derived foam cells (Argmann et al. 2001).
3.2 Aims of experimental studies
The studies presented in this chapter have been carried out using the THP-1 cell line, 
a widely used model for macrophage function and gene expression during 
inflammatory disorders. THP-1 is a human monocytic leukaemia cell line first 
established by Tsuchiya et al. (1980) that can be differentiated into macrophages 
using phorbol esters. Differentiated THP-1 cells have similar characteristics to and 
behave in the same way as native monocyte-derived macrophages (Auwerx 1991). 
Conserved responses between THP-1 cells and primary cultures have been observed 
in numerous studies (Kohro et al. 2004). In addition to this, lipid accumulation can be 
observed in differentiated THP-1 macrophages cultured in medium containing 
acetylated LDL, making them a useful model for macrophage-derived foam cells 
(Kohro et al. 2004). These characteristics o f THP-1 macrophages make them a 
suitable model for studies relating to atherosclerosis and foam cell formation (Kohro
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et al. 2004). Table 3.1 details examples of studies on atherosclerosis that have been 
carried out using the THP-1 cell line and/or primary human monocyte-derived 
macrophages.
120
CHAPTER 3: TGF-P-regulated expression o f  genes implicated in macrophage cholesterol homeostasis
Table 3.1 Studies utilising THP-1 cells and/or HMDMs to study various key aspects of atherosclerosis
Aspect of 
atherosclerosis
Monocyte/ 
M acrophage source
Key findings References
Monocyte adhesion to 
vascular endothelium
THP-1 monocytes Adhesion of monocytes to endothelial cells is dependent 
on shear stress and is mediated by the platelet integrins, 
L-selectin and P-selectin.
Theilmeier et al. 1999
THP-1 monocytes MCSF induces the mRNA expression of MCP-1 and 
promotes the adhesion of monocytes to endothelial cells.
Shyy et al. 1993
Monocyte migration THP-1 monocytes Elevated LDL levels increase the expression of the 
MCP-1 receptor and enhance the chemotactic response 
to MCP-1, to help recruit monocytes to the endothelium.
Han et al. 1998
THP-1 monocytes PDGF-C and PDGF-D can stimulate the activity of 
MMP-1 and MMP-9 to enhance the migration of 
monocytes.
Wagsater et al. 2009
Human monocytes Migration of monocytes is induced by VEGF and 
mediated through the VEGF receptor, Flt-1.
Barleon et al. 1996
Foam cell formation- 
Cholesterol uptake
THP-1 macrophages and 
HMDMs
IL-8 and MCP-1 expression are induced by cholesterol 
loading (AcLDL) of macrophages.
Wang et al. 1996
THP-1 macrophages IL-1 expression is induced by ligand binding to 
scavenger receptors.
Palkama 1991
THP-1 macrophages Adipocyte lipid binding protein expression is 
upregulated in foam cells, in response to oxLDL.
Fu et al. 2002
THP-1 macrophages IFN-y induces foam cell formation. Reiss et al. 2004
THP-1 macrophages and 
HMDMs
Identification of LOX-1, an oxLDL receptor, expression 
in macrophages.
Yoshida et al. 1998
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THP-1 macrophages Identification of CD36 as a receptor for oxLDL. Endemann et al. 1993
THP-1 macrophages CD36 expression is stimulated by oxLDL and inhibited 
by IFN-y.
Nakagawa et al. 1998
HMDMs SR-B1 is expressed in macrophages of atherosclerotic 
lesions and its mRNA and protein expression is 
increased by oxLDL and AcLDL.
Hirano et al. 1999
Foam cell formation- 
Cholesterol efflux
THP-1 macrophages and 
HMDMs
ABCA1 promotes the secretion of apoE from 
macrophages.
Von Eckardstein et al. 2001
HMDMs ApoAI promotes the recruitment of apoE and enhances 
cholesterol efflux from foam cells.
Bielicki et al. 1999
THP-1 macrophages and 
HMDMs
Activators of PPARa and PPARy induce the expression 
of ABCA1 and promote cholesterol efflux in 
macrophages.
Chinetti et al. 2001
Immune responses THP-1 monocytes Immune complexes of LDL bind to Fc receptors on 
monocytes to initiate atherogenic responses.
Ibeas et al. 2009; Kiener et al. 
1995
THP-1 monocytes and 
human monocytes
Inflammatory protein, phospholipase A2 type IIA, 
enhances the adhesion and migration of monocytes and 
the expression of cell surface markers and the T-cell 
proliferation capacity of these cells.
Ibeas et al. 2009
THP-1 monocytes Advanced ligation end products (formed following 
reactions between proteins and lipid intermediates) 
increase the expression of pro-inflammatory markers 
such as MCP-1, IL-6 and iNOS, and can also increase 
monocyte binding to endothelial and smooth muscle 
cells.
Shanmugam et al. 2008
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HMDMs
HMDMs
Immune complexes of LDL can activate macrophages.
Toll-like receptor-4 (TL4), involved in innate immune 
and inflammatory responses, is expressed in 
macrophages and is upregulated by oxLDL.
Virellaetal. 1995 
Xu et al. 2001
Plaque stability HMDMs
THP-1 monocytes
Increased density/activation of macrophages in 
atherosclerotic plaques can promote collagen breakdown 
through the enhanced secretion of MMPs.
Interactions between monocytes and VSMCs increase 
the production of MMP-1 and this contributes to plaque 
instability.
Shah et al. 1995 
Zhu et al. 2000
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There are a number of advantages o f using a cell line over HMDMs and in vivo 
models. In contrast to primary cells which are limited in availability and have a 
defined lifespan, cells lines can be cultured to grow indefinitely. It is also possible to 
extract larger amounts o f RNA or protein from cell lines and to avoid the possible 
issue o f donor-specific variations that arise with the use of primary cells. Use of a cell 
line can avoid complex interactions that occur in vivo. It also avoids the ethical issues 
that accompany the use of animal models or material from patients in scientific 
research.
The primary aims of the studies presented in this chapter were two-fold. The first aim 
was to verify the use of THP-1 macrophages as a human model system for studies on 
the regulation o f macrophage gene expression. Although the cytokine regulation of a 
number o f macrophage-expressed genes has been reported by our laboratory and 
others, the majority o f studies have used murine macrophages or in vivo mice models 
of atherosclerosis as model systems (Table 3.2) (Harvey et al. 2007; Hughes et al. 
2002; Singh and Ramji 2006). It was therefore important to establish the regulation of 
expression o f key genes implicated in macrophage cholesterol homeostasis in the 
THP-1 macrophage cell line. This was the second aim o f the studies presented in this 
chapter. The genes we investigated included LPL, SR-A, SR-B1 and CD36; genes 
implicated in cholesterol uptake by macrophages, and ApoE, ABCA-1 and ABCG-1; 
genes involved in cholesterol efflux by macrophages. The regulation o f ApoE and 
LPL has previously been investigated by our laboratory using THP-1 monocytes and 
the mouse macrophage cell line J774.2 (Table 3.2) but their regulation has not been 
fully investigated in THP-1 macrophages (Irvine et al. 2005; Singh and Ramji 2006). 
Regulation of other key genes, including the class A and class B scavenger receptors, 
has been reported in the literature but not studied by our laboratory. It was our aim to 
firstly characterise the responses of these key genes to TGF-P stimulation and then to 
establish a time point of optimal induction or inhibition of expression by the cytokine 
in order to provide a basis for further studies into the mechanisms controlling the 
regulation of expression of these genes by TGF-P, as set out in Chapters 4 and 5. This 
would also confirm the use of THP-1 as a suitable cell line for these studies. The 
experimental strategy for this work is summarised in Figure 3.1.
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Throughout the studies presented in this thesis, TGF-P was used at a concentration o f 
30ng/ml as our laboratory had previously determined this as the TGF-P concentration 
that optimally regulated ApoE and LPL expression in THP-1 macrophages (Irvine et 
al. 2005; Singh and Ramji 2006). Previous dose-response studies (using 0, 2, 5, 10, 
20 and 30ng/ml TGF-P) carried out in our laboratory had demonstrated that mRNA 
and protein levels of ApoE were optimally upregulated following 30ng/ml TGF-P 
treatment and time course experiments (0, 1,6, 12 and 24hr) demonstrated that this 
up-regulation was optimal after 24hr of TGF-P treatment (see Supplementary data- 
Singh and Ramji 2006).
Gene regulation was primarily studied at the mRNA level with key results also 
investigated at the protein level using western blotting. To confirm the use o f THP-1 
as a suitable model for human macrophages, the TGF-p regulation of ApoE 
expression was also studied in human monocyte-derived macrophages.
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PARTI PART 2
Effects of TGF-p on gene 
expression
THP-1 macrophages 
TGF-P treatment
Primary macrophages 
TGF-p treatment
Establish THP-1 as model human cellular
system for fu ture studies
Western blotting
Analyse protein 
expression
Analyse mRNA 
expression
1  1
RT-qPCR Western blotting
Determine optimal time point Confirm key findings from
for regulation by TGF-p THP-1 in primary
macrophages
Figure 3.1 Experimental Strategy
Initially, studies on the regulation of gene expression by TGF-P used RT-PCR 
analysis. Although this is semi-quantitative in nature and cannot be used to gauge 
exact levels of mRNA expression, an indication of the changes in expression can be 
observed effectively by densitometric analysis of the data. Hence, as RT-qPCR 
analysis became available in the laboratory, the expression of later-studied genes was 
analysed using this method. Western blot analysis was used for analysis of protein 
expression where an antibody to the protein of interest was available in the laboratory. 
For ease of reading, results have been presented on a gene by gene basis.
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3.3 Results
3.3.1. Effect of TGF-p on the mRNA expression of LPL
To investigate the effect of TGF-P on LPL expression, THP-1 cells were seeded into 
6 -well plates and differentiated for 24hr with PMA (0.16pM). Cells were then 
cultured in the presence or absence of TGF-p (30ng/ml) for 12hr or 24hr as indicated 
in Figure 3.2 and harvested for isolation o f total RNA. These time points were chosen 
based on previous studies in the laboratory that had suggested that these were suitable 
for the study of TGF-p-regulated gene expression. Integrity of RNA preparations was 
analysed by resolving an aliquot on a 1.5% (w/v) agarose gel. As expected for good 
quality RNA, the relative intensity of the 28S rRNA band was approximately twice 
that o f the 18S rRNA band (Figure 3.2A). RNA of this quality was produced in 
studies throughout this thesis and hence data is not shown. RT-PCR (Section 2.4.2) 
was carried out to amplify LPL and P-2 microglobulin using the conditions specified 
in Table 2.4. These conditions had been previously optimised by other members of 
the laboratory and correct amplification confirmed by sequence analysis. P-2- 
microglobulin has previously been shown to be a good control gene for RT-PCR 
studies in human hepatoma cell lines such as Hep3B and also in leukocytes (Cicinnati 
et al. 2008; Lupberger et al. 2002) and has been used in our laboratory for studies on 
cytokine-regulated gene expression in both the Hep3B and THP-1 cell lines. The 
PCR products were size-fractionated using agarose gel electrophoresis and correct 
amplification was verified by comparison to a standard DNA molecular weight 
marker (see Appendix I). Figure 3.2B shows the PCR products fractionated by 
agarose gel electrophoresis. The absence o f any PCR product in the no reverse 
transcriptase (-RT) sample indicates that any product produced is due to correct 
amplification o f the relative mRNA and not because of contamination of the samples 
with genomic DNA.
The relative intensity of LPL and p-2 microglobulin PCR products was determined 
using densitometric analysis (see Section 2.9). The Syngene GeneTools software 
assigns numerical values to each product that are related to its intensity. The intensity
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of each LPL product was compared relative to the intensity of the equivalent p-2 
microglobulin control (housekeeping) gene product. LPL expression was high in 
untreated cells and was dramatically inhibited by TGF-P at the 24hr and 48hr time 
points. The data is expressed as the fold change (mean± SD) with values from 
untreated samples arbitrarily assigned as 1 (Figure 3.2C). A standard statistical 
Student’s t-test was carried out on the data. P-2 microglobulin remained unaffected 
by TGF-p throughout the time course verifying that TGF-P does not globally affect 
gene expression and that any changes in LPL expression are a result of TGF-P 
treatment and not to the state o f the cells at the different time points.
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Figure 3.2 TGF-p down-regulates LPL mRNA expression in THP-1 
macrophages. THP-1 cells were treated with TGF-P or left untreated (UT) for the 
time points indicated and then harvested for total RNA extraction. RNA integrity was 
analysed by agarose gel electrophoresis (Panel A). Total RNA was subjected to RT- 
PCR analysis and the PCR amplification products for LPL and $2-microglobulin were 
resolved by agarose gel electrophoresis (Panel B). The size of the product was 
determined by comparison with a standard DNA molecular weight marker (Appendix 
I). -RT denotes a reaction in which no reverse transcriptase was included in cDNA 
preparation (using 24hr, untreated RNA). Panel C shows the relative expression 
(mean ±SD) of LPL normalised to the expression of p-2 microglobulin (untreated 
samples for each time point assigned as 1 ) from three independent experiments 
(**P<0.01).
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3.3.2 Time dependent effect of TGF-p on LPL mRNA expression
In light of the results presented in Figure 3.2 it was important to determine whether 
the effect o f TGF-p on LPL expression was time-dependent and to determine an 
optimal time point for future studies on LPL expression. This was investigated using 
RT-qPCR analysis as it became available in the laboratory. Differentiated THP-1 
cells were untreated (Ohr) or treated with TGF-p for periods of 6 , 12 and 24hr. Cells 
were harvested for total RNA and reverse transcribed using M-MLV reverse 
transcriptase. The resulting cDNA template was subjected to real-time qPCR analysis 
(RT-qPCR) (Section 2.4.3) using specific primers against LPL and the control gene 
28SrRNA as detailed in Table 2.5. 28SrRNA was used as a control gene in place of 
P-2 microglobulin as the conditions for 28SrRNA RT-qPCR had been optimised in 
the laboratory while those for P-2 microglobulin were not. 28SrRNA is a widely used 
validated control for RT-PCR and RT-qPCR and has previously been used in our 
laboratory as a control for TGF-P-regulated expression of ApoE (Singh and Ramji 
2006).
Real-time qPCR was carried out using the SYBR method using the amplification 
conditions set out in Table 2.6. These conditions were previously optimised by other 
members of the laboratory and correct amplification verified by sequence analysis. 
SYBR green is a DNA-binding dye that emits fluorescence on incorporation into 
dsDNA (Giulietti et al. 2001). A melting curve was constructed to ensure single- 
product amplification and the comparative Ct method was used for analysis as 
described by Livak and Schmittgen (2001). Data from qPCR methods can be 
analysed using absolute quantification (by comparison o f transcript copy number with 
a standard curve) or using relative quantification (by comparison with a reference 
group such as an untreated control or the stable expression o f a control gene, such as 
the housekeeping genes p-2-microglobulin and 28S rRNA) (Livak and Schmittgen 
2001). The Ct method is a commonly used method for relative quantification o f 
qPCR data. The Ct method relies on the number of cycles/rounds of amplification 
required for the fluorescence of a gene to surpass a pre-set threshold level (the Ct 
value). The value o f this for the gene of interest is compared relative to the equivalent 
Ct value for the control gene to normalise the data (Ginzinger 2002; Livak and 
Schmittgen 2001).
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The data presented in Figure 3.3 is displayed as the relative expression of LPL 
compared to the untreated (Ohr) sample. LPL expression was high in untreated cells 
and significantly reduced by TGF-p, 6 hr after treatment with the cytokine. Levels of 
LPL mRNA expression remained significantly inhibited by TGF-P over the 24hr time 
course with maximal inhibition at the 24hr time point. Levels of the control 
28SrRNA were unaffected by the cytokine.
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Figure 3.3 TGF-p inhibits LPL expression in a time-dependent manner in 
THP-1 macrophages. THP-1 cells were left untreated (Ohr) or treated with TGF-P 
for the time points indicated before being harvested for total RNA extraction. Total 
RNA was reverse-transcribed and the resulting cDNA subjected to RT-qPCR analysis 
using primers specific to LPL and the control gene 28SrRNA. Data is presented as 
the relative expression of LPL (mean ±SD) normalised to 28S rRNA expression (Ohr 
(untreated) sample assigned as 1 ) from four independent experiments (**/><0 .0 1 , 
***P<0 .0 0 1 ).
3.3.3 Effect of TGF-P on the protein expression of LPL
To confirm that the inhibition of LPL mRNA by TGF-p resulted in a corresponding 
change in the expression of the LPL protein, western blot analysis was carried out. 
THP-1 cells were seeded into 6 -well plates and differentiated for 24hr with PMA.
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Cells were then treated with TGF-P or left untreated for the requisite time. Total 
cellular protein was extracted using Laemmli buffer (Section 2.7.1), subjected to 
SDS-PAGE using a 10% (v/v) polyacrylamide gel and transferred to a PVDF 
membrane. The membrane was probed with an antibody against LPL and then re- 
probed with an antibody for a P-actin control to ensure equal loading of samples. The 
membrane was placed in contact with X-ray film and developed using 
chemiluminescent detection as described in Section 2.7.10. Figure 3.4A shows the 
images from western blotting. The relative density o f LPL and P-actin protein was 
determined using densitometric analysis (Section 2.9). P-actin has been widely used 
as a control for protein expression and has been used as a control for TGF-p-regulated 
gene expression (Draude and Lorenz 2000; Irvine et al. 2005) and for cytokine- 
regulated protein expression (Foka et al. 2009; Harvey et al. 2007) by our laboratory 
and others. The data was normalised to the untreated control for each time point and 
expressed as the mean fold change relative to this. Figure 3.4B shows that TGF-p 
inhibited the expression of LPL protein at the 24hr and 48hr time points. This change 
is synonymous with the changes in mRNA expression shown in Figure 3.2.
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Figure 3.4 TGF-P inhibits LPL protein expression in THP-1 macrophages.
THP-1 cells were left untreated (UT) or stimulated with TGF-p for 24 or 48hr. Whole 
cell protein extracts were subjected to SDS-PAGE and western blotting using 
antibodies against LPL and p-actin (Panel A). Protein size was determined by 
comparison against a standard protein molecular weight marker (Appendix I), p-actin 
was used as a loading control. Panel B shows the mean relative expression of LPL 
normalised to P-actin expression (untreated samples for each time point assigned as 1) 
from two independent experiments.
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3.3 .4  Effect of TGF-P on th e protein expression of SR-A
SR-A expression was analysed at the protein level as no primers to SR-A were present 
in the laboratory but an antibody against SR-A was available. THP-1 cells were 
treated with TGF-p or left untreated for the indicated time periods. Western blot 
analysis was carried out as for LPL (Section 3.3.3). The three bands present on the 
SR-A image represent the three isoforms of the protein. Figure 3.5 shows that SR-A 
expression was high in untreated cells and was significantly inhibited by TGF-P 
treatment at the 12hr and 24hr time points.
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Figure 3.5 TGF-p inhibits SR-A protein expression in THP-1 macrophages.
Whole cell-protein extracts from THP-1 macrophages that were untreated (UT) or 
treated with TGF-p for 12 or 24hr were subjected to SDS-PAGE and western blotting 
using antibodies against SR-A and P-actin (Panel A). Panel B shows the relative 
expression (mean± SD) of SR-A normalised to the expression of p-actin (untreated 
samples for each time point assigned as 1) from three independent experiments
(*/><o.o5, **/><0.01).
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3.3.5 Effect of TGF-P on th e mRNA expression of SR-B1
SR-B1 expression was analysed at the mRNA level as no antibodies to SR-B1 were 
available in the laboratory. A 24hr time course was prepared to study any time- 
dependent effects of TGF-p treatment on SR-B1 expression. THP-1 cells were left 
untreated (Ohr) or treated with TGF-p for the requisite time period and then harvested 
for total RNA and RT-qPCR analysis. The cDNA template was subjected to RT- 
qPCR analysis as described in Section 3.3.2. SR-B1 expression was high in untreated 
cells and was significantly reduced by TGF-p, 6 hr after treatment with the cytokine 
with maximal inhibition at the 24hr time point.
Ohr 6hr 12hr 24hr
Figure 3.6 TGF-p down-regulates SR-B1 mRNA expression in a time 
dependent manner in THP-1 macrophages. Total RNA from untreated (Ohr) or 
from TGF-p-stimulated (6 , 12 or 24hr) THP-1 cells was reverse-transcribed and the 
resulting cDNA subjected to RT-qPCR analysis using primers specific to SR-B1 and 
the control gene 28S rRNA. Data is presented as the relative expression (mean± SD) 
of SR-B1 normalised to the expression of 28S rRNA (untreated (Ohr) sample assigned 
as 1) from four independent experiments (*P<0.05, ***P<0.001).
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3.3.6 Effect o f TGF-P on th e mRNA expression of CD36
CD36 expression was also analysed at the mRNA level as no antibodies to the protein 
were available in the laboratory. A time course was prepared to analyse any time- 
dependent effects of TGF-p treatment on CD36 expression. CD36 expression was 
high in untreated cells and was significantly attenuated by TGF-p, 6 hr after treatment 
with the cytokine with maximal inhibition at the 24hr time point.
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Figure 3.7 TGF-p down-regulates CD36 mRNA expression in a time- 
dependent manner in THP-1 macrophages. Total RNA from untreated (Ohr) or 
TGF-P-treated (6 , 12 or 24hr) THP-1 cells was reverse-transcribed and the resulting 
cDNA subjected to RT-qPCR analysis using primers specific to CD36 and the control 
gene 28SrRNA. Data is presented as the relative expression (mean± SD) of CD36 
normalised to the expression of 28S rRNA (untreated (Ohr) sample assigned as 1) 
from four independent experiments (***/><0 .0 0 1 ).
3.3.7 Effect o f TGF-p on the mRNA expression o f ApoE
THP-1 cells were cultured in the presence or absence of TGF-P for the requisite time 
period and then harvested for total RNA extraction. Total RNA was quantified and 
then used for RT-PCR analysis. PCR was carried out to amplify ApoE and P-2 
microglobulin using the conditions specified in Table 2.4 and the PCR products were 
size-fractionated using agarose gel electrophoresis. Figure 3.8 A shows the PCR 
products fractionated by agarose gel electrophoresis. The results indicated that ApoE
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mRNA expression was low in untreated THP-1 macrophages and was dramatically 
induced by TGF-P treatment with maximal induction at the 24hr time point (Figure 
3.8B).
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Figure 3.8 TGF-p up-regulates ApoE mRNA expression in THP-1 
macrophages. Total RNA from untreated (UT) or TGF-p-treated (24 or 48hr) THP-1 
cells was subjected to RT-PCR analysis. ApoE and p2-microglobulin amplification 
products were resolved by agarose gel electrophoresis (Panel A). The size of the 
product was determined by comparison with a standard DNA molecular weight 
marker (Appendix I). -RT denotes a reaction in which no reverse transcriptase was 
included in cDNA preparation (24hr, TGF-p-treated RNA). Panel B shows the 
relative expression (mean± SD) of ApoE normalised to the expression of P-2 
microglobulin (untreated samples for each time point assigned as 1) from three 
independent experiments (*P<0.05, NS-not significant).
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3.3 .8  Effect o f TGF-p on th e protein expression of ApoE
To confirm that the induction of ApoE mRNA by TGF-(3 in THP-1 macrophages 
resulted in a corresponding change in the expression of ApoE protein, western blot 
analysis was carried out. THP-1 cells were treated with TGF-P or left untreated for 
the requisite time period. Western blot analysis was carried out as for LPL (Section 
3.3.3). Figure 3.9A shows the image from western blotting. TGF-P significantly 
induced the expression of ApoE protein (Figure 3.9B). This change is synonymous 
with the changes in mRNA expression shown in Figure 3.8.
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Figure 3.9 TGF-p up-regulates ApoE protein expression in THP-1 
macrophages. Whole cell-protein extracts from untreated (UT) or TGF-P treated (24 
or 48hr) THP-1 cells were subjected to SDS-PAGE and western blotting using 
antibodies against ApoE and P-actin (Panel A). Panel B shows the relative expression 
(mean± SD) of ApoE normalised to the expression of P-actin (untreated samples for 
each time point assigned as 1) from three independent experiments (*P<0.05).
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3.3.9 Effect of TGF-p on ApoE protein expression in human m onocyte-derived
m acrophages (HMDMs)
In order to confirm the use of THP-1 as a suitable model for HMDMs it was 
important to see if the responses observed in THP-1 macrophages were conserved in 
primary cultures of HMDMs. For this, the ApoE response was investigated in 
HMDMs. HMDMs were prepared in 12-well plates as described in Section 2.3.8. A 
single time point was chosen and total cellular protein extracts were subjected to 
western blotting as described in Section 3.3.3. Figure 3.10 shows that ApoE 
expression was low in untreated primary human macrophages and was significantly 
induced by TGF-p at the 24hr time point.
(A)
(B)
Figure 3.10 TGF-p up-regulates ApoE expression in HMDMs. HMDMs were 
treated with TGF-P or left untreated (UT) for 24hr. Whole cell-protein extracts were 
subjected to SDS-PAGE and western blotting using antibodies against ApoE and P- 
actin (Panel A). Panel B shows the relative expression (mean± SD) of ApoE 
normalised to p-actin expression (untreated sample assigned as 1) from four 
independent experiments (*P<0.05).
24hr
P-actin
□ Untreated 
■ +TGF-P
24hr
139
CHAPTER 3: TGF-P-regulated expression of genes implicated in macrophage cholesterol homeostasis
3.3.10 Effect of TGF-P on th e mRNA expression o f ABCA-1
THP-1 cells, cultured in the presence or absence of TGF-p, were harvested for total 
RNA extraction. Total RNA was quantified and then used for RT-PCR analysis of 
ABCA-1 and p~2 microglobulin. Figure 3.11(A) shows the PCR products 
fractionated by agarose gel electrophoresis. The results indicated that ABCA-1 
mRNA expression was low in untreated THP-1 macrophages and was induced by 
TGF-p treatment but this induction was not statistically significant (Figure 3.1 IB). 
The effect of TGF-p on ABCA-1 expression was therefore investigated further using 
western blot and RT-qPCR analysis (Section 3.3.11 and Section 3.3.12).
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Figure 3.11 ABCA-1 mRNA expression is upregulated by TGF-p in THP-1 
macrophages. Total RNA from untreated (UT) or TGF-p-treated (24 or 48hr) THP-1 
cells was subjected to RT-PCR analysis and the PCR amplification products for 
ABCA-1 and p2-microglobulin were resolved by agarose gel electrophoresis (Panel 
A). Panel B shows the relative expression (mean± SD) of ABCA-1 normalised to P-2 
microglobulin expression (untreated samples for each time point assigned as 1) from 
three independent experiments (NS-not significant).
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3.3.11 Effect of TGF-p on the protein expression of ABCA-1
To confirm that the induction of ABCA-1 mRNA expression by TGF-p in THP-1 
macrophages resulted in a corresponding change in the expression of the ABCA-1 
protein, western blot analysis was carried out. THP-1 cells were treated with TGF-P 
or left untreated for the requisite time period. Total cellular protein was extracted 
using whole-cell extraction buffer (Section 2.7.2) and subjected to SDS-PAGE and 
western blot analysis using a 7.5% polyacrylamide gel. Figure 3.12A shows the 
image from western blotting. TGF-p induced the expression of ABCA-1 protein at 
the 24hr time point (Figure 3.12B). The change in expression is synonymous with the 
data presented in Figure 3.11 but the time point at which this occurs in a significant 
manner (24hr) is not in agreement with the data on mRNA expression (48hr). The 
optimal time point for TGF-P regulation o f ABCA-1 was therefore investigated 
further to establish an optimal period for TGF-p treatment for further studies into its 
regulation (Section 3.3.12).
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Figure 3.12 ABCA-1 protein expression is upregulated by TGF-p in THP-1 
macrophages. Whole cell-protein extracts from untreated (UT) or TGF-P-treated (24 
or 48hr) THP-1 cells were subjected to SDS-PAGE and western blotting using 
antibodies against ABCA-1 and P-actin (Panel A). Panel B shows the relative 
expression (mean± SD) of ABCA-1 normalised to P-actin expression (untreated 
samples for each time point assigned as 1) from three independent experiments 
(*P<0.05, NS-not significant).
3.3.12 Tim e-dependent effect of TGF-P on ABCA1 mRNA expression
In light of the results presented in Figures 3.11 and 3.12, a time course was prepared 
to analyse any time-dependent effects of TGF-P treatment on ABCA-1 expression. 
Due to difficulties of reproducibly obtaining good western blots with ABCA-1, 
because of the extremely large size of this protein (220kDa), it was decided that any 
further investigations into its regulation would be performed at the mRNA level. 
Initially a 24hr time course was prepared (Figure 3.12A) based on the regulation of 
other key genes by TGF-p as presented in this chapter and previous studies carried out
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on ABCA-1 expression in the laboratory. Total RNA extracts were reverse- 
transcribed and the cDNA template was subjected to RT-qPCR analysis using specific 
primers against ABCA-1 and the control gene RPL13A. RPL13A is a ribosomal 
protein that was used as a control for RT-qPCR analysis of ABCA-1 expression as 
unanticipated problems with the 28S rRNA qPCR were experienced at the time of 
these studies. ABCA-1 expression was low in untreated cells and was significantly 
induced by TGF-p following 6 hr o f cytokine treatment (Figure 3.13 A). However, no 
significant changes were observed at later time points. This suggested that ABCA-1 
was optimally up-regulated by TGF-p at an earlier time point to the other genes 
studied in this chapter. For this reason, a shorter time course (0-6hr) was prepared to 
analyse time-dependent effects of TGF-p treatment on ABCA-1 expression. Figure 
3.13B shows that ABCA-1 expression was significantly up-regulated lhr after TGF-p 
treatment and was up-regulated in a time dependent manner with maximal induction 
after 6 hr TGF-P treatment.
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Figure 3.13 Time-dependent changes in ABCA-1 expression by TGF-p. Total 
RNA from untreated (Ohr) or TGF-j3-treated THP-1 cells was reverse-transcribed and 
the resulting cDNA subjected to RT-qPCR analysis using primers specific to ABCA-1 
and the control gene RPL13A. The relative expression (mean± SD) of ABCA-1 was 
investigated over 2 time courses, a longer (24hr) time course (Panel A) and a shorter 
(6hr) time course (Panel B). Data is presented as the relative expression of ABCA-1 
(mean± SD) from four independent experiments (*P<0.05, **P<0.01, NS-not 
significant).
3.3.13 Effect of TGF-P on the mRNA expression of ABCG-1
ABCG-1 expression was analysed at the mRNA level as no antibody against ABCG-1 
was available in the laboratory. Based on our observations of TGF-P-regulated 
ABCA-1 expression and the similarities between the two proteins at the functional 
level, it was likely that ABCG-1 would be regulated by TGF-p in the same manner as
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ABCA-1. We therefore decided to prepare a short time course (up to 6hr) to analyse 
ABCG-1 expression. RT-qPCR analysis was carried out as for ABCA-1 (Section 
3.3.12). ABCG-1 expression was significantly induced by TGF-J3 following 6hr of 
cytokine treatment (Figure 3.14). However, no significant changes were observed at 
earlier time points.
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Figure 3.14 ABCG-1 expression is upregulated by TGF-p in THP-1 
macrophages. Total RNA from untreated (Ohr) or TGF-P treated (1, 3 or 6hr) THP-1 
cells was reverse-transcribed and the resulting cDNA subjected to real-time 
quantitative PCR analysis using primers specific to ABCG-1 and the control gene 
RPL13A. Data is presented as the relative expression of ABCG-1 (mean± SD) from 
four independent experiments (*P<0.05, NS-not significant).
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3.3 Discussion
The regulation of expression of key genes involved in macrophage cholesterol 
homeostasis has implications in foam cell formation. TGF-P is a negative regulator of 
foam cell formation and a significant part o f the cytokine’s anti-atherogenic effects is 
due to its actions on the expression of genes involved in the uptake and efflux of 
cholesterol from macrophages. The regulation o f a number o f macrophage-expressed 
genes by TGF-P has been previously studied. However, the majority of these studies 
have been carried out using murine macrophage cell lines or in vivo mice models of 
atherosclerosis as detailed in Table 3.2. The genes chosen for study in this chapter 
included LPL, SR-A, SR-B1 and CD36; genes with roles in cholesterol uptake; and 
ApoE, ABCA-1 and ABCG-1; genes involved with cholesterol efflux. These genes 
were chosen because their roles in atherosclerosis are well-defined and the expression 
of some of these in J774.2 macrophages and THP-1 monocytes had previously been 
studied in our laboratory (Table 3.2) (Hughes et al. 2002; Irvine et al. 2005; Singh and 
Ramji 2006). Although the action of TGF-p on several o f these key genes expressed 
by macrophages has previously been described in the published literature, a detailed 
study o f their regulation in THP-1 macrophages has not been carried out. To establish 
an optimal time point for TGF-P regulation and to provide a foundation for further 
studies into the mechanisms of TGF-P action on these genes (as presented in Chapters 
4 and 5) it was important to determine how the cytokine regulates gene expression 
over time. The action o f TGF-p on these key genes involved in cholesterol uptake 
and efflux was studied in THP-1 macrophages as a model system for human 
macrophages.
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Gene Macrophage source Regulation of expression by TGF-P References
ABCA-1 Macrophage derived foam cells from ApoE'/_ 
mice
Murine J774A.1 macrophage cell line
mRNA and protein expression up-regulated 
mRNA expression up-regulated
Panousis et al. 2001 
Argmann et al. 2001
ABCG-1 Murine J774A. 1 macrophage cell line mRNA expression up-regulated Argmann et al. 2001
ACAT-1 Primary human monocytes/ macrophages mRNA and protein expression is up-regulated on 
monocyte-macrophage differentiation
Hori et al. 2004
ApoE Cholesterol loaded and non-cholesterol loaded 
mouse peritoneal macrophages
THP-1 monocytes and THP-1 macrophages
mRNA expression and protein secretion up- 
regulated
mRNA and protein expression up-regulated
Zuckerman et al. 1992 
Singh and Ramji 2006
CD 163 Primary human macrophages mRNA and protein expression is down-regulated Pioli et al. 2004
CD36 THP-1 monocytes and primary human 
monocytes
Macrophages from non-atherosclerotic mice, 
ApoE'' mice and LDLR'' mice
THP-1 macrophages
mRNA and protein expression down-regulated 
mRNA expression down-regulated 
mRNA and protein expression down-regulated
Draude and Lorenz 2000 
Zuckerman et al. 2001 
Han et al. 2000
LDL receptor Murine J774A. 1 macrophage cell line mRNA expression and receptor activity down- 
regulated
Argmann et al. 2001
LOX-1 (lectin-like 
oxLDL receptor-1)
THP-1 monocytes and primary human 
monocytes
Murine peritoneal macrophages
mRNA expression up-regulated 
mRNA expression upregulated
Draude and Lorenz 2000 
Minami et al. 2000
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LPL Murine J774A.1 macrophage cell line
Murine J774.2 macrophages and primary human 
macrophages
mRNA expression and enzyme activity down- 
regulated
mRNA and protein expression down-regulated
Argmann et al. 2001 
Irvine et al. 2005
SR-A THP-1 macrophages
THP-1 monocytes and primary human 
monocytes
mRNA expression down-regulated 
mRNA expression down-regulated
Bottalico et al. 1991 
Draude and Lorenz 2000
SR-B1 Macrophages from non-atherosclerotic mice, 
ApoE" mice and LDLR/_ mice
mRNA expression down-regulated Zuckerman et al. 2001
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As expected, the expression o f LPL, SR-A, SR-B1 and CD36 was attenuated by TGF- 
P at both the mRNA and protein level. This is consistent with published studies on 
the regulation of expression o f these genes in macrophages (Table 3.2). In all cases, 
maximal inhibition occurred following 24hr of TGF-P treatment and this time point 
was therefore used for further studies on these genes, as presented in Chapters 4 and 
5. Also in agreement with the published literature (Table 3.2), TGF-P induced the 
expression o f ApoE, ABCA-1 and ABCG-1 at both the mRNA and protein level. In 
addition, induction of ApoE by the cytokine was observed in primary human 
macrophage cultures thereby signifying that any changes in gene expression observed 
in THP-1 were indicative of changes that could be replicated in primary macrophages. 
This verified the use of the THP-1 cell line as a model system for the study of TGF-p 
regulation o f gene expression in macrophages. Maximal and significant induction of 
ApoE mRNA expression occurred following 24hr o f TGF-P treatment and maximal 
protein expression occurred after 48hr o f TGF-P treatment. For consistency, it was 
decided that the 24hr time point would be used for further studies into ApoE 
regulation. In contrast to the other genes studied, ABCA-1 and ABCG-1 were not 
optimally up-regulated following 24hr TGF-P treatment. An extensive time course of 
ABCA-1 regulation by TGF-P was prepared to investigate the disparity between 
mRNA and protein induction. Maximal induction o f ABCA-1 and ABCG-1 was 
observed after 6 hr TGF-P treatment and this time point was used in further studies 
into the regulation of their expression by the cytokine.
Despite a number o f studies, the mechanism of the regulation of expression of genes 
implicated in macrophage cholesterol homeostasis by TGF-P remains unclear. 
Studies by our laboratory have highlighted the importance o f the JNK, p38 kinase and 
CK2 pathways in the ApoE response to TGF-P (Section 3.1.6) but the involvement o f 
the classical and other TGF-P signalling pathways in gene regulation remains poorly 
understood. Only the mechanisms behind the regulation of LPL, ApoE and CD36 
expression by TGF-P have previously been investigated. The current knowledge 
regarding the mechanisms o f gene regulation by TGF-P in macrophages is 
summarised in Figure 3.15. The regulation of LPL expression by the cytokine occurs 
at the transcriptional level and is mediated through a change in transactivation 
potential of Spl and Sp3 by TGF-p (Irvine et al. 2005). The regulation of CD36 has 
also been described at the transcriptional level where the gene is a direct target for
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PPARy, which becomes inactivated by MAPK phosphorylation in response to TGF-P 
(Han et al. 2000). Interestingly, published literature suggests that PPARy is able to 
regulate the expression o f each of the genes studied in this chapter, either directly or 
indirectly. This may therefore be a potential link to their regulation by TGF-p.
PPARy is part o f a larger family o f nuclear receptors, including PPAR-a, -P and - 7 . 
Like other nuclear receptors the PPARs contain a ligand-binding domain and a DNA- 
binding domain. The primary role o f PPARs is in metabolic regulation where they 
stimulate fatty acid breakdown. PPARy is involved in the storage and release of fat 
from adipose tissue through the regulation o f adipose gene expression (Fernandez 
2008; Neve et al. 2000). PPARy is expressed as two isoforms; PPARyl is expressed 
within monocytes and macrophages while PPARy2 is restricted to adipose tissue 
(Kintscher et al. 2002). Both PPARa and PPARy are expressed in vascular cells and 
have been associated with atherosclerosis. PPARy can be detected in the macrophage- 
rich regions o f atherosclerotic plaques and is overexpressed in foam cells (Duan et al. 
2008; Fernandez 2008; Galetto et al. 2001; Worley et al. 2003). Ligands of PPAR 
have been associated with reduced progression of atherosclerotic lesions and reduced 
intimal thickness whilst activators of PPARy can inhibit the proliferation of VSMCs 
by inhibiting the expression of MMP-9. Agonists o f PPARy can reduce the 
expression of pro-inflammatory cytokines TNFa and EL- 6  and the chemokine MCP-1 
in monocytes (Duan et al. 2008; Neve et al. 2000).
PPARy activates target genes through heterodimerisation with RXRa, another nuclear 
receptor. Heterodimers can be activated by ligands of PPARy and ligands of RXRa. 
Ligands for PPARy include metabolites o f arachidonic acid and fatty acid derivatives 
of oxLDL such as 1 6 -deoxy-A-i2, 14-prostaglandin J2 (15-dPGJ2). Thiazolidinediones 
(TZDs), used in the treatment o f type 2 diabetes are also ligands for PPARy (Neve et 
al. 2000). Heterodimerisation is followed by binding to a PPARy response element 
(PPRE) in the promoter of target genes (Fernandez 2008; Worley et al. 2003). The 
consensus sequence for this response element is a repeat of AGGTCA. In addition to 
direct gene regulation, PPAR also negatively regulates inflammatory gene 
transcription by modulating the recruitment of cofactors or through interaction with 
other transcription factors such as AP-1, STAT and NFkB (Neve et al. 2000). This is 
mediated by a conformational change in the heterodimer complex following ligand
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binding allowing DNA binding and release of corepressors. In macrophages, this 
allows the binding o f PPARy to NFkB and the recruitment of corepressors to 
negatively regulate NFkB target genes such as iNOS (Duan et al. 2008; Neve et al. 
2000).
Similar to TGF-P, PPARy has been suggested to play an anti-atherogenic role in foam 
cell formation (Akiyama et al. 2002). Macrophages deficient in PPARy have reduced 
levels of oxLDL uptake and reduced cholesterol efflux (Akiyama et al. 2002). Bone 
marrow transfer o f macrophages deficient in PPARy into LDLR7 mice produces 
larger atherosclerotic lesions than in wildtype counterparts and in vivo transfer of 
PPARy into rat artery reduces neointima formation following balloon injury (Duan et 
al. 2008). Agonists o f PPARy reduce atherosclerosis in human and animal models, 
and in cultured human endothelial cells can inhibit the expression of chemokine genes 
and adhesion molecules such as VCAM-1 to reduce adherence of monocytes to 
endothelial cells (Duan et al. 2008; Fernandez 2008). Connections between TGF-p 
and PPARy have been demonstrated in VSMCs where TGF-p transiently induces the 
expression of PPARy before inhibiting its expression through activation of AP-1 and 
Smad-3. Interestingly, PPARy is able to negatively-regulate the TGF-p pathway in 
these cells and stimulation of PPARy disrupts Smad-3 activation to inhibit the TGF-P- 
induced expression of connective tissue growth factor. These observations suggest 
that crosstalk between TGF-P and PPARy signalling does exist (Fu et al. 2003). The 
cytokine has also been shown to up-regulate PPARy mRNA and protein expression in 
THP-1 monocytes (Kintscher et al. 2002).
As described in Section 3.1.5, CD36 is a direct target gene for PPARy and induction 
of PPARy results in the up-regulation of CD36 expression. Mice deficient in 
macrophage PPARy have reduced levels of CD36 expression suggesting that the 
receptor is required for the basal expression o f CD36. The reduced uptake of oxLDL 
observed in macrophage PPARy deficient mice may partly be a result of the down- 
regulation o f CD36 expression (Akiyama et al. 2002; Duan et al. 2008). Similar to 
the regulation o f CD36, activators o f PPARy can induce the expression of SR-B1 in 
primary cultures o f human macrophages and in the ApoE'7' mice. This indicates that 
PPARy positively regulates class B scavenger receptor expression (Chinetti et al.
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2000). TGF-P stimulation may therefore inactivate PPARy through phosphorylation 
to achieve inhibition o f CD36 and SR-B1 expression.
As an inhibitor o f macrophage activation, PPARy inhibits the expression of SR-A, 
through interaction with AP-1, STAT and NFkB transcription factors (Ricote et al. 
1998). Transcriptional activation o f SR-A by pro-inflammatory cytokines is also 
inhibited by PPARy (Ricote et al. 1998). In addition to reduced scavenger receptor 
expression, mice deficient in macrophage PPARy present with reduced expression of 
LPL suggesting that (as is the case for CD36) the receptor is required for basal 
expression o f macrophage LPL. In support o f this, a requirement for PPARy in the 
basal expression o f LPL has been demonstrated in adipose and liver tissue and a 
PPRE has been identified within the LPL promoter region (Akiyama et al. 2002; 
Schoonjans et al. 1996).
PPARy has effects on both cholesterol uptake and efflux from macrophages. 
Macrophages deficient in PPARy have reduced cholesterol efflux and reduced 
expression o f ABCA-1, ABCG-1 and ApoE (Akiyama et al. 2002). The PPARy 
ligand, ciglitazone and the RXRa ligand, 9-cis retinoic acid can up-regulate ApoE 
expression in THP-1 cells and a PPRE has been identified in the intergenic region of 
the ApoE and ApoCI promoters (Galetto et al. 2001). Ligands o f PPARy induce 
ABCA-1 and ABCG1 expression through the up-regulation o f the oxysterol-regulated 
LXRa, leading to high levels of cholesterol efflux (Nicholson 2004). ABCA-1 and 
ABCG-1 are up-regulated through an LXRa-dependent pathway and contain LXR 
response elements within their promoters, whilst ApoE is also a direct target for the 
receptor (Akiyama et al. 2002; Nicholson 2004).
In conclusion, although there is a link between the regulation o f expression of 
cholesterol uptake and efflux genes through PPARy, the regulation of these genes by 
TGF-P has only been partly defined for CD36, LPL and ApoE. In addition to this, 
whilst there are some clues to the transcriptional regulation of these genes, very little 
is known about the molecular mechanisms behind their regulation by TGF-p. In 
particular, the involvement of the classical and other TGF-p signalling pathways in 
gene regulation remains poorly understood. Current knowledge regarding the TGF-p 
regulation of genes implicated in macrophage cholesterol homeostasis is summarised
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in Figure 3.15. Specifically, the classical TGF-p/Smad signalling pathway has been 
comprehensively characterised but its role in the regulation of a large number of TGF- 
P target genes has not been described. This will be the focus of Chapter 4 o f this 
thesis.
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SARA
PPARy
Ippary
Figure 3.15 Current knowledge of TGF-p-regulated expression of genes 
implicated in macrophage cholesterol homeostasis and the involvement of TGF- 
P signalling pathways and transcriptional mediators in this regulation. CD 163 is
the only gene known to be directly regulated by the classical TGF-(3-Smad signalling 
(Pioli et al. 2004). TGF-p-regulated expression of ApoE, LPL, CD36 and ABCA-1 is 
thought to involve components of the MAPK pathways but whether these act 
independently or in cooperation with the Smad pathway is currently unclear. 
Signalling pathways can act independently of each other or may interact with other 
signalling pathways to mediate the TGF-P response (Section 1.14). Nuclear receptors 
and transcription factors may also interact with other transcription factors or proteins 
to mediate the TGF-p response, such as PPARy and LXRa in the case of ABCA-1. 
Abbreviations: AP-1-activator protein-1 (comprising the transcription factors c-Jun 
and c-Fos), CK2-casein kinase 2, ERK-extracellular signal-regulated kinase, JNK-c- 
Jun N-terminal kinase, LXR-liver-X-receptor, P-phosphate group, PPAR-peroxisome 
proliferator-activated receptor, SARA-Smad anchor for receptor activation, S2/S3/S4- 
Smad-2/-3/-4, TF-transcription factor.
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CHAPTER 4 
The role of Smads in the TGF-p-regulated 
expression of key genes involved in the control 
of macrophage cholesterol homeostasis
4.1 Introduction
4.1.1 Smad-regulated gene transcription
Although the TGF-P-Smad pathway is well characterised, less is known about how 
this pathway contributes to individual regulation of target genes. Genes known to be 
regulated through the Smad proteins are few in number. One of the most cited 
examples o f a Smad-mediated TGF-p response is the induced expression of cyclin- 
dependent kinase inhibitors p i5 and p21, in epithelial cells, which leads to growth 
arrest o f these cells (Wrighton and Feng 2008). Sequence specific binding of Smads 
to promoters of target genes has been observed for plasminogen activator inhibitor-1 
(PAI-1) where they bind directly to a Smad binding element in the promoter region 
(Mallat et al. 2001). Often the exact mechanism of regulation of these genes by 
Smads is rendered difficult by the interaction of Smad proteins with various other 
proteins and/or transcription factors to regulate gene transcription. An example of this 
is the activation of al-collagen gene expression in response to TGF-p, which is 
mediated through the binding of Smad-2 and Spl to the promoter. Smad-2 binding to 
a TGF-P response element present in the promoter enhances the binding of Spl to 
activate the promoter (Sysa et al. 2009). TGF-p-mediated stimulation of type-I 
collagen expression in cultured human fibroblasts is mediated by an interaction
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between activated Smads and p300/CBP, which accumulates at consensus Smad- 
binding elements (Ghosh et al. 2000).
Very little is currently known about the involvement of the Smads in atherosclerosis 
and the vasculature. Immunohistochemistry and RT-PCR have demonstrated that 
Smad-2, -3 and -4 are expressed in macrophages and foam cells of fatty lesions 
(Kalinina et al. 2004). Smad expression is up-regulated following monocyte- 
macrophage differentiation in both macrophages o f lesions and in THP-1 cells. Such 
an expression profile suggests that the Smads may contribute to monocyte 
accumulation (Kalinina et al. 2004). Interestingly, the expression pattern of Smads in 
VSMCs is distinct from that in macrophages. Smad-2, -3 and -4 are not expressed in 
VSMCs of fatty lesions but are present in more advanced fibrous plaques, suggesting 
that they could contribute to the accumulation of collagen (Kalinina et al. 2004).
The identification o f the Smad pathway as a mediator for the TGF-[3-regulated 
expression of a number of genes implicated in lesion development and/or stability has 
connected the pathway with atherosclerosis. The Smad pathway has been shown to 
mediate the induction o f cyclin-dependent kinase inhibitors expression in 
macrophages (Fu et al. 2003; Kalinina et al. 2004), which play roles in apoptosis and 
cell proliferation. The TGF-P-regulated induction o f connective tissue growth factor 
(CTGF) involved in the production of the ECM by VSMCs is also mediated by the 
Smad pathway. In human aortic smooth muscle cells, the induction of CTGF 
promoter activity by ligands of PPARy could be reversed by overexpression of Smad- 
3 and plasmids specifying for Smad-3/-4 could increase promoter activity in 
transfected cells (Fu et al. 2003).
In macrophages, the TGF-p-regulated activation o f IL-23 expression is thought to 
involve Smad-3 (Al-Salleeh and Petro, 2008). The Smad pathway, in particular 
Smad-3, has also been demonstrated to mediate the inhibitory effects of TGF-p on 
macrophage activation. TGF-p inhibits the expression of MMP-12 and iNOS, both 
markers o f macrophage activation. Transient transfection o f murine RAW264.7 
macrophages demonstrated that promoter activity of MMP-12 and iNOS could be 
inhibited by Smad-3 and that this was further enhanced by treatment with TGF-P 
(Wemer et al. 2000).
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In relation to foam cell formation, only the TGF-P-regulated expression of the CD 163 
gene is known to be directly regulated through the Smad pathway. CD 163 is a 
scavenger receptor expressed exclusively by monocytes and macrophages. It is 
thought to mediate the endocytosis o f haemoglobin complexes to attenuate 
inflammatory responses linked with haemolysis but can take up lipoproteins into cells 
in an atherogenic environment (Pioli et al. 2004). The expression of CD 163 has been 
demonstrated to be reduced by TGF-p, at the transcriptional level (Pioli et al. 2004). 
The direct involvement of Smad-3 in this response was demonstrated by Pioli and 
colleagues in 2004. Transient transfection studies demonstrated that the inhibitory 
effect o f TGF-p on CD 163 promoter activity could be antagonised by co-transfection 
with a dominant-negative Smad-3 plasmid but not with dominant-negative Smad-2. 
This implicated Smad-3 as the primary mediator of this TGF-P response (Pioli et al. 
2004).
4.1.2 RNA interference (RNAi)
RNAi describes the process by which double-stranded RNA (dsRNA) triggers the 
destmction o f a target mRNA that shares the same sequence. This was initially 
discovered in transgenic plants where it was termed post-transcriptional gene 
silencing (Meister and Tuschl 2004). The RNAi pathway was discovered in 
eukaryotic cells in 1998 when it was shown that double-stranded RNA could induce 
gene silencing in C.elegans (de Fougerolles et al. 2007; Hajeri and Singh 2009; 
Hutvagner and Zamore 2002). This was followed by the finding in 2001 that 21- 
nucleotide siRNA duplexes could suppress gene expression in mammalian cell lines 
including human embryonic (293) and HeLa cells (Elbashir et al. 2001).
The RNAi pathway is an evolutionary conserved mechanism of cellular defence by 
which the expression of ‘foreign genes’ randomly integrated into the host genome 
(such as those from viruses) is regulated. Foreign genes often express dsRNA and the 
presence o f this is used to initiate processes to post-transcriptionally inhibit the 
expression of these genes (Tuschl and Borkhardt 2002).
4.1.2.1 RNAi and small interfering RNA (siRNA)
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As shown in Figure 4.1, long dsRNA is cleaved into smaller dsRNA fragments known 
as small-interfering RNAs (siRNA). This cleavage is carried out by the enzyme 
Dicer, a member o f the RNase III family of endonucleases that is specific for dsRNA. 
Dicer contains both an RNA binding domain and a RNase domain. Dicer is located 
within the cytoplasm and interacts with a partner protein that also binds dsRNA 
known as TAR RNA-binding protein (TRBP). Dicer is the only member of the 
RNase III family of endonucleases that requires ATP for cleavage and this is due to 
the presence of an ATP-dependent RNA helicase domain within its amino terminus. 
Helicases use ATP to break the hydrogen bonds that join the two strands of DNA or, 
in this case, dsRNA. In dsRNA cleavage, the ATP is likely to be used for catalytic 
activity and may help to move Dicer along the dsRNA (Hajeri and Singh 2009; 
Hutvagner and Zamore 2002; Meister and Tuschl 2004; Rao et al. 2009).
The siRNAs produced following cleavage of dsRNA by Dicer are 21-25 nucleotides 
in length (length is species specific) and contain a phosphate group at their 5’ end and 
a hydroxyl group at their 3’ end (Hajeri and Singh 2009; Hutvagner and Zamore 
2002). Duplexes o f siRNA interact with a protein complex known as the RNA- 
induced silencing complex (RISC). RISC is a multi-enzyme complex that is made up 
of RISC and Argonaute 2 (AG02/ EIF2C2-eukaryotic translation initiation factor C2) 
(de Fougerolles et al. 2007; Meister and Tuschl 2004). Fluoresence spectroscopy 
studies have indicated that RISC shuttles between the nucleus and the cytoplasm (Rao 
et al. 2009). siRNA fragments bind tightly to the AG02 protein (Pratt and MacRae 
2009). If the siRNA sequence has perfect sequence complementarity then AG02 
unwinds and cleaves the sense strand, leaving one guide strand (the antisense strand), 
complementary to the target mRNA, attached to RISC as shown in Figure 4.1. 
Binding of the RNA strand to the RISC protein activates the complex (now known as 
RISC*). The siRNA then targets active RISC to the target mRNA through 
complementary base pairing (Hajeri and Singh 2009; Hutvagner and Zamore 2002).
Radiolabelled siRNAs demonstrated that the target mRNA is cleaved at nucleotides 
close to the centre o f the guide strand and further studies showed that the target 
mRNA is cleaved between nucleotides complementary to nucleotides 10 and 11 from 
the 5’ end of the guide siRNA strand. This cleavage results in a disrupted reading 
frame for the encoded protein and promotes degradation of the mRNA by
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exonucleases. Cleavage is independent of ATP but requires a catalytically active 
RNase, which has been aptly named Slicer. Slicer is thought to be the AG02 protein, 
as it contains a catalytically active RNase domain (de Fougerolles et al. 2007; Meister 
and Tuschl 2004; Rao et al. 2009). Although the exact mechanism of mRNA 
cleavage is not clear, it has been suggested that a catalytic triad (aspartate, aspartate 
and aspartate or histidine) is used to coordinate catalytic metal ions and position a 
water molecule for nucleophilic attck of the phosphodiester backbone of the mRNA 
(Pratt and MacRae 2009). Although cleavage does not require ATP, multiple rounds 
of cleavage where products (including RISC) are released to go on to target new 
mRNAs, is enhanced by ATP (Meister and Tuschl 2004).
4.1.2.2 Short hairpin RNA (shRNA) and microRNA (miRNA)
Gene silencing can also be induced by short hairpin RNAs (shRNAs) or by micro 
RNAs (miRNA) which are derived from non-coding hairpin RNA structures. This is 
shown in Figure 4.1. shRNAs have a hairpin-like stem loop structure. miRNAs are 
encoded within introns or intergenic regions and are initially processed in the nucleus 
by an enzyme known as Drosha. Drosha is another member o f the RNase HI 
endonuclease family that like Dicer contains both an RNase and an RNA-binding 
domain. Drosha processes and shortens double-stranded shRNA and miRNA to form 
a precursor that can be exported from the nucleus using the nuclear export protein, 
exportin-5. The shRNA and miRNA undergo further processing by Dicer in the 
cytoplasm to form mature shRNA/miRNA (de Fougerolles et al. 2007; Hajeri and 
Singh 2009; Meister and Tuschl 2004; Rao et al. 2009). On loading of RISC with 
shRNA or miRNA, the sense strand is unwound to leave the guide strand (mature 
shRNA/miRNA) to target activated RISC to the mRNA target. In contrast to siRNA 
which is complementary to and results in the cleavage o f the target mRNA sequence, 
mature shRNA/miRNA is not perfectly complementary to the target sequence and 
instead of cleaving the target mRNA, mediates repression of its translation as shown 
in Figure 4.1 (de Fougerolles et al. 2007; Pratt and MacRae 2009; Rao et al. 2009). 
Only 2-7 bases of the guide and target sequence must pair up to initiate translational 
repression of the target mRNA. Often, the miRNA recognises sites within the 3’ 
untranslated region of the target mRNA to inhibit translation (de Fougerolles et al.
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2007). The exact mechanism of translational repression by shRNA/miRNA is unclear 
but may be mediated through protein: protein interactions (Pratt and MacRae 2009).
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Figure 4.1 The RNA interference pathway. Gene silencing is induced by 
dsRNA. miRNA is processed by Drosha in the nucleus before undergoing processing 
in the cytoplasm by Dicer, where siRNA is also processed in an ATP-dependent 
process. Dicer produces siRNAs, 21-25 nucleotides in length which interact with the 
RISC complex. Duplexes are cleaved (siRNA) or unwound (miRNA) by the AG02 
protein to produce an activated RISC complex which is guided to the target mRNA 
through complementary base pairing. The target mRNA is cleaved (siRNA) or 
translationally repressed (miRNA) by an unknown mechanism. Abbreviations: 
dsRNA-double stranded RNA, miRNA-microRNA, RISC-RNA-induced silencing 
complex, siRNA-small interfering RNA (Adapted from de Fougerolles et al., 2007).
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4.1.2.3 Methods o f siRNA/shRNA delivery 
A recently developed method of delivering siRNA or shRNA into cells is using viral- 
vectors such as adenoviral vectors. This method has a high infection efficiency and is 
effective for integrating exogenous DNA sequences. One of the primary concerns 
with the use o f this method for clinical applications is that it is likely to induce 
unwanted immune responses and activate immune receptors through the adenoviral 
components o f the vector (Rao et al. 2009). Non-viral delivery methods including 
ones comprised o f biodegradable components may bypass this issue. These are often 
complexes of lipid and nucleic acid known as lipoplexes and are cationic in nature. 
Laboratory transfection reagents often employ this method of siRNA/shRNA 
delivery. The complexes bind to the membrane either through electrostatic 
interactions or through interactions with cell surface receptors and are taken into cells 
by endocytosis. The positive charge o f these vehicles facilitates interaction with 
proteins o f the plasma membrane to promote endocytosis, in addition to facilitating 
interaction with negatively charged siRNA/shRNA. Lipoplexes have a high 
transfection efficiency and are often complexed with targeting molecules that 
recognise cell surface markers to facilitate endocytosis and/or the release o f the 
siRNA/shRNA. Release of the siRNA/shRNA from endosomes is likely to be 
mediated through lipid: lipid interactions and movement into the nucleus may be 
active (through nuclear importins) or passive (i.e. during mitosis, when the nuclear 
membrane breaks down) (Elouahabi and Ruysschaert 2005; Rao et al. 2009).
4.2 Aims of experimental studies
The primary aim of the studies presented in this chapter was to determine the role of 
the Smad pathway in the TGF-P-regulated expression of key genes implicated in the 
control of macrophage cholesterol homeostasis. The TGF-p-regulation of expression 
of these genes (LPL, SR-A, SR-B1, CD36, ApoE, ABCA-1 and ABCG1) has been 
characterised by previous studies, as presented in Chapter 3 of this thesis. Although 
the Smad signalling pathway is the classical mediator of TGF-p responses, its 
involvement in the TGF-P-mediated regulation of expression of these key genes has
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not been investigated. As explained in more detail in Section 1.10, the Smad pathway 
is triggered following activation of the TGF-P receptor complex by TGF-pi. This 
results in the phosphorylation o f R-Smad-2 or R-Smad-3 which form a complex with 
the common mediator Smad protein, Smad-4 to translocate to the nucleus to regulate 
transcription o f target genes. The only macrophage expressed gene known to be 
regulated directly through the Smad pathway is the scavenger receptor CD 163 as 
described in Section 4.1.1.
The expression o f Smads is up-regulated following monocyte-macrophage 
differentiation in both HMDMs and in THP-1 cells and Smad activation has been 
observed in macrophages o f fatty lesions. In order to carry out studies on the 
involvement o f the Smad proteins in the TGF-p-regulated expression of key genes, it 
was necessary to characterise the activation o f Smad proteins by TGF-P in THP-1 
macrophages. This aim was carried out using western blot analysis of the activated 
(phosphorylated) forms of Smad-2 and Smad-3 to determine the kinetics and levels of 
Smad activation in this cell line. Following this, the involvement o f Smad-2 and/or 
Smad-3 in the regulation o f gene transcription was carried out using siRNA-mediated 
knockdown. Figure 4.2 outlines the experimental strategy used during these studies.
The use o f stable RNAi against the Smad proteins has been used in a number of 
studies to determine the role of Smads in TGF-P-regulated responses. siRNA- 
mediated knockdown of Smads has identified Smad-3 as a mediator of the TGF-P- 
mediated activation o f inhibitor o f differentiation-1 (Idl) in epithelial cells (Liang et 
al. 2009) and also as a regulator o f TGF-p-mediated apoptosis in the Hep3B cell line 
(Yu et al. 2008). siRNA-mediated knockdown of Smad-2, -3 or -4 demonstrated an 
involvement for all three Smads and therefore implicated the Smad pathway in the 
TGF-p stimulation of the angiotensin II type I receptor expression in human lung 
fibroblasts (Martin et al. 2007). A role for Smad-3 in the autoinduction of TGF-pl in 
proximal tubular epithelial cells was also verified using siRNA against the Smad-3 
gene (Zhang et al. 2006). Based on these studies and the commercial availability of 
validated siRNAs against Smad-2 and Smad-3, it was decided that siRNA-mediated 
knockdown of Smad expression would be used to determine the role of the pathway in 
gene expression. This method had previously been optimised in the laboratory and 
the technique had been used previously in the laboratory to investigate the
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involvement o f signalling pathways in cytokine-mediated gene expression. RNA 
interference has a number o f advantages over alternative techniques for knockdown of 
gene expression or function such as the use of pharmacological inhibitors. The use of 
RNAi in low concentrations avoids possible problems with off-target effects and 
specificity issues that can arise with the use of inhibitors, in particular with higher 
concentrations o f inhibitor. Cell cultures are also prone to issues with toxicity arising 
from the use o f pharmacological inhibitors which can be avoided with the use of 
RNAi. The ability to use RNAi in cell lines also means that functional studies do not 
have to rely solely on experiments in knockout animal models which are often time 
consuming and difficult and conclusions from which cannot always be reconciled 
with studies in human cells or subjects. RNAi can allow functional studies to be 
carried out in human cells.
The role of each Smad was investigated first. Differential contributions of Smad-2 
and Smad-3 had to be considered based on studies that have established that some 
TGF-P responses are mediated by Smad-3 as opposed to Smad-2 and vice versa 
(Brown et al. 2007). The use of siRNA against Smads has also identified subsets of 
genes that are regulated by Smad-2 and Smad-3 (Yu et al. 2008). In addition to this, 
the effects of siRNA-mediated knockdown of both Smads on gene expression was 
investigated as it has been suggested that competition between the two Smads for 
gene transcription may occur and also that functional redundancy between the Smad 
proteins may exist (Yu et al. 2008).
In order to confirm that any responses observed in THP-1 macrophages would be 
indicative of what would be observed in human macrophages, adenoviral infection of 
HMDMs with shRNA against Smad-2 shRNA was carried out in conjunction with Dr 
Daryn R. Michael. TGF-P-regulated expression o f key genes was studied. Data from 
siRNA knockdown studies in THP-1 cells was analysed for effects on basal and TGF- 
P regulated expression. Mostly, the effects on mRNA expression were analysed using 
RT-qPCR and initially, where antibodies to the protein were available, effects on 
protein expression were investigated with further studies carried out at the mRNA 
level. For ease o f reading studies are presented on a gene by gene basis.
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4.3 Results
4.3.1 Kinetics of Smad activation in THP-1 macrophages
To investigate the effect of TGF-P on Smad activation by phosphorylation in THP-1 
macrophages, cells were seeded into 6-well plates and differentiated for 24hr using 
PMA. Differentiated THP-1 cells were left untreated or treated with TGF-p for the 
requisite time periods. Total cellular protein was extracted using Laemmli buffer 
(Section 2.7.1) and subjected to SDS-PAGE using a 10% (v/v) polyacrylamide gel. 
Western blotting was carried out using antibodies against the phosphorylated forms of 
Smad-2 and Smad-3 and against total Smad-2+3 as indicated in Figure 4.3. Initially a 
24hr time course was prepared (Figure 4.3 A) as the action o f TGF-P on the expression 
of key macrophage genes (as presented in Chapter 3) was optimal within this time 
frame. Expression of both phospho-Smad-2 and -3 was low in untreated cells. 
Expression o f phospho-Smad-2 was high in TGF-p-treated cells and was significantly 
induced following 3hr TGF-P treatment. The expression o f phospho-Smad-3 was 
significantly induced after 6hr TGF-p treatment but this significant induction was not 
evident at later time points. No changes were observed in levels of total Smad-2+3, 
verifying that any changes observed were due to Smad activation (phosphorylation) 
by TGF-p. The high levels of phospho-Smad-2 and -3 at earlier time points and the 
loss of significant induction observed with longer TGF-p treatment suggested that 
Smad-2 and -3 may be activated by TGF-P at earlier time points. A second, shorter 
time course was prepared to investigate this (Figure 4.3B). Expression of both 
phospho-Smad-2 and -3 was indeed induced by TGF-p with rapid kinetics. 
Expression o f phospho-Smad-2 and -3 was significantly induced within 5min of TGF- 
P treatment and remained at significantly induced levels throughout the time course.
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Figure 4.3 TGF-p activates Smad-2 and Smad-3 with rapid kinetics in THP-1 
macrophages. THP-1 macrophages were left untreated (Ohr) or treated with TGF-p 
for 3, 6, 12 or 24hr (Panel A) or for 5, 15, 30, 60 or 180min (Panel B), as indicated. 
Whole-cell protein extracts were subjected to SDS-PAGE and western blotting and 
levels of phospho-Smad-2 and -3 were compared to levels of total Smad-2+3. Protein 
size was determined by comparison against a standard molecular weight marker 
(Appendix I). The relative expression (mean± SD) of phospho-Smad-2 and -3 
normalised to total Smad-2+3 expression (untreated samples (Ohr) arbitrarily assigned 
as 1), from three independent experiments is shown (*P<0.05, **P<0.01, 
***p<0.001, NS-not significant).
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4.3.2 Smad activation in HMDMs
To confirm that the Smad activation observed in THP-1 macrophages was 
representative of that in HMDMs, the expression of phospho-Smad-2 and -3 
following TGF-P treatment was investigated in primary cultures of HMDMs. The 
60min time point was chosen for this study as this had shown maximal induction of 
phospho-Smad-2 and -3 expression in THP-1 macrophages. Whole-cell protein 
extracts were prepared and subjected to SDS-PAGE and western blotting as described 
in Section 4.3.1. Expression of phospho-Smad-2 and -3 was low in the absence of 
TGF-p and was significantly induced by the cytokine.
Human monocyte-derived m acrophages
P h o s p h o  S m a d - 2
P h o s p h o  S m a d - 3  
T o ta l  S m a d - 2 /3
*?
0 . Untreated + TGF-P
lhr
Figure 4.4 TGF-p activates Smad-2 and Smad-3 in HMDMs. HMDMs were 
left untreated or treated with TGF-P for lhr. Whole-cell protein extracts were 
subjected to SDS-PAGE and western blotting using antibodies against phospho- 
Smad-2, -3 and total Smad-2+3. Relative expression (mean± SD) of phospho-Smad-2 
or phospho-Smad-3, normalised to levels of total Smad-2+3 (untreated samples 
arbitrarily assigned as 1) from three independent experiments is shown (*P<0.05).
□  Smad-2 
■  Smad-3
Untreated +TGF-B
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4.3.3 siRNA-mediated knockdown of control gene, GAPDH
Control siRNAs used for siRNA interference assays include scramble siRNA or 
siRNAs against housekeeping genes such as GAPDH. A number of studies have 
successfully employed GAPDH as a control for siRNA-mediated knockdown 
(Chinetti-Gbaguidi et al. 2005; Larigauderie et al. 2004) and based on this, and its 
previous successful use in the laboratory, GAPDH was chosen as a control for these 
studies. THP-1 monocytes were transfected with 7.5nM siRNA as described in 
Section 2.6.1. This concentration was chosen following an initial dose-response 
experiment based on previous work carried out in the laboratory. Cells were 
differentiated for 24hr using PMA and then left untreated or treated with TGF-p for 
24hr as this was previously shown to be the time point for optimal gene 
inhibition/induction by the cytokine (Chapter 3). As an antibody to GAPDH was not 
available in the laboratory, GAPDH expression was analysed by RT-PCR. Total 
RNA was subjected to RT-PCR to amplify GAPDH and P-2 microglobulin using 
primers against GAPDH and P-2 microglobulin (Table 2.4). Amplification products 
were size-fractionated by agarose gel electrophoresis. Samples treated with Smad-2 
siRNA were used as a positive control. Figure 4.5 shows that GAPDH mRNA 
expression was high in cells transfected with a siRNA against Smad-2 and were 
significantly reduced in cells transfected with GAPDH siRNA.
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Figure 4.5 GAPDH siRNA-mediated knockdown in THP-1 macrophages.
THP-1 cells were transfected with 7.5nM siRNA (Smad-2 or GAPDH) using 
INTERFERin™ (Section 2.6.1). Total RNA from untreated and TGF-p-treated cells 
(24hr) was subjected to RT-PCR using specific primers against GAPDH and p-2 
microglobulin. Amplification products were resolved by agarose gel electrophoresis 
(Panel A). Product size was determined by comparison against a standard DNA 
molecular weight marker (Appendix I). Relative expression (mean± SD) of GAPDH 
from three independent experiments is shown, with values from Smad-2 transfected 
cells arbitrarily assigned as 1 (**/><0.01).
The suitability of GAPDH siRNA as a control for these studies was validated by RT- 
qPCR studies analysing the constitutive and TGF-p-regulated expression of the genes 
studied in this chapter in GAPDH-transfected cells compared to mock-transfected 
cells (Figure 4.6). Knockdown of GAPDH had no effect on the constitutive 
expression of any of the genes studied with the exception of LPL whose constitutive 
expression was reduced following transfection of GAPDH siRNA. No significant 
change in the TGF-P-regulated expression of any of the genes was observed and the 
TGF-p response was conserved following transfection making GAPDH a suitable 
control for siRNA studies investigating the expression of these genes in the THP-1 
macrophage cell line.
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Figure 4.6 GAPDH siRNA control has no effect on the TGF-p-regulated 
expression of key genes in THP-1 macrophages. Total RNA from untransfected or 
GAPDH siRNA-transfected cells, left untreated or treated with TGF-P, were subjected 
to RT-qPCR using primers specific to LPL (Panel A), SR-A (Panel B), SR-B1 (Panel 
C), CD36 (Panel D), ApoE (Panel E) and RPL13A. Relative expression (mean± SD) 
of each gene, normalised to RPL13A with the values from untransfected and untreated 
cells arbitrarily assigned as 1, from three independent experiments is shown 
(**P<0.01, NS-not significant).
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4.3.4 siRNA-mediated knockdown of Smad expression in THP-1 macrophages
Before the effects o f Smad knockdown on TGF-p-regulated gene expression could be 
investigated, it was necessary to determine the level of Smad knockdown following 
siRNA transfection in THP-1 macrophages. Initially individual knockdown of Smad- 
2 and Smad-3 was investigated (Figures 4.7A and 4.7B) and then the double 
knockdown of Smad-2 and -3 was analysed (Figure 4.7C). The final concentration of 
siRNA used throughout these studies was 7.5nM. Total Smad expression following 
siRNA-mediated knockdown was validated by western blotting using an antibody that 
detected total levels of Smad-2 and -3 as no antibody to separate total Smad-2 and 
total Smad-3 was available. Whole-cell protein extracts from GAPDH or Smad- 
transfected, untreated or TGF-P-treated THP-1 cells were subjected to SDS-PAGE 
and western blot analysis using antibodies specific against Total Smad-2/3 and P- 
actin. Smad knockdown was validated by western blot analysis for each siRNA 
transfection experiment presented in this chapter. Where gene expression was 
analysed at the mRNA level, extracts for total RNA and total protein were prepared 
simultaneously allowing Smad knockdown levels to be determined. A significant 
reduction in Smad expression was observed following single Smad-2 or Smad-3 and 
double Smad-2+3 siRNA-mediated knockdown (Figure 4.7).
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Figure 4.7 Smad expression following siRNA-mediated knockdown in THP-1 
macrophages. Whole-cell protein extracts were prepared from untreated or TGF-P- 
treated THP-1 cells transfected with validated GAPDH siRNA or Smad-2 (Panel A), 
Smad-3 (Panel B) or Smad-2 and Smad-3 (Panel C) siRNA as described in Section 
2.6.1. Extracts were subjected to SDS-PAGE and western blotting and levels of total 
Smad-2/3 were compared against levels of P-actin. Relative expression (mean± SD) 
of Smad-2/3 normalised to p-actin levels, with values from GAPDH-transfected cells 
arbitrarily assigned as 1, from four (Panel A) or five (Panel B) or three (Panel C) 
independent experiments is shown (*P<0.05, ***P<0.001).
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4.3.5 Effect of Smad knockdown on the expression of LPL
The effect of Smad knockdown on the expression of LPL was initially investigated at 
the protein level (Figure 4.8A). Transfection of siRNA and subsequent western 
blotting was carried out as for Smad expression (Section 4.3.4). Unanticipated 
problems with the detection o f the LPL protein product following western blotting 
meant that subsequent studies on LPL expression were necessarily carried out using 
RT-qPCR. THP-1 cells were transfected with 7.5nM of GAPDH siRNA or the 
requisite Smad siRNA. Total RNA extracts from untreated and TGF-p-treated (24hr) 
cells were reverse-transcribed and the resulting cDNA subjected to qPCR analysis 
using previously optimised amplification conditions (Table 2.6) and primers against 
LPL and 28SrRNA (Table 2.5). As expected, LPL expression was significantly 
reduced by TGF-P in GAPDH-transfected cells. In Smad-2 siRNA-transfected cells, 
this reduction was no longer significant at the protein (Figure 4.8A) or mRNA (Figure 
4.8B) level. Similarly, mRNA expression o f LPL was no longer significantly 
reduced in Smad-3 siRNA-transfected cells (Figure 4.8C) or Smad-2+3 siRNA- 
transfected cells (Figure 4.8D). As expected, the reversal o f TGF-p-regulated LPL 
expression was notably higher following Smad-2+3 double siRNA-mediated 
knockdown.
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Figure 4.8 Smad knockdown attenuates the TGF-p-mediated inhibition of 
LPL expression in THP-1 macrophages. Whole-cell protein extracts (Panel A) or 
total RNA extracts (Panels B-D) were prepared from untreated or TGF-p-treated 
THP-1 macrophages transfected with GAPDH or validated Smad-2 (B), Smad-3 (C) 
or Smad-2+3 (D) siRNA. Western blotting was carried out using antibodies against 
LPL and P-actin. RT-qPCR was carried out using primers against LPL and 
28SrRNA. Relative expression (mean± SD) of LPL, normalised to P-actin (for 
western blotting) or 28SrRNA (for RT-qPCR) levels (values from untreated samples 
arbitrarily assigned as 1), from three independent experiments is shown (*P<0.05, 
NS-not significant, # significant induction-.P<0.05).
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4.3.6 Effect of Smad knockdown on the expression of SR-A
As an antibody to SR-A was available in the laboratory, the effect of Smad 
knockdown on SR-A expression was primarily investigated at the protein level. THP- 
1 cells were transfected and whole-cell extracts from untreated and TGF-p-treated 
cells were prepared using Laemmli buffer (Section 2.7.1) and subjected to SDS- 
PAGE and western blot analysis using a 10% (v/v) polyacrylamide gel (Sections 2.7.7 
and 2.7.8) and antibodies against the three isoforms of SR-A and P-actin. The 
different bands represent the three post-tanslational isoforms of SR-A. As expected, 
SR-A expression was high in untreated cells and was significantly reduced by TGF-p 
in GAPDH-transfected cells. Unlike LPL, knockdown of Smad-2 had no effect on the 
TGF-P-mediated inhibition o f SR-A expression (Figure 4.9A) and a similar 
expression profile was observed following knockdown o f Smad-3 (Figure 4.9B). 
However, following double knockdown of Smad-2 and -3, the TGF-P-regulated 
inhibition o f SR-A was notably reversed (Figure 4.9C). Consistent with this 
observation, Smad-2 and -3 knockdown resulted in a marked reversal o f the TGF-p- 
mediated inhibition of SR-A mRNA expression (Figure 4.9D).
4.3.7 Effect of Smad knockdown on the expression of SR-B1
The effect o f Smad knockdown on the expression of SR-B1 was investigated at the 
mRNA level. Transfection and preparation of total RNA extracts and RT-qPCR was 
carried out as for LPL (Section 4.3.5). Expression of SR-B1 was significantly 
reduced by TGF-p in GAPDH-transfected cells. Following Smad-2 knockdown, the 
expression o f SR-B1 was no longer significantly inhibited by TGF-P (Figure 4.10A). 
The TGF-p-regulated expression o f SR-B1 was similarly attenuated by Smad-3 
knockdown (Figure 4.1 OB) but to a larger extent than Smad-2. Double knockdown of 
Smad-2 and -3 also resulted in the attenuation of TGF-p-regulated SR-A expression 
(Figure 4 .10C).
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Smad-2 and Smad-3 are required for the TGF-p-mediated 
inhibition of SR-A expression in THP-1 macrophages. Whole-cell protein extracts 
from untreated and TGF-P-treated cells transfected with validated GAPDH or Smad-2 
(Panel A), Smad-3 (Panel B) or Smad-2 and -3 (Panel C) siRNAs were subjected to 
SDS-PAGE and western blotting using antibodies against SR-A (all three isoforms) 
and p-actin. In panel D, total RNA was reverse-transcribed and subjected to RT- 
qPCR using primers specific for SR-A and 28SrRNA. Relative expression (mean 
±SD) of SR-A normalised to p-actin (or 28SrRNA), with values from untreated 
samples arbitrarily assigned as 1, from three independent experiments is shown 
(*P<0.05, **P<0.01, ***p<0.001, NS-not significant).
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Figure 4.10 Smad knockdown negates the TGF-p-mediated inhibition of SR-B1 
expression in THP-1 macrophages. Total RNA extracts from untreated and TGF-p- 
treated cells transfected with GAPDH or Smad-2 (Panel A), Smad-3 (Panel B) or 
Smad-2 and -3 (Panel C) were subjected to RT-qPCR using primers specific to SR-B1 
and 28SrRNA. Relative expression (mean ±SD) of SR-B1 normalised to 28SrRNA 
from three independent experiments is shown, with values from untreated samples 
arbitrarily assigned as 1 (*P<0.05, NS-not significant).
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4.3.8 Effect of Smad knockdown on the expression of CD36
As for SR-B1, the effect of Smad knockdown on CD36 expression was investigated at 
the mRNA level. Expression of CD36 was down-regulated by TGF-p in GAPDH- 
transfected cells. Knockdown of Smad-2 expression resulted in a loss of significant 
down-regulation o f CD36 by TGF-P (Figure 4.11 A). Smad-3 knockdown was also 
able to attenuate the TGF-p-regulation o f CD36 to a larger extent than Smad-2 
knockdown and produced a notable reversal of CD36 inhibition (Figure 4.1 IB). 
Knockdown of Smad-2 and -3 also produced a marked reversal of TGF-P-regulated 
CD36 inhibition (Figure 4.11C).
4.3.9 Effect of Smad knockdown on the expression of ApoE
As an antibody to ApoE was available in the laboratory and for consistency with 
previous studies on TGF-p-regulated ApoE protein expression (Chapter 3), the effect 
of Smad knockdown on ApoE expression was investigated at the protein level. 
Preparation o f protein extracts and western blotting was carried out as for SR-A 
(Section 4.3.6). As expected, ApoE expression was significantly induced by TGF-p 
in GAPDH-transfected cells. Knockdown of Smad-2 had no effect on the TGF-p- 
regulated expression o f ApoE (Figure 4.12A) and similarly, knockdown of Smad-3 
had no effect on ApoE induction (Figure 4.12B). In contrast to this, knockdown of 
Smad-2 and -3 had a marked effect on the TGF-p-regulated induction o f ApoE protein 
expression (Figure 4.12C). Consistent with this, analysis of ApoE mRNA levels 
following Smad-2 and -3 knockdown showed a dramatic reduction in TGF-P- 
stimulated ApoE induction (Figure 4.12D).
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Figure 4.11 Smad knockdown negates the TGF-p-mediated regulation of CD36 
expression in THP-1 macrophages. RT-qPCR was carried out using primers 
specific to CD36 and 28SrRNA using total RNA extracts from cells transfected with 
GAPDH or Smad-2 (Panel A), Smad-3 (Panel B) or Smad-2 and -3 (Panel C) siRNA. 
Relative expression (mean ±SD) of CD36, normalised to 28SrRNA is shown, with 
values from untreated samples arbitrarily assigned as 1 (*/><0.05, NS-not significant).
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Figure 4.12 Both Smad-2 and Smad-3 are required for the TGF-P-mediated 
induction of ApoE expression in THP-1 macrophages. Whole-cell protein extracts 
from untreated and TGF-p-treated cells transfected with validated GAPDH or Smad-2 
(Panel A), Smad-3 (Panel B) or Smad-2 and -3 (Panel C) siRNAs were subjected to 
SDS-PAGE and western blotting using antibodies against ApoE and P-actin. In panel 
D, total RNA was reverse-transcribed and subjected to RT-qPCR using primers 
specific for ApoE and 28SrRNA. Relative expression (mean ±SD) of ApoE 
normalised to p-actin (or 28SrRNA) from three independent experiments is shown, 
with values from untreated samples arbitrarily assigned as 1 (*P<0.05, ***P<0.001, 
NS-not significant, #-significant inhibition P<0.05).
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4.3.10 Effect of Smad knockdown on the expression of ABCA-1
The effect of Smad knockdown on the expression of ABCA-1 was initially 
investigated at the protein level but due to difficulties with reproducibility of good 
westerns for ABCA-1 because o f the large size o f the protein, further studies had to be 
carried out at the mRNA level. Following siRNA transfection and differentiation of 
THP-1 cells, cells were left untreated or treated with TGF-P for 6hr based on previous 
studies that showed maximal induction o f ABCA-1 mRNA expression in response to 
TGF-P at this time point (Chapter 3). The control gene RPL13A was used for studies 
on ABCA-1 and ABCG-1 due to unexpected problems with the amplification of the 
28SrRNA gene by RT-qPCR. Knockdown of Smad-2 resulted in the TGF-p-mediated 
induction of ABCA-1 being no longer significant (Figure 4.13B), although this could 
be due to the large variation observed in the relative levels of ABCA-1 expression. 
Knockdown of Smad-3 resulted in a similar expression pattern, with high variation in 
relative levels o f ABCA-1 expression (Figure 4.13C). Only knockdown of Smad-2 
and -3 produced a marked reduction in the TGF-p-mediated induction of ABCA-1 
expression (Figure 4.13D) to levels below those in untreated cells.
4.3.11 Effect of Smad knockdown on the expression of ABCG-1
Similar to ABCA-1, the expression of ABCG-1 following Smad knockdown was 
investigated at the mRNA level following 6hr stimulation with TGF~p. Smad-2 
knockdown produced a notable reduction in the TGF-p-regulated levels of ABCG-1 
to levels comparable with those in untreated cells (Figure 4.14A). Smad-3 
knockdown resulted in a similar expression pattern (Figure 4.14B). Interestingly, 
knockdown o f Smad-2 and -3 resulted in a reduction of TGF-P-mediated ABCG-1 
induction that was similar to that observed following single Smad knockdown.
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Figure 4.13 Knockdown of Smad-2 and Smad-3 attenuates the TGF-p- 
mediated induction of ABCA-1 expression in THP-1 macrophages. Total RNA 
extracts from untreated and TGF-p-treated cells transfected with validated GAPDH or 
Smad-2 (Panel B), Smad-3 (Panel C) or Smad-2 and -3 (Panel D) siRNAs were 
subjected RT-qPCR using primers specific to ABCA-1 and RPL13A. Relative 
expression (mean ±SD) of ABCA-1 normalised to RPL13A, with values from 
untreated samples arbitrarily assigned as 1, from three independent experiments is 
shown (*/><0.05, NS-not significant, #-significant inhibition P<0.05). In panel A, 
whole-cell protein extracts were subjected to SDS-PAGE and western blotting using 
antibodies against for ABCA-1 and p-actin. Mean relative expression of ABCA-1 
normalised to p-actin, with values from untreated samples arbitrarily assigned as 1, 
from two independent experiments is shown.
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Figure 4.14 Smad knockdown attenuates the TGF-p-mediated induction of 
ABCG-1 expression in THP-1 macrophages. RT-qPCR was carried out using 
primers specific to ABCG-1 and RPL13A using total RNA extracts from cells 
transfected with GAPDH or Smad-2 (Panel A), Smad-3 (Panel B) or Smad-2 and -3 
(Panel C) siRNA. Relative expression (mean ±SD) of ABCG-1, normalised to 
RPL13A with values from untreated samples arbitrarily assigned as 1, is shown 
(*P<0.05, NS-not significant).
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4.3 .12 A denoviral-m ediated shRNA knockdown of Smad-2 in HMDMs:
Effects on expression  of key gen es
To validate the results observed in THP-1 cells, it was necessary to knockdown Smad 
expression in HMDMs. The effect of a Smad-2 knockdown on the mRNA expression 
of representative genes was analysed by RT-qPCR. Preparation of an adenovirus type 
5 (Ad5) vector, engineered to express Smad-2 shRNA and subsequent infection of 
HMDMs was carried out in the laboratory by Dr Daryn R. Michael. A Smad-2 
shRNA flanked by sequences from the mouse BIC gene (+134/+161 and +221/+265), 
targeting a sequence of the Smad-2 gene (AAGAGCAGCAAATTCCTGGTT) was 
inserted into the Ad5 vector using recombineering technology (Chung et al. 2006; 
Stanton et al. 2008). Two oligonucleotides (Table 4.1) that overlap by 25 base pairs 
at their 3’ and 5’ ends respectively were designed to contain the appropriate Smad-2 
shRNA sequence and arms of homology to facilitate homologous recombination into 
the Ad5 vector. Each oligonucleotide (lOOng) was transformed into SW102 E-coli 
that contained the Ad5 vector genome in a modified bacterial artificial chomosome 
(BAC) and appropriate recombinants were identified. Recombinant adenovims was 
then amplified, purified and titred (Stanton et al. 2008). A recombinant adenovims 
expressing a scrambled shRNA sequence (RAdscrambled shRNA) was also generated 
for use as a control. HMDMs were infected at a multiplicity of infection (MOI) of 
100 for 72hr which was sufficient to infect >90% HMDMs as measured by flow 
cytometry (Figure 4.15A).
Table 4.1 Sequences of Smad shRNA oligonucleotides
shRNA
oligonuculeotide
Sequence (5’-3’)
Smad-2
Forward
CAGCCTGGATCCCTGGAGGCTTGCTGAAGGCTGTATGCTG 
A AG AGC AGC AA ATT CCTGGTT GTTTT GGC C ACT G ACT G AC 
AAC
Smad-2
Reverse
TTT GTT C C AT GT G AGT GC T AGT A AC AGGCCTT GT GT C CT G A 
AGAGCAGCAATCCTGGTTGTCAGTCAGTGGCCAAAACAAC
Smad-3
Forward
CAGCCTGGATCCCTGGAGGCTTGCTGAAGGCTGTATGCTG 
T GC AGGT CC AAGTT ATT AT GT GTTTT GGCC ACT G ACT GAC A 
CA
Smad-3
Reverse
ACACAAAACCGGTGACTGACTGTGTATTATAACCTGGACG
TGTCCTGTGTTCCGGACAATGATCGTGAGTGTACCTTGTTT
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Figure 4.15B shows that Smad-2 expression was significantly reduced in untreated 
and TGF-p treated HMDMs following transfection o f RAd-Smad-2 shRNA into 
HMDMs. RT-qPCR analysis o f gene expression (Figure 4.16) demonstrated that 
knockdown o f Smad-2 in HMDMs reversed the TGF-p-mediated inhibition of CD36, 
consistent with observations in THP-1 macrophages (Section 4.3.8). Knockdown of 
Smad-2 reduced the TGF-P-mediated induction o f ABCA-1, consistent with 
observations in THP-1 macrophages (Section 4.3.10). Interestingly, the TGF-P- 
mediated induction of ApoE expression was also reduced following Smad-2 
knockdown whereas in THP-1 macrophages, only a double knockdown of Smad-2 
and -3 was able to reduce ApoE induction by the cytokine (Section 4.3.9). This could 
potentially be due to the larger percentage knockdown o f Smad-2 in Smad-2 shRNA 
infected HMDMs compared to the siRNA knockdown o f Smad-2 achieved in THP-1 
macrophages.
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Figure 4.15 Ad5-GFP infection of HMDMs. HMDMs were infected with an 
adenovirus type 5 vector linked to green fluorescent protein (GFP) at a multiplicity of 
infection of 100 for 72hr. Percentage of GFP-positive cells was measured using flow 
cytometry (Panel A). In panel B, total RNA extracts from RAd-Scrambled shRNA or 
RAd-Smad-2 shRNA transfected cells were subjected to RT-qPCR using primers 
specific to Smad-2 and GAPDH. The relative expression (mean ±SD) of Smad-2 
normalised to GAPDH from three experiments is shown, with values from RAd- 
scrambled shRNA transfected cells arbitrarily assigned as 1 (**P<0.01). This work 
was carried out by Dr Daryn R. Michael.
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Figure 4.16 The effects of Smad-2 knockdown on TGF-p-regulated gene 
expression in HMDMs. Total RNA from RAd-Scrambled shRNA or RAd-Smad-2 
shRNA transfected cells were subjected to RT-qPCR using primers specific to CD36 
(Panel A), ApoE (Panel B), ABCA-1 (Panel C) and GAPDH. The relative expression 
(mean± SD) of each gene, normalised to GAPDH (mean ±SD) from three experiments 
is shown, with values from untreated cells arbitrarily assigned as 1 (*P<0.05, 
**P<0.01, NS-not significant).
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4.3.13 Effect of Smad knockdown on constitutive gene expression
To understand the effects o f Smad knockdown on the TGF-P-regulated expression of 
the genes studied above, it was necessary to determine if the knockdown of Smad 
expression had any effect on the constitutive expression of these key genes (the 
expression of each gene induced by PMA as part of the differentiation process) or if 
its effects were limited to TGF-P-regulated gene expression. To determine this, data 
was analysed for changes in gene expression in untreated cells transfected with Smad- 
2, Smad-3 or Smad-2 and -3 siRNA relative to gene expression in untreated cells 
transfected with GAPDH siRNA. The mRNA expression o f LPL, SR-B1, CD36, 
ABCA-1 and ABCG-1 was determined by RT-qPCR. 28SrRNA was used as a 
control gene except for ABCA-1 and ABCG-1 expression where RPL13A was used 
as a control gene due to unexpected problems with the amplification o f 28SrRNA by 
RT-qPCR when the experiments were carried out. The protein expression of SR-A 
and ApoE was determined by Western blotting. Figure 4.17 shows that knockdown of 
Smad-2, Smad-3 and Smad-2 and -3, had no significant effect on the constitutive 
expression of LPL (Panel A), SR-A (Panel B), ApoE (Panel E), ABCA-1 (Panel F) or 
ABCG-1 (Panel G). Interestingly, the constitutive expression of SR-B1 (Panel C) and 
CD36 (Panel D) were down-regulated by Smad knockdown. Constitutive expression 
of CD36 was significantly reduced by Smad-2 and Smad-3 single knockdown and by 
Smad-2 and -3 knockdown. Basal levels of SR-B1 were similarly affected with 
significant knockdown produced in response to Smad-2 and Smad-2 and -3 
knockdown whilst Smad-3 knockdown had no significant effect on basal expression 
of SR-B1.
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Figure 4.17 Smad knockdown down-regulates the basal expression of SR-B1 
and CD36 but has no effect on the constitutive expression of other genes in THP- 
1 macrophages. RT-qPCR was carried out using primers specific to LPL (Panel A), 
SR-B1 (Panel C), CD36 (Panel D), ABCA-1 (Panel F), ABCG-1 (Panel G) using total 
RNA from cells transfected with GAPDH or Smad-2, Smad-3 or Smad-2 and -3 
siRNA. Relative expression (mean ±SD) of each gene, normalised to 28SrRNA or 
RPL13A with GAPDH-transfected samples arbitrarily assigned as 1, is shown. For 
SR-A (Panel B) and ApoE (Panel E) expression, western blotting using antibodies 
against SR-A, ApoE and P-actin was carried out. Relative expression (mean ±SD) of 
SR-A or ApoE, normalised to P-actin is shown, with GAPDH-transfected samples 
arbitrarily assigned as 1 (*P<0.05, **.P<0.01, NS-not significant).
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4.4 Discussion
Previous studies, presented in Chapter 3, have shown that TGF-p inhibits the 
expression of key genes involved in cholesterol uptake into macrophages and up- 
regulates the expression o f genes involved in macrophage cholesterol efflux. This is 
critical to the ability o f the cytokine to attenuate foam cell formation, a key stage in 
atherosclerosis development. Many TGF-P actions are signalled through the Smad 
pathway. Although this classical TGF-p signalling pathway is well defined, very little 
is known about its role in relation to gene regulation by the cytokine in macrophages. 
Only the TGF-p-regulated inhibition o f CD 163 expression in macrophages is known 
to be mediated through the Smad pathway, via Smad-3 (Pioli et al. 2004). Further 
studies into the involvement of this pathway in TGF-P-regulated gene expression will 
enhance our understanding o f the anti-inflammatory actions of TGF-P and the 
molecular basis o f foam cell formation.
TGF-P, its receptors and Smads-2, -3 and -4 are all highly expressed in macrophages 
and in foam cells found in early stage atherosclerotic lesions (Bobik 2006; Kalinina et 
al. 2004). Following injury to the artery TGF-p is activated by furin-like proprotein 
convertases (Bobik 2006). Whether Smads are activated in response to arterial injury 
is currently unclear. However, we have shown that the Smad signalling pathway is 
activated by TGF-P in both THP-1 macrophages and HMDMs and that this activation 
has rapid kinetics (Figure 4.3 and Figure 4.4). This finding correlates well with 
previous studies which have shown that signalling through the Smad pathway is 
active in human atherosclerotic lesions (Bot et al. 2009) and can be enhanced in 
vascular smooth muscle cells (VSMCs) by statins (Rodriguez-Vita et al. 2008).
The role of the Smad pathway in the TGF-p regulation of gene expression was 
investigated using siRNA knockdown o f Smad-2 and Smad-3. Knockdown of Smad 
expression was determined using western blotting. As antibodies to individual total 
Smad-2 and total Smad-3 were not available, an antibody that detected total levels of 
Smad-2 and -3 was used. One disadvantage o f an antibody that detects both R-Smads
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is that the expression levels o f individual Smads following siRNA knockdown can not 
be determined accurately. It is possible that following a drop in levels of one Smad, 
levels o f the ‘other’ Smad increase to compensate. However, studies using Smad-2 or 
Smad-3 null fibroblasts have suggested that this does not occur (Roberts et al. 2003). 
The use o f validated siRNA sequences against each Smad suggests that any residual 
Smad expression observed following knockdown is due to the expression of the 
‘other’ Smad.
GAPDH siRNA was used as a control for studies on siRNA knockdown. In RNA 
interference assays, the use o f a siRNA against a housekeeping gene or against a 
random sequence o f bases (Scramble siRNA) is used as a control. The use of 
Scramble siRNA has the obvious advantage o f targeting random sequences instead of 
targeting a sequence coding for a functional molecule, ensuring that no adverse effects 
resulting from loss o f expression are observed. One disadvantage is that due to the 
random base sequence, no gene is knocked down by a control Scramble siRNA. 
Although GAPDH siRNA targets a key housekeeping gene in the cell (GAPDH 
catalyses the breakdown of glyceraldehyde-3-phosphate, as part of glycolysis) 
GAPDH siRNA has been successfully used in a number o f RNA interference studies 
(Ding et al. 2009; Zhang et al. 2005; Zhao et al. 2008). It also appeared to have no 
effect on the TGF-P-regulated expression o f any o f the genes studied in this chapter 
(Figure 4.6).
The results presented in this chapter demonstrate for the first time that the Smad 
signalling pathway plays a key role in the expression o f key genes implicated in the 
regulation o f foam cell formation by TGF-p. The use of siRNA knockdown assays 
using siRNA specific against Smad-2 and Smad-3 showed that the Smad pathway was 
required for the TGF-p-regulated inhibition o f LPL, SR-A, SR-B1 and CD36 
expression (Figures 4.8 to 4.11) and also for the TGF-P-regulated induction of ApoE, 
ABCA-1 and ABCG-1 (Figures 4.12 to 4.14) in THP-1 macrophages. Representative 
experiments in HMDMs (Figure 4.16) suggested that these changes would be 
conserved in primary macrophages. This is summarised in Figure 4.18. The 
contribution o f each R-Smad to the transcriptional regulation of the genes studied was 
assessed using single Smad knockdown to take into account the possibility of 
differential regulation by each o f the R-Smads. The effect of a Smad-2 and -3
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knockdown was assessed to take into account the possibility of functional redundancy 
or competition between the R-Smads. As expected, knockdown of Smad-2 and -3 
produced markedly more dramatic changes in all genes investigated as compared to 
single knockdown o f either Smad-2 or Smad-3. Our findings suggested crucial roles 
for Smad-2 and Smad-3 in the regulation of genes implicated in macrophage 
cholesterol homeostasis suggesting that they may have key roles in foam cell 
formation.
Microarray analysis of human keratinocytes has shown that there are subsets of genes 
that depend on regulation by Smad-2, by Smad-3 and by both Smad-2 and -3 
(Kretschmer et al. 2003). In our study, TGF-P-stimulated levels of ABCG1 showed 
similar reductions in response to Smad-2 or Smad-3 knockdown in addition to Smad- 
2 and -3 knockdown (Figure 4.14) while TGF-P-stimulated levels of ABCA-1 showed 
similar reductions in response to Smad-2 or Smad-3 knockdown but showed a more 
marked reduction following Smad-2 and -3 knockdown (Figure 4.13). This could 
suggest that either both Smads are required for this regulation or that regulation can 
be mediated by either Smad-2 or Smad-3 to the same effect.
Of notable interest in our study, TGF-p-inhibited levels of LPL, CD36 and SR-B1 
showed greater changes in response to Smad-3 knockdown (Figures 4.8 to 4.11) that 
could suggest that this set of genes is regulated through Smad-3 although Smad-2 may 
also contribute to this action, particularly in the case of SR-B1. In support of this, the 
expression of CD36 has previously been shown to be regulated by a reduction in 
PPAR-y activity mediated by TGF-P through Smad-3 and the transcription factor AP- 
1 (Fu et al. 2003).
This observation could suggest that Smad-3 is a key player in the inhibition of 
cholesterol uptake and therefore in foam cell formation. However, a number of 
factors could contribute to this effect including the larger knockdown of Smad-3 
protein expression following siRNA-mediated transfection (Figure 4.7) and this 
cannot be ruled out as a contributor to this effect. Compensatory mechanisms 
between Smad-2 and Smad-3 also exist. The specificity of the siRNA sequences 
against individual Smad knockdown also needs to be verified before firm conclusions 
can be drawn on the involvement of individual Smads in gene expression.
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One interesting observation is that o f the genes studied; only SR-A and ApoE 
demonstrated a requirement for both Smads in their regulation by TGF-P (Figure 4.9 
and Figure 4.12 respectively). Whether this is due to functional redundancy between 
Smads or a requirement for regulation by both Smad-2 and Smad-3 is unclear. Smad- 
2 and Smad-3 can be differentially regulated to mediate distinct TGF-p responses, 
although the relative importance and mechanism of regulation of each remains 
unclear. Interestingly, it has previously been shown that Smad-2 and Smad-3 null 
fibroblasts do not display any changes in the expression or phosphorylation of the 
‘other’ Smad suggesting that they do not compete for receptor binding and may be 
phosphorylated by different receptor pools located in distinct endosomal 
compartments (Janknecht et al. 1998; Roberts et al. 2003). Association and 
availability o f SARA may also control the phosphorylation ability o f Smad-2 versus 
Smad-3 (Brown et al. 2007). Studies have shown that cellular context can result in 
differential roles for individual Smads. Interactions with different proteins may also 
contribute to specific Smad activation. For instance TRAP-1 like protein is able to 
activate Smad-2 responses whilst blocking the formation o f Smad-3/4 complexes to 
inhibit Smad-3 dependent responses (Brown et al. 2007). In addition to this Smads 
can be differentially negatively regulated by E3 ubiquitin ligases such as PRAJA 
which targets Smad-3 and TG-interacting factor (TGEF)-interacting ubiquitin ligase 
which targets Smad-2 (Ross and Hill 2008).
Although the two regulatory Smad proteins are highly homologous, one of the key 
differences between the two is that Smad-3 to be able to bind directly to DNA through 
its MH1 domain whilst Smad-2 requires Smad-4 for DNA binding due to a 30 amino- 
acid insert in its MH1 domain (Brown et al. 2007). This difference may be important 
in the regulation o f genes involved in macrophage cholesterol homeostasis and foam 
cell formation. It has previously been demonstrated that Smad-3 can directly activate 
early TGF-P target genes while Smad-2 regulates early and intermediate target genes 
through TGF-P and Smad-3 (Brown et al. 2007). The high frequency of Smad 
binding elements in promoters means that it is often necessary for Smads to interact 
with other transcription factors to facilitate transcription o f target genes, this may also 
have a role in the differential actions o f Smads (Ross and Hill 2008). The MH2 
domain present in both Smads is involved with interactions with cofactors and other
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transcription factors such as p300/CBP which is required for the transactivation of 
Smad-3 activated promoters such as PAI-1 (Janknecht et al. 1998). Protein: protein 
interactions and the regulation o f transcription factors such as Spl in the case of LPL 
(Irvine et al. 2005) could mediate some o f the effects of the Smads.
Whilst the mechanisms behind TGF-P regulation o f gene activation and inhibition in 
relation to foam cell formation and atherosclerosis are not well characterised, several 
lines o f evidence have suggested that Smad-3 is the key player in gene repression by 
TGF-p. Smad-3 has been implicated in the repression o f class II MHC expression 
(Dong et al. 2001), the expression o f c-myc and human telomerase reverse 
transcriptase, both implicated in cancer (Frederick et al. 2004; Li and Liu 2007). An 
involvement of Smad-3 in the repression o f adipocyte differentiation and skeletal 
muscle differentiation has also been identified (Choy and Derynck 2003; Liu et al. 
2001). Transfection of macrophages with a Smad-3 expression plasmid can 
reproduce the inhibitory effect o f TGF-p on MMP-12 and iNOS, two markers of 
macrophage activation and this action requires the MH1 domain of Smad-3 (Werner 
et al. 2000). Smad-3-deficient macrophages also display altered chemotactic
responses (Ashcroft et al. 1999). Targeted deletion o f Smad-3 enhances neointimal 
hyperplasia suggesting a protective role in the vascular response to injury (Yokote et 
al. 2006). Further studies are needed to elucidate the roles o f individual Smads in 
foam cell formation. However, these studies, together with our findings, suggest that 
Smads have a role in macrophages consistent with the protective, antiatherogenic 
action of TGF-P in atherosclerosis.
Interestingly, our study also revealed a role for the Smads in the constitutive 
expression o f SR-B1 and CD36 in THP-1 macrophages (Figure 4.17). Constitutive 
expression o f SR-B1 appeared to be dependent on Smad-2 whilst CD36 expression 
was reduced by both Smad-2 and Smad-3 knockdown. This suggests that Smad 
signalling is necessary for the constitutive expression of SR-B1 and CD36 following 
PMA-induced differentiation in addition to their regulation by TGF-p in THP-1 
macrophages. The decrease in SR-B1 levels in response to Smad-2 and not Smad-3 
could indicate that constitutive SR-B1 expression in THP-1 cells is dependent on 
Smad-2.
195
CHAPTER 4: Role o f Smads in TGF-P-regulated expression of key macrophage genes
In conclusion, the studies presented in this chapter have identified a role for the Smad 
signalling pathway in the control o f macrophage cholesterol homeostasis by TGF-p. 
This is summarised in Figure 4.18. The TGF-P-regulation of expression of genes 
implicated in macrophage cholesterol homeostasis is defined for key genes (see 
Chapter 3), but very little is known about the role o f signalling pathways in this 
regulation. The Smad signalling pathway is the classical TGF-p signalling pathway 
and these studies suggest a critical role for this pathway in the TGF-p-regulation of 
LPL, SR-A, SR-B1, CD36, ApoE, ABCA-1 and ABCG-1 expression in THP-1 
macrophages and primary macrophages. This suggests that the pathway is crucial for 
the attenuation o f foam cell formation by TGF-P and therefore contributes to the anti­
atherogenic role o f TGF-P in atherosclerosis.
Further work will be needed to extend these findings at a cellular level and to further 
elucidate the exact molecular mechanisms behind the TGF-P regulation o f genes 
implicated in macrophage cholesterol homeostasis. In particular, studies on the 
involvement o f Smad-4 in the TGF-p-regulation o f gene expression will be important 
to enhance understanding of the exact mechanisms behind the TGF-p-regulation of 
individual genes. Signalling through the Smad pathway involves the formation of 
complexes between either Smad-2 and Smad-4 or Smad-3 and Smad-4 to allow 
translocation o f the Smads to the nucleus (Schmierer and Hill 2007). However, some 
studies have shown that Smad-4 has a variable role in TGF-P signalling (Liu et al. 
1997; Sirard et al. 2000). Analysis o f the promoter sequence o f the genes investigated 
in this chapter for transcription factor binding sites will also be required to determine 
if Smad binding sites are present within the promoter regions o f these genes.
TGF-P is also able to signal through non-classical pathways such as the MAPK and 
PI3 kinase pathways. These pathways have been well-characterised and their 
involvement in a large number o f cellular processes and regulation o f genes has been 
suggested by a range o f studies. However, the involvement of MAPK pathways in 
TGF-P-regulated gene expression, in particular in relation to macrophages and foam 
cell formation has not been described. This is the focus of Chapter 5 o f this thesis.
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Figure 4.18 The involvement of the Smad signalling pathway in the TGF-p- 
regulated expression of key genes implicated in macrophage cholesterol 
homeostasis. Previously, the only macrophage-expressed gene known to be directly 
regulated through the TGF-p-Smad pathway (via Smad-3) was CD 163 whose 
expression is down-regulated by the cytokine (Pioli et al. 2004). From the results 
presented in this chapter the TGF-p-regulated expression of LPL, SR-A, SR-B1, 
CD36, ApoE, ABCA-1 and ABCG-1 can be added to this list. Whilst some genes 
(SR-A and ApoE) showed a requirement for both Smads in their regulation, others 
showed similar responses to single Smad-2 and Smad-3 knockdown (ABCA-1 and 
ABCG-1). Of the genes studied that were implicated in cholesterol efflux, LPL, SR- 
B1 and CD36 showed greater responses to Smad-3 knockdown compared to Smad-2 
(LPL, SR-B1, CD36) although single knockdown of Smad-2 did also effect their 
expression. The exact contribution of each to their TGF-p-regulated gene expression 
remains unclear.
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CHAPTER 5 
The role of MAPKs in the TGF-p-regulated 
expression of key genes involved in the control 
of macrophage cholesterol homeostasis
5.1 Introduction
5.1.1 MAPK-regulated gene transcription
A large number of proteins involved in gene transcription have been identified as 
targets of the MAPKs and, as explained in more detail in Section 1.12, the MAPKs 
are mediators of transcriptional responses to a number o f external stimuli including 
stress, growth factors, hormones and cytokines. In addition to this, the MAPKs can 
also modulate the localisation and binding ability of other transcriptional regulators 
(Qureshi et al. 2005, Whitmarsh 2007). Often, the roles o f MAPKs in gene regulation 
appear cell-type-, gene-, and MAPK-specific. For instance, the induction of iNOS 
expression by IFN-y can be augmented by ERK but inhibited by p38 kinase in the 
murine RAW264.7 macrophage cell line (Chan and Riches 2001).
Activation of MAPKs by TGF-p and roles for these signalling pathways in TGF-P- 
regulated gene transcription has been demonstrated in a number of cell types. For 
example, TGF-p activates ERK and p38 kinase in human gingivial fibroblasts and 
induction of MMP-13 by the cytokine in these cells can be blocked using the p38 
kinase specific inhibitor SB203580 or an adenovirally-expressed dominant-negative 
form of p38 kinase (Ravanti et al. 1999). Similarly, TGF-P-regulated induction of 
fibronectin mRNA and protein expression in mesangial cells is accompanied by an
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increase in ERK activity and can be blocked using the ERK specific inhibitor, 
PD98059 (Inoki et al. 2000). The use of ERK specific inhibitors PD98059 and 
U0126 in chondrocytes has also implicated ERK in the TGF-P-regulated induction of 
mRNA and protein expression of the MMP and aggrecanase inhibitor, TIMP-3 
(Qureshi et al. 2005). In VSMCs, TGF-P can induce the activity of p38 kinase and 
this activation is required for the upregulation o f VSMC marker genes such as serum- 
response factor and the GATA transcription factor (Deaton et al. 2005).
Apoptotic mechanisms downstream of TGF-P have consistently been found to involve 
MAPKs with a number of studies implicating JNK in this regulation. In both 
hepatocytes and epithelial cells, an interaction between the TGF-P type II receptor and 
the pro-apoptotic adaptor protein Daxx has been demonstrated to lead to the activation 
of JNK signalling and induction o f apoptosis (Moustakas and Heldin 2005).
5.1.2 MAPK-regulated gene transcription and inflammation and atherosclerosis
The action of MAPKs on the expression of genes implicated in inflammation appears 
to show some uniformity. NFkB is a central regulator o f genes involved in 
inflammation and the immune response. A number of studies on the MAPK 
regulation of NFicB-regulated genes have shown that they augment NFicB-driven gene 
transcription (Sun et al. 2008, Xiao et al. 2002). For example, the induction of NFkB- 
mediated cytokine and chemokine gene expression in macrophages by inflammatory 
mediators including serum amyloid A (SAA) and Substance P has been shown to be 
augmented by MAPKs. SAA is an acute phase protein produced by the liver in 
response to pro-inflammatory cytokines and is a biomarker for inflammation with 
elevated levels in cardiovascular disease and in atherosclerotic plaques. In addition to 
this, SAA can up-regulate the expression of a number of genes in macrophages 
including IL-1 (3, IL-6, IL-8, MCP-1 and MIP-1 and the use of MAPK inhibitors has 
demonstrated that this induction is mediated through MAPK signalling pathways 
(Song et al. 2009). Substance P is another inflammatory mediator able to activate the 
MAPK pathways in macrophages. Substance P is able to enhance antigen 
presentation and phagocytosis by macrophages but can also induce the release of the 
chemokines MCP-1 and MIP-2 from macrophages. This is mediated through
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activation of the ERK and p38 kinase pathways and can be blocked by inhibitors of 
these MAPKs (Sun et al. 2008).
hi relation to atherosclerosis, roles for the MAPKs in the expression of genes induced 
by shear stress have been noted in endothelial cells and VSMCs. The expression of 
IL-8 in endothelial cells is induced under low shear stress and can be blocked by 
pharmacological inhibitors of ERK, JNK and p38 kinase (Cheng et al. 2008). In 
addition to this, ERK and p38 kinase have been implicated in the shear-stress induced 
expression of MMP-9 in endothelial cells (HUVECs) (Sun et al. 2007) and p38 kinase 
has been implicated in the mechanical stress-induced expression of IL-6 in smooth 
muscle cells (Zampetaki et al. 2005). Interestingly, the expression of MAPK 
phosphatase-1 (MKP-1), which negatively regulates ERK and JNK expression 
through de-phosphorylation and inactivation, is also activated in the arteries in 
response to shear stress and increases in blood pressure(Li and Xu 2000, Metzler et al. 
1999). It is thought that a balance between MAPK activation and MKP-1 induction 
can modulate cellular responses to external stimuli (Li and Xu 2000, Metzler et al. 
1999). Interestingly, LDL can stimulate the expression o f MPK-1 in VSMCs which 
can lead to the inhibition o f ERK and Elk-1-mediated transcription in these cells (Li 
and Xu 2000, Metzler et al. 1999).
A number of roles for MAPKs in monocyte/macrophage gene regulation have been 
identified. Induction o f calveolin-1 expression in response to oxLDL is dependent on 
the phosphorylation and activation o f all three MAPKs (Wu et al. 2009). Calveolin-1 
is present in higher amounts in ApoE /_ mice and in oxLDL-treated murine RAW264.7 
macrophages (Wu et al. 2009). Induction by oxLDL is associated with increased 
adherence o f monocytes to endothelial cells and subsequent monocyte accumulation 
in the intima following hypercholesterolemia implicating the MAPKs in this process 
(Wu et al. 2009). Phosphorylation of p38 kinase can be modulated by angiotensin II 
in atherosclerotic regions of arteries and is associated with reduced collagen 
accumulation in LDLR’ ’ mice (Dandapat et al. 2008). In addition to this, the 
upregulation of macrophage ACAT-1 expression in response to angiotensin II can be 
blocked by the ERK inhibitor PD98059 (Kanome et al. 2008). A role for p38 kinase 
has been identified in the induction o f chemokine receptor CXCR2 expression in 
human monocytes and U937 cells in response to oxLDL (Lei et al. 2002). Similarly,
200
CHAPTER 5: The role of MAPKs in TGF-P-regulated expression of key macrophage genes
the induction o f phospholipase II by oxLDL is mediated by p38 kinase in THP-1 
monocytes (Wang et al. 2009).
In addition to the regulation of target gene expression through MAPK activation, it 
appears that the expression o f some MAPK target genes can activate the MAPKs. For 
instance, studies by Rahaman and colleagues (2006) have shown that oxLDL-induced 
activation of JNK in macrophages is dependent on CD36 expression (Rahaman et al. 
2006). Co-immunoprecipitation and pull-down assays showed that macrophage 
CD36 associates with a complex containing the upstream MAPK regulator MEKK2 
(Rahaman et al. 2006). In addition to this, oxLDL activated JNK in wildtype but not 
in CD36 null mice and inhibition o f JNK significantly reduced CD36-dependent 
oxLDL uptake and foam cell formation in vitro and in vivo (Rahaman et al. 2006). 
The expression o f ERK, JNK and p38 kinase expression can be induced by M-CSF in 
macrophages and by MCP-1 in endothelial cells (Werle et al. 2002, Zhu et al. 2008).
A role for the MAPKs in cytokine-regulated gene transcription in macrophages has 
previously been described for EFN-y. EFN-y can activate each o f the MAPK pathways 
in macrophages (Baldassare et al. 1999, Valledor et al. 2008). The cytokine has the 
most potent action on the p38 kinase pathway which interestingly, appears to be 
involved in IFN-y-regulated effects on inflammation. Pharmacological inhibitors and 
knockout models have demonstrated distinct roles for each of the MAPKs in IFN-y- 
regulated gene transcription. While p38 kinase appears to have roles in the expression 
of pro-inflammatory cytokine genes involved in inflammatory responses, such as 
TNF-a and IL-lp, and chemokine genes involved in monocyte chemotaxis such as 
CXCL9, CXCL10 and the chemokine receptor CCR2, ERK appears to have more 
modest effects on the expression o f pro-inflammatory genes while JNK is implicated 
in the IFN-y-mediated regulation o f genes involved in antigen presentation such as the 
transctivator CUTA (Baldassare et al. 1999, Valledor et al. 2008).
In contrast to IFN-y, very little is currently known about the activation and role of the 
MAPKs in TGF-(3-regulated effects in macrophages. One action of the cytokine that 
is known to be regulated through MAPK pathway activation is the inhibitory action of 
TGF-p on the production o f pro-inflammatory cytokines by macrophages. This is 
crucial to producing an anti-inflammatory phenotype following phagocytosis of
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apoptotic cells by macrophages (Xiao et al. 2002). This inhibition of pro- 
inflammatory cytokine production is mediated by ERK and p38 kinase pathways 
where the activation o f ERK by TGF-P up-regulates MKP-1, resulting in the 
inactivation o f p38 kinase and subsequent reduction in NFicB-driven transcription of 
pro-inflammatory cytokine genes. This is an example of crosstalk between different 
MAPK signalling pathways (Xiao et al. 2002).
5.2 Aims of experimental studies
The primary aim o f the studies presented in this chapter was to investigate the role of 
the MAPK pathways in the TGF-p-regulated expression of key genes implicated in 
macrophage cholesterol homeostasis. The TGF-P-regulated expression of these genes 
(LPL, SR-A, SR-B1, CD36, ApoE, ABCA-1 and ABCG-1) has been characterised by 
previous studies, as described in Chapter 3 o f this thesis. As the classical mediator of 
TGF-P responses, activation and role o f the Smad pathway in TGF-P-mediated gene 
expression has also been investigated, as presented in Chapter 4 o f this thesis. In 
addition to this however, the cytokine is known to activate other signalling cascades 
to regulate target genes. These include the three primary MAPK pathways, ERK, 
JNK and p38 kinase. The activation of these kinases in macrophages has not been 
investigated in detail so the initial aim of the studies presented in this chapter was to 
determine if each o f the MAPK pathways were activated by TGF-p in THP-1 and 
primary macrophages and to investigate the kinetics o f this activation. This was 
carried out using western blot analysis of the phosphorylated forms of ERK, JNK and 
p38 kinase. It was also important to determine if  any increase in MAPK 
phosphorylation led to a functional increase in activity o f these kinases-this was 
investigated using non-radioactive kinase activity assays. Figure 5.1 outlines the 
experimental strategy used during these studies.
Following this, the involvement of each o f the MAPKs in TGF-P-regulated gene 
expression was investigated using siRNA-mediated knockdown as described in 
Section 4.1.2. The majority o f studies on MAPK involvement in gene expression 
have relied on pharmacological inhibitors against the MAPKs or transfection of 
dominant-negative forms o f upstream regulators. Although specific inhibitors to each
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MAPK have been widely and successfully used in a large number of studies (Section 
5.1.1) including studies on the roles o f MAPKs in gene expression, there are a number 
of disadvantages o f using pharmacological inhibitors in cell lines, not least with 
balancing specificity and concentration with unwanted off-target and possible toxic 
effects. For instance, the p38 kinase specific inhibitor PD169316 has been 
demonstrated to inhibit TGF-p signalling in ovarian cells through a reduction in 
phosphorylation o f Smad-2 and -3 (Fu et al. 2003, Moustakas and Heldin 2005), 
whilst the p38 kinase inhibitor SB203580 activates the ERK and JNK pathways in 
human hepatoma cells (Henklova et al. 2008). Although these effects are highly 
likely to be cell-type specific, they do highlight the disadvantages of using 
pharmacological inhibitors. In contrast, a relatively small number of studies have 
used siRNA against MAPKs to investigate the role o f these signalling pathways in 
gene expression. These studies are outlined in Table 5.1.
Data from siRNA knockdown studies in THP-1 cells was analysed for effects on basal 
and TGF-p regulated expression. Mostly, the effects on mRNA expression were 
analysed using RT-qPCR and initially, where antibodies to the protein were available, 
effects on protein expression were analysed with further studies carried out at the 
mRNA level. For ease o f reading, studies are presented on a gene by gene basis.
Following on from this, and as previous work in the laboratory had implicated the 
JNK pathway in the TGF-P-mediated expression of LPL, further studies into the 
mechanism of its regulation by TGF-p were carried out. Previous work in U937 cells 
had shown an involvement for SEK-1, JNK and c-Jun in TGF-P-mediated LPL 
promoter activity (Section 5.3.15). Transient transfection assays were employed to 
assess the TGF-P-regulation of LPL promoter activity and the effects o f dominant- 
negative forms of key components o f the JNK pathway (SEK-1, JNK and c-Jun) on 
this regulation. Preliminary data obtained in the laboratory using transient 
transfection had also suggested a role for the SRC-1 coactivator in LPL expression 
(Section 5.3.16). The effect o f SRC-1 siRNA on LPL expression was investigated in 
THP-1 macrophages to see if this would support previous data.
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Table 5.1 Recent studies using siRNA against MAPKs
siRNA Details of study Reference
JN K -1 
ERK-2
Resveratrol acts through JNK and ERK pathways to  
enhance the expression o f  perforin in natural killer cells.
Lu and Chen 2010
E R K -1/2 
JNK-1
B asic fibroblast growth factor stim ulates human dermal 
fibroblast proliferation through the ERK and JNK  
pathways.
Makino et al. 2009
ERK-2 The ERK pathway is involved  in the formation o f  joint 
adhesion in vivo through increased co llagen  expression  
and fibroblast proliferation in response to TGF-p.
Li et al. 2009
JNK In cultured endothelial ce lls , expression  o f  kallistatin is 
negatively regulated by oxidative stress activated JNK  
pathway.
Shen et al. 2010
JNK Prostaglandin-E2 inhibits the IL -lp  induction o f  MMP-1 
and M M P-13 by suppressing the JNK pathway in 
human articular chondrocytes.
Nishitani et al. 2009
JN K -1/2 The JNK pathway has a role in com plem ent-m ediated  
cell death.
Gancz et al. 2009
JN K -1/2 The TGF-P-regulated induction o f  connective tissue  
growth factor expression in human cornea stroma 
fibroblast ce lls  is m ediated by upregulation o f  the JNK  
pathway and can be inhibited by siR N A  against JNK- 
1/2.
Chang and Wu 2009
p38 kinase p38 kinase regulates pigm entation in B 1 6 m elanom a  
ce lls  by proteosom al degradation o f  tyrosinase proteins.
B ellei et al. 2010
p 38a
kinase
Lysophosphatidic acid induction o f  IL-6 secretion from  
human aortic sm ooth m uscle ce lls  is p 38a  kinase 
dependent.
Hao et al. 2009
p 38a
kinase
siR N A  against p 38a  kinase suppresses the proliferation 
o f  ER -negative breast cancer cells .
Chen et al. 2009
c-Jun Thrombin induction o f  endothelial arginase-I involves 
the activation o f  the JNK and p38 kinase pathways 
w hich result in the activation o f  c-Jun (A P-1) 
transcription factors.
Zhu et al. 2009
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5.3 Results
5.3.1 Kinetics of MAPK activation in THP-1 macrophages
To investigate the effect o f TGF-p on MAPK activation by phosphorylation in THP-1 
macrophages, cells were seeded into 6-well plates and differentiated for 24hr using 
PMA. Differentiated THP-1 cells were left untreated or treated with TGF-P for the 
requisite time periods. Total cellular protein was extracted using Laemmli buffer 
(Section 2.7.1) and subjected to SDS-PAGE using a 10% (v/v) polyacrylamide gel. 
Western blotting was carried out using antibodies against the phosphorylated forms of 
p44/42 (ERK), JNK and p38 kinase and against total p44/42 (ERK), JNK and p38 
kinase as indicated in Figure 5.2. A 24hr time course was prepared as the action of 
TGF-p on the expression of key macrophage genes (as presented in Chapter 3) was 
optimal within this time frame.
Expression o f phospho-ERK, -JNK and -p38 kinase was low in untreated cells and 
was induced by TGF-P treatment with maximal induction at the 24hr time point. Both 
phospho-ERK and phospho-p38 kinase showed significant induction at the 24hr time 
point (Figure 5.2A and Figure 5.2C). In comparison, levels of phospho-JNK showed 
the largest increase in response to TGF-p although, due to unanticipated problems 
withsubsequent western blot analysis, only the mean phosphorylation levels of JNK 
from two independent experiments could be analysed (Figure 5.2B). The induction of 
MAPK phosphorylation by TGF-p at the 24hr time point suggests that MAPKs are 
activated with slow kinetics by the cytokine.
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Figure 5.2 TGF-p activates ERK, JNK and p38 kinase with slow kinetics in 
THP-1 macrophages. THP-1 macrophages were left untreated (Ohr) or treated with 
TGF-P for 3, 6, 12 or 24hr as indicated. Whole-cell protein extracts were subjected to 
SDS-PAGE and western blotting and levels of phospho-ERK (Panel A), -JNK (Panel 
B) and -p38 kinase (Panel C) were compared to total levels of these proteins. Protein 
size was determined by comparison against a standard molecular weight marker 
(Appendix I). The relative expression (mean± SD) of phospho-ERK, -JNK and -p38 
kinase (untreated samples (Ohr) arbitrarily assigned as 1), normalised to total ERK, 
JNK or p38 kinase expression respectively, from three independent experiments is 
shown (*/><0.05, NS-not significant).
24hr
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5.3.2 MAPK activation in HMDMs
To confirm that the MAPK activation observed in THP-1 macrophages was 
representative o f MAPK activation in HMDMs, the expression of phospho-ERK, - 
JNK and -p38 kinase following TGF-p treatment was investigated in primary cultures 
of HMDMs. Two time points (12 and 24hr) were chosen for this study as they had 
shown maximal levels o f MAPK induction in THP-1 macrophages. Whole-cell 
protein extracts were prepared and subjected to SDS-PAGE and western blotting as 
described in Section 5.3.1. Expression o f phospho-ERK was low in the absence of 
TGF-p and was induced by the cytokine in all the experiments, although this 
induction was not statistically significant due to large variations in signal. More 
experiments would need to be done to confirm a significant induction of ERK in 
HMDMs (Figure 5.3A). Levels of phospho-p38 kinase were similarly low in the 
absence of TGF-P and were significantly induced by the cytokine at the 12hr time 
point (Figure 5.3B). Unanticipated problems with the JNK phosphorylation western 
meant that levels o f phospho-JNK in HMDMs could not be investigated.
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Figure 5.3 TGF-p augments ERK and p38 kinase phosphorylation in 
HMDMs. HMDMs were left untreated or treated with TGF-P for 12 or 24hr. Whole­
cell protein extracts were subjected to SDS-PAGE and western blotting using 
antibodies against phospho-ERK (Panel A) or p38 kinase (Panel B) and total ERK or 
total p38 kinase. Relative expression (mean± SD) of phospho-ERK or phospho-p38 
kinase, normalised to total levels of ERK or p38 kinase respectively (untreated 
samples arbitrarily assigned as 1) from three independent experiments is shown 
(*P<0.05, NS-not significant).
5.3.3 Assay o f MAPK activity in THP-1 m acrophages
To confirm that the induction of MAPK phosphorylation was indicative of an increase 
in MAPK activity, the kinase activity of ERK and JNK was investigated. The activity 
of p38 kinase could not be investigated as no activity assay kit was available in the 
laboratory. THP-1 macrophages were left untreated or stimulated with TGF-P for the 
requisite time periods. For the investigation of ERK activity whole cell extracts were 
prepared and incubated overnight with protein beads attached to an immobilised 
antibody against p44/42. The MAPK was immunoprecipitated as described in Section 
2.7.6 and incubated with ATP and an Elk-1 substrate. SDS-PAGE and western
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blotting was carried out using the immunoprecipitated extracts and an antibody 
against phospho Elk-1, p-actin was used as a loading control and the western was 
carried out using the original extracts. For the investigation of JNK activity whole 
cell extracts were prepared and incubated overnight with protein beads attached to a c- 
Jun fusion protein. The MAPK was immunoprecipitated as described in Sections
2.7.5 and then incubated with ATP to allow JNK to phosphorylate the c-Jun substrate. 
SDS-PAGE and Western blotting was carried out using an antibody against phospho 
c-Jun (Ser63). Expression o f both phospho Elk-1 and phospho c-Jun was low in 
untreated cells and was induced following TGF-P treatment. Expression of phospho 
Elk-1 was significantly induced at the 3, 6 and 24hr time points. Expression of 
phospho c-Jun was significantly induced at the 6 and 12hr time points (Figure 5.4). 
This increase in levels o f phospho-Elk-1 and phospho-c-Jun is directly related to the 
activity of ERK and JNK respectively and suggests that the activity o f these MAPKs 
was increased by TGF-p. To confirm that the increase in expression observed was 
due to increased kinase activity in response to TGF-p and not to the status of the cells, 
a single time point was chosen and untreated and TGF-P-treated extracts from a single 
experiment were subjected to the same assay. An increase in phospho-Elk-1 and 
phospho-c-Jun expression indicated that this increase was solely due to TGF-P 
treatment.
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Figure 5.4 TGF-p induces the activity of ERK and JNK in THP-1
macrophages. THP-1 macrophages were left untreated (Ohr) or treated with TGF-P 
for 3, 6, 12 or 24hr. ERK or JNK was immunoprecipitated as described in Sections
2.7.6 and 2.7.5 respectively and incubated with ATP to allow phosphorylation of an 
exogenous substrate. The kinase reaction with immunoprecipitated protein was 
subjected to SDS-PAGE and western blotting using antibodies against phospho-Elk-1 
(Panel A) or phospho-c-Jun (Panel B). Whole-cell protein extracts were used for the 
P-actin western blot. Relative expression (mean± SD) of phospho-Elk-1 or phospho- 
c-Jun, normalised to levels of p-actin (untreated samples arbitrarily assigned as 1) 
from four independent experiments is shown (*P<0.05, **P<0.01, NS-not 
significant).
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5.3.4 Assay of MAPK activity in HMDMs
To determine if  the induction o f MAPK activity in THP-1 macrophages was 
indicative o f changes in primary macrophages, the kinase activity of ERK and JNK 
was investigated in HMDMs. HMDMs were left untreated or treated with TGF-P for 
the requisite time periods. Assay o f ERK and JNK kinase activity was carried out as 
described in Section 5.3.3. Expression o f both phospho-Elk-1 and phospho-c-Jun was 
low in untreated cells and was induced by TGF-P treatment. Expression of phospho- 
Elk-1 was significantly induced at the 12hr time point. Expression o f phospho-c-Jun 
was significantly induced at the 6hr time point (Figure 5.5). This increase in levels of 
phospho-Elk-1 and phospho-c-Jun is directly related to the activity of ERK and JNK 
respectively and suggests that the activity o f these MAPKs is increased by TGF-P in 
HMDMs.
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Fieure 5.5 TGF-p induces the activity of ERK and JNK in HMDMs. HMDMs 
were left untreated (Ohr) or treated with TGF-P for 6, 12 or 24hr. ERK or JNK was 
immunoprecipitated as described in Sections 2.7.6 and 2.7.5 respectively and 
incubated with ATP to allow phosphorylation of an exogenous substrate. The kinase 
reaction with immunoprecipitated protein was subjected to SDS-PAGE and western 
blotting using antibodies against phospho-Elk-1 (Panel A) or phospho-c-Jun (Panel
B). Whole-cell protein extracts were used for the P-actin western blot. Relative 
expression (mean± SD) of phospho-Elk-1 or phospho-c-Jun, normalised to levels of 
P-actin (untreated samples arbitrarily assigned as 1) from three independent 
experiments is shown (*P<0.05, ***P<0.001, NS-not significant).
5.3.5 siRNA-mediated knockdown of MAPKs in THP-1 macrophages
Before the effects of MAPK knockdown on the TGF-p-regulated gene expression 
could be investigated, it was necessary to determine the level of MAPK knockdown 
following siRNA transfection in THP-1 macrophages. This was determined for each 
individual experiment. Individual knockdown of ERK 1/2, c-Jun and p38 kinase was 
investigated (Figures 5.6A, 5.6B and 5.6C). Knockdown of JNK was initially 
investigated but due to unexpected problems with producing a significant knockdown
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of JNK expression following siRNA-mediated knockdown, it was decided to use 
siRNA against c-Jun, the downstream substrate of JNK, to investigate the role of the 
JNK pathway in TGF-P-regulated gene expression. Whole-cell protein extracts from 
GAPDH or MAPK-transfected, untreated or TGF-p-treated THP-1 cells were 
subjected to SDS-PAGE and western blot analysis. Total ERK 1/2, c-Jun and p38 
kinase expression following siRNA-mediated knockdown was validated by western 
blotting using antibodies against total p44/42 (ERK), c-Jun and p38 kinase 
respectively and knockdown levels were validated by western blot analysis for each 
siRNA transfection experiment presented in this chapter. Where gene expression was 
analysed at the mRNA level, extracts for total RNA and total protein were prepared 
simultaneously allowing MAPK knockdown levels to be determined. A significant 
reduction in ERK, c-Jun and p38 kinase expression was observed following siRNA- 
mediated knockdown in both untreated and TGF-P-treated THP-1 macrophages 
(Figure 5.6).
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Figure 5.6 siRNA-mediated knockdown of ERK 1/2, c-Jun and p38 kinase in 
THP-1 macrophages. Whole-cell protein extracts prepared from untreated or TGF- 
p-treated THP-1 cells transfected with 7.5nM validated GAPDH siRNA or ERK 1/2 
(Panel A), c-Jun (Panel B) or p38 kinase (Panel C) siRNA as described in Section 
2.6.1. Extracts were subjected to SDS-PAGE and western blotting and levels of total 
ERK, c-Jun or p38 kinase were compared against levels of p-actin. Relative 
expression (mean± SD) of ERK, c-Jun or p38 kinase normalised to p-actin levels, 
with GAPDH-transfected cells arbitrarily assigned as 1, from three (Panel A) or four 
(Panels B and C) independent experiments is shown (*P<0.05, **P<0.01, 
***P<0.001).
215
CHAPTER 5: The role of MAPKs in TGF-p-regulated expression of key macrophage genes
5.3.6 Effect of MAPK knockdown on the expression of LPL
The effect o f MAPK knockdown on the expression of LPL was initially investigated 
at the protein level. Transfection o f siRNA and subsequent western blotting was 
carried out as for MAPK expression (Section 5.3.5). Initially, LPL expression was 
investigated at the protein level however, unanticipated problems with detection in 
western blot analysis meant that subsequent studies on LPL expression were 
necessarily carried out using RT-qPCR. THP-1 cells were transfected with 7.5nM of 
GAPDH siRNA, c-Jun or p38 kinase siRNA. Total RNA extracts from untreated and 
TGF-P-treated (24hr) cells were reverse-transcribed and the resulting cDNA subjected 
to qPCR analysis using previously optimised amplification conditions (Table 2.6) and 
primers against LPL and 28SrRNA (Table 2.5). As expected, LPL expression was 
significantly reduced by TGF-P in GAPDH-transfected cells. In ERK 1/2 siRNA- 
transfected cells, no change in TGF-P-regulated LPL expression was observed (Figure 
5.7A). In c-Jun siRNA-transfected cells, the TGF-p-regulated inhibition of LPL was 
no longer significant at the mRNA (Figure 5.7B) and protein (Figure 5.7D) levels. At 
the mRNA level, a significant increase in LPL expression following TGF-P treatment 
was observed (Figure 5.7B). Similarly, mRNA expression of LPL was no longer 
significantly reduced by TGF-p in cells transfected with p38 kinase siRNA and 
instead showed a significant increase in LPL expression (Figure 5.7C). However, this 
change was not observed at the protein level (Figure 5.7D). This may be due to the 
higher sensitivity of RT-qPCR in comparison to western blotting.
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Figure 5.7 Knockdown of p38 kinase and c-Jun attenuates the TGF-p-
mediated inhibition of LPL expression in THP-1 macrophages. Total RNA 
(Panels A-C) or whole-cell protein extracts (Panel D) were prepared from untreated or 
TGF-P-treated THP-1 macrophages transfected with GAPDH or validated ERK 1/2 
(A), p38 kinase (B) or c-Jun (C) siRNA. Western blotting was carried out using 
antibodies against LPL and P-actin. RT-qPCR was carried out using primers against 
LPL and 28SrRNA. Relative expression (mean± SD) of LPL, normalised to p-actin 
(for western blotting) or 28SrRNA (for RT-qPCR) levels (untreated samples 
arbitrarily assigned as 1), from three independent experiments is shown (*/><0.05, 
**P<0.01, NS-not significant, #-significant induction P<0.05, ##-P<0.01).
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5.3.7 Effect of MAPK knockdown on the expression of SR-A
As an antibody to SR-A was available in the laboratory, the effect of MAPK 
knockdown on SR-A expression was primarily investigated at the protein level. THP- 
1 cells were transfected and whole-cell extracts from untreated and TGF-P-treated 
cells were prepared using Laemmli buffer (Section 2.7.1) and subjected to SDS- 
PAGE and western blot analysis using a 10% (v/v) polyacrylamide gel (Sections 2.7.7 
and 2.7.8) and antibodies against the three isoforms of SR-A and p-actin. As 
expected, SR-A expression was high in untreated cells and was significantly reduced 
by TGF-p in GAPDH-transfected cells. Knockdown o f ERK 1/2 had no effect on the 
TGF-P-regulated inhibition of SR-A protein expression (Figure 5.8A) and a similar 
expression profile was observed following knockdown of c-Jun and p38 kinase 
(Figure 5.8B). In contrast to this, at the mRNA level, knockdown of c-Jun resulted in 
a notable reversal o f TGF-P-regulated SR-A inhibition (Figure 5.8C). Similarly, 
knockdown of p38 kinase was able to attenuate the TGF-p-regulated inhibition of SR- 
A mRNA expression (Figure 5.8D). The contrast between mRNA and protein 
expression may be due to the higher sensitivity of RT-qPCR in comparison to 
Western blotting.
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Figure 5.8 c-Jun and p38 kinase are required for the TGF-p-mediated 
inhibition of SR-A in THP-1 macrophages. Whole-cell protein extracts from 
untreated and TGF-p-treated cells transfected with validated GAPDH or ERK 1/2 
(Panel A), c-Jun or p38 kinase (Panel B) siRNAs were subjected to SDS-PAGE and 
western blotting using antibodies against SR-A (recognises all three isoforms) and P- 
actin. In panels C and D, total RNA was reverse-transcribed and subjected to RT- 
qPCR using primers specific for SR-A and 28SrRNA. Relative expression (mean 
±SD) of SR-A normalised to P-actin (or 28SrRNA), with untreated samples arbitrarily 
assigned as 1, from three independent experiments is shown (*P<0.05, **/><0.01, 
***P<0.001, NS-not significant).
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5.3.8 Effect of MAPK knockdown on the expression of SR-B1
The effect o f MAPK knockdown on the expression of SR-B1 was investigated at the 
mRNA level. Transfection and preparation of total RNA and RT-qPCR was carried 
out as for LPL (Section 5.3.6). As expected, the expression of SR-B1 was 
significantly reduced by TGF-P in GAPDH-transfected cells. This regulation was not 
affected by knockdown o f ERK 1/2 (Figure 5.9A). Following c-Jun knockdown, the 
expression of SR-B1 was no longer significantly inhibited by TGF-P (Figure 5.9B). 
The TGF-P-regulated expression of SR-B1 was similarly attenuated by p38 kinase 
knockdown (Figure 5.9C) but to a larger extent so that a significant induction in SR- 
B1 expression was observed.
5.3.9 Effect of MAPK knockdown on the expression of CD36
As for SR-B1, the effect o f MAPK knockdown on CD36 expression was investigated 
at the mRNA level. Expression of CD36 was down-regulated by TGF-p in GAPDH- 
transfected cells. Knockdown o f ERK 1/2 expression resulted in the loss of 
significant down-regulation of CD36 by TGF-p (Figure 5.10A). However, the mean 
expression levels of CD36 following ERK 1/2 knockdown are not significantly 
different to that following GAPDH knockdown and show a wide variation in 
expression, suggesting that the loss o f significant down-regulation may be due to this 
variation as opposed to the knockdown of ERK 1/2 itself. Knockdown of c-Jun and 
p38 kinase were able to attenuate the TGF-P-regulation of CD36 and produced a 
notable reversal of CD36 inhibition (Figure 5.1 OB and Figure 5.IOC).
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Figure 5.9 Knockdown of p38 kinase or c-Jun negates the TGF-p-mediated 
inhibition of SR-B1 expression in THP-1 macrophages. Total RNA from untreated 
and TGF-P-treated cells transfected with siRNAs against GAPDH, ERK 1/2 (Panel 
A), c-Jun (Panel B) or p38 kinase (Panel C) were subjected to RT-qPCR using 
primers specific to SR-B1 and 28SrRNA. Relative expression (mean ±SD) of SR-B1 
normalised to 28SrRNA from three independent experiments, with untreated samples 
arbitrarily assigned as 1, is shown (*P<0.05, **P<0.01, ##-significant induction 
PO.Ol, NS-not significant).
221
CHAPTER 5: The role o f MAPKs in TGF-p-regulated expression o f key macrophage genes
(A) 1.20
o
c  1.000 
'35
S 0.80
!  1 0.SO
Z1
E 0.40o>
73 0.20o>
DC 0.00
siRNA
GAPDH
J
□ Untreated 
■ +TGF-p
ERK
(B) 2 .5
2.0
b 
c  
o"5in 9 S Q.
2  to  1 .5< co Q 
£  u
Eo>
75 0.0
a:
0 .5
NS
s iR N A
Lb
GAPDH
rl
c-Jun
□  Untreated 
■  +TGF-P
(C) 2 .5
2.0
b  
c0
"in w5  
a .
2  to 1 .5  
< Q
1 °  10
E
|  0 .5
(0a) 0.0a:
i i
NS
n
H | |
i
■ 1
s iR N A
GAPDH p 3 8
□  Untreated 
■ +TGF-P
Figure 5.10 Knockdown of c-Jun and p38 kinase negates the TGF-0-regulation 
of CD36 expression in THP-1 macrophages. RT-qPCR was carried out using 
primers specific to CD36 and 28SrRNA using total RNA from cells transfected with 
siRNA against GAPDH or ERK 1/2 (Panel A), c-Jun (Panel B) or p38 kinase (Panel 
C). Relative expression (mean ±SD) of CD36, normalised to 28SrRNA, with 
untreated samples arbitrarily assigned as 1, is shown (*P<0.05, **P<0.01, NS-not 
significant).
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5.3.10 Effect of MAPK knockdown on the expression of ApoE
For consistency with previous studies on TGF-P-regulated ApoE expression (Chapter 
3 and Chapter 4), the effect o f MAPK knockdown on ApoE expression was 
investigated at the protein level. Preparation o f protein extracts and western blotting 
was carried out as for SR-A (Section 5.3.7). As expected, ApoE expression was 
significantly induced by TGF-P in GAPDH-transfected cells. Knockdown of all three 
kinases had no effect on the TGF-p-regulated induction of ApoE expression (Figures 
5.11A-5.11C).
5.3.11 Effect of MAPK knockdown on the expression of ABCA-1
For consistency with previous studies on ABCA-1 expression (Chapter 3 and Chapter 
4) the effect o f MAPK knockdown on the expression o f ABCA-1 was investigated at 
the mRNA level. Following siRNA transfection and differentiation of THP-1 cells, 
they were left untreated or treated with TGF-p for 6hr based on previous studies that 
showed maximal induction of ABCA-1 mRNA expression in response to TGF-P at 
this time point (Chapter 3). Knockdown of ERK 1/2 (Figure 5.12A), c-Jun (Figure 
5.12B) and p38 kinase (Figure 5.12C) all resulted in a notable reduction of TGF-P- 
mediated induction o f ABCA-1 expression so that it was no longer significant. The 
most notable change was observed following knockdown of p38 kinase which instead 
produced a significant decrease in the TGF-P-regulated levels of ABCA-1 (Figure 
5.12C).
5.3.12 Effect of MAPK knockdown on the expression of ABCG-1
As with ABCA-1, the expression o f ABCG-1 following MAPK knockdown was also 
investigated at the mRNA level following 6hr stimulation with TGF-p. Knockdown 
of ERK 1/2 (Figure 5.13A) resulted in a loss of significant TGF-P-mediated ABCG-1 
induction. Knockdown of c-Jun (Figure 5.13B) and p38 kinase (Figure 5.13C) 
produced analogous changes in the TGF-P-mediated induction of ABCG-1.
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Figure 5.11 Knockdown of individual MAPKs has no effect on the TGF-|3- 
mediated induction of ApoE expression. Whole-cell protein extracts from untreated 
and TGF-P-treated cells transfected with validated siRNA against GAPDH or ERK 
1/2 (Panel A), c-Jun (Panel B) or p38 kinase (Panel C) were subjected to SDS-PAGE 
and western blotting using antibodies against ApoE and P-actin. Relative expression 
(mean ±SD) of ApoE normalised to p-actin, with untreated samples arbitrarily 
assigned as 1, from three independent experiments is shown (*P<0.05, **P<0.01, 
***P<0.001).
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Figure 5.12 MAPK knockdown attenuates the TGF-p-mediated induction of 
ABCA-1 expression in THP-1 macrophages. Total RNA extracts from untreated 
and TGF-P-treated cells transfected with validated siRNAs against GAPDH or ERK 
1/2 (Panel A), c-Jun (Panel B) or p38 kinase (Panel C) were subjected RT-qPCR 
using primers specific to ABCA-1 and RPL13A. RPL13A was used as a control for 
consistency with previous work on ABCA-1 and ABCG-1 expression as presented in 
Chapters 3 and 4 of this thesis. Relative expression (mean ±SD) of ABCA-1 
normalised to RPL13A, with untreated samples arbitrarily assigned as 1, from three 
independent experiments is shown (**P<0.01, NS-not significant, ##-significant 
inhibition P<0.05).
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Figure 5.13 MAPK knockdown attenuates the TGF-p-mediated induction of 
ABCG-1 expression in THP-1 macrophages. RT-qPCR was carried out using 
primers specific to ABCG-1 and RPL13A using total RNA from cells transfected with 
siRNAs against GAPDH or ERK 1/2 (Panel A), c-Jun (Panel B) or p38 kinase (Panel
C). Relative expression (mean ±SD) of ABCG-1, normalised to RPL13A with 
untreated samples arbitrarily assigned as 1, is shown (*P<0.05, NS-not significant).
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5.3.13 Effect of MAPK knockdown on constitutive gene expression
To understand the effects o f MAPK knockdown on the TGF-[3-regulated expression 
of the genes studied above, it was necessary to determine if  the knockdown of any of 
the MAPKs had any effect on the constitutive expression of these key genes (in 
response to PMA-induced differentiation) or if  its effects were limited to TGF-J3- 
regulated gene expression. To determine this, data was analysed for changes in gene 
expression in untreated cells transfected with siRNA against ERK 1/2, c-Jun or p38 
kinase relative to gene expression in untreated cells transfected with GAPDH siRNA. 
Relative expression o f each gene was normalised to a control gene 28SrRNA (for 
LPL, SR-B1 and CD36) or RPL13A (for ABCA-1 and ABCG-1), or P-actin (for SR- 
A and ApoE protein expression). Figure 5.14 shows that knockdown of ERK 1/2, c- 
Jun and p38 kinase had no significant effect on the constitutive expression of ApoE 
(Figure 5.14E), ABCA-1 (Figure 5.14F) or ABCG-1 (Figure 5.14G). The constitutive 
expression of LPL (Figure 5.14A) was also unaffected by MAPK knockdown 
although a marginal increase in expression was observed following ERK 1/2 
knockdown. Interestingly, the constitutive expression o f SR-A (Figure 5.14B) was 
down-regulated by c-Jun knockdown. Basal levels of SR-B1 (Figure 5.14C) and 
CD36 (Figure 5.14D) were similarly affected by knockdown of p38 kinase and 
showed significant down-regulation in response to knockdown o f this kinase.
227
CHAPTER 5: The role o f  MAPKs in TGF-P-regulated expression o f key macrophage genes
(A) (B)
2.5
2.01
! ? , ,  
i i
NS
1.0
»  •  0.5 
1 0.0
(C)’
6.0
1  *- 5.0 
E 2
2 m 4.0
I o
1 § 30 
8 S 2.0
I IS * 1.0
<2 0.0
NS
l l l l
GAPDH c-Jun p38
NS
4.0
c
|  3.5
I  £  3.0
® COI * 2 5 
I I 20
o  S  1.5° s> 1 10 33 ®5 05
5 0.0
NS
(D) siRNA3.0
GAPDH
I NS
■  . ■
ERK c-Jun p38
NS I
Es
5 O 2.0 i  O
3  §  1.55 1
8 i  1.0 
1 &
«  •  0.5 -
6 o.o 4
NS NS
i l l .
siRNA
(E),
c
I  1.4 o uio. 2 1.2
i f  ’= o 0-8
o •  0.6O •
s> & H i  > x
J *  0.2 
“ 0
GAPDH ERK c-Jun p38
NS
NS
■ ill
(F)
siRNA
8.0
GAPDH
1 j  70E 5 6.0 
|  3  5.0
1140 
8 8 30 
§ i. 2.0
1 8100.0
ERK c-Jun p38
NS
NS
. I I I
(G),
siRNA GAPDH ERK
6.0
5.0
c-Jun
NS
p38
siRNA
GAPDH ERK c-Jun p38
E 8.1 3 40
2  ’S
^  C 3.0 - 
c  o
8 2 2.0 2 c
I I 1.0 
& 0.0 -
NS
ill
siRNA
GAPDH ERK c-Jun P38
Figure 5.14 The effect of MAPK knockdown on the constitutive expression of 
cholesterol uptake and efflux genes in THP-1 macrophages. RT-qPCR was 
carried out using primers specific to LPL (Panel A), SR-B1 (Panel C), CD36 (Panel
D), ABCA-1 (Panel F), ABCG-1 (Panel G) using total RNA from cells transfected 
with siRNAs against GAPDH or ERK 1/2, c-Jun or p38 kinase. For SR-A (Panel B) 
and ApoE (Panel E) whole cell extracts were subjected to SDS-PAGE and western 
blotting using antibodies against SR-A, ApoE and p-actin. Relative expression (mean 
±SD) of each gene, normalised to 28SrRNA, RPL13A or p-actin with GAPDH- 
transfected samples arbitrarily assigned as 1, is shown (*P<0.05, ***.P<0.001, NS-not 
significant).
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5.3.14 The action of TGF-p on LPL promoter activity
As previous work in the laboratory had suggested a role for the JNK pathway in the 
TGF-P-regulation o f LPL expression, and in light of the action of siRNA-mediated 
knockdown o f c-Jun on TGF-P-regulated LPL expression (Figure 5.7) it was decided 
to further investigate the involvement o f the JNK pathway in LPL regulation. As 
explained in Section 3.1.2, previous work carried out in the laboratory had shown that 
promoter activity o f LPL was reduced by TGF-P in U937 cells (Irvine et al. 2005) and 
that this regulation was mediated through suppression o f the transactivation potential 
of Spl/Sp3 (Irvine et al. 2005). Before carrying out further detailed studies, previous 
findings (the inhibitory action o f TGF-P on LPL promoter activity) was confirmed. 
Since THP-1 cells are difficult to transfect with exogenous DNA it was necessary to 
use another cell line for transient transfection assays. U937 cells are a widely used 
model for promoter analysis in relation to monocyte/macrophage gene expression and 
cytokine actions (Section 2.3.1) making this cell line the obvious choice for this work. 
Cells were transfected with an LPL promoter construct specifying the -101/+188 
region of the LPL promoter which contains the minimal TGF-p-responsive elements 
(Irvine et al. 2005).
U937 cells were transfected with 0.75, 1 or 2pg of the LPL -101/+188-luciferase gene 
plasmid (Figure 5.15A), either left untreated or stimulated with TGF-P and harvested 
as described in Sections 2.5.1 and 2.5.2. Luciferase counts were normalised to protein 
concentration as many promoters o f control plasmids are regulated by cytokines. This 
was determined using the BCA protein assay kit (Section 2.7.4). Initial experiments 
showed that 2pg of the LPL promoter-luciferase DNA plasmid produced the largest 
inhibition in response to TGF-P treatment. More experiments were therefore carried 
out using this concentration of the plasmid and Figure 5.15B shows that, as expected 
TGF-P was able to significantly inhibit the promoter activity o f LPL in U937 cells.
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Figure 5.15 TGF-p inhibits the prom oter activity of LPL in U937 cells. U937 
cells were transfected with the -101/+188 LPL promoter-luciferase DNA construct 
using Superfect™ as described in Section 2.5.1. Cells were either left untreated or 
treated with TGF-P overnight. PMA was added immediately following transfection 
and cells were harvested using lx passive lysis buffer (Promega) and measured for 
luciferase activity. Luciferase readings were normalised to protein concentration as 
determined by the BCA protein assay (Section 2.7.4). Data shown is the ratio of 
luciferase activity:protein concentration normalised to the untreated samples and 
expressed as the fold change from this. Data (excluding Panel A which represents a 
single experiment) is representative of three independent experiments (***P<0.001).
Unfortunately, differentiation of new U937 cells purchased from ECACC became 
defective, meaning that future work using this cell line became unfeasible. As 
adherent Hep3B cells were available in the laboratory, are easy to transfect and have 
previously been used for studies on the cytokine regulation of gene expression 
(Section 2.3.1) this cell line was used for further studies on the regulation of LPL 
promoter activity. Figure 5.16A shows the effect of TGF-P treatment on LPL 
promoter activity in the Hep3B cell line. Promoter activity is significantly reduced by 
the cytokine. Since it had been demonstrated that, in macrophages, the transactivation 
potential of Spl is suppressed by TGF-P to inhibit LPL promoter activity, it was 
reasoned that Spl must be required for basal LPL promoter activity. Hep3B cells 
were transfected with plasmids specifying for Sp3 and Spl. The pcDNA3 plasmid is
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an empty vector used as a control for the Spl and Sp3 expression plasmids and an Spl 
multimer containing 4 Spl sites was used as a positive control. The basal activity of 
the LPL promoter was significantly increased by Spl (Figure 5.16B) confirming an 
involvement for these sites in LPL regulation.
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Figure 5.16 TGF-p inhibits the promoter activity of LPL in Hep3B cells.
Hep3B cells were transfected with the -101/+188 LPL promoter-luciferase construct 
using Superfect™ as described in Section 2.5.1. Cells were either left untreated or 
treated with TGF-P overnight (Panel A). In Panel B, cells were co-transfected with 
the -101/+188 LPL promoter-luciferase construct with plasmids specifying for Sp3, 
Spl, or the control vector pcDNA3. For the positive control the Spl (x4) multimer 
was cotransfected with the Spl expression plasmid. Cells were harvested using lx 
passive lysis buffer (Promega) and measured for luciferase activity. Luciferase 
readings were normalised to protein concentration as determined by the BCA protein 
assay (Section 2.7.4). Data shown is the ratio of luciferase activity:protein 
concentration normalised to the untreated samples and expressed as the fold change 
from this. Data is representative of three independent experiments (*P<0.05, 
**P<0.01***.P<0.001, NS-not significant).
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5.3.15 The role of the JNK pathway in TGF-p-regulated LPL promoter activity
Previous work carried out in the laboratory by Dr Peli Foka and Dr Scott Irvine had 
demonstrated an involvement for the JNK pathway in TGF-(3-mediated inhibition of 
LPL expression. In murine J774.2 macrophages and in THP-1 cells, use of 
pharmacological inhibitors showed attenuation o f TGF-P-mediated LPL mRNA 
expression by the JNK inhibitor curcumin, but not by other inhibitors targeting the 
ERK and p38 kinase pathways. Transfection o f U937 cells had also shown that the 
TGF-P-mediated inhibition of LPL (-101/+188) promoter activity was attenuated by 
co-transfection o f dominant-negative forms o f JNK, SEK-1 and c-Jun (unpublished 
data, Dr Peli Foka). Due to unexpected problems with the U937 cell line, Hep3B 
cells were used for further investigation o f the role o f the JNK pathway in TGF-P- 
regulated LPL promoter activity using transient transfection. Dominant-negative 
constructs of JNK, SEK-1 and c-Jun were co-transfected with lpg  of the LPL 
-101/+188 promoter construct in Hep3B cells and these were left untreated or treated 
with TGF-P overnight. Transfection and harvesting o f cells was carried out as 
described in Section 5.3.14 and luciferase counts were normalised to protein 
concentration. Figure 5.17 shows that transfection o f dominant-negative JNK has 
little effect on TGF-P-regulated inhibition o f LPL promoter activity. This contrasts 
with findings in U937 cells where reversal o f LPL inhibition following transfection of 
dominant-negative JNK, c-Jun and SEK-1 was observed at several concentrations 
suggesting that this may be a cell-type specific response. However, transfection of 
dominant-negative c-Jun resulted in a loss o f significant LPL inhibition at low (lpg) 
concentration whilst transfection of dominant-negative SEK-1 showed the most 
marked effect and resulted in a loss o f significant LPL inhibition using higher (2 and 
3pg) concentrations o f construct. This suggests that differences are likely to be due 
to variation rather than any changes in the trend observed.
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Figure 5.17 The role of the JNK pathway in the TGF-p-regulation of LPL in 
Hep3B cells. Hep3B cells were transfected with lpg LPL -101/+188 promoter 
construct and l, 2 or 3pg of pcDNA3 , DN JNK, DN c-Jun or DN SEK-l as indicated,
using Superfect™ as described in Section 2.5.1. Cells were either left untreated or 
treated with TGF-P overnight. Cells were harvested using lx passive lysis buffer 
(Promega) as described in Section 2.5.2 and measured for luciferase activity. Data 
shown is the ratio of luciferase activity: protein concentration normalised to the 
untreated samples and expressed as the fold change from this. Data is representative 
of three independent experiments (*P<0.05, **P<0.01, ***P<0.001, NS-not 
significant).
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5.3.16 Identification of coactivators involved in LPL expression
Previous work in the laboratory had suggested a role for the steroid receptor 
coactivator-1 (SRC-1) in the TGF-P-regulation o f LPL promoter activity. Transient 
transfection of U937 cells had shown that the TGF-P-mediated inhibition of LPL 
-101 /+188 promoter activity was attenuated by cotransfection with plasmids 
specifying for SRC-1 but not with the ubiquitous coactivator p300 (unpublished data, 
Dr Peli Foka). Figure 5.18A shows that SRC-1 attenuates the TGF-P-mediated 
inhibition of LPL promoter activity in U937 cells. However, this is only 
representative o f a single initial experiment due to subsequent problems with the 
U937 cell line.
Figure 5.18B shows that, in Hep3B cells, the SRC-1 plasmid has no significant effect 
on the TGF-P-regulation of LPL promoter activity whilst p300 changes levels of LPL 
promoter activity so that they are no longer significantly inhibited by TGF-p (Figure 
5.18C). This is in contrast to previous work which showed an involvement for SRC-1 
but not p300 in the TGF-p-regulation o f LPL in U937 cells, suggesting that this action 
may be cell-type specific.
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Figure 5.18 The role of coactivators in the TGF-p-regulation of LPL promoter 
activity. U937 (Panel A) or Hep3B cells (Panels B and C) were transfected with lpg 
LPL -101/+188 promoter construct and 1, 2 or 3pg of pcDNA3, p300 or SRC-1 as 
indicated, using Superfect™ as described in Section 2.5.1. Cells were either left 
untreated or treated with TGF-P overnight and then harvested using lx passive lysis 
buffer. Luciferase activity readings were normalised to protein concentration. Data 
shown is the ratio of luciferase activityiprotein concentration normalised to the 
untreated samples and expressed as fold change from this. With the exception of 
Panel A which is representative of a single experiment, data is representative of three 
independent experiments (*P<0.05, **P<0.01, ***P<0.001, NS-not significant).
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5.3.17 The role of SRC-1 in LPL expression
In order to address any cell specificity issues, a siRNA against SRC-1 was obtained 
and the action of SRC-1 knockdown on LPL expression was investigated in THP-1 
macrophages. Whole-cell protein extracts from THP-1 cells transfected with siRNAs 
against GAPDH or SRC-1 were either left untreated or stimulated with TGF-P, and 
then subjected to SDS-PAGE and western blot analysis. Expression of SRC-1 
following siRNA-mediated knockdown was validated by western blotting using an 
antibody against this coactivator. The effect of SRC-1 knockdown on LPL mRNA 
expression was investigated using RT-qPCR. Transfection o f siRNA, TGF-P 
treatment, harvesting o f total RNA and RT-qPCR was carried out as described in 
Section 5.3.6. Figure 5.19A shows that SRC-1 expression is significantly reduced in 
both untreated and TGF-p-treated THP-1 macrophages. Knockdown of SRC-1 
resulted in the loss o f significant TGF-p-regulated inhibition of LPL (Figure 5.19B) 
and also reduced constitutive levels o f LPL mRNA expression (Figure 5.19C).
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Figure 5.19 SRC-1 has a role in the constitutive and TGF-p-regulated 
expression of LPL in THP-1 macrophages. Whole cell extracts from untreated and 
TGF-P-treated cells transfected with validated GAPDH or SRC-1 siRNA were 
subjected to western blotting using antibodies against SRC-1 and p-actin. Relative 
expression (mean ±SD) of SRC-1 normalised to p-actin, with untreated samples 
arbitrarily assigned as 1, from three independent experiments is shown. In panel B and 
C, total RNA extracts were subjected to RT-qPCR using primers specific to LPL and 
RPL13A. Relative expression (mean ±SD) of LPL normalised to RPL13A, with 
untreated samples arbitrarily assigned as 1, from three independent experiments is 
shown (*P<0.05, **/><0.01).
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5.4 Discussion
Previous studies, presented in Chapter 4, have demonstrated a crucial role for the 
Smad pathway in the regulation o f expression of key genes implicated in the control 
of macrophage cholesterol homeostasis by TGF-p. In addition to activating and 
mediating responses through the Smad pathway TGF-p is also able to activate and 
mediate gene expression through other signalling pathways, including the MAPK 
pathways. As explained in more detail in Section 1.13, MAPKs are expressed in the 
cardiovascular system in a number o f cell types including endothelial cells and 
VSMCs, and are activated by a number o f stimuli including LDL and mechanical 
stress. Pro-atherogenic roles in foam cell formation and neointimal formation for 
MAPKs have been suggested by knockout of macrophage JNK2 and p38 kinase 
expression respectively in ApoE " mice (Ohashi et al. 2000, Proctor et al. 2008, Ricci 
et al. 2004, Seimon et al. 2009).
Activation of the MAPKs has been noted in macrophages. However, little is currently 
known about the kinetics of this activation and the contribution of MAPKs to TGF-p- 
regulated gene expression in these cells. We have shown that phosphorylation of 
ERK, JNK and p38 kinase is increased by TGF-p in THP-1 macrophages and 
HMDMs (Figures 5.2 and 5.3) and that this is accompanied by a corresponding 
increase in kinase activity (Figure 5.4 and 5.5). This finding correlates well with 
studies that have shown that MAPK signalling is active in macrophages and human 
atherosclerotic lesions (Cheng et al. 2008, Li and Xu 2000). Data from our laboratory 
has also shown that TGF-P activates the JNK (c-Jun) and p38 kinase pathways in 
THP-1 monocytes (Singh and Ramji, 2006). The MAPKs are activated with slow 
kinetics with maximal induction occurring between 12 and 24hr. Slow kinetics may 
be suggestive of MAPK activation following Smad pathway activation and possibly 
Smad-dependent transcriptional responses whilst fast kinetics would suggest Smad- 
independent activation o f MAPKs by TGF-p.
The role o f each of the MAPK pathways in the TGF-p regulation of gene expression 
was investigated using siRNA-mediated knockdown o f ERK 1/2, c-Jun and p38
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kinase. An siRNA against c-Jun, the downstream target of JNK was used in place of 
a siRNA against JNK as a significant siRNA-mediated knockdown of JNK expression 
could not be produced in the THP-1 cell line. Knockdown of ERK, c-Jun and p38 
kinase expression was determined using western blotting and analysis demonstrated a 
significant reduction in protein levels of each of the MAPKs following siRNA- 
mediated knockdown (Figure 5.6).
The results presented in this chapter demonstrate for the first time that the MAPK 
signalling pathways have a key role in the expression o f key genes implicated in the 
regulation of foam cell formation by TGF-(3. The use o f siRNA knockdown assays 
showed that the p38 kinase pathway was required for the TGF-p-regulated inhibition 
of LPL, SR-A, SR-B1 and CD36 mRNA expression (Figures 5.7 to 5.10) and also for 
the TGF-P-regulated induction o f ABCA-1 and ABCG-1 expression (Figures 5.12 and 
5.13). The most potent effects o f p38 kinase siRNA-mediated knockdown on TGF-p- 
regulated gene expression were observed for LPL and SR-B1 whose expression was 
significantly induced and for ABCA-1 whose expression was significantly decreased 
by p38 kinase knockdown. This is consistent with a number o f studies suggesting that 
p38 kinase is required for foam cell formation. Inhibition of the p38 kinase pathway 
using pharmacological inhibitors has demonstrated a requirement for the kinase in the 
12/15 lipoxygenase-regulated reduction of ABCG-1 expression and also in the TNF- 
a-regulated reduction of scavenger receptor expression in murine macrophages (Hsu 
and Twu 2000, Nagelin et al. 2009). Blockade o f the p38 kinase pathway in murine 
J774 macrophages has also demonstrated a requirement for p38 kinase in oxLDL 
induced CD36 expression and subsequent foam cell formation through the 
transactivation of PPARy (Zhao et al. 2002).
Interestingly our study also revealed roles for p38 kinase in the constitutive 
expression of both SR-B1 and CD36. Knockdown o f p38 kinase resulted in a 
significant reduction in the mRNA expression o f SR-B1 and CD36 (Figure 5.14) 
suggesting that p38 kinase is required for the basal expression of these scavenger 
receptors following PMA differentiation of THP-1 cells.
Assays using siRNA specific against c-Jun demonstrated a requirement for c-Jun in 
the TGF-P-regulated expression o f LPL, SR-A, SR-B1, CD36, ABCA-1 and ABCG-1
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with the TGF-p-regulated expression o f LPL appearing to be most potently affected 
by c-Jun knockdown. The involvement o f p38 kinase and c-Jun in the TGF-|3- 
regulated expression o f such a large number of genes suggests a critical role for these 
MAPKs in the control of foam cell formation. In contrast to this, knockdown of ERK 
1/2 had little effect on TGF-P-regulated gene expression. Only the TGF-P-regulated 
expression of CD36 (Figure 5.10), ABCA-1 and ABCG-1 (Figures 5.12 and 5.13) 
were reversed following ERK 1/2 knockdown. This finding however is consistent 
with studies that have demonstrated a role for ERK in the expression of CD36 (Han et 
al. 2000, Nicholson et al. 2001). As explained in more detail in Section 3.1.5, a 
requirement for ERK (p44/42) in the TGF-p-regulated expression of CD36 has been 
shown previously in macrophages where suppression o f CD36 is thought to be 
mediated through an increase in ERK activity leading to inactivation of PPARy (Han 
et al. 2000, Nicholson et al. 2001). An involvement for ERK in ABCA-1 and ABCG- 
1 expression was not supported by a recent study that showed that in murine 
RAW264.7 macrophages pharmacological and siRNA-mediated inhibition of ERK 
1/2 activity resulted in increased ABCA-1 expression and increased cholesterol efflux 
to ApoAI whilst ERK 1/2 activation resulted in a reduction in both (Zhou et al. 
2009). However, this may represent a species-specific difference.
One interesting finding in our study is that the knockdown of ERK 1/2, c-Jun or p38 
kinase had no effect on the TGF-p-regulated expression o f ApoE (Figure 5.11). This 
may be due to sensitivity issues with western blotting as compared to RT-qPCR. 
Changes in the protein expression o f SR-A and LPL following p38 kinase knockdown 
were not consistent with those observed at the mRNA level suggesting that this may 
be the case. This finding contrasts with previous findings in our laboratory that have 
demonstrated, using pharmacological inhibitors, a requirement for the JNK and p38 
kinase pathways in the TGF-p-mediated induction o f ApoE mRNA and protein 
expression in THP-1 monocytes and macrophages (Singh and Ramji 2006). As 
described in Section 3.1.6, dominant-negative forms o f JNK, c-Jun and p38 kinase 
blocked ApoE induction while binding of AP-1 was induced by the cytokine but 
blocked by inhibitors o f JNK and p38 kinase (Singh and Ramji 2006). As with the 
action of the Smad signalling pathway on ApoE expression (Chapter 4), functional 
redundancy may exist between the MAPKs and this could partly explain the lack of 
response seen following individual MAPK knockdown. It is also possible that
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residual kinase expression following knockdown may be sufficient for the response. 
Futher studies using siRNA-mediated knockdown of multiple pathway components 
would be needed to investigate this possibility.
Whilst the mechanisms behind TGF-P regulation of gene activation and inhibition in 
relation to foam cell formation and atherosclerosis are not well characterised, an 
involvement for the MAPKs (in particular p38 kinase and c-Jun) in this has been 
suggested by the results presented in this chapter. However, it is well established that 
TGF-p classically signals through the Smad pathway and a crucial role for this 
pathway in the regulation o f expression of genes implicated in macrophage 
cholesterol homeostasis has been demonstrated in Chapter 4 of this thesis. Several 
lines of evidence have demonstrated an involvement for the Smad pathway and one or 
more of the MAPK pathways in TGF-P-regulated gene expression. For example, 
expression of the tumour-suppressor gene PTEN is inhibited at a post-transcriptional 
level by TGF-p in a number o f cell lines and this can be blocked by inhibitors of p38 
kinase and the TGF-P type I receptor, suggesting an involvement for both Smad and 
MAPK pathways in this regulation (Yang et al. 2009). TGF-P-induced expression of 
CTGF in osteoblasts is Smad-3 dependent but can be blocked by the ERK inhibitor 
PD98059 and by a dominant-negative ERK (Amott et al. 2008) and induction of 
TIMP-3 by the cytokine in chondrocytes also shows a requirement for Smad and ERK 
pathways (Qureshi et al. 2008, Qureshi et al. 2005).
In light of this, it seems likely that both the Smad and MAPK pathways play critical 
roles in the TGF-P-regulated expression of key genes implicated in the control of 
macrophage cholesterol homeostasis and the possibility o f crosstalk between the 
pathways cannot be dismissed. The kinetics of Smad and MAPK activation and the 
crossover observed in their regulation of the TGF-p-mediated expression of a number 
of the genes studied in Chapters 4 and 5 o f this thesis certainly seem to point towards 
the regulation of gene expression through crosstalk between different TGF-P- 
activated signalling pathways. A number of studies on TGF-p-regulated gene 
expression have evidenced crosstalk between Smad and MAPK pathways although 
the exact mechanism o f crosstalk is often unclear. In human gingivial fibroblasts, 
MMP-13 expression is upregulated by TGF-P (Leivonen et al. 2002). Adenoviral 
gene delivery o f each o f the Smads demonstrated an involvement for Smad-3 in this
241
CHAPTER 5: The role of MAPKs in TGF-P-regulated expression of key macrophage genes
regulation and a dominant negative Smad-3 containing adenovims was able to block 
this induction (Leivonen et al. 2002). Inhibitors of the upstream regulators of p38 
kinase- MKK3b and MKK6b, and the p38 kinase inhibitor SB203580 were able to 
block Smad-3 induced expression o f MMP-13 whilst activation of p38a kinase 
induced Smad-3 nuclear translocation suggesting that p38a kinase activated Smad-3 
(Leivonen et al. 2002). The MKK6-p38 kinase pathway has also been implicated in 
the activation o f the ATF-2 transcription factor in response to TGF-p (Hanafusa et al.
1999). Induction of a TGF-P-inducible reporter construct by Smad-2 and -4 
expression was modestly enhanced by MKK6 suggesting that p38 kinase and Smad 
pathways may act cooperatively, possibly through complex formation in the nucleus 
(Hanafusa et al. 1999).
Interaction between signalling pathways can often be cell-type and gene specific. For 
instance, cells o f mesangial origin tend to show a synergy between ERK and Smad 
pathways whilst epithelial cells tend to show that this interaction inhibits downstream 
events (Hayashida et al. 2003). Stimulation of collagen I and fibronectin production 
by TGF-p in mesangial cells is mediated by the Smads but can be inhibited by 
blocking the expression of ERK. The activity o f a TGF-P-responsive promoter can 
also be reduced by blocking the expression of ERK suggesting that maximal induction 
of Smad activity requires this kinase (Hayashida et al. 2003). Another example of 
where crosstalk between Smad and MAPK pathways enhances TGF-p-dependent 
responses in mesangial cells is the regulation of PAI-1 gene expression by the ERK 
and Smad pathways (Hong et al. 2006). The TGF-p-Smad pathway is stimulated by 
oxLDL to lead to an increase in the mRNA expression of PAI-1. However this is not a 
direct regulation and can be inhibited by the ERK inhibitors PD98059 or U0126. 
Instead, oxLDL causes an increase in ERK activation by TGF-P and this is associated 
with an increase in the nuclear expression of Smad-3 and subsequent formation of 
DNArprotein complexes at Smad binding sites within the PAI-1 promoter (Hong et al.
2006).
Interplay between Smad and MAPK pathways is increasingly being observed in 
relation to atherosclerosis. Overexpression of angiotensin II in LDLR'7 mice reduced 
collagen accumulation and the expression of MMPs (Dandapat et al. 2008). In 
addition, such overexpression can modulate p38 kinase phosphorylation in
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atherosclerotic regions o f arteries in these mice (Zhang et al. 2009). Stimulation of 
angiotensin II in human dermal fibroblasts activates Smad-2 and Smad-2-dependent 
transcription and this activation is dependent on p38 kinase activation suggesting that 
both pathways are active in the regulation of angiotensin II (Dandapat et al. 2008, 
Zhang et al. 2009). In VSMCs, the ERK and Smad pathways have been implicated in 
the TGF-P-mediated induction of PAI-1 expression. PAI-1 promotes ECM 
accumulation and fibrosis therefore impacting on vascular remodelling, neointimal 
growth and VSMC migration and proliferation and is used as a biomarker for 
cardiovascular disease-associated mortality (Samarakoon and Higgins 2008). The 
ERK pathway and Rho/ROCK pathways are required for PAI-1 induction by TGF-p 
and can modulate duration of Smad phosphorylation and nuclear accumulation 
(Samarakoon and Higgins 2008). Interplay between the p38 kinase and Smad 
pathways has also been reported in VSMCs (Dadlani et al. 2008). Both these 
pathways are involved in proteoglycan synthesis and the elongation of the GAG 
chains of proteoglycans. This has physiological relevance to cardiovascular disease 
as this elongation promotes the binding o f proteoglycans to LDL that is a key part of 
the pathogenesis o f atherosclerosis. Inhibitors against both pathways reduced chain 
elongation and proteoglycan binding to LDL (Dadlani et al. 2008).
Of particular interest in our study was the finding that all the genes studied (with the 
exception of ApoE) showed a requirement for p38 kinase and c-Jun in their TGF-P- 
regulated expression (Figures 5.7 to 5.10 and Figures 5.12 and 5.13). This 
involvement of multiple signalling pathways is likely to require convergence of 
signals at the transcriptional level, possibly through common transcription factors 
such as AP-1 (Zhang et al. 1998). This has been observed to be the case for the TGF- 
P-regulated expression of ApoE in THP-1 monocytes and macrophages where an 
involvement for the JNK and p38 kinase pathways has been suggested and AP-1 
binding to the ApoE promoter is induced by the cytokine (Singh and Ramji 2006).
The interaction o f the MAPKs and Smads with transcription factor substrates adds 
complexity to the interplay between different signalling pathways. MAPK-associated 
transcription factors can modulate the activity of Smads and conversely these 
transcription factors can be modulated by the Smad pathway (Javelaud and Mauviel 
2005). This regulation can be positive or negative and often occurs in a cell-type-,
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gene- and/or MAPK-specific manner (Javelaud and Mauviel 2005). ERK, JNK and 
p38 kinase are able to phosphorylate Smads within the linker region of the protein. 
Phosphorylation o f Smads by MAPKs can affect their ability to move to the nucleus 
or thereby affect transcriptional activity. For instance, ERK phosphorylation of Smad- 
1, -2 and -3 reduces the nuclear translocation of Smads following TGF-P stimulation 
(Javelaud and Mauviel 2005). TGF-P activated JNK can also phosphorylate Smad-3 
to induce its nuclear translocation and activity. MSK1 kinase, a substrate of p38 
kinase, can modulate the transcriptional activity o f Smad-3 by promoting association 
with the p300 coactivator (Moustakas and Heldin 2005).
The transcription factor AP-1 and Smads tend to cooperate to regulate AP-1-driven 
promoters while they antagonise each other on Smad-dependent transcription 
(Javelaud and Mauviel 2005). Smad-3 and c-Jun can interact at the transcriptional 
level through AP-1 sites. Interestingly, the c-Jun promoter itself contains both AP-1 
and Smad3/4 binding sites and can be induced by TGF-P (Dennler et al. 2000). 
Repression of the Smad pathway by JNK activation in HepG2 cells is mediated by an 
interaction between Smad-3 and c-Jun (Dennler et al. 2000). Overexpression of 
constitutively active MKK4 and MEKK1 inhibited TGF-p-induced transcription and 
disrupts the c-Jun/Smad-3 interaction suggesting that this interaction impairs TGF-P- 
mediated transcription (Dennler et al. 2000).
Recent evidence has suggested that the inhibitory effect o f c-Jun/Smad-3 interaction is 
a result o f the ability o f c-Jun to stabilise the interaction o f Smad-3 with co-repressors 
(Javelaud and Mauviel 2005; Pessah et al. 2001). The TGF-P-regulated inhibition of 
forkhead activin signal transducer-1 (FAST-1) expression is mediated by an 
interaction between c-Jun and Smad-2 where JNK activation represses Smad-2 
activity and enhances the association o f c-Jun with the co-repressor TGEF (Pessah et 
al. 2001). This blocks the association between Smad-2 and coactivators such as 
CBP/p300 and stabilises interaction with TGIF (Pessah et al. 2001). Association of c- 
Jun with the Smad corepressor Ski has also been demonstrated. This association, in 
the absence o f TGF-p signalling functions to keep Smad-2-regulated genes in a 
repressed state until TGF-P stimulation when the complex disassociates to allow gene 
transcription (Javelaud and Mauviel 2005, Pessah et al. 2002).
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Of particular interest in our study, is the finding that the TGF-p-regulated inhibition of 
LPL expression is reversed by siRNA-mediated knockdown of c-Jun (Figure 5.7). 
Previous work carried out in the laboratory had suggested an involvement for the JNK 
pathway in the TGF-p-regulation o f LPL expression in macrophages (Section 5.3.15). 
This was partly confirmed using transient transfection of dominant-negative forms of 
JNK, SEK-1 and c-Jun in Hep3B cells but cell-type-specific differences were 
observed (Figure 5.17).
Previous work carried out in the laboratory had also demonstrated a role for SRC-1 in 
LPL expression (Section 5.3.16). In addition to the transfection studies described in 
Section 5.3.16, plasmid constructs specifying for multiple copies of the Sp1(62/65) 
and Spl(44) sites o f the promoter were used to demonstrate a role for SRC-1 in the 
TGF-P-mediated inhibition o f LPL, which was reversed following co-transfection 
with SRC-1 in U937 cells but not in Hep3B cells (Figure 5.18). This response is 
therefore likely to be cell-type specific. Indeed LPL is expressed in foetal liver but 
not adult liver (Semenkovich et al. 1989) and cancerous cell lines tend to have 
properties o f foetal cells. In addition, the basal expression o f LPL was increased 
following co-transfection with SRC-1, suggesting a role for the coactivator in 
constitutive LPL expression (unpublished data, Dr Peli Foka). We have confirmed 
these findings in THP-1 macrophages using a siRNA against SRC-1 where 
knockdown of SRC-1 resulted in a reversal o f TGF-P-mediated inhibition of LPL 
mRNA expression and a reduction in its basal expression (Figure 5.19). This finding, 
coupled with the effect o f c-Jun knockdown on LPL expression suggests that the 
TGF-P-regulated expression o f LPL is mediated through the JNK pathway and 
involves interaction with SRC-1. Based on this it is possible that the mechanism of 
TGF-P-mediated LPL inhibition in THP-1 macrophages is mediated through 
activation of the JNK pathway. Subsequent activation of c-Jun/ AP-1 may serve to 
‘mop up’ SRC-1 (the likely required coactivator for constitutive LPL expression) or 
inactivate the coactivator through dephosphorylation resulting in a reduction o f LPL 
expression following TGF-P stimulation. As explained in more detail in Section 
1.16.1, SRC-1 has previously been linked with TGF-P signalling. The coactivator has 
been shown to potentiate TGF-P signalling through Smad-3 by enhancing interaction 
between the Smad and p300/CBP, a coactivator associated with Smad-mediated 
transcription (Dennler et al. 2005). In addition, the coactivator contains consensus
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sites for MAPK phosphorylation and has been shown to be phosphorylated by ERK-2 
in vitro suggesting that SRC-1 is a regulatory target o f the MAPK pathways (Rowan 
et al. 2000).
In conclusion, the studies presented in this chapter have identified a role for the 
MAPK signalling pathways in the control o f macrophage cholesterol homeostasis by 
TGF-p. This is summarised in Figure 5.20. The TGF-P-regulation of expression of 
genes implicated in macrophage cholesterol homeostasis is defined for key genes (see 
Chapter 3), but very little is known about the role o f non-classical signalling pathways 
in this regulation. These studies suggest a critical role for the MAPK pathways in the 
TGF-P-regulation o f LPL, SR-A, SR-B1, CD36, ABCA-1 and ABCG-1 expression in 
THP-1 macrophages. This suggests that the JNK, p38 kinase and (to a lesser extent) 
ERK pathways are crucial for the attenuation o f foam cell formation by TGF-p and 
therefore contribute to the anti-atherogenic role o f TGF-p in atherosclerosis.
Further work will be needed to extend these findings at a cellular level and to further 
elucidate the exact molecular mechanisms behind the TGF-p regulation of expression 
of genes implicated in macrophage cholesterol homeostasis as has been partly carried 
out for LPL. In particular, studies on the how the involvement o f multiple signalling 
pathways converges to regulate target gene expression will be important to enhance 
understanding about the exact mechanisms o f gene regulation by TGF-p.
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Figure 5.20 The involvement of the MAPK signalling pathways in the TGF-p- 
regulated expression of key genes implicated in macrophage cholesterol 
homeostasis. Previously, the only macrophage-expressed gene known to be regulated 
through a TGF-(3-MAPK pathway was CD63 whose expression is down-regulated by 
the cytokine through activation of ERK and subsequent phosphorylation of PPARy 
(Han et al. 2000). From the results presented in this chapter the TGF-p-regulated 
expression of LPL, SR-A, SR-B1, ABCA-1 and ABCG-1 can be added to this list. 
Whilst the mechanism behind LPL regulation has been partly characterised the exact 
mechanism of regulation through MAPK activation of the other genes studied is 
unclear. Interestingly, with the exception of CD36 and ApoE, all the genes studied 
showed some requirement for both c-Jun and p38 kinase pathways in their TGF-P- 
regulation. The exact contribution of these pathways to gene regulation and the 
mechanisms of crosstalk remain unclear.
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CHAPTER 6 
Investigations into the regulation of 
ADAMTS-4 expression by TGF-p
6.1 Introduction
The ADAMTS proteases have only recently come to light as possible contributors to 
inflammation and atherosclerosis. ADAMTS-4 has been found to be present within 
macrophages of atherosclerotic lesions and is up-regulated by the pro-inflammatory 
cytokine IFN-y (Wagsater et al. 2008). It seems likely therefore that ADAMTS-4 will 
be regulated by the anti-inflammatory cytokine TGF-p. The role of the ADAMTS 
proteases in the breakdown o f proteoglycans may point to a role in plaque stability 
and the latter stages o f atherosclerosis (Wight 2005). It was therefore of interest to 
study the regulation o f ADAMTS-4 as a new TGF-P target gene in macrophages. 
This would increase our knowledge o f TGF-P-mediated regulation of gene expression 
with respect to both foam cell formation and plaque stability. As the structure and 
function of ADAMTS proteases has not been discussed previously in this thesis, a 
review of the current knowledge regarding them has been included in this chapter.
6.1.1 The ADAMTS family of proteases
The ADAMTS family of proteases are a distinct family o f 19 members, ADAMTS-1 
to ADAMTS-19, that are structurally related to the ADAM and MMP families of 
proteinases, as detailed in Section 6.1.2 (Jones and Riley 2005; Porter et al. 2005). 
ADAMTS proteases are non-membrane bound enzymes that bind to components of 
the ECM such as pro-collagen, hyalectans and cartilage oligomeric matrix protein to
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cause their degradation (Jones and Riley 2005; Wang et al. 2003). They are cleaved 
to become active through their pro-domain which contains at least one furin cleavage 
consensus motif (Tang 2001). Following secretion, mature ADAMTS proteases can 
undergo further processing at the C-terminal end. Cleavage occurs within the spacer 
region but while studies on ADAMTS-4 have shown that this can be autocatalytic, it 
is also possible that cleavage is mediated by matrix metalloproteinases (Jones and 
Riley 2005; Porter et al. 2005).
The ADAMTS family is usually subdivided into four classes based on structural 
and/or functional similarities. These are the aggrecanases (hyelectanases), the 
procollagen-n-peptidases, von Willibrand cleaving factor (ADAMTS-13) and the 
other ADAMTS proteins (Jones and Riley 2005). The mammalian ADAMTS 
proteases share between 20 and 40% homology with ADAMTS-13 being the most 
distinct (Porter et al. 2005; Tang 2001). Little is known about the function of a 
number of the ADAMTS members with most o f the genes are only expressed at low 
levels. ADAMTS-1, -4 and -7 are the most abundant o f the proteases (Tang 2001). 
ADAMTS members with unknown function include ADAMTS-6, -7, -10, -11, -12 
and -16 to -19 (Jones and Riley 2005; Porter et al. 2005).
6.1.1.1 The aggrecanases 
ADAMTS-1, -4, -5, -8, -9 and -15 are collectively known as the aggrecanases as they 
cleave the hyalectan, aggrecan. Aggrecan is a 1000-2000kDa protein with 3 globular 
domains, 2 in the N-terminal region connected by an interglobular domain and one in 
the C-terminus linked through a large GAG attachment region (Malfait et al. 2002; 
Yamanishi et al. 2002). It is present in large amounts in the articular cartilage and is 
important for withstanding compressive deformation during joint movement and for 
protecting collagen from degradation (Naito et al. 2007; Tang 2001). Aggrecan is 
cleaved by both MMPs and ADAMTS proteases at distinct sites and may itself 
contain a conserved recognition site for cleavage by the ADAMTS proteases (Miwa et 
al. 2009). ADAMTS proteases cleave aggrecan at the Glu373-Ala374 bond within the 
interglobular region and also at four other sites (Glu1480-G ly1481, Glu1667-G ly1668, 
Glu1771-A la1772 and Glu1871-L eu1872) within the GAG region (Haddock et al. 2007; 
Hashimoto et al. 2001; Malfait et al. 2002; Porter et al. 2005).
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ADAMTS-1 was the first o f the ADAMTS proteases to be discovered in 1997 (Kuno 
et al. 1997) and was later identified as a potent inhibitor o f angiogenesis (Vazquez et 
al. 1999) and then as an ‘aggrecanase’ (Kuno et al. 2000). A role for the ADAMTS 
proteases in ECM degradation was first suggested by knockout of ADAMTS-1 in 
mice where impaired formation o f adipose tissue and accumulation of collagen within 
the skin tissue suggested that the processing o f collagen and other ECM molecules 
was defective (Shindo et al. 2000).
ADAMTS-4 and -5 show the highest aggrecanase activity and have been implicated 
in osteoarthritis and rheumatoid arthritis (Bondeson et al. 2008; Huang and Wu 2008). 
Studies in knockout mice revealed that ADAMTS-5 was the primary protease 
responsible for aggrecan degradation in mice (Glasson et al. 2004; Glasson et al. 
2005). Although ADAMTS-4 is predominantly expressed in human osteoarthritic 
cartilage it is currently unclear whether ADAMTS-4 or ADAMTS-5 is responsible for 
aggrecan degradation in humans (Huang and Wu 2008; Naito et al. 2007). In 
osteoarthritis aggrecan is cleaved by ADAMTS proteases, and fragments are released 
into the synovial fluid (Haddock et al. 2007; Hashimoto et al. 2001; Malfait et al. 
2002; Porter et al. 2005). This cleavage may be caused by overproduction of 
cytokines by synovial macrophages. TNF-a and IL -lp  have been identified as likely 
key players in this process. Studies using cultures o f osteoarthritic synovial cells have 
shown that ADAMTS-4 expression can be induced by TNF-a and IL -lp  and down- 
regulated in response to blocked TNF-a and IL -lp  signals (Bondeson et al. 2006; 
Naito et al. 2007). Studies in mice have shown that knockout o f ADAMTS-5 (and not 
ADAMTS-4) can prevent degradation o f cartilage suggesting that ADAMTS-5 is the 
active cartilage proteinase in mice while ADAMTS-4 is active in human cartilage 
(Jones and Riley 2005; Naito et al. 2007).
In addition to aggrecan, the ADAMTS proteases have been shown to cleave additional 
proteoglycan substrates. ADAMTS-4 also cleaves brevican, one of the primary 
proteoglycans in the central nervous system (CNS). This action may be relevant to 
the pathophysiology o f stroke (Haddock et al. 2007). ADAMTS-1, -4 and -9 are able 
to cleave versican, a proteoglycan structurally similar to aggrecan but found within 
the vasculature. Its expression is upregulated in all forms o f vascular disease and it
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accumulates in blood vessels susceptible to atherosclerosis (Porter et al. 2005; Wight 
md Merrilees 2004). Interestingly aggrecan, brevican and versican are all cleaved by 
Ihe aggrecanases at specific Glu-Xaa bonds (Haddock et al. 2007).
6.1.1.2 The procollagen-n-proteinases
ADAMTS-2, -3 and -14 are termed procollagen-n-proteinases due to their 
involvement in the removal o f N-terminal peptides from procollagen to form mature 
collagen. ADAMTS-2 is thought to play a role in the formation o f skin and (similar 
to other collagen C-proteinases) its expression can be up-regulated by the cytokine 
TGF-P (Wang et al. 2003). ADAMTS-3 and -14 are thought to function primarily in 
cartilage and tendon respectively (Jones and Riley 2005).
6.1.1.3 Von WiUibrand cleaving factor
ADAMTS-13 has been identified as the protease that cleaves the multimeric 
glycoprotein, von-Willibrand factor (VWF) (Fujikawa et al. 2001). This protein, 
present predominantly in the plasma, has a key role in coagulation. VWF is a carrier 
for clotting factor VIII and has a significant role in coagulation and thrombus 
formation as part o f the thrombin pathway. In atherosclerosis, VWF binds to ECM 
molecules to promote platelet adhesion and aggregation at sites o f damage to the 
vascular wall (Jones and Riley 2005; Porter et al. 2005). ADAMTS-13 has been 
demonstrated to colocalise with VWF in thrombi o f human coronary arteries. 
Cleavage of VWF by ADAMTS-13 is thought to attenuate thrombus formation in 
atherosclerotic plaques and a role for the dinsintegrin domain o f ADAMTS-13 in this 
process has been identified (Moriguchi-Goto et al. 2009).
6.1.2 Domain structure of ADAMTS proteases
The ADAMTS proteases have a domain structure, as shown in Figure 6.1, that is 
conserved throughout the family. ADAMTS proteases are synthesised as proproteins 
which are cleaved to become active through the removal o f the pro-domain by a furin 
proprotein convertase within the trans-Golgi (Kuno et al. 1999; Wang et al. 2004). 
The catalytic region of ADAMTS proteases is comprised of a catalytic zinc 
coordinated by three histidine residues. This active site m otif is followed by a highly 
conserved methionine residue, a pattern also observed in the ADAM and MMP
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families (Jones and Riley 2005). The catalytic region is followed by a smaller, 
disintegrin-like domain. This region shares 25-45% homology with the snake venom 
disintegrins but does not interact with integrins. Following this region are the 
thrombospondin type 1-like repeats (TSR). These sequences are unique to the 
ADAMTS proteases amongst the matrix protease families and are homologous to the 
type-1 repeats found within thrombospondins 1 and 2. One important function of this 
domain is to bind to the ECM and to glycosaminoglycans such as heparin (Jones and 
Riley 2005; Porter et al. 2005; Tang 2001). The highly conserved cysteine-rich 
domain (CRD) follows the TSR region and contains 10 cysteine residues. The crystal 
structure of ADAMTS-1 revealed that this was stacked against the active site of the 
protease (Gerhardt et al. 2007). It is followed in by a spacer region that varies in 
length and sequence but usually contains several hydrophobic residues towards the N- 
terminal end. Between 1 and 14 TSRs follow the CRD and spacer in all ADAMTS 
proteases except ADAMTS-4 (Jones and Riley 2005; Tang 2001).
A D A M TS structure
 ^ Furin recognition site
|  Signal peptide | | Disintegrin-like domain
|  Pro do main • Thrombospondin type 1-like repeat (TSR)
( 3  Catalytic Zinc c m Cysteine-rich domain
Catalytic domain ■ Spacer region
Figure 6.1 The domain structure of the ADAMTS proteases. The prodomain 
of the protein is cleaved by furin to form the mature form of the proteinase. 
ADAMTS proteases are zinc-metalloproteinases so their catalytic domain contains 
zinc coordinated by three histidine residues at the active site. The thrombospondin 
type 1-like repeats and the lack of a transmembrane domain distinguishes the 
ADAMTS from the ADAM proteases.
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The ability o f the ADAMTS proteases to bind to the extracellular matrix is one 
important property that distinguishes the ADAMTS family from the ADAM and 
MMP families (Kuno et al. 1999). The proteases bind to sulphated glycosminoglycans 
present in the ECM including heparin and aggrecan (Porter et al. 2005). Both the 
catalytic and the non-catalytic regions o f the ADAMTS proteases are required for full 
proteolytic activity and substrate binding. This is achieved through post-translational 
processing (C-terminal truncation) of mature ADAMTS proteases within the spacer 
region and may be mediated by MMPs (Gao et al. 2002).
Studies using murine ADAMTS-1 domain-deletion constructs and C-terminally 
processed forms of human ADAMTS-4 identified the TSP type 1 motifs and the 
cysteine-rich and spacer regions in the C-terminal domain as crucial for ECM binding, 
with truncation of this region resulting in a loss o f ECM binding (Kuno and 
Matsushima 1998; Porter et al. 2005). In addition, the spacer and cysteine rich 
regions together with the thrombospondin motifs are required for substrate 
recognition and cleavage by the proteases (Flannery et al. 2002; Tortorella et al.
2000). Cleavage of the cysteine rich and spacer regions reduces the affinity of 
ADAMTS-4 for heparin and reduces its ability to cleave aggrecan (Hashimoto et al. 
2004; Jones and Riley 2005).
6.1.3 Regulation of ADAMTS proteases
Regulation of the ADAMTS proteases remains a poorly understood area. One 
regulatory property that is known is that the ADAMTS can be regulated by the tissue 
inhibitors of metalloproteinases (TIMPs) (Porter et al. 2005; Wight 2005). TIMPs -1, 
-2, -3 and -4 are endogenous inhibitors o f the MMPs (Galis and Khatri 2002). 
However, TIMP-3 has been found to be an important specific inhibitor of ADAMTS- 
4 and -5. In addition TIMP-2 and TIMP-3 can inhibit ADAMTS-1 aggrecanase 
activity (Rodriguez-Manzaneque et al. 2002). Hashimoto et al. (2001) incubated 
ADAMTS-4 with TIMPs to demonstrate the inhibitory action of these molecules on 
the ability of ADAMTS-4 to cleave aggrecan. Analysis of the IC50 values revealed 
that the activity of TIMP-3 was 50-fold higher than that observed with TIMPs-1 and 2
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and approximately 250-fold higher than the activity o f TIMP-4, suggesting that this 
inhibitory action on ADAMTS-4 is specific to TIMP-3 (Hashimoto et al. 2001). 
Although the mechanism o f inhibition has not been fully elucidated, a study by 
Kashiwagi et al. (2001) demonstrated that the N-terminal domain of TIMP-3 was able 
to inhibit the aggrecanase activity o f ADAMTS-4 and -5 suggesting that the N- 
terminal end of TIMP-3 may interact with ADAMTS. A recent study has 
demonstrated that this interaction is enhanced by the C-terminal domain of 
ADAMTS-4 and ADAMTS-5. Binding o f TIMP-3 may prevent interaction between 
the ADAMTS and aggrecan by altering the active site to favour interaction with 
TIMP-3 rather than the aggrecan substrate (Kashiwagi et al. 2001; Troeberg et al. 
2009).
6.1.4 ADAMTS proteases -  Links with inflammation and atherosclerosis
Changes in the degradation o f ECM by MMPs and other proteases have been 
associated with a number o f pathological inflammatory conditions including 
atherosclerosis and rheumatoid arthritis. This shift in balance of synthesis and 
degradation is often driven by inflammation, injury and oxidative stress (Galis and 
Khatri 2002; Galis et al. 1994; Malemud 2006; Wagsater et al. 2008). In 
atherosclerosis, macrophages and monocytes are known to secrete proteolytic 
enzymes to influence the development o f the lesion and/or the stability of the plaque 
(Worley et al. 2003; Wagsater et al. 2008). Differentiation o f monocytes to 
macrophages is also accompanied by an increase o f matrix-degrading proteases 
(Whatling et al. 2004). Immunohistochemical analysis o f human carotid lesions and 
advanced atherosclerotic plaques has shown that ADAMTS-1, -4, -5 and -8 are 
present within lesions (Wagsater et al. 2008). O f these, ADAMTS-4, -5 and -8 
colocalise with macrophages whilst ADAMTS-1 colocalises with endothelial and 
smooth muscle cells (Jonsson-Rylander et al. 2005; Wagsater et al. 2008). 
ADAMTS-1 and ADAMTS-4 are the most abundant of the proteases and have 
consequently been the focus o f studies on the link between ADAMTS proteases and 
atherosclerosis (Jones and Riley 2005).
The enhanced expression of ADAMTS-1 in the kidney and heart observed in response 
to in vivo lipopolysaccharide (LPS) administration first suggested that ADAMTS
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proteases were associated with inflammatory processes. The observation that murine 
ADAMTS-1 mRNA expression could be up-regulated by IL-1 (a pro-inflammatory 
mediator) was also consistent with a proposed role for ADAMTS-1 in inflammation 
(Kuno and Matsushima 1998; Tang 2001; Wight 2005).
In endothelial cells ADAMTS-1 expression can be induced by the pro-inflammatory 
cytokines TNF-a and LPS and this up-regulation is significantly reduced in the 
presence o f HDL (Norata et al. 2004). This demonstrates that ADAMTS-1 can be 
produced in response to inflammatory stimuli and may promote inflammation. This 
can be countered by HDL, possibly due to its protective role in endothelial cell 
function and atherosclerosis (Norata et al. 2004). It is possible that HDL may inhibit 
the expression of genes coding for proteolytic enzymes by endothelial cells as can be 
observed for the expression o f several adhesion molecules by endothelial cells (Norata 
et al. 2004). ADAMTS-1 has also been shown to inhibit the proliferation of 
endothelial cells by sequestration o f VEGF. This is achieved through direct binding 
of the protease to VEGF, thereby preventing its interaction with the cognate receptor 
(Luque et al. 2003; Norata et al. 2004). Conversely, the expression of ADAMTS-1 
can be up-regulated by VEGF and this is protein kinase C-dependent, suggesting a 
feedback mechanism for the regulation of angiogenesis (Xu et al. 2006). The 
expression of both ADAMTS-1 and VEGF in endothelial cells can be induced by 
hypoxia (Hatipoglu et al. 2009).
ADAMTS-1 has been linked with atherosclerosis development through a role in 
promoting inflammation and VSMC migration (Jonsson-Rylander et al. 2005; 
Wagsater et al. 2008). Immunohistochemistry has shown that ADAMTS-1 mRNA is 
present at high levels in the aorta and colocalises with endothelial cells and VSMCs in 
atherosclerotic lesions (Jonsson-Rylander et al. 2005; Wagsater et al. 2008). 
Expression of ADAMTS-1 is higher in migrating and proliferating VSMCs. Mice 
overexpressing ADAMTS-1 crossed with ApoE-deficient mice show an increased 
thickening of the arterial intima suggesting that ADAMTS-1 could be involved with 
expansion of lesions (Wight 2005). ADAMTS-1 expression is also up-regulated by 
shear stress in endothelial cells (HUVECs) suggesting a role for the protease in the 
adaptations in the vessel structure during vascular events (Bongrazio et al. 2000).
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In contrast with ADAMTS-1, ADAMTS-4 colocalises with macrophages of 
atherosclerotic lesions (Wagsater et al. 2008). Studies using the LDL-receptor and 
ApoB 100/100 deficient, atherosclerotic mouse model, have shown that the levels of 
ADAMTS-4 mRNA are induced almost three-fold during lesion development 
(Wagsater et al. 2008). In vitro experiments in THP-1 cells and primary monocytes 
have shown that the expression of ADAMTS-4 and -8 expression are increased 
following the differentiation o f monocytes to macrophages whilst the expression of 
ADAMTS-1, -2, -5, -7 and -10 remains unchanged (Porter et al. 2005; Worley et al. 
2003; Wagsater et al. 2008). The induction of ADAMTS-4 and -8 expression is 
thought to be mediated through a secondary signal. IL-113 is a suggested candidate for 
this as it is induced by PMA in monocytes and has also been demonstrated to induce 
ADAMTS-4 expression in human chondrocytes (Worley et al. 2003) and decrease 
versican synthesis in arterial smooth muscle cells (Lemire et al. 2007). However, 
studies have shown that IL-ip does not induce ADAMTS-4 expression in 
differentiating THP-1 cells (Wagsater et al. 2008) suggesting that this regulation may 
be cell-type specific.
6.1.5 Cleavage of versican by ADAMTS proteases -  relevance to atherosclerosis
The ability of both ADAMTS-1 and -4 to cleave the proteoglycan versican is likely to 
be central to hypothesised roles for the proteases in atherosclerosis (Worley et al.
2003). Versican fragments are present in both arterial samples and in non-human 
primate vascular graft models, indicating that versican undergoes processing and this 
processing is likely to be carried out by the ADAMTS proteases (Kenagy et al. 2005).
6.1.5.1 Versican
Versican is a proteoglycan belonging to the same ‘hyaluronan-binding’ family as 
aggrecan and brevican and is similar in structure to aggrecan in particular in the N and 
C-terminal domains (Sandy et al. 2001). Versican is a key component of the ECM 
where it can interact with a number o f molecules to regulate cellular processes 
including adhesion, proliferation and migration (Wight 2002).
Four isoforms of versican (V0, V I, V2 and V3) arise from alternative splicing of the 
same gene, located on chromosome 5q in humans (Rahmani et al. 2006; Wight 2002).
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The four isoforms differ by the presence or absence of two glycosaminoglycan 
binding domains designated a-GAG and [3-GAG. All versican isoforms are made up 
of an N-terminal globular domain which contains binding elements for interaction 
with ECM components such as hyaluronan, and a C-terminal globular domain 
containing two EGF-like repeats, a complement-regulatory protein-like repeat and a 
C-type lectin domain (Rahmani et al. 2006; Wight and Merrilees 2004). The 
glycosaminoglycan binding domains contain between 5 and 23 chondroitin sulphate 
attachment regions depending on versican isoform and tissue type and location 
(Rahmani et al. 2006). V0 contains both a-GAG and (3-GAG binding domains, VI 
contains a-GAG, V2 contains P-GAG and V3 has no glycosaminoglycan binding 
domains (Kenagy et al. 2006; Wight 2002).
6.1.5.2 Versican and atherosclerosis 
The contribution o f versican to atherosclerosis is not straightforward. In addition to 
being present within developing blood vessels, the expression of versican is 
upregulated in all forms of vascular disease and has also been found to accumulate in 
different arterial lesions including restenotic lesions and atherosclerotic plaques 
(Lemire et al. 2007; Wight 2005; Worley et al. 2003). Studies in non-human primates 
have shown that the proteoglycan localises with macrophages in developing and 
advanced atherosclerotic lesions but is the dominant proteoglycan in areas rich in 
VSMCs (Raines 2000; Worley et al. 2003). Versican is present within all layers of 
arteries and expression is increased in intimal thickenings (Wight 2002; Wight and 
Merrilees 2004). O f the different isoforms, the V0, VI and V3 forms are detectable in 
the human aorta and expressed by VSMCs (Sandy et al. 2001). Versican is 
synthesised by arterial smooth muscle cells and is able to influence the phenotypes of 
arterial smooth muscle cells and endothelial cells (Lemire et al. 2007). In addition, 
versican expression has been detected at the plaque thrombus interface where it is 
thought to promote platelet adhesion and aggregation (Mazzucato et al. 2002).
In non-disease states versican is likely to provide structure to vasculature through its 
interaction with hyaluronan (Wight and Merrilees 2004). Formation of complexes 
between hyaluronan and versican are necessary for the migration and proliferation of 
VSMCs following wounding. This complex formation is rapid and occurs during the
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detachment stage o f SMC migration (Evanko et al. 1999) and can be up-regulated by 
PDGF in arterial SMCs (Evanko et al. 2001). In addition to binding to versican, 
hyaluronan can serve an attachment ligand for macrophages and lymphocytes 
suggesting that hyaluronan-versican complexes may also influence the retention and 
adhesion of inflammatory cells (Wight and Merrilees 2004). The chondroitin sulphate 
(CS) chains of versican can interact with a number of adhesion molecules and 
chemokines such as L-selectin and P-selectin that may influence the migration and 
recruitment of vascular cells including macrophages (Hirose et al. 2001; Kawashima 
et al. 2000).
In advanced atherosclerosis, the location o f versican close to accumulated lipoproteins 
at the edge of lesions, suggests that versican and versican complexes may have a role 
in the retention o f lipoproteins in addition to inflammatory cells (Wight and Merrilees
2004). Multiple LDL particles are able to bind to the CS chains o f versican and other 
proteoglycans. Elongation o f CS chains is observed in vascular injury and promotes 
binding to LDL (Wight and Merrilees 2004). Versican-LDL complex formation can 
modulate (increase) lipoprotein uptake in both SMCs and macrophages (Ismail et al. 
1994; Srinivasan et al. 1995). Versican-LDL complexes are rapidly taken up by 
macrophages and can be taken up through the LDL receptor pathway in SMCs (Hurt- 
Camejo et al. 1992; Llorente-Cortes et al. 2002). Formation of these complexes is 
enhanced by LPL (Olin et al. 1999).
6.1.5.3 Versican cleavage and atherosclerosis 
Sandy et al. (2001) first showed that in the human aorta, versican fragments could be 
generated by ADAMTS-1 and ADAMTS-4 digestion o f human intact versican (Sandy 
et al. 2001). The production o f a 70kDa fragment demonstrated that consensus motifs 
(Glu-X bonds) for ADAMTS cleavage were present within versican and other 
aggregating proteoglycans. The inability o f other MMP enzymes to cleave at this site 
(despite their ability to degrade the protein) further supported the cleavage of versican 
by ADAMTS proteases (Sandy et al. 2001). It is now known that the ADAMTS-1 
and -4 proteases cleave versican (isoformsV0 and V I) at the Glu441-Ala442/ 
Glul428-Alal429 bond (Jonsson-Rylander et al. 2005; Sandy et al. 2001). In the case 
of ADAMTS-1, the degradation o f the primary proteoglycan component of the
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vascular ECM could facilitate the migration of VSMCs (Jonsson-Rylander et al.
2005). Interestingly, ADAMTS-7 has been demonstrated to facilitate the migration of 
VSMCs and intimal thickening in a rat vascular balloon-injury model and this is 
thought to be mediated by the breakdown of cartilage oligomatrix protein (COMP) by 
the protease (Wang et al. 2009).
In addition to increased proliferation and migration of VSMCs, versican fragments 
have also been linked with changes in ECM volume of vascular lesions and therefore 
with intimal growth and regression (Kenagy et al. 2005; Sandy et al. 2001). The 
ECM plays a large role in neointimal thickening, contributing between 60 and 80% to 
the mass in vascular lesions. The high number o f glycosaminoglycan chains present 
in versican contributes to the water content and volume of the intima making the 
removal/deposition of proteoglycans a highly effective way to control ECM volume 
(Kenagy et al. 2005). Using a graft repair model, it is possible to show that generation 
of versican fragments can be increased by high blood flow, indicating that the activity 
of ADAMTS proteases in blood vessels may be mediated by shear stress (Kenagy et 
al. 2005). Intimal tissue regression following balloon- or stent-mediated injury has 
been shown to be associated with increased blood flow and loss of versican. In a 
baboon vascular graft model high blood flow causes cell death and loss of ECM. This 
is accompanied by an increase o f a versican cleavage product that can be generated by 
the ADAMTS proteases -1, -4, -5 and -9. Kenagy and colleagues measured the 
mRNA levels o f ADAMTS proteases in this graft model and found that levels of 
ADAMTS-4 were significantly increased following a switch to high blood flow and 
that this was linked with tissue atrophy (Kenagy et al. 2005; Kenagy et al. 2009).
6.1.5.4 Regulation of versican cleavage by cytokines 
Versican degradation by ADAMTS proteases may be regulated by cytokines. Little is 
currently known about cytokine regulation of ADAMTS proteases in relation to 
atherosclerosis although the expression of ADAMTS-1 and ADAMTS-4 are 
upregulated by pro-inflammatory cytokines (Wagsater et al. 2008). In contrast, the 
regulation of versican expression is known to be regulated by a number of cytokines 
including PDGF, TGF-p and IL-ip (Schonherr et al. 1991; Lemire et al. 2007). 
Studies in monkey arterial smooth muscle cells showed that PDGF and TGF-p
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upregulate the expression of versican mRNA (Schonherr et al. 1991). In addition, 
immunostaining o f atherosclerotic lesions from hypercholesterolemic nonhuman 
primates have shown colocalisation o f versican-hyaluronan complexes with TGF-p 
and PDGF positive cells in the ECM (Evanko et al. 1998). Further studies in arterial 
smooth muscle cells have shown that IL-ip reduces the mRNA stability of versican 
leading to decreased levels o f synthesis (Lemire et al. 2007) and interestingly the 
cytokine is also able to upregulate decorin expression and induce aggrecan 
degradation through the upregulation o f ADAMTS aggrecanase activity (Lemire et al.
2007). This is an area for further study.
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6.2 Aims of experimental studies
A role for the ADAMTS proteases in atherosclerosis is only beginning to be 
investigated. Previous studies have shown that ADAMTS-1 and ADAMTS-4 are 
highly expressed in vascular cells and in atherosclerotic lesions. In particular, it has 
been shown that ADAMTS-4 colocalises with macrophages of lesions (Wagsater et 
al. 2008). We therefore wanted to investigate the expression and regulation of 
ADAMTS-4 in the THP-1 cell line as this is widely accepted as a model for human 
monocyte-derived macrophages. As previous work in our laboratory has concentrated 
on the regulation o f key genes implicated in atherosclerosis by cytokines, it was of 
particular interest to us to characterise the regulation o f ADAMTS-4 by the anti­
inflammatory cytokine TGF-P and to delineate the mechanisms underlying this 
regulation.
Very few studies have demonstrated the regulation o f the ADAMTS proteases by 
growth factors, hormones and cytokines and many o f the studies focus on cell lines 
relevant to osteoarthritis as a major role for ADAMTS-4 in this process has been 
defined. In the case of TGF-P, the cytokine has been demonstrated to induce 
ADAMTS-4 expression in a number o f cell lines including human synoviates and 
articular chondrocytes (Moulharat et al. 2004; Yamanishi et al. 2002). In articular 
chondrocytes ADAMTS-4 is also up-regulated by the pro-inflammatory cytokines 
TNF-a and IL-1 but by different pathways to that of TGF-P (Thirunavukkarasu et al.
2006). This suggests that TGF-P may act in a pro-inflammatory manner in this 
context. However, TGF-p is known to stimulate the synthesis of proteoglycans, 
collagen and TIMPs in a number o f cell types so enhancing the deposition of ECM 
during the early stages o f osteoarthritis and antagonising the effects of pro- 
inflammatory mediators (Moulharat et al. 2004). In this way TGF-P may enhance 
cartilage turnover by stimulating both synthesis and degradation. It will be interesting 
to see if this is the case in relation to ECM turnover in atherosclerosis.
To our knowledge only one study has been conducted that investigated the expression 
of ADAMTS proteases by cytokines in THP-1 cells. It demonstrated that treatment
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with pro-inflammatory cytokines TNF-a or IFN-y up-regulated the expression of 
ADAMTS-4, -7, -8 and -9 but had no effect on ADAMTS-1 (Wagsater et al. 2008). 
Initial studies in our laboratory had indicated that ADAMTS-4 expression was 
inhibited by TGF-p treatment in THP-1 cells (Amaoutakis 2008). We therefore 
wanted to investigate this further as an initial step towards functional dissection of the 
ADAMTS-4 promoter. The aims o f the studies presented in this chapter were to 
investigate the regulation of ADAMTS-4 by TGF-p. Initially this was carried out 
using RT-PCR and Western blot analysis with key results confirmed in primary 
cultures of HMDMs. siRNA technology was used to try and define which TGF-P 
signalling pathways were involved in the action o f TGF-P on ADAMTS-4. Following 
this the aims were to characterise the action of TGF-P on the promoter activity of 
ADAMTS-4 using transfection studies and to identify the region of the promoter 
involved in this response. DNA:protein interactions were investigated by EMSA. 
The final aim of the studies was to confirm any results observed with EMSA by 
cloning fragments of the promoter region into a heterologous promoter followed by 
transfection studies to further investigate the response and attempt to characterise any 
transcription factors required for the action o f TGF-p on ADAMTS-4 with the aim of 
characterising the mechanism behind TGF-p regulation of ADAMTS-4. Figure 6.2 
outlines the experimental strategy used during these studies.
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6.3 Results
6.3.1 Effect of TGF-p on the mRNA expression of ADAMTS-4
THP-I cells were seeded into 6-well plates and differentiated for 24hr with PMA. 
Cells were then cultured in the presence or absence of TGF-P for 12hr or 24hr as 
indicated in Figure 6.3. These time points were picked based on previous studies 
(presented in Chapter 3) that had suggested that these were suitable time points to 
study gene expression regulated by TGF-p. Cells were harvested for total RNA 
extraction and total RNA was quantified and used for RT-PCR analysis. PCR was 
carried out to amplify ADAMTS-4 and p-2 microglobulin using the conditions 
specified in Table 2.4 and the PCR products were size-fractionated using agarose gel 
electrophoresis. The relative intensity of ADAMTS-4 and p-2 microglobulin PCR 
products was determined using densitometric analysis (Section 2.9). Figure 6.3 shows 
that ADAMTS-4 expression was high in untreated cells and was significantly 
inhibited by TGF-P at both 12hr and 24hr with optimal inhibition at the 24hr time 
point.
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Figure 6.3 TGF-p down-regulates ADAMTS-4 mRNA expression in THP-1 
macrophages. THP-1 cells were treated with TGF-P or left untreated for 12 or 24hr 
and harvested for total RNA extraction. Total RNA was subjected to RT-PCR 
analysis and the PCR amplification products for ADAMTS-4 and P-2 microglobulin 
were resolved by agarose gel electrophoresis (Panel A). The size of the product was 
determined by comparison with a standard DNA molecular weight marker (see 
Appendix I). -RT denotes a reaction in which no reverse transcriptase was included 
in cDNA preparation (untreated sample from the 24hr time point was used). Panel B 
shows the relative expression (mean± SD) of ADAMTS-4 normalised to P-2 
microglobulin (untreated samples arbitrarily assigned as 1) from three independent 
experiments (*P<0.05, **P<0.01).
6.3.2 Effect o f TGF-P on th e protein expression  o f ADAMTS-4 in THP-1 and 
primary human m acrophage cultures
To confirm that the inhibition of ADAMTS-4 mRNA by TGF-P resulted in a 
corresponding change in the expression of ADAMTS-4 protein, western blot analysis 
was carried out. Differentiated THP-1 cells were treated with TGF-p or left untreated 
for the indicated time periods. Total cellular protein was extracted using Laemmli
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buffer, subjected to SDS-PAGE using an antibody against ADAMTS-4. P-actin was 
used as a loading control. Figure 6.4A shows that TGF-p significantly inhibited the 
expression of ADAMTS-4 protein at both the 12hr and 24hr time point. This change 
is synonymous with the changes in mRNA expression shown in Figure 6.3.
It was also important to determine if the ADAMTS-4 response to TGF-p was 
conserved in primary cultures of human monocyte-derived macrophages (HMDMs). 
For this, a single time point was chosen and total cellular protein extracts were 
subjected to western blotting as described above. Figure 6.4B shows that ADAMTS- 
4 expression in HMDMs was significantly inhibited by TGF-p at the 24hr time point.
6.3.3 Time dependent effect of TGF-p on ADAMTS-4 mRNA expression
In light of the results presented in Figures 6.3 and 6.4 it was important to determine 
how ADAMTS-4 was regulated by TGF-p over a time course. This would also 
determine an optimal time point for future studies on ADAMTS-4 expression. 
Untreated and TGF-p-treated THP-1 cells were harvested for total RNA and reverse 
transcribed. The resulting cDNA template was subjected to RT-qPCR analysis using 
specific primers against ADAMTS-4 and the control gene RPL13A as detailed in 
Table 2.5 and the amplification conditions set out in Table 2.6. RT-qPCR was used 
here as the technique had become available in the laboratory. Figure 6.5 shows that 
ADAMTS-4 expression was high in untreated cells and was significantly reduced by 
TGF-p, lhr after treatment with the cytokine. Levels of ADAMTS-4 mRNA 
expression remained significantly inhibited by TGF-P over the 24hr time course.
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Figure 6.4 TGF-p inhibits ADAMTS-4 protein expression in THP-1 and 
HMDMs. THP-1 cells or HMDMs were treated with TGF-p or left untreated for the 
time points indicated. Whole cell-protein extracts were subjected to SDS-PAGE and 
western blotting using antibodies against ADAMTS-4 and p-actin. Protein size was 
determined by comparison against a standard protein molecular weight marker (see 
Appendix I). P-actin was used as a loading control. Panel A (THP-1) and Panel B 
(HMDMs) show the relative expression (mean ± SD) of ADAMTS-4 normalised to P- 
actin (values from untreated samples arbitrarily assigned as 1) from three independent 
experiments (**P<0.01, ***P<0.001).
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Figure 6.5 TGF-p inhibits ADAMTS-4 mRNA expression over a 24hr time 
course. THP-1 cells were left untreated (Ohr) or treated with TGF-P for 1, 3, 6, 12 or 
24hr before being harvested for total RNA extraction. Total RNA was reverse- 
transcribed and the resulting cDNA subjected to RT-qPCR analysis using primers 
specific to ADAMTS-4 and the control gene RPL13A. The relative expression of 
ADAMTS-4 (mean ± SD) normalised to p-actin from three independent experiments 
is shown, with values from untreated (Ohr) samples arbitrarily assigned as 1 (*/><0.05, 
**P<0.01, ***P<0.001).
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6.3.4 TGF-p signalling pathways that mediate the action of this cytokine on 
ADAMTS-4 expression
As we had characterised the action of TGF-P on ADAMTS-4 expression in THP-1 
cells we wanted to investigate which TGF-p signalling pathways were involved in this 
response. Previous studies presented in this thesis have focused on the use of siRNA 
technology to determine the contribution of different TGF-P signalling pathways to 
the expression of a number of key genes implicated in atherosclerosis. This technique 
was also suitable to use to investigate the TGF-p regulation of ADAMTS-4 
expression. The involvement of the classical TGF-p/Smad signalling pathway and the 
non-classical TGF-p/MAPK pathways were assessed, consistent with studies on gene 
expression presented in Chapter 4 and Chapter 5 of this thesis.
THP-1 cells were transfected with siRNA as described previously (Section 2.6.1). 
Extracts were prepared for both total RNA and total protein. Protein extracts were 
used to validate the siRNA knockdown for each experiment whilst total RNA extracts 
were used to analyse the mRNA expression of ADAMTS-4. Knockdown of Smad 
and MAPK expression by siRNA is shown in Figure 6.6. Significant reduction in 
protein expression following siRNA knockdown was observed for Smad-2, Smad-3, 
Smad-2+3, ERK 1/2, c-Jun and p38 kinase in both untreated and TGF-P-treated 
samples. Protein extracts were prepared with Laemmli buffer and subjected to SDS- 
PAGE and western blotting. Total RNA extracts were reverse-transcribed and the 
resulting cDNA analysed by RT-qPCR using specific primers against ADAMTS-4 
and RPL13A. Figure 6.7 and Figure 6.8 show the effect of siRNA-mediated Smad 
knockdown and MAPK knockdown respectively on ADAMTS-4 mRNA expression.
The inhibition o f ADAMTS-4 by TGF-P was no longer significant following 
knockdown of Smad-2 or Smad-3. Knockdown of Smad-3 showed the largest change 
in ADAMTS-4 expression with the TGF-p-regulated inhibition being reversed (Figure 
6.7B). Knockdown of both Smad-2 and -3 also reversed ADAMTS-4 inhibition 
suggesting that the Smad pathway is involved in this response and that Smad-2 and 
Smad-3 may act in a functionally redundant manner. Knockdown of c-Jun and p38 
kinase similarly resulted in a loss o f significant ADAMTS-4 inhibition by TGF-p. 
This suggests that both c-Jun and p38 kinase may be involved in the action of TGF-P
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on ADAMTS-4 in addition to Smad-2 and -3. One noteworthy observation was that 
knockdown o f p38 kinase had a negative effect on the constitutive expression of 
ADAMTS-4 (PMA-induced expression during differentiation) as well as its TGF-p 
regulated expression (Figure 6.8C) suggesting a role for the kinase in the constitutive 
expression of ADAMTS-4. Knockdown o f ERK 1/2 had no effect on ADAMTS-4 
expression as shown in Figure 6.8A.
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Figure 6.6 Smad and MAPK expression following siRNA-mediated 
knockdown in THP-1 macrophages. Whole-cell protein extracts were prepared 
from untreated or TGF-|3-treated THP-1 cells transfected with validated GAPDH 
siRNA or Smad-2 (Panel A), Smad-3 (Panel B), Smad-2 and Smad-3 (Panel C), ERK 
1/2 (Panel D), c-Jun (Panel E), or p38 (Panel F) siRNA as described in Section 2.6.1. 
Extracts were subjected to SDS-PAGE and western blotting and levels of expression 
were compared against levels of P-actin. Relative expression (mean± SD) of each 
protein normalised to p-actin levels, with values from GAPDH-transfected cells 
arbitrarily assigned as 1, from three independent experiments is shown (*P<0.05, 
**P<0.01, ***P<0.001).
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Figure 6.7 The effect of Smad knockdown on the mRNA expression of 
ADAMTS-4. THP-1 cells were transfected with 7.5nM siRNA using Interferin™ as 
described in Section 2.6.1. At 24hr following transfection cells were differentiated 
using 0.16pM PM A and subsequently treated with TGF-P or left untreated for 24hr. 
Cells were harvested for total RNA and subjected to RT-qPCR analysis using primers 
specific to ADAMTS-4 and the control gene RPL13A. The relative expression 
(mean± SD) of ADAMTS-4 normalised to RPL13A (values from untreated samples 
arbitrarily assigned as 1) from three independent experiments is shown (**T><0.01, 
NS-not significant). Panel A: Smad-2 knockdown; Panel B: Smad-3 knockdown; 
Panel C: Smad-2 and -3 knockdown.
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Figure 6.8 The effect of MAPK knockdown on the mRNA expression of 
ADAMTS-4. THP-1 cells were transfected as described in Figure 6.6. Following 
transfection, cells were differentiated using PMA and then treated with TGF-P or left 
untreated for 24hr. Cells were harvested for total RNA and subjected to RT-qPCR 
analysis. The relative expression (mean± SD) of ADAMTS-4 normalised to RPL13A 
(values from untreated samples arbitrarily assigned as 1) from three independent 
experiments is shown (**P<0.01, NS-not significant). Panel A: ERK 1/2 knockdown; 
Panel B: c-Jun knockdown; Panel C: p38 knockdown; Panel D: basal expression of 
ADAMTS-4 following p38 knockdown.
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6.3.5 Effect o f TGF-P on ADAMTS-4 prom oter activation
Next, the effect of TGF-p on the promoter activity of ADAMTS-4 was investigated. 
This was necessary as an initial step towards delineating the mechanism of action 
behind the inhibitory effect of TGF-P on ADAMTS-4 expression. THP-1 cells are 
difficult to transfect necessitating the use of another cell line for investigations 
involving transient transfection. U937 cells are a widely used model for promoter 
analysis in relation to monocyte/macrophage gene expression making this cell line the 
obvious choice for this work. Unfortunately, problems with the differentiation of the 
U937 cells meant that future work using this cell line became unfeasible. As adherent 
Hep3B cells were available in the laboratory and are easy to transfect, we decided to 
use this cell line for our studies into the ADAMTS-4 promoter. ADAMTS-4 
promoter constructs designed on those produced by Mizui et al. (2000) were kindly 
provided by Dr. Alvin Kwan (Cardiff University, School of Biosciences) and are 
detailed in Figure 6.9 below.
/
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I | LUC p-789-LUC
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Figure 6.9 Constructs of the human ADAMTS-4 promoter. The ADAMTS-4 
promoter (l,132bp) was inserted into a luciferase reporter plasmid upstream of the 
firefly luciferase gene. Deletion constructs (789bp, 506bp and 396bp) were 
constructed using restriction enzyme digestion as shown and inserted into the 
luciferase reporter plasmid. Numbers indicate positions relative to the transcription 
start site. Sites for the transcription factors AP-2, Spl, NF-1, NF-IL6 and the CCAAT 
box are also indicated. Figure adapted from Mizui et al. (2000).
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Before we could investigate the action of TGF-p on the ADAMTS-4 promoter it was 
necessary to determine that the effect of this cytokine on its expression was conserved 
in the Hep3B cell line. This was ascertained by western blot analysis. Hep3B cells 
were either treated with TGF-P or left untreated for 48hr. This time point was chosen 
following an initial time course that demonstrated inhibition at this time point. Total 
cellular protein was extracted using Laemmli buffer and the extracts subjected to 
SDS-PAGE and western blotting. Membranes were probed with an anti-ADAMTS-4 
antibody and subsequently re-probed with an antibody against a P-actin control. 
Figure 6.10 shows that, as expected, TGF-p down-regulated the protein expression of 
ADAMTS-4 in Hep3B cells, verifying the use of this cell line as a feasible model for 
studying the action of TGF-P on the ADAMTS-4 promoter.
48hr
+TGF-P
ADAMTS-4
(3-actin
□  Untreated 
■  +TGF-P
Fieure 6.10 ADAMTS-4 protein expression is inhibited by TGF-p in Hep3B 
cells. Confluent Hep3B cells were treated with TGF-p or left untreated for 48hr and 
harvested for protein extraction. Extracts were subjected to SDS-PAGE and western 
blotting using antibodies specific to ADAMTS-4 and P-actin. The relative expression 
(mean± SD) of ADAMTS-4 normalised to RPL13A (values from untreated samples 
arbitrarily assigned as 1) from three independent experiments is shown (*P<0.05).
275
CHAPTER 6: Investigations into the regulation of ADAMTS-4 by TGF-P
Initially, the action of TGF-P on the full length (l,132bp) ADAMTS-4 promoter was 
examined. Hep3B cells were cultured in 12-well plates until they reached 
approximately 70% confluency when transfection was carried out. Prior to 
transfection the medium was replaced with fresh complete DMEM. The transfection 
mix was prepared as described in Section 2.5.1 with the Superfect™ and DNA added 
in a ratio of 3:1. Varying amounts of the p-1,132-LUC construct were used to identify 
if the response would occur in a concentration-dependent manner. The complete 
transfection mix was added to Hep3B cells and cells were left untreated or treated 
with TGF-P, 30min after transfection. Cells were incubated overnight and then 
harvested using lx passive lysis buffer as described in Section 2.5.2. Relative 
luciferase activity (RLA) readings were normalised to protein concentration rather 
than to another internal control plasmid (such as CMV-P-galactosidase) as previous 
studies have shown that many such control plasmids are themselves affected by 
cytokines. Figure 6.11 shows that the promoter activity of ADAMTS-4 was 
significantly inhibited by TGF-P at all concentrations of promoter construct used.
1.2
□  Untreated
lug 2ug 3ug
Figure 6.11 Effect of TGF-p on the prom oter activity of ADAMTS-4. Hep3B 
cells were transfected with the ADAMTS-4 (l,132bp) promoter plasmid using 
Superfect™ as described in Section 2.6.2. Cells were either left untreated or treated 
with TGF-P overnight. Cells were harvested using lx passive lysis buffer (Section 
2.5.2) and measured for luciferase activity. Relative luciferase activity (RLA) 
readings were normalised to protein concentration as determined by the BCA protein 
assay (Section 2.7.4). The relative luciferase activity (mean ±SD) of ADAMTS-4 
normalised to protein concentration (values from untreated samples arbitrarily 
assigned as 1) from three independent experiments is shown (**P<0.01, ***P<0.001).
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6.3.6 Identifying th e  minimal prom oter region of ADAMTS-4 that is necessary for 
TGF-p action
In order to try and identify the minimal region of the ADAMTS-4 promoter that 
contains the TGF-p response elements necessary for the action of TGF-P on 
ADAMTS-4, deletion constructs of the promoter were used as detailed in Figure 6.8 
above. Transfection was carried out as described previously. Figure 6.12 shows that 
when cells were transfected with the p-789-LUC and the p-506-LUC deletion 
constructs, a significant reduction in the relative luciferase activity was observed. No 
significant reduction in relative luciferase activity occurred following transfection of 
the p-396-LUC deletion construct, suggesting that the minimal promoter region 
containing the necessary TGF-p response elements is between -396 and -506.
1.4
£  1.2
1 1.0 u 8X 0.8
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Figure 6.12 Effect of TGF-p on the luciferase activity of deletion constructs of 
the ADAMTS-4 promoter. Hep3B cells were transfected with the deletion 
constructs of the ADAMTS-4 promoter (see Figure 6.7) using Superfect™ as 
described in Section 2.6.2. Cells were either left untreated or treated with TGF-P 
overnight. Cells were harvested and measured for luciferase activity. Relative 
luciferase activity (RLA) readings were normalised to protein concentration as 
determined by the BCA protein assay. The relative luciferase activity (mean ±SD) of 
ADAMTS-4 normalised to protein concentration (values from untreated samples 
arbitrarily assigned as 1) from three independent experiments is shown (***P<0.001, 
*P<0.05, NS-not significant).
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6.3.7 Analysis of DNA: protein interactions with the minimal ADAMTS-4 
promoter region
Cytokine-regulated gene expression is mediated through the interaction of 
transcription factors with both regulatory parts of the promoter sequence and other 
transcription factors. It was therefore important to study the interaction of proteins 
with this DNA sequence using EMSA. Further studies could then focus on the region 
of the promoter that interacted with DNA-binding proteins, with particular emphasis 
on those whose binding was regulated by TGF-p, with a view to identifying any 
transcription factors involved with the TGF-P response on ADAMTS-4. This strategy 
had previously been successfully carried out in the laboratory for studies on the 
minimal regulatory regions of the LPL promoter required for the inhibitory action of 
IFN-y and TGF-p (Hughes et al. 2002; Irvine et al. 2005). The sequence of the 
ADAMTS-4 promoter region was taken from Mizui et al. 2000 and identified using 
the NCBI Entrez Nucleotide database (accession number AB039835).
To design suitable oligonucleotides for analysis, it was necessary to identify any 
potentially important transcription factors present within the ADAMTS-4 promoter 
region (-506 to -396). To do this a scan of the sequence was undertaken using 
software that identifies binding sites for transcription factors. The sequence was 
submitted to four different sources of freely available software; SignalScan 
(Prestridge 1991), Transcription element search system (TESS) (Schug 2003), 
TFSearch (Heinemeyer et al. 1998) and Matlnspector by Genomatix (Cartharius et al. 
2005) and the results used to produce a map of transcription factor binding sites 
within the region (see Appendix IV). Key binding sites o f interest were identified and 
oligonucleotides were designed so that these sites were not disrupted (Figure 6.13). 
The sequences of the four overlapping double-stranded oligonucleotides that spanned 
the -506/-396 region (-502/-463; -464/-439; -443/-423; -423/-390) are shown in Table 
2.13. Oligonucleotides were designed with 5’ overhangs containing a G residue to 
allow for radiolabelling using [a-32P]-dCTP available in the School. EMSA was 
carried out to determine if any increase or decrease in DNA:protein binding was 
observed after incubation of the cells with TGF-p.
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Figure 6.13 The -510 to -390 region of the human ADAMTS-4 promoter. Key transcription factor binding sites were identified using 
TESS and Matlnspector software (see Appendix II). Binding sites of interest have been marked along with the oligonucleotides used for 
EMSA. Oligonucleotides were designed so that key TF binding sites were not disrupted and contained a 5’overhang containing at least one 
G residue to allow radiolabelling using [a-32P]-dCTP.
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Nuclear extracts were prepared from untreated and TGF-p treated Hep3B cells as 
described in Section 2.7.3 and harvested at the 48hr time point. Oligonucleotides 
were annealed and radiolabelled as described in Section 2.8.1. Nuclear extracts (2pg) 
were added to the radiolabelled probe in a DNArprotein binding reaction (Section 
2.8.2) before being resolved on a non-denaturing polyacrylamide gel (Section 2.8.4). 
The gel was exposed to X-ray film for varying time periods.
Figure 6.14 shows that TGF-p treatment induced the formation o f 6 DNA:protein 
complexes within the -502/-463 promoter region. The 6 complexes were present in 
untreated nuclear extracts but induced (albeit at varying levels) by TGF-p. Five 
DNA:protein complexes were produced with the -423/-390 promoter region and of 
these, TGF-p induced the formation o f 2 DNA: protein complexes. Regions -464/- 
439, and -443/-423, presented with 5 and 3 DNA: protein complexes respectively and 
none showed any increase in binding following treatment o f the cells with TGF-p. 
Within the -464/-439 region, complexes (B) and (C) presented in untreated samples 
displayed a small decrease in binding following TGF-p treatment in all three 
experiments although faint signals make it difficult to determine if  this is a 
reproducible change. In summary, the -502/-463 and -423/-390 promoter regions 
showed increases in DNA:protein binding following TGF-p treatment suggesting that 
these promoter regions are most likely to be involved in the regulation o f ADAMTS-4 
by TGF-P in Hep3B cells. In contrast the -464/-439 and -443/-423 regions showed no 
changes in protein binding. This data is summarised in Table 6.1.
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-502/-463 -464M39 -443M23 -423/-390
+TGF-P +TGF- +TGF-3
£lRure 6«14 Effect ot TGF-p on protein binding to the minimal ADAMTS-4 promoter region. Hep3B cells were treated with TGF-P or 
left untreated for 48hr. Nuclear extracts were used for EMSA. Nuclear extracts (2pg) were added to the radiolabelled oligonucleotide (Oligo 
1, 2, 3 or 4) in a DNA: binding reaction before being resolved on a 6% non-denaturing polyacrylamide gel. Complexes were visualised by 
autoradiography. Images shown are representative of three independent experiments (-502/-463: Oligo 1; -464/-439: Oligo 2; -443/-423: 
Oligo 3 ;-423/-390: Oligo 4).
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The specificity of the DNA:protein binding reaction was next investigated by 
competition EMSA analysis. This would also allow us to see whether common 
factors bound to different oligonucleotides. Nuclear extracts (2pg) were incubated 
with a 250-fold excess o f an unlabelled competing oligonucleotide for 20min prior to 
the protein binding reaction. TGF-P treated extracts were used for the analysis. 
Figures 6.15 shows that an excess of oligonucleotides was able to compete out protein 
binding to the corresponding oligonucleotide sequence. For the -502/-463 region 
(corresponding to oligonucleotide 1), an excess o f unlabelled oligonucleotide 1 
competed out DNA: protein complexes (A), (C) and (D) while an excess of 
oligonucleotides 2 and 3 did not compete out binding at complex (A). This suggests 
that protein binding is specific. An excess o f oligonucleotide 4 also competed out 
complexes (B), (C) and (D). Taking these findings together, this suggests that binding 
at complex (A) is specific and other binding to this promoter region can be classed as 
non-specific binding or that the same transcription factors bind to more than one 
oligonucleotide. Interestingly, an excess o f oligonucleotide 2 increased the binding of 
complex (C) whilst an excess of oligonucleotide 3 did compete out one of the 
complexes (D).
Competition screens using the -464/-439 and -443/-423 promoter regions were 
included for comparative purposes (Figure 6.16). As no change in protein binding 
was observed following TGF-P treatment (Figure 6.14) it can be expected that any 
DNA:protein complexes formed will not be specific to the TGF-P response. With the 
-464/-439 region (corresponding to oligonucleotide 2) all visible complexes were 
competed out by excesses of all four oligonucleotides with the notable exception of 
complex (B) which was not competed out by an excess o f oligonucleotide 2. In 
contrast to this, binding to the -443/-423 region (corresponding to oligonucleotide 3) 
was competed out by an excess of oligonucleotide 3 but not by the other 
oligonucleotides. This suggests that there is some specific binding to the -443/-423 
region. As there was no visible change in DNA: protein binding following TGF-p 
treatment, it is possible that any DNA: protein complexes within this region are due to 
proteins involved in constitutive ADAMTS-4 expression whose trans-activation 
potential is inhibited by TGF-p or that are part of the transcriptional machinery.
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For the -423/-390 region (corresponding to oligonucleotide 4), complexes (A), (B), 
(C) and (D) were all competed out by an excess of oligonucleotide 4. This was not 
seen with an excess of other oligonucleotides suggesting that binding in this region is 
specific. Interestingly, competition EMSA using oligonucleotide 1 and 
oligonucleotide 2 did decrease complexes (A) and (B) but competition with 
oligonucleotide 2 and oligonucleotide 3 resulted in an increase in complex (C). Taken 
together with the data presented in Figure 6.14, analysis by EMSA indicates that it is 
the -502 to -463 (Oligo 1) region and the -423 to -390 (Oligo 4) region that are most 
likely to be involved in the inhibitory action of TGF-p on ADAMTS-4. This data is 
summarised in Table 6.1.
_________________ -502/-463__________________________    -4647-439_
NC Oligo 1 Oligo 2 Oligo 3 Oligo 4 NC Oligo 2 Oligo 1 Oligo 3 Oligo 4
Figure 6.15 Competition EMSA analysis of the DNA:protein complexes 
produced in response to TGF-p. Competition EMSA was carried out by adding a 
250-fold excess of unlabelled competing oligonucleotides to the DNA:protein binding 
reaction prior to addition of the radiolabelled probe for oligonucleotide 1 (-502/-463) 
or oligonucleotide 2 (-463/-439). EMSA analysis was carried out as described in 
Figure 6.14 and complexes visualised by autoradiography. Images shown are 
representative of three independent experiments.
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-443Z-423__________________  -423/-390
NC Oligo 3 Oligo 1 Oligo 2 Oligo 4 NC Oligo 4 Oligo 1 Oligo 2 Oligo 3
Figure 6.16 Competition EMSA analysis of the DNA:protein complexes 
produced in response to TGF-p. Competition EMSA was carried out by adding a 
250-fold excess of unlabelled competing oligonucleotides to the DNA:protein binding 
reaction prior to addition of the radiolabelled probe for oligonucleotide 3 (-443/-423) 
or oligonucleotide 4 (-423/-390). EMSA analysis was carried out as described in 
Figure 6.14 and complexes visualised by autoradiography. Images shown are 
representative of three independent experiments.
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Table 6.1 Summary Table of EMSA data
Promoter
Region
Number of 
DNA:protein 
complexes 
present
Increase in 
protein 
binding 
following 
TGF-p 
treatment?
Number of 
DNA:protein 
complexes 
induced
Specific
binding
to
promoter
region?
Complexes
induced
following
TGF-p
treatment
-502/-463 6 Yes 6 Yes A
-464/-439 5 No - No -
-443/-423 3 No - Yes A, B
-423/-390 5 Yes 2 Yes C, D
6.3.8 Identification of key transcription factors present in minimal ADAMTS-4 
prom oter region
In order to decipher the mechanism behind the action of TGF-0, it was important to 
try and identify any transcription factors involved in the response. As previous data 
(Figures 6.14, 6.15 and 6.16) had indicated that regions -502/-463 and -423/-390 were 
most likely to be involved in this response it was necessary to identify key 
transcription factors present in these regions. A screen of competing oligonucleotides 
was carried out using oligonucleotides specifying for binding sequences of 
transcription factors that were available in the laboratory and shown previously to be 
involved in TGF-P responses. Competition EMSA was carried out as described 
previously. The results are shown in Figure 6.17. Specific oligonucleotides 
corresponding to the binding sequences of the transcription factors NF-1, API, Spl 
and C/EBPa were used. For the -502/-463 region competition with NF-1 had the 
most effect whilst for the -423/-390 region competition with API had the most effect. 
However none of the competing oligonucleotides investigated were able to fully 
compete out all complexes. More work is therefore required to determine the 
involvement of transcription factors in the TGF-P response.
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-502/-463 -423/-390
NC NF-1 AP-1 Spl xC/EBP NC NF-1 AP-1 Spl xC/EBP
Figure 6.17 EMSA screen for competing Oligonucleotides for DNA:protein 
complexes produced in response to TGF-p. Competition EMSA analysis was 
carried out as described in Figure 6.13 but in place of competing ADAMTS-4 
oligonucleotides, specific oligonucleotides coding for the transcription factors NF-1, 
AP-1, Spl, and C/EBP were used in a 250-fold excess. Images shown are 
representative of two independent experiments.
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6.3.9 The role of the transcription factor binding sites in the TGF-p response
In light of the results presented in the previous section, the importance of the 
identified promoter regions to the suppression of ADAMTS-4 promoter activity was 
investigated. This was done by testing the ability of the oligonucleotides to confer the 
TGF-P response to a heterologous SV40 promoter present in the pGL2 promoter 
vector. The pGL2 promoter vector contains a multiple cloning region upstream of the 
SV40 promoter and luciferase gene allowing the luciferase activity in cells transfected 
with the plasmid to be analysed (see Appendix II for plasmid map). Oligonucleotides 
spanning the -506 to -396 ADAMTS-4 promoter region were designed so that they 
contained part of the ADAMTS-4 promoter flanked by an overhang coding for a cut 
Xmal restriction site or a cut Xhol restriction site at the 5’ end to produce cohesive 
ends to allow their direct cloning into the pGL2 promoter vector as described in 
Sections 2.4.10 and 2.4.11. Table 2.8 shows the oligonucleotide sequences used for 
cloning. Unfortunately due to difficulties with cloning and time restrictions this work 
was not able to be carried out in full. Several attempts were made but no positive 
clones were isolated. This will be an important area of future research into the 
regulation of ADAMTS-4 by TGF-p and will allow the identification of key 
transcription factors involved in this response.
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6.4 Discussion
Macrophages are a major source o f proteases in the atherosclerotic plaque. Plaques 
that are prone to rupture have high levels of macrophages, macrophage-derived foam 
cells and MMPs (Galis et al. 1995; Raines 2000). Activation of macrophages and 
subsequent release of proteases, such as MMPs and other proteases, including the 
ADAMTS proteases, is likely to lead to destabilisation of the plaque and subsequent 
acute coronary events (Loftus et al. 2002; Newby 2007). However, very little is 
known about the role or regulation of the ADAMTS proteases in relation to 
atherosclerosis. ADAMTS-4 has been shown to colocalise with macrophages in 
atherosclerotic lesions and cleaves the primary vascular proteoglycan versican (Porter 
et al.2005; Wagsater et al. 2008). It was therefore o f interest to study the expression 
of macrophage ADAMTS-4 as a protease recently identified to be expressed in 
atherosclerotic lesions. Studies into the cytokine regulation of ADAMTS-4 will help 
to further understanding about the role of the ADAMTS proteases in relation to 
inflammation and atherosclerosis and may lead to potential therapeutic targets for 
treatment o f inflammatory diseases.
The studies presented in this chapter demonstrate that the expression of ADAMTS-4 
(at both the mRNA and protein level) is down-regulated by TGF-p in the THP-1 cell 
line (Figure 6.3 and 6.4A). This is a novel finding as to our knowledge there are no 
published studies detailing the regulation of ADAMTS-4 by TGF-p in a macrophage­
like cell line. A negative action of TGF-P on the expression of ADAMTS-4 in the 
THP-1 cell line correlates well with one of the few studies carried out on the 
regulation of ADAMTS proteases in THP-1 cells which showed that pro- 
inflammatory cytokines could up-regulate the expression of a number o f ADAMTS 
proteases (Wagsater et al. 2008). These authors studied the expression of ADAMTS- 
1, -4, -7, -8, and -9 in differentiated THP-1 cells and demonstrated that following 
treatment with IFN-y or TNF-a, ADAMTS-4, -7, -8 and -9 showed enhanced mRNA 
expression. Induced levels were observed after 6hr treatment with IFN-y for 
ADAMTS-4 and at later time points for the other proteases (Wagsater et al. 2008). It 
is well established that TGF-p antagonises many of the actions o f IFN-y and often has 
opposing effects on gene expression (Greenow et al. 2005; McLaren and Ramji 2009;
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Panousis et al. 2001). We have shown that the mRNA expression o f ADAMTS-4 is 
significantly reduced within lhr of TGF-p treatment and that this reduced level o f 
expression is sustained over a 24hr time course (Figure 6.5). This is the first time that 
the TGF-P-regulated expression of ADAMTS-4 has been studied over an extensive 
time course in THP-1 cells.
Consistent with our observation that TGF-p inhibits ADAMTS-4 expression, the 
cytokine has also been shown to inhibit the expression of a number of MMPs 
including MMP-1 (White et al. 2000), MMP-9 (Ogawa et al. 2004) and MMP-3 (Kerr 
et al. 1990). The promoters of MMP-1, MMP-3 and MMP-9 contain a TGF-p 
inhibitory element (TIE). In MMP-3 this is able to bind to AP-1 while in MMP-9 
deletion of the TIE has no effect on MMP-9 expression but deletion constructs o f the 
promoter suggest that NFkB is essential for the TGF-P regulated expression o f this 
metalloprotease (Kerr et al. 1990; Ogawa et al. 2004)
Interestingly, the study by Wagsater et al. (2008) showed that the expression of 
ADAMTS-1 remained unchanged in response to IFNy and TNFa treatment suggesting 
that ADAMTS proteases can be differentially regulated, perhaps in a cell-type 
specific manner. This may be the case for ADAMTS-4. In contrast to the down- 
regulation by TGF-P observed in macrophages, ADAMTS-4 expression can be up- 
regulated by TGF-p in articular chondrocytes, human synoviates and also in prostate 
cells (Cross et al. 2005; Moulharat et al. 2004; Yamanishi et al. 2002). It is also 
possible that functional redundancy exists between the ADAMTS proteases. A 
number of ADAMTS proteases have been shown to be present within atherosclerotic 
lesions. However, only ADAMTS-4 has been demonstrated to colocalise with 
macrophages of lesions (Wagsater et al. 2008).
Differentiated THP-1 cells share many o f the same characteristics and properties as 
human monocyte-derived macrophages. ADAMTS-4 and ADAMTS-8 are 
upregulated following differentiation of THP-1 monocytes and human monocyte- 
derived macrophages (Worley et al. 2003; Wagsater et al. 2008). We show here that 
the regulatory action of TGF-p on ADAMTS-4 is conserved between THP-1 cells and 
primary human monocyte-derived macrophages (Figure 6.4B). Taken together with
289
CHAPTER 6: Investigations into the regulation of ADAMTS-4 by TGF-P
the data o f Wagsater et al. (2008) these data suggest that ADAMTS-4 may play a pro- 
inflammatory role in relation to atherosclerosis.
The ability of the protease to cleave the proteoglycan versican is likely to be key to its 
actions in atherosclerosis. Versican is the primary proteoglycan component of the 
ECM that surrounds VSMCs. In normal physiological situations the ECM prevents 
migration of VSMCS into the arterial intima. In atherosclerosis however, degradation 
of the ECM by proteases results in the migration of VSMCs into the intima (Lusis et 
al. 2004; Raines 2000). It is possible that during the early stages of the disease the 
action of TGF-P on ADAMTS-4 that we have observed in THP-1 macrophages is 
anti-atherogenic as reduced levels of the ADAMTS-4 protease may prevent versican 
cleavage and subsequent ECM breakdown and VSMC migration into the arterial 
intima. ADAMTS-7 has been demonstrated to facilitate the migration o f VSMCs and 
intimal thickening in a rat vascular balloon-injury model and this is thought to be 
mediated by the breakdown of cartilage oligo matrix protein (COMP) by the protease 
(Wang et al. 2009).
In the later stages of atherosclerosis the production of ECM by VSMCs is important 
for the formation o f a stable plaque to prevent rupture (Lusis et al. 2004). TGF-P is 
known to promote a stable ECM-rich plaque phenotype and may achieve this partly 
through inhibition of ADAMTS-4 expression. The cytokine increases deposition of 
proteoglycans and collagen to promote a stable plaque and has been shown to 
stimulate the synthesis of collagens type I and III in human arterial SMCs and 
increase versican mRNA expression in monkey arterial SMCs (Schmidt et al. 2006). 
The synthesis and secretion of certain proteases including plasminogen activator and 
collagenase are inhibited by TGF-p (Kahari et al. 1991) and the synthesis o f TIMP-3 
(an inhibitor of ADAMTS-4 expression) is induced by TGF-P in cartilage and also in 
rabbit aortic SMCs (Fabunmi et al. 1996; Qureshi et al. 2008).
The action of ADAMTS-4 on versican may also contribute to lesion regression or 
growth during atherosclerosis. Intimal tissue regression following balloon- or stent- 
mediated injury has been shown to be associated with increased blood flow and loss 
of versican (Kenagy et al. 2005). In a baboon vascular graft model high blood flow 
causes cell death and loss of ECM. This is accompanied by an increase of a versican
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cleavage product that can be generated by the ADAMTS proteases -1, -4, -5 and -9 
(Kenagy et al. 2005). Kenagy and colleagues measured the mRNA levels of 
ADAMTS proteases in this graft model and found that levels o f ADAMTS-4 were 
significantly increased following a switch to high blood flow and that this was linked 
with tissue atrophy (Kenagy et al. 2005; Kenagy et al. 2009).
In addition to characterising the response of ADAMTS-4 to TGF-P we also used 
siRNA technology with the aim of determining which of the TGF-P signalling 
pathways played a role in mediating this response in THP-1 cells. The Smads are the 
classical transducers of the TGF-P signal and are expressed in macrophages and foam 
cells of atherosclerotic lesions (Kalinina et al. 2004). Data presented in Chapter 4 of 
this thesis suggests that this pathway plays a critical role in the regulation of 
expression of genes implicated in foam cell formation and atherosclerosis by TGF-p. 
We therefore wanted to see if this was the case with the regulation o f ADAMTS-4. 
Our findings indicate that the Smad pathway may be involved in the action o f TGF-p 
on ADAMTS-4. The Smad pathway has been demonstrated to be involved in the 
TGF-P-regulated induction of TIMP-3 (a negative regulator o f ADAMTS-4 
expression) in chondrocytes. Qureshi and colleagues showed that pharmacological 
and siRNA-mediated inhibition of Smad-2 and Smad-3 resulted in the inhibition of 
TIMP-3 induction by TGF-P (Qureshi et al. 2008).
Following siRNA-mediated knockdown of Smad-2 and Smad-3 the TGF-P-mediated 
inhibition of ADAMTS-4 mRNA expression was no longer significant (Figure 6.7A 
and 6.7B). It is interesting to note that knockdown of Smad-3 produces a more potent 
change on the ADAMTS-4 response than knockdown of Smad-2 although again, this 
is likely to be due to different levels of knockdown and is likely to be affected by the 
unspecific nature of Smad-2 versus Smad-3 knockdown using siRNA. Knockdown of 
both Smad-2 and -3 also showed a reversal of TGF-p-mediated inhibition that was 
akin to that seen with Smad-3 knockdown (Figure 6.7C). Smad-3 has been implicated 
in the repression of a number of genes including MCP-1 and the scavenger receptors 
CD36 and CD 163 as discussed in more detail in Chapter 4 (Feinberg et al. 2004a; Fu 
et al. 2003; Pioli et al. 2004). An involvement o f Smad-3 in the repression o f VSMC 
activation and macrophage activation has also been identified (Feinberg et al. 2004b; 
Wemer et al. 2000). This finding is also consistent with the data presented in Chapter
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4 of this thesis that suggests that Smad-3 is the key player in the repression o f LPL, 
CD36 and SR-B1 by TGF-p. It is possible that a conserved mechanism for negative 
regulation of gene expression by the cytokine may exist in THP-1 cells and that 
ADAMTS-4 is regulated in this manner.
As TGF-P can signal through Smad-independent pathways the effect o f MAPK 
knockdown on the expression of ADAMTS-4 was also investigated. Both siRNA- 
mediated knockdown of c-Jun and p38 kinase resulted in increased levels o f 
ADAMTS-4 expression in TGF-P treated cells as compared to knockdown of the 
control gene GAPDH (Figure 6.8A and 6.8B). This suggests that in addition to the 
Smad pathway, these pathways may also contribute to the TGF-P-regulated 
expression of ADAMTS-4. Whether these pathways act independently or in 
conjunction with the classical Smad pathway is unclear. The TGF-p-mediated 
induction of TIMP-1 expression and inhibition of MMP-1 expression has been shown 
to be dependent on the AP-1 sites found within their promoters (Hall et al. 2003). 
TIMP-1 induction requires JunD, c-fos and c-Jun but is Smad independent while the 
AP-1 site of MMP-1 is able to interact with Smads to mediate the TGF-p-regulated 
expression (Hall et al. 2003).
Various studies have suggested that crosstalk between the Smad pathway and the p38 
MAPK pathway mediates the TGF-P regulation of MMP expression. For example, 
the induction of MMP-13 expression by TGF-p in human gingival fibroblasts is 
dependent on p38 kinase activity (Ravanti et al. 1999). Adenoviral-mediated gene 
delivery of Smads has shown that Smad-3 augments this induction and that delivery 
of a dominant-negative Smad-3 blocks the induction of MMP-13 by TGF-p and p38 
kinase. Nuclear translocation of Smad-3 was also induced by p38 kinase activation 
suggesting that crosstalk between the two pathways is responsible for the TGF-p- 
mediated induction of MMP-13 (Leivonen et al. 2002). Interestingly sites for AP-1 
are present within both the -502/-463 and -423/-390 promoter regions o f ADAMTS-4 
(Figure 6.13). No Smad binding elements were identified suggesting that Smads are 
likely to mediate the TGF-P response through interactions with other proteins or 
transcription factors.
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Following the identification o f TGF-P signalling pathways that are likely to be 
involved in the inhibition of ADAMTS-4 expression, we wanted to identify the 
regulatory region of the ADAMTS-4 promoter involved in this response. Although 
many of the ADAMTS proteases have now been cloned and characterised only the 
promoters of ADAMTS-4 and ADAMTS-5 have been investigated. A study by 
Thirunavukkarasu and colleagues found that the ADAMTS-4 promoter contains 
consensus binding sites for the nuclear factor o f activated T-cells (NFAT) 
transcription factors that are identical to those found in the regulatory regions of 
cytokine genes (including EFNy and TNFa) expressed by T-lymphocytes. 
Overexpression of NFAT can enhance ADAMTS-4 promoter activity suggesting that 
transactivation by NFAT can take place (Thirunavukkarasu et al. 2006). Other 
binding sites of interest identified in this study included PEA3 binding sites, also 
found in the promoters of MMPs, and a site for NF-IL6 (Mizui et al. 2000).
Mizui et al (2000) have identified the -383 to +10 region of the ADAMTS-4 promoter 
as the region required for full promoter activity. This region contains one site for Spl 
and three sites for AP2. Studies of the promoter activity o f various deletion constructs 
by the group also suggested that the region between -726 and -384 is likely to contain 
silencer elements. The presence of an NF-1 site within this region suggests that this 
site may be involved in negative regulation of the ADAMTS-4 promoter; deletion of 
the NF-1 site did result in a recovery of promoter activity. NF-1 transcription factors 
have been shown to negatively regulate the transcription o f a number of genes 
including the growth arrest and DNA damage inducible gene 153 (gaddl53) in 
vascular smooth muscle cells and von-Willibrand factor in endothelial cells (Jahroudi 
et al. 1996; Nakamura et al. 2001).
We show here that ADAMTS-4 promoter activity is suppressed by TGF-P treatment 
(Figure 6.11). Transient transfection of ADAMTS-4 promoter deletion constructs 
demonstrates a potential involvement for the -506/-396 region in the negative 
regulation of the ADAMTS-4 promoter by TGF-P (Figure 6.12). This is consistent 
with the findings of Mizui et al. (2000) as these regions fall within the promoter 
region identified as likely to be involved in negative regulation of the ADAMTS-4 
promoter. Further studies using EMSA analysis identified the regulatory regions 
involved in changes in DNAiprotein interactions. DNA:protein binding increased in
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response to TGF-P in the -502/-463 and -423/-390 regions of the promoter (Figure 
6.14) and competition EMSA showed that this binding was specific (Figures 6.15 and 
6.16).
Analysis of the ADAMTS-4 promoter -506/-396 region for putative Smad binding 
elements did not identify any Smad binding sites in this region of the promoter. 
However, the search did reveal putative binding sites for other transcription factors 
that could mediate the TGF-P response. Putative binding sites of interest present in 
both promoter regions identified by EMSA include sites for RXRa, Spl, c-fos, NF-1 
and Kruppel-like factor (KLF) (Figure 6.13). Of these, Spl and RXR have previously 
been shown to mediate TGF-P responses in THP-1 macrophages (Fu et al. 2003; 
Hughes et al. 2002; Irvine et al. 2005).
Spl is a zinc finger protein that binds to GC-rich sequences and is generally thought 
to act as a constitutive promoter element that supports basal transcription by recruiting 
the TATA binding protein (TBP). However, Spl sites have also been shown to be 
involved in tissue-specific gene expression and transcription controlled by a number 
of stimuli (Black et al. 2001). It is therefore possible that the ADAMTS-4 response is 
mediated by Spl. As explained in more detail in Section 3.1.2, studies in our 
laboratory have shown that Spl is involved in both the IFN-y- and TGF-p-mediated 
inhibition of LPL gene transcription in macrophages (Hughes et al. 2002; Irvine et al. 
2005). Spl has also been shown to interact with Smads however; competition EMSA 
data (Figure 6.16) suggested that Spl is not involved in the ADAMTS-4 response.
Another possibility is the TGF-p response on ADAMTS-4 is mediated through 
RXRa. RXR forms heterodimers with PPARs to exert its effects on gene expression. 
As explained in more detail in Chapter 3, PPARs have been shown to be involved in 
the TGF-p-mediated regulation of expression of a number o f genes. The induction of 
TIMP-3 and collagen by TGF-P has been shown to mediated by PPAR5 in human 
aortic smooth muscle cells (Kim et al. 2009) and the inhibition o f scavenger receptor 
CD36 expression is also mediated through PPAR and Smad-3 (Fu et al. 2003) as 
explained in Chapter 3. Interestingly Worley and colleagues have shown that the 
expression of ADAMTS-4 in THP-1 macrophages can be suppressed by both the 
PPARy agonist GW9662 and the RXR ligand 9-cis retinoic acid both individually and
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in combination (Worley et al. 2003). This suggests that regulation of constitutive 
expression of ADAMTS-4, mediated by PMA as part of the differentiation process in 
THP-1 macrophages, can be modulated by PPAR/RXR. Whether this effect extends 
to TGF-P-regulated expression of ADAMTS-4 has not been investigated.
Further work will be needed to elucidate the transcription factors involved in the 
TGF-p-mediated ADAMTS-4 response. In particular, analysis of the full-length 
ADAMTS-4 promoter could reveal binding sites for Smads or c-Jun that may 
participate in the inhibition of gene expression. Although these may not be contained 
within the minimal promoter region identified in this chapter they may become 
located close to the regulatory region following activation through folding and 
changes to the 3D structure of DNA within chromatin. Alternatively, involvement of 
Smad or p38 kinase/c-Jun may serve to enhance other transcription factors either 
indirectly or through protein:protein interactions.
In conclusion, we have characterised the regulation o f ADAMTS-4 by TGF-p in 
THP-1 macrophages and identified the signalling pathways and minimal promoter 
regulatory region involved in this as summarised in Figure 6.18. Further studies will 
be needed to elucidate the exact mechanism of ADAMTS-4 regulation by TGF-p.
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PPARy?
■506bp ADAMTS-4 promoter -396bp
Figure 6.18 Regulation of ADAMTS-4 promoter activity by TGF-p in THP-1 
macrophages. The Smad, JNK and p38 kinase pathways contribute to the inhibitory 
action of TGF-P on ADAMTS-4 as demonstrated by siRNA interference assays. 
Whether crosstalk between these pathways mediates this action is currently unclear 
(as indicated by dashed arrows). Transient transfection and EMSA analysis has 
identified the -506 to -396bp region of the ADAMTS-4 promoter as the minimal 
regulatory region for TGF-p action and other studies have shown that this region 
contains silencer elements such as the NF-1 transcription factor (Mizui et al, 2000). 
No Smad binding sites are present within this region suggesting that the Smads exert 
their effect through interaction with other transcription factors (TF) such as AP-1. 
Other transcription factors such as Spl and RXRa, binding sites which are found 
within this promoter region may be required for constitutive and/or TGF-p-regulated 
expression of ADAMTS-4.
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CHAPTER 7 
General Discussion
Atherosclerosis, the underlying cause of cardiovascular disease, is a progressive, 
inflammatory disorder modulated by cytokines at all stages. TGF-P is a key anti­
inflammatory cytokine involved in all the major stages o f disease development. 
Extensive studies have linked TGF-P with reduced development and progression of 
atherosclerosis and the cellular actions and downstream signalling events are therefore 
an attractive research area. The Smad signalling pathway has been established as the 
classical mediator of TGF-p action; however more recent studies have demonstrated 
activation of other signalling pathways by the cytokine. Despite this, many aspects of 
the molecular mechanisms underlying the regulation of gene expression by TGF-p 
remain unclear; in particular the actions of TGF-P on the expression of genes 
implicated in macrophage cholesterol homeostasis, warrants further study. The work 
detailed in this thesis has used several different approaches to delineate the molecular 
mechanisms underlying TGF-P-regulation o f gene expression. The majority of this 
work has been carried out in macrophages as these cells have a central role in the 
pathology of atherosclerosis and are an important target for the actions of TGF-p. 
The aim of these studies was not only to enhance understanding about TGF-P 
signalling associated with atherosclerosis but potentially identify novel therapeutic 
avenues of investigation.
CHAPTER 7: General D iscussion
7.1 Mechanisms underlying the TGF-p regulation of gene 
expression
7.1.1 TGF-p-regulation of gene expression in macrophages
Experiments based on RT-qPCR demonstrated an inhibitory effect of TGF-P on the 
mRNA expression of genes implicated in cholesterol uptake and up-regulatory effect 
on genes implicated in cholesterol efflux (Chapter 3). Expression of LPL, SR-A, SR- 
B1 and CD36 was inhibited following TGF-P treatment o f THP-1 macrophages and 
remained at low levels over a 24hr time course. Treatment with TGF-p resulted in the 
up-regulation of ApoE, ABCA-1 and ABCG-1 mRNA expression. Effects of the 
cytokine were substantiated at the protein level using Western blot analysis. An 
optimal time point for regulation by TGF-p in the THP-1 macrophage cell line was 
established by these studies to provide a foundation for further studies on the 
regulation of these chosen genes. In addition, these data demonstrated that the TGF- 
P-regulation of gene expression in THP-1 macrophages was consistent with literature 
on their regulation in murine macrophage cell lines and in vivo models as detailed in 
Chapter 3.
7.1.2 Roles of the Smad pathway in TGF-P-regulated gene expression
TGF-P markedly and rapidly induced the phosphorylation (and activation) of Smad-2 
and Smad-3 in THP-1 macrophages (Chapter 4). This finding was extended to 
primary human monocyte-derived macrophages and suggested that the Smad 
signalling pathway was active in macrophages, consistent with a study showing that 
active Smad signalling is present in atherosclerotic lesions (Kalinina et al., 2004). 
The rapid kinetics of activation suggested that Smad phosphorylation is mediated 
through direct binding of TGF-P to its cognate receptors directly leading to Smad 
recruitment and activation.
Knockdown of Smad-2 and Smad-3 expression was achieved using siRNA 
transfection-based assays. Significant knockdown of Smad-2 and Smad-3 in THP-1 
macrophages both singularly and together was demonstrated at the protein level using 
Western blotting. The use of siRNA combined with RT-qPCR and Western blotting 
revealed that the Smad pathway played a crucial role in the TGF-p regulation of
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expression o f LPL, SR-A, SR-B1 and CD36 and also in the TGF-P regulation o f  
ApoE, ABCA-1 and ABCG-1 (Chapter 4). Knockdown of Smad-2 and -3 attenuated 
the TGF-P-induced expression of ApoE, ABCA-1 and ABCG-1 (with significant 
reductions in TGF-p-mediated expression levels observed for ApoE and ABCA-1). 
Smad-2 and -3 knockdown also produced a substantial attenuation o f TGF-P-mediated 
inhibition o f LPL, SR-A, SR-B1 and CD36 expression. It is difficult to determine the 
exact contribution o f Smad-2 and Smad-3 to the regulation of gene expression for a 
number o f reasons including differences in levels of knockdown using siRNA, and 
possible involvement o f compensatory and regulatory mechanisms. However, the 
data undoubtedly demonstrates a crucial role for the Smad pathway in the TGF-p- 
regulation o f gene expression in macrophages.
In addition, analysis o f constitutive gene expression suggested roles for the Smads in 
the basal expression o f SR-B1 and CD36 (Chapter 4). It is unclear how genes whose 
basal expression requires Smads are then differentially regulated by TGF-p through 
the Smad proteins, however, Smads may be a required part o f the differentiation 
programme of THP-1 cells using PMA. Their expression is increased following 
monocyte-macrophage differentiation (Kalinina et al., 2004) and Smads are required 
for monocytic differentiation o f myeloid leukemia cells by synthetic triterpenoids (Ji 
et al., 2006).
These studies were subsequently extended to primary macrophages using adenovirus- 
mediated delivery of Smad-2 shRNA (Chapter 4). Together, these studies suggest 
that TGF-P regulation of gene expression associated with macrophage cholesterol 
homeostasis is mediated through the Smad signalling pathway, specifically through 
phosphorylation and activation of Smad-2 and Smad-3 in macrophages. This is 
consistent with a study demonstrating direct involvement for Smad-3 in TGF-p- 
inhibited expression of the scavenger receptor CD 163 (Pioli et al., 2004) which has 
been linked with foam cell formation in atherosclerosis. Our findings are also 
consistent with a number of studies that have suggested an involvement for Smads in 
TGF-p-regulated gene expression in macrophages (Al-Salleeh and Petro, 2008; Fu et 
al., 2003; Werner et al., 2000) as detailed in Chapter 4.
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7.1.3 Roles of the MAPK pathways in TGF-f3-regulated gene expression
TGF-P was also able to induce the phosphorylation of the MAPKs, ERK 1/2 (p44/42), 
JNK and p38 kinase in THP-1 macrophages (Chapter 5). This induction in 
phosphorylation translated to an increase in activity as measured by increased 
phosphorylation levels o f downstream transcription factors targets Elk-1 and c-Jun 
through non-radioactive kinase activity assays. These findings were extended to 
primary human monocyte-derived macrophages and suggested that MAPKs are 
activated by TGF-p in macrophages. The slow kinetics of this activation suggest that 
although it is possible that the MAPKs can be activated by the cytokine through a 
direct route, activation is likely to be mediated by activation of other signalling 
mediators such as the Smad proteins or other signalling molecules or transcription 
factors. Although some downstream actions o f TGF-P in macrophages have been 
shown to be mediated in part by the MAPKs (see Chapter 5), specific activation o f the 
pathways had not previously been demonstrated in THP-1 macrophages.
Knockdown o f individual MAPK expression (ERK 1/2, c-Jun, p38 kinase) using 
siRNA transfection o f THP-1 macrophages revealed roles for c-Jun and p38 kinase in 
the TGF-P-regulated expression o f LPL, SR-A, SR-B1, CD36, ABCA-1 and ABCG-1 
(Chapter 5). TGF-P-mediated induction o f ABCA-1 and ABCG-1 was reduced 
following knockdown of either p38 kinase or c-Jun. TGF-p-mediated inhibition of 
LPL, SR-A, SR-B1 and CD36 was attenuated following knockdown of either p38 
kinase or c-Jun. A role for ERK 1/2 in the expression o f ABCA-1, ABCG-1 and 
CD36 was also demonstrated. This is consistent with studies linking an increase in 
ERK activity with increased CD36 expression (Han et al., 2000) but contrasts with a 
study showing that siRNA against ERK 1/2 and activation of LXR increased ABCA-1 
expression and activity in murine macrophages (Zhou et al., 2009). Contrasting data 
may reflect differences between murine and human macrophages, emphasising the 
necessity o f data from human macrophages in addition to data from murine cell lines 
or in vivo disease models. No involvement of the MAPKs in the TGF-P-regulated 
expression o f ApoE was demonstrated following siRNA knockdown, contrasting with 
previous studies by our laboratory using pharmacological inhibitors, and dominant- 
negative constructs in transfection assays, that had suggested a role for JNK and p38 
kinase (Singh and Ramji, 2006). This may be due to functional redundancy between
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the MAPKs/MAPK substrates. Another possibility is that the amount o f kinase 
remaining following siRNA-mediated knockdown was sufficient for the response. 
This is one limitation of the siRNA knockdown technique.
Analysis o f constitutive gene expression demonstrated a requirement for c-Jun in the 
expression o f SR-A and a requirement for p38 kinase in the expression o f SR-B1 and 
CD36 (Chapter 5). Taken together, these studies suggest that the MAPK pathways 
contribute to the TGF-P-regulation of genes associated with macrophage cholesterol 
homeostasis. Since a number o f studies have demonstrated crosstalk between Smad 
and MAPK pathways in gene regulation this may be a potential mechanism of  
regulation o f these genes (see Chapter 5). Documented interactions between Smad 
proteins and the AP-1 transcription factor complex (Dennler et al., 2000; Pessah et al., 
2002; Pessah et al., 2001) may be an important part of the mechanism o f gene 
regulation through these signalling pathways.
7.1.4 Mechanisms underlying TGF-P-regulation of LPL expression
The effect o f c-Jun siRNA-mediated knockdown on the expression o f LPL (Chapter 
5) was consistent with unpublished data from our laboratory that suggested a role for 
the JNK pathway in the TGF-p-regulated inhibition of LPL expression. Transfection 
of dominant-negative constructs of JNK pathway components in the Hep3B cell line 
resulted in a small attenuation in the TGF-p-mediated inhibition o f LPL promoter 
activity suggesting that the pathway had a role in this regulation, although some cell- 
type specific differences were observed between previous data from U937 cells and 
our data in Hep3B cells. Further studies focussed on identifying the co-factor 
involved in the TGF-p-mediated regulation o f LPL. Transfection o f siRNA targeting 
SRC-1 resulted in the attenuation o f TGF-P-regulated LPL inhibition but also 
significantly reduced the constitutive expression of LPL (Chapter 5). This suggests 
that SRC-1 has a crucial role in both the constitutive and TGF-P-regulated expression 
of LPL. One potential mechanism of LPL regulation may involve activation o f the 
JNK pathway (and subsequent activation of c-Jun/AP-1) by TGF-p which may then 
serve to mop up the limited amounts of SRC-1 co-activator required for basal LPL 
expression. Repression o f LPL by TGF-P can then take place through suppression o f  
Spl/Sp3 transactivation potential (Irvine et al., 2005). The Smad pathway may also
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contribute to this possibly through activation of JNK or through interaction with c- 
Jun/AP-1.
7.2 Characterisation of ADAMTS-4 regulation by TGF-p
The action of TGF-p on the expression of genes involved in the later stages of 
atherosclerosis is partially understood. The cytokine up-regulates the expression of 
genes encoding collagens and fibronectin and inhibits the expression o f matrix 
metalloproteinases to promote stability and prevent rupture of the atherosclerotic 
plaque (Kahari et al., 1991; Schmidt et al., 2006). The ADAMTS proteases are a 
group of secreted proteins that cleave components of the extracellular matrix, in 
particular the proteoglycans aggrecan, in cartilage, and versican, in the vasculature 
(Porter et al. 2005). A small number o f studies suggest roles for ADAMTS-1 and -4 
in atherosclerosis (see Chapter 6) and ADAMTS-4 has been shown to co-localise with 
macrophages in lesions (Wagsater et al. 2008). Relatively little is understood about 
the expression and cytokine-regulation of ADAMTS-4 in macrophages and it is 
therefore a young and rapidly developing research area and may represent a novel 
avenue of therapeutic benefit.
7.2.1 TGF-P-regulation of ADAMTS-4 expression in macrophages
RT-qPCR demonstrated that treatment of THP-1 macrophages with TGF-P resulted in 
a significant decrease in ADAMTS-4 expression (Chapter 6). A time course 
demonstrated that inhibition of ADAMTS-4 had rapid kinetics. ADAMTS-4 
expression remained low between 1 and 24hr following TGF-P treatment. Western 
blot analysis revealed that TGF-P also down-regulated levels of ADAMTS-4 protein 
expression. These findings were extended to human monocyte-derived macrophages 
and demonstrated that protein levels of ADAMTS-4 were down-regulated following 
TGF-P treatment of macrophages. Taken together, these data suggest that ADAMTS- 
4 expression is down-regulated by TGF-P in macrophages. This finding is consistent 
with the finding that IFN-y, which antagonises the actions of TGF-p, up-regulates 
ADAMTS-4 expression in the THP-1 macrophage cell line (Wagsater et al., 2008).
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The use o f siRNA against Smad-2 and Smad-3 attenuated the TGF-P-mediated 
inhibition o f ADAMTS-4 mRNA expression (Chapter 6). Further studies using 
siRNA targeting p38 kinase and c-Jun showed that following knockdown of p38 
kinase or c-Jun, the TGF-P-mediated expression o f ADAMTS-4 was no longer 
significantly inhibited. Knockdown o f p38 kinase also significantly reduced 
constitutive ADAMTS-4 expression indicative o f a role for the kinase in the basal 
expression o f ADAMTS-4. Together these studies revealed crucial roles for the Smad 
pathway in the TGF-p-mediated inhibition o f ADAMTS-4 and, in addition, suggested 
roles for p38 kinase and c-Jun. Taken together, these studies suggest that TGF-P- 
mediated inhibition o f ADAMTS-4 in macrophages is Smad-dependent but may also 
require p38 kinase and c-Jun. This is consistent with studies showing Smad 
involvement in the TGF-p-mediated induction o f TIMP-3 (a negative regulator of 
ADAMTS-4) and the requirement o f AP-1 sites within the promoter for TGF-p- 
regulated inhibition o f MMPs (Hall et al., 2003; Qureshi et al., 2008). Further studies 
would be required to elucidate the exact mechanism underlying TGF-P-regulation of 
ADAMTS-4 expression in macrophages.
Transient transfection o f a full-length promoter construct in Hep3B cells 
demonstrated that TGF-p down-regulated the promoter activity o f ADAMTS-4 
suggesting that TGF-p mediates ADAMTS-4 expression levels through effects at the 
gene promoter (Chapter 6). Further studies focussed on delineating the minimal 
sequence qjements involved in the inhibitory effect o f TGF-P on the activity of the 
ADAMTS-4 promoter. Transfection-based assays using deletion constructs o f the 
ADAMTS-4 promoter located the minimal response elements for TGF-P action to the 
. -506/-396 region. Subsequent EMSA analysis identified increased protein binding to 
the -502/-463 and -423/-390 regions o f the promoter while competition EMSA 
showed that binding to these regions was specific. Due to limited availability of 
oligonucleotides, competition EMSA using oligonucleotides encoding known 
transcription factors failed to identify the transcription factors responsible for the 
increase in protein binding to the promoter. However, these data indicate that TGF-P 
down-regulates ADAMTS-4 expression through effects on promoter activity and the 
minimal response elements for this inhibitory action are located within the -506/-396 
region o f the ADAMTS-4 promoter. This is consistent with a study that suggested
303
C H A PTER  7: General D iscussion
that the -726/-384 region contained elements involved with negative regulation of the 
promoter (Mizui et al., 2000).
In summary, the work presented in this thesis has been successful in enhancing our 
understanding o f the signalling pathways by which TGF-P regulates gene expression 
with relation to macrophage cholesterol homeostasis, in addition to the regulation of 
ADAMTS-4 by TGF-P in THP-1 macrophages. The main findings of this work are 
summarised below. The roles o f Smads and MAPKs in individual gene expression 
are outlined in Table 7.1.
1. TGF-p down-regulates the expression o f genes involved in macrophage 
cholesterol uptake (e.g. LPL, SR-A, SR-B1 and CD36) and up-regulates the 
expression o f genes involved in macrophage cholesterol efflux (e.g. ApoE, 
ABCA-1 and ABCG-1) in THP-1 macrophages.
2. The Smad signalling pathway is activated by TGF-P with rapid (within lhr) 
kinetics in THP-1 macrophages and primary human monocyte-derived 
macrophages.
3. Smad-2 and Smad-3 are crucial mediators in the regulation o f gene expression
by TGF-p in THP-1 macrophages and primary human monocyte-derived 
%
macrophages.
4. Smads are required for the constitutive expression o f SR-B1 and CD36 in 
THP-1 macrophages.
5. ERK 1/2, JNK and p38 kinase are activated by TGF-p with slow (within 24hr) 
kinetics in THP-1 macrophages and primary human monocyte-derived 
macrophages.
6. Both p38 kinase and c-Jun are important mediators in the regulation o f LPL, 
SR-A, SR-B1, CD36, ABCA-1 and ABCG-1 expression by TGF-P in THP-1 
macrophages.
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7. ERK 1/2 is an important mediator o f TGF-P-regulated expression of CD36 
ABCA-1 and ABCG-1 in THP-1 macrophages.
8. c-Jun may be required for constitutive expression o f SR-A and p38 kinase may 
be required for the constitutive expression of SR-B1 and CD36 in THP-1 
macrophages.
9. TGF-p down-regulates the mRNA and protein expression o f ADAMTS-4 in 
THP-1 macrophages with rapid kinetics (within lhr) and expression remains 
inhibited over a 24hr time course.
10. Smad-2 and -3, p38 kinase and c-Jun are important mediators of the TGF-p- 
regulated expression o f ADAMTS-4 and p38 kinase may be required for 
constitutive expression o f ADAMTS-4 in THP-1 macrophages.
11. TGF-p down-regulates the promoter activity o f ADAMTS-4 in Hep3B cells 
through minimal response elements within the -506/-396 region o f the 
ADAMTS-4 promoter and specific protein binding to two regions within this 
promoter sequence (-502/-463 and -423/-390) is increased following TGF-p 
stimulation.
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Table 7.1 Involvement of Smads and MAPKs in constitutive and TGF-p- 
regulated gene expression in THP-1 macrophages
Gene Smad-2 Smad-3 Smad-2 and -3 ERK 1/2 c-Jun p38 kinase
TGF-p-regulated gene expression
LPL Y Y Y X Y Y
SR-A X X Y X Y Y
SR-B1 Y Y Y X Y Y
CD36 ✓ Y Y Y Y Y
ApoE X X Y X X X
ABCA-1 Y ✓ Y Y Y Y
ABCG-1 Y Y Y Y Y Y
ADAMTS-4 Y Y Y X Y Y
Constitutive gene expression
LPL X X X X X X
SR-A X X X X Y X
SR-B1 Y X Y X X Y
CD36 Y Y Y X X Y
ApoE X X X X X X
ABCA-1 X X X X X X
ABCG-1 X X X X X X
ADAMTS-4 X X X X X Y
KEY: Y  Role in expression o gene x No role in expression of gene
7.3 Future work
A number o f avenues for further investigation have been highlighted by the results of 
this study. These can be split into investigations of Smads and MAPKs in the 
regulation of gene expression and cellular responses by TGF-p and the further 
characterisation of the ADAMTS-4 response to TGF-p.
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7.3.1 Future investigations into the roles of the Smad and MAPK pathways in the 
regulation of gene expression by TGF-p
Although a key step in the Smad signalling pathway involves the formation of 
complexes between either Smad-2 and Smad-4 or Smad-3 and Smad-4 for 
translocation to the nucleus, some studies have noted a variable role for Smad-4 in 
TGF-P signalling (Liu et al., 1997; Sirard et al., 2000). Extending our studies to 
determine the role o f Smad-4 is therefore important to fully understand the molecular 
mechanisms behind TGF-p-regulated gene expression and could be achieved using 
siRNA combined with RT-qPCR as for Smad-2 and -3. Studies in primary cultures of 
human monocyte-derived macrophages will be o f great importance in extending the 
findings o f our studies and determining their biological relevance. These studies 
could use adenovirus-mediated delivery of shRNA (as described in Chapter 4) against 
the Smads and MAPKs into primary macrophages. It would also be of interest to 
confirm some o f our findings using cells derived from Smad-2/Smad-3/MAPK- 
deficient mice.
To investigate the roles o f Smads and MAPKs in cellular responses, total cholesterol 
uptake and total cholesterol efflux from macrophages could be measured following 
siRNA-mediated knockdown of Smads/MAPKs. This would involve measuring 
uptake o f  radioactively labelled or fluorescent oxLDL/AcLDL, and/or efflux of 
radioactive cholesterol from foam cells to acceptors such as ApoAI (Geng and 
Hansson 19^2; Kennedy et al. 2005). Additionally, lipid accumulation could be 
measured through staining o f lipids within cells using a dye such as Oil Red O. Such 
studies would further understanding o f the roles of TGF-P signalling pathways in 
cholesterol homeostasis and foam cell formation. Use o f in vivo model systems may 
be helpful here to link changes in cellular response to pathophysiological changes 
such as changes in atherosclerotic lesion size or plaque stability. For example, an in 
vivo model o f foam cell formation can be created by interperitoneal injection of J774 
murine macrophage cells preloaded with radioactively labelled cholesterol into mice. 
This model is useful for analysing reverse cholesterol transport from macrophages 
into the plasma, liver and bile (Zhang et al., 2005; Zhang et al., 2003).
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Crosstalk between signalling pathways is relatively common in the regulation of gene 
expression, as described in Chapter 5. To further investigate this possibility with 
relation to our genes o f interest it would first be important to determine the effects of 
multiple knockdowns (Smads and individual MAPKs) on gene expression in THP-1 
cells. Another method o f investigating crosstalk between signalling pathways or 
pathway components could look at activation o f a pathway/factor of interest in cells 
where key components o f the other signalling pathways have been inhibited through 
pharmacological agents or siRNA-mediated knockdown. Interactions between Smads 
and MAPK-activated transcription factors such as AP-1 have been documented to 
regulate a number of genes (Chapter 5) and it would be important to investigate the 
activation o f such transcription factors following Smad knockdown. It is also known 
that MAPKs can have effects on the phosphorylation status o f Smads and vice versa. 
It would therefore be important to measure phosphorylated forms of the Smads and 
MAPKs following siRNA-mediated knockdown. These studies would greatly 
enhance our understanding o f the molecular mechanisms o f TGF-p-regulated gene 
expression. The use o f pull-down assays and/or co-immunoprecipitation could be 
used here to determine if any complexes are formed between Smads and 
MAPKs/MAPK-activated transcription factors (Brown et al. 1999; Funaba et al. 2002; 
Quinn et al. 2001). An important consideration for these studies, particularly in terms 
of the requirement o f Smads and/or MAPKs in constitutive gene expression, would be 
the levels o f negative regulators o f Smad and MAPK pathways such as inhibitory 
Smads, MAPK phosphatases and co-repressors and how these may be affected
m
through activation o f transcription factors by TGF-p signalling.
Of additional interest would be the investigation of promoter activity in cells with 
reduced or abolished Smad/MAPK expression. EMSA and promoter analysis could 
be used with the aim of identifying transcription factors/binding elements involved in 
TGF-p-regulated expression o f each gene. Analysis of promoter sequences for 
transcription factor binding sites (see Chapter 6) would support these investigations 
and allow the exact mechanism by which TGF-P signalling regulates the expression of 
each gene.
One factor likely to play a role in TGF-P-regulated expression of our genes of interest 
either directly or indirectly is PPARy. The factor has been linked with each of the
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genes studied in this thesis, as explained in detail in Chapter 3. It would therefore be 
of significant importance to study its role in the TGF-(3-regulation of these genes and 
its interactions/links with Smads and MAPKs using the techniques described above. 
Expression o f PPARy could be analysed using Western blot or RT-qPCR analysis 
following knockdown o f Smads and/or MAPKs using pharmacological agents or 
siRNA while interactions with Smad/MAPK binding elements within the promoter of 
the gene o f interest and with Smad and MAPK-activated transcription factors could 
also be an avenue for further investigation.
7.3.2 Future investigations into the regulation of ADAMTS-4 by TGF-P
Incomplete characterisation o f TGF-(3-mediated regulation o f ADAMTS-4 promoter 
activity and expression necessitates further studies into this regulation. Expansion of 
competition EMSA data using oligonucleotides encoding the binding sequences of 
transcription factors o f interest (i.e. those present within the minimal promoter 
response region) would be an initial step towards identifying the factors responsible 
for negative regulation o f ADAMTS-4 promoter activity by TGF-p. Completion of  
studies designed to confer the response to a heterologous promoter would also provide 
a foundation for further studies using transient transfection such as analysis of the 
effects o f mutation in these sites. Suggestions for further investigations into the exact 
roles o f Smads and MAPKs as described in Section 7.3.1 are also applicable here. 
One important avenue for study is the investigation o f what the down-regulation of 
ADAMTS-4 expression by TGF-p means in terms of ADAMTS-4 activity and 
cellular responses. Western blotting using an antibody targeted to cleaved versican 
fragments could be used to detect levels o f ADAMTS-4 activity/versican cleavage. 
Alternatively, levels of radioactively labelled full length versican and cleaved versican 
fragments could be analysed using chromatography to separate molecules based on 
their molecular weights. Cells derived from ADAMTS-4 deficient mice and in vivo 
models would also be useful here to analyse effects on versican expression and 
cleavage, lesion development and plaque stability.
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7.3.3 Future investigations into the role of TGF-p in macrophages
It has been shown that different subsets of monocytes and macrophages exist. These 
follow inflammatory pathways and are present in atherosclerotic lesions. In mice 
there are two primary monocyte phenotypes: Ly6Chlgh, CCR2+, CX3CRllow which 
rapidly move into areas o f inflammation in response to pro-inflammatory cytokines 
and chemokines (including CCL2), and Ly6Clow, CCR2', CX3CRlhlgh which move 
into inflamed tissues at later stages o f inflammation in a CX3CL1 dependent manner 
(Johnson and Newby, 2009; Shimada, 2009). Interestingly, high levels of CCL2 are 
observed in early plaques o f ApoE null mice while CX3CL1 only increases in 
advanced and unstable plaques (Johnson and Newby, 2009). In humans, the abundant 
CD14 , CD 16', CCR2+ monocytes are equivalent to the Ly6hlgh mouse phenotype and 
appear to be anti-inflammatory as they release IL-10 in response to LPS. The less 
abundant CD 14', CD16+, CCR2' monocytes are equivalent to the Ly6Clow mouse 
phenotype and appear to be pro-inflammatory as they produce pro-inflammatory 
cytokines and mediators in response to LPS (Johnson and Newby, 2009; Shimada, 
2009).
Two distinct macrophage phenotypes exist. Ml macrophages have been classically 
activated, M2 macrophages have been alternatively activated (Charo, 2007). Thl 
cytokines (LFNy, II-lp and LPS) induce so called classical activation (M l) and Th2 
cytokines (11-4 and IL-13) induce alternative activation (M2). Human monocytes 
differentiated with GM-CSF have Ml properties and those differentiated with M-CSF 
have M2 properties (Gordon and Martinez, 2010; Johnson and Newby, 2009; 
Mantovani et al., 2004). Ml macrophages are pro-inflammatory with roles in 
phagocytosis, killing pathogens and production o f proteases and have high levels of 
IL-12 and IL-23. M2 macrophages are anti-inflammatory with roles in scavenging 
cell debris, promoting angiogenesis, tissue remodelling and repair. They release 
arginase-1 to counter production o f iNOS and have high levels o f IL-10 and low 
levels o f IL-12 (Bouhel et al., 2007; Charo, 2007; Mantovani et al., 2004). 
Macrophages can switch between states in response to different signals (Bouhel et al., 
2007; Shimada, 2009).
310
CHAPTER 7: General D iscussion
How TGF-(3 signalling and regulation o f gene expression influences or is influenced 
by different subsets o f macrophages is currently unclear, although TGF-P is 
associated with M2 macrophages by its anti-inflammatory properties. Ml 
macrophages can be switched to M2 macrophages in vitro by incubation with medium 
from M2 macrophages and this occurs through production of anti-inflammatory 
mediators including IL-10 and TGF-P (Bouhel et al 2007; Shimada 2009). The 
cytokine has a key role in differentiation of T-cell subsets, promoting the 
differentiation o f CD4+ T cells into Treg cells through induction of transcription of the 
Foxp3 gene, and also (with IL-6) promoting differentiation o f CD4+ T cells into Thl7 
cells. Knockout o f T-cell Smad expression has demonstrated roles for Smad-3 and 
Smad-2 respectively in these processes (Malhotra et al., 2010). Further studies could 
investigate TGF-p signalling and regulation o f key genes involved in foam cell 
formation in different subsets o f macrophages.
PPARy has been shown to be a crucial regulator o f M1/M2 polarisation (Bouhel et al 
2007; Duan et al 2009). Agonists o f PPARy can inhibit activation of the Ml 
phenotype and deletion of macrophage PPARy shifts the balance of pro-inflammatory 
cytokines towards the M l phenotype (Duan et al 2009). In contrast, IL-4-mediated 
monocyte differentiation into M2 macrophages can increase PPARy expression and 
activity, and the expression o f PPARy correlates with the expression of other M2 
markers including CD36, mannose receptor and IL-10 in human carotid lesions 
(Bouhel et al 2007). The inability o f PPARy to promote a switch of Ml or M0 
(resting) macrophages to the M2 phenotype suggests that PPARy promotes 
differentiation o f monocytes to M2 macrophages (priming) and may not have any 
effect in fully differentiated macrophages. In terms of foam cell formation, deletion 
of PPARy in macrophages can reduce IL-4-induction o f LPL and CD36 expression 
and reduce the expression o f ABCG-1, suggesting that PPARy has roles in both 
uptake and efflux o f cholesterol from macrophages Duan et al 2009; Odegaard et al
2007). Further studies into the role o f PPARy with relation to TGF-P-mediated 
regulation gene expression in different subsets o f macrophages could help delineate 
the role o f PPARy in foam cell formation.
311
CHAPTER 7: General D iscussion
In addition to TGF-p, other anti-inflammatory (Th2) cytokines have been 
demonstrated to have atheroprotective roles in atherogenesis, disease development 
and foam cell formation. These include IL-10 and IL-33.
IL-10 is an anti-inflammatory cytokine and a key regulator of the immune response to 
viral, bacterial and fungal infections (Couper et al., 2008). The cytokine can regulate 
Thl or Th2 responses (often to inhibit excessive cytokine production or immune cell 
function) to regulate immunopathology following infection (Couper et al., 2008). 
Although IL-10 can act directly on T cells to inhibit proliferation and cytokine 
production, many o f the effects o f IL-10 on T cell function are mediated though direct 
effects on monocytes/macrophages such as the inhibition o f MHC class II molecules 
to limit production o f pro-inflammatory cytokines and chemokines (Couper et al.,
2008). A number o f studies have suggested IL-10 has an anti-atherogenic role and 
overexpression o f macrophage IL-10 can suppress atherosclerosis in LDLR"~ mice 
(Han et al., 2010). Interestingly, IL-10 can promote both cholesterol uptake and 
cholesterol efflux from macrophages through the up-regulation o f CD36 and SR-A 
and the upregulation o f ABCA-1 through the PPARy-LXR pathway (Han et al.,
2009). In addition, IL-10 can inhibit the down-regulation o f ABCA-1 by TNFa (Mei 
et al., 2007). Foam cells treated with IL-10 display reduced apoptosis as well as 
reduced expression o f pro-inflammatory mediators including TNFa and ICAM-1 
(Han et al., 2009).
0
Our laboratory has recently demonstrated an anti-atherogenic role for IL-33 in foam 
cell formation (McLaren et al., 2010). ApoE'/_ mice treated with IL-33 showed 
significant reductions in macrophage foam cell accumulation and treatment of THP-1 
macrophages and primary HMDMs with IL-33 reduced uptake of oxLDL, total and 
esterified cholesterol content, and enhanced cholesterol efflux (McLaren et al., 2010). 
These changes were associated with down-regulation o f genes involved in cholesterol 
uptake and up-regulation of genes involved in cholesterol efflux by the cytokine, 
similar to the effects o f TGF-p treatment as presented in Chapter 3 o f this thesis 
(McLaren et al., 2010). It would be interesting to investigate whether IL-10 or IL-33 
are able to synergise with TGF-p to enhance anti-atherogenic effects on gene 
regulation and foam cell formation in atherosclerosis.
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7.4 Therapeutic implications for atherosclerosis
There is a significant need for new therapeutic strategies or improvements to existing 
drugs to prevent the clinical symptoms o f atherosclerosis. Currently, 70% of clinical 
events resulting from atherosclerosis cannot be prevented with existing drugs. Novel 
drugs to reduce cardiovascular inflammation must be designed not to interfere with 
the cardiovascular risk profiles such as lipid balance. Current strategies for the design 
of novel drugs to reduce atherosclerosis include the blockade of the pro-inflammatory 
cytokine TNF-a, the IL-1 receptor and leukotrienes (Klingenberg and Hansson, 2009). 
Antagonists o f TNF-a reduce the expression o f pro-inflammatory cytokines and 
chemokines in addition to TNF-a and also reduce the effects o f  TNF-a on MMP 
production. Blockade o f this cytokine has been shown to be effective in reducing the 
incidence o f cardiovascular events in rheumatoid arthritis patients (Klingenberg and 
Hansson, 2009).
The use o f siRNA targeting pro-inflammatory or pro-atherogenic molecules such as
adhesion molecules, chemokines or for selectively blocking inflammatory monocytes
or T-cells could prove useful in reducing atherosclerosis development. The use o f
RNAi as a research tool for molecular biology applications such as functional gene
analysis and the dissection o f signalling pathways have become widespread.
However, its use for therapeutic drug design has so far been limited (de Fougerolles et 
0
al., 2007; Hajeri and Singh, 2009). Outside o f the laboratory there are many 
considerations that need to be taken into account when designing siRNAs and the 
carrier system that goes with them. Some o f the issues with the design and potential 
for RNAi based drugs include drug specificity and stability. Although highly specific 
in nature, siRNAs can sometimes recognise and interfere with the expression of off- 
target genes in vitro. Many o f these effects occur because of sequence similarity 
between the gene and the 5’ end o f the guide siRNA strand (de Fougerolles et al., 
2007; Hajeri and Singh, 2009). siRNAs may also induce unwanted effects through 
activation of the immune system and immune receptors. Careful design o f the carrier 
system is important to restrict these effects and some o f these effects can be partially 
countered by the use o f miRNA, as this occurs naturally within the human genome (de 
Fougerolles et al., 2007; Hajeri and Singh, 2009). Stability and half life o f siRNAs is
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often dependent on the carrier system and siRNAs for therapeutic use are often 
conjugated to molecules such as cholesterol or contained within liposomes. Many of 
the considerations for the design o f RNAi based drugs are also cell type specific (de 
Fougerolles et al., 2007; Hajeri and Singh, 2009). Despite this, scope remains for the 
use o f RNAi in the design o f drugs to combat a number o f critical diseases such as 
human immunodeficiency virus (HIV). RNAi based drugs have successfully gone 
through phase I trials for age-related macular degeneration and also for respiratory 
syncytial virus (de Fougerolles et al., 2007; Hajeri and Singh, 2009).
Statins are widely acknowledged as a hugely successful group of drugs for reducing 
the incidence o f cardiovascular events and they are currently the best available drugs 
for primary prevention against atherosclerosis (Steinberg, 2006; Waters, 2010). 
Statins were discovered by Akira Endo in 1976 through identification of a fungal 
metabolite that inhibited 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG 
CoA reductase), a key rate-limiting enzyme in the cholesterol synthesis pathway 
(Buhaescu and Izzedine, 2007; Kapur and Musunuru, 2008). Statins lower serum 
LDL cholesterol levels by competitively inhibiting the HMG CoA reductase enzyme 
to reduce levels o f cholesterol synthesis in the liver. They are also able to block the 
synthesis o f isoprenoid intermediates o f the cholesterol synthesis pathway (Steinberg, 
2006; Waters, 2010). Examples o f statins include lovastatin, pravastatin, atorvastatin 
and simvastatin (Kapur and Musunuru, 2008).
The first trial showing that statins reduced the incidence o f cardiovascular events was 
published in 1994. Since then a large number of clinical trials have demonstrated that 
statins can reduce the incidence o f cardiovascular events over 5 years by 20%. Statins 
have been shown to reduce cardiovascular events in patients irrespective of levels of 
LDL cholesterol and also in patients with no evidence of vascular disease but elevated 
levels o f  the biomarker C-reactive protein (Kapur and Musunuru, 2008; Steinberg, 
2006; Waters, 2010). Increasing evidence suggests that statins exert their effects 
through mechanisms beyond lowering cholesterol. Statins also exert anti­
inflammatory effects such as reducing levels of C-reactive protein, lowering levels of 
pro-inflammatory cytokines and inhibiting T-cell activation (Buhaescu and Izzedine,
2007).
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Statins may provide an avenue to increase TGF-P through increasing TGF-p 
signalling pathway activation without non-specific and unwanted off-target side 
effects that could occur using overexpression o f TGF-P or agonists for the TGF-p 
receptors and this may allow the development o f therapies that induce and support 
anti-inflammatory and anti-atherogenic responses. A large number of cellular 
responses are mediated by statins through the blockade o f isoprenoid production and 
intracellular signalling pathways including actions on transcription factors and the 
MAPK cascades (Redondo et al., 2007; Rodriguez-Vita et al., 2008). Interestingly, 
statins can increase circulating levels o f TGF-p and synthesis o f this cytokine by 
monocytes in atherosclerotic patients (Redondo et al., 2007; Rodriguez-Vita et al.,
2008). Activation o f the Smad pathway is increased by statins in cultured VSMCs 
and this activation mediates TGF-P-induced apoptosis and ECM production by 
VSMCs (Rodriguez-Vita et al., 2008).
A number o f studies have suggested that PPARs may exert cardio-protective effects
through its anti-inflammatory actions. This has led to the development o f PPAR
agonists. Many o f the anti-inflammatory actions o f PPARs are mediated through the
inhibition of AP-1, NFkB and ST AT transcription factors leading to transrepression of
gene expression. Regulation o f genes involved in lipid, glucose and cholesterol
metabolism by PPARs makes them attractive targets for therapeutic agents to
modulate their function (Shearer and Billin, 2007; Touyz and Schiffrin, 2006). Two
classes o f drugs, the fibrates and the glitazones are successful PPAR-targeting agents 
£
used in diabetes and metabolic syndrome. In rat models o f vascular injury, PPAR 
activators limit intimal hyperplasia and in Angiotensin-H infused rats they prevent 
development o f hypertension and reduce vascular inflammation. In LDL-deficient 
mice PPARy activators reduce atherosclerotic lesion size and reduce inflammation. In 
addition, PPAR activators are able to modulate markers of vascular disease such as 
CRP, E-selectin and VwF (Shearer and Billin, 2007; Touyz and Schiffrin, 2006).
PPAR agonists have been shown to target the TGF-P pathway to block the pro- 
fibrotic actions o f the cytokine. For example, PPAR agonists target and block the 
TGF-p pathway to attenuate renal interstitial fibrosis and inflammation linked with 
diabetic nephropathy and non-diabetic kidney diseases (Kawai et al., 2009; Wang et 
al., 2007). However, there is limited literature linking PPAR agonists with TGF-P-
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mediated effects in atherosclerosis. Neointimal growth in hypercholesterolemic 
rabbits can be reduced by the PPARy agonist Pioglitazone and this was linked with 
reduced release o f TGF-p and MCP-1 (Joner et al., 2007). In addition to this, 
pioglitazone can induce apoptosis o f human vascular smooth muscle cells from 
diabetic patients through activation o f TGF-p and Smad-2 (Ruiz et al., 2007).
Despite some success therefore, PPAR activators have not been without dose-limiting 
adverse side effects, mainly through off-target transactivation. Mitigating these side 
effects is a major target o f newly designed PPAR-targeting agents (Shearer and Billin, 
2007; Touyz and Schiffrin, 2006).
The most important hurdle to overcome with the design o f many drugs targeting 
atherosclerosis is the problem of specificity. The development o f drugs/molecules 
that are tissue or cell-type specific is a therapeutic approach o f vital importance to 
reduce unwanted side-effects o f drugs designed to reduce or combat atherosclerosis.
7.5 Concluding remarks
From the work presented in this thesis it is clear that TGF-p regulates the expression
of genes involved in macrophage cholesterol homeostasis through activation of
several signalling cascades. The TGF-p signalling pathways and the genes studied 
%
have important functions in the pathogenesis o f atherosclerosis. The studies presented 
in this thesis also characterised the regulation of ADAMTS-4 by TGF-P in 
macrophages. A complete understanding o f the molecular mechanisms involved in 
gene regulation and signalling pathways will hopefully lead to the development of 
novel therapeutic strategies to combat atherosclerosis.
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Appendix I
Mr x n p Color
225- < . Blue
150- |m m  Red
102- «• — Green
76- Yellow
52- ( Purple
38- 1MM Blue
31- Orange
2k- ' Green
17- i* ■  8lue
12- - Red
Base Pairs Mass(rtg)
45-  1,517
-  1,200 35
1.000 95
-  900 27
-  800 24
-  700 21
-  eoo 18
-  500/517 97
400 38
300 29
-2 0 0 25
100 48
KJotoases Mass <ng)
- IOO 42 
SjO 42
-  SjO 42
Full-range rainbow protein molecular weight 
marker
(GE Healthcare-RPN800E)
Quickload® lOObp DNA ladder 
(New England Biolabs, UK)
Quickload® 1Kb DNA ladder 
(New England Biolabs, UK)
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Appendix II
► 1 ; C E J S lQ lp J S « O C O f O <
Pvul
pcDNA3
5.4 kb
Smal
Tth111l
Bsml pcDNA3 vector
X
s pGL2 promoter vector (Promega)
pSP64 (polyA) vector
(lor background 
reduction)
/S m a l  
\  /  KpnlA /  Sacl 
L \  /  Mlul
▼ \ /  Nhel 
Xhol
■  I Promoter
2937 [s5 i 
2931 BamHI
poMAM 
signal 
(lor luc 
reporter)!
pGL2Promoter
Vector
(5790bp)
potytA) signal
12138
PSP64 Ptly(A) 
Vector
(aoaobp)
3P6 I 1 1
Hnd III 7
PSfl 20
Sail 22
Aocl 23
Hnc II 24
Xbe 1 28
8am H 1 34
Ava 1 39
Smal 41
Sacl 50
(dA dT)^
fcoRI 86
Ssp
Xmn 11933
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DN JNK/SAPK plasmid
The DN JNK/SAPK plasmid, SAPKa-VPA was generated by changing the 
phosphorylation site Thr-Pro-Tyr to Val-Pro-Ala (Kawasaki et al. 1996).
DN c-Jun and SEK-1 plasmids
The DN c-Jun (Tam67) plasmid was generated by the removal of the transactivation 
domain (amino acids 3-122) o f c-Jun (Brown et al. 1993). The DN SEK-1 plasmid 
was sourced from JR Woodgett (Ontario Cancer Laboratory, Canada) (Sanchez et al. 
1994).
SRC-1 and p300 plasmids
pSP64-p300 and pSP64-SRC-l in the pSP64(polyA) vector were constructed by 
cloning the full-length cDNA encoding human p300 or SRC-1 respectively (Li et al. 
2000). They were both generously given by D M Livingston (Dana-Farber Cancer 
Institute, Boston, MA, USA).
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Appendix HI
Student's t test
Mean 1 = x\ Standard deviation 1 = Oi
Mean 2 = * 2  Standard deviation 2 = 0 2  
Variance = od1
ni n2
A difference between two means is significant (at the given probability level) if  the 
calculated t value is greater than the value given in this table. A probability of p =
0.05 (95% probability of making a correct statement) is usually acceptable for 
biological work. When comparing two means, the number of degrees of freedom is 
(nl + n2)-2, where nl is the number o f replicates o f treatment 1, and n2 is the number 
of replicates of treatment 2 (adapted from: The Really Easy Statistics Site. Jim 
Deacon. Biology Teaching Organisation, University o f Edinburgh, Edinburgh, 
Scotland, UK. URL (accessed on 03/05/10):
http://www.biology.ed.ac.uk/research/groups/ideacon/statistics/tablel.html
Degrees of 
Freedom
t value
P value 0.1 0.05 0.01 0.001
1 6 .31 12 .71 6 3 .6 6 6 3 6 .6 2
2 2 .9 2 4 .3 0 9 .9 3 3 1 .6 0
3 2 .3 5 3 .1 8 5 .8 4 12 .92
4 2 .1 3 2 .7 8 4 .6 0 8.61
5 2 .0 2 2 .5 7 4 .0 3 6 .8 7
6 1 .9 4 2 .4 5 3.71 5 .9 6
7 1 .89 2 .3 7 3 .5 0 5 .41
8 1 .86 2 .3 1 3 .3 6 5 .0 4
9 1 .83 2 .2 6 3 .2 5 4 .7 8
10 1.81 2 .2 3 3 .1 7 4 .5 9
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Appendix IV
Transcription factor binding site search results
SignalScan TFD-transcription factor database (Prestridge 1991)
Processed sequence:
1 CCCTCTTGATGCCTCCTTACCTGTTCCCTACCTTCTTTTCTCAGGCAGCT
51 CACTCAGTCCCCTCAGCCCTGGAAACCAGCCACTAGGGCCAAAGGGCAGC
101 ATGAGGGAGCCTTGAGAAAA
Links to BioBase at gene-regulation.com (Free, but registration/login required)
Input sequence contained 120 base pairs 
Signal File(s): mammal
Factor or Site Name Loc.(Str.) Signal Sequence SITE
S00922
S01622
S00973
input.seq: 12 0 base pairs
polyoma.1 site 2 (-) AGAGG
gamma-IRE_CS site 5 (+) CWKKANNY
T"Ag fact 11 (-) GAGGC
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LVa fact 21 ( - ) GAACAG
LVa fact 21 ( - ) GAACAG
TCF-1 fact 21 ( - ) MAMAG
TCF-1 fact 35 ( - ) MAMAG
CAP-site site 4 6 ( +  ) CANYYY
CAP-site site 55 ( + ) CANYYY
CAP-site site 6 4 ( + ) CANYYY
gamma-IRE_CS site 6 9 ( + ) CWKKANNY
H-APF-1 fact 6 9 ( + ) CTGGRAA
NFI fact 70 ( + ) TGGNNNNNNGCCA
NF-I fact 70 ( + ) YGGMNNNNNGCCA
CP2 fact 78 (+) AGCCACT
LBP-1 fact 82 ( + ) WCTRG
LF-A1 fact 86 ( - ) TGRMCC
element_II_rs-3 site 87 ( - ) TTTGGCC
Ad-conserved-se site 88 ( + ) GCCAA
TCF-1 fact 9 0 ( + ) MAMAG
S 0 0 0 3 8  
S 0 0 9 0 0  
S 0 2 0 2 3  
S 0 2 0 2 3  
S 0 0 0 8 9  
S 0 0 0 8 9  
S 0 0 0 8 9  
S 0 1 6 2 2  
S O I 9 7 1  
S 0 0 0 4 4  
S 0 1 9 9 4  
S 0 0 0 9 9  
S 0 0 4 8 7  
S 0 0 2 5 0  
S 0 1 5 0 6  
S 0 1 0 8 9  
S 0 2 0 2 3
Prestridge, D. 
203-206.
1991. SIGNAL SCAN: A computer program that scans DNA sequences for eukaryotic transcriptional elements. CABIOS 7, pp.
Transcription element search system (TESS) (Schug 2003)
TESS Job M0399015305 : Summary Page 
Home AnGEL CRM Searches Site Searches
Guide Recall Search Combined
Query Databases 
Strings
Other Stuff 
Filtered Strings
Need help? Check our FAQ page then please send questions and comments to
Strand
Factor Model Beginning
(N-normal, R-reverse 
complementary) Length Sequence
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_00000 TCF-1 100029 (TCF-1) 90 N 6 CAAAGG
_00000 F0XC1 J00032 (MA0032) 29 R 8 TACCTTCT
_ 0 0 0 0 0  Ttk 100261 (Ttk) 14 R 6 TCCTTA
_00000 SPI1 J00080 (MA0080) 23 R 6 GTTCCC
_00000 R1 100042 (R l) 10 N 9 TGCCTCCTT
_00000 HAND1-TCF3 J00092 (MA0092) 73 R 10 AAACCAGCCA
0 0 0 0 0  zeste 100263 (zeste) 47 R 6 AGCTCA
_00000 R1 100042 (R l) 25 N 9 TCCCTACCT
00000 PR 100288 (PR) 115 R 6 AGAAAA
T00029 AP-1 Q00004 (-) 50 N 7 TCACTCA
00000 Bapxl J00122 (MAO 122) 49 R 9 CTCACTCAG
TO 1498 IL-6  RE-BP TO 1499 IL-6  
RE-BP R01907 () 69 N 6 CTGGAA
T02691 Dof3 M00354 (P$DOF3_01) 87 N 11 GGCCAAAGGGC
T00306 GATA-1 Q00069 (-) 114 N 7 GAGAAAA
T00479 LyF-1 M00141 (V SL Y F101) 111 N 9 CTTGAGAAA
T02983 Pax-4a M00378 (VSPAX4 03) 58 N 12 TCCCCT CAGCCC
_00000 AT-BP1/AT-BP2 100141 (AT-BP1/AT-BP2) 56 R 8 AGTCCCCT
_00000 Dof2 J00020 (MA0020) 33 R 6 TTCTTT
T00913 Yi R03154 () 98 R 10 AGNNNGNGGG
TO 1427 p300 M00033 (V$P300_01) 51 R 14 CACTCAGTCCCCTC
_00000 ABM J00123 (MAO 123) 55 N 10 CAGTCCCCTC
TO 1599 LCR-F1 M00285 (V$TCF11_01) 93 R 13 AGGGCAGCATGAG
_00000 LyF-1 100084 (LyF-1) 111 N 9 CTTGAGAAA
_00000 BSAP 100008 (BSAP) 61 R 11 CCTCAGCCCTG
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_00000 H-2RIIBP 100178 (H-2RIIBP) 57 N 6 GTCCCC
T00029 T00030 T00031 T00032 
TO 1115 TO 1140 T01156 T00027 AP- 
1 MOO 174 (V SA P1Q 6) 48 R 11 GCT C ACT C AGT
T00395 Hb R03023 () 110 R 10 CCTTGAaAAA
_00000 TFII-I 100216 (TFII-I) 104 R 6 AGGGAG
_00000 RXR-alpha 100038 (RXR-alpha) 12 N 11 CCTCCTTACCT
00000 E74A 100237 (E74A) 18 R 8 TACCTGTT
TOO 114 c-Ets-l_54 T00111 c-Ets-1 M00032 (VSCETS1P 5 4 0 1) 68 N 10 CCTGGAAACC
T02841 FACB R08603 () 58 R 16 TCCNNNNNNNNNNGGA
T00751 Sn Q00157 (-) 19 R 7 ACCTGTT
_00000 MNF1 100352 (MNF1) 92 N 7 AAGGGCA
_00000 DEP2 100390 (DEP2) 18 N 8 TACCTGTT
_00000 IL-6 .RE-BP 100218 (IL-6 .RE-BP) 38 R 7 TTCTCAG
T02450 GKLF R05016 () 26 R 14 CCYYtYYYTYNTTY
00000 LBP-1 100280 (LBP-1) 76 N 8 CCAGCCAC
00000 NHP-1 100285 (NHP-1) 97 N 8 CAGCATGA
T00114 c-Ets-1 _54 M00074 (VSCETS 1P54_02) 66 N 13 GCCCTGGAAACCA
_00000 CTF 100123 (CTF) 70 N 14 TGGAAACCAGCCAC
TOO 108 C/EBPalpha Q00024 (-) 111 R 10 CTTGAGAAAA
_00000 AP-2 100151 (AP-2) 61 N 8 CCTCAGCC
_00000 GAGA 100244 (GAGA) 49 R 7 CTCACTC
_00000 deltaEFl J00103 (MAO 103) 18 N 6 TACCTG
_00000 RXR-alpha 100038 (RXR-alpha) 86 R 11 GGGCCAAAGGG
T00753 Spl R01540 () 94 N 6 GGGCAG
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_00000 c-ETS J00098 (MA0098) 70 R 6 TGGAAA
T00759 Spl M00008 (V$SP1_01) 74 R 10 AACCAGCCAC
_00000 ID1 J00120 (MAO 120) 81 R 12 CACTAGGGCCAA
_00000 RUSHl-alfa J00109 (MAO 109) 35 N 8 CTTTTCTC
_00000 NIP 100061 (NIP) 93 R 8 AGGGCAGC
T00084 CBF (2) TOO 150 CPI 
T00537 NF-1 R05057 () 87 N 10 RRCCAAtSRG
_00000 LBP-1 100191 (LBP-1) 76 R 5 CCAGC
00000 SP1 J00079 (MA0079) 25 R 10 TCCCTACCTT
_00000 ID1 J00120 (MAO 120) 22 N 12 TGTTCCCTACCT
_00000 ZNF42_l-4 J00056 (MA0056) 58 R 6 TCCCCT
_00000 NF-IL6 100088 (NF-IL6 ) 112 N 9 TTGAGAAAA
_00000 ELK1 J00028 (MA0028) 66 N 10 GCCCTGGAAA
_00000 TFAP2A J00003 (MA0003) 79 N 9 GCCACTAGG
T00305 GATA-1 Q00068 (-) 16 R 13 CTTACCTGTTCCC
T00368 HNF-1A TO 1950 HNF-1B 
T01951 HNF-1C R03302 () 76 R 7 CCAGCCA
_00000 deltaEFl J00103 (MAO 103) 29 N 6 TACCTT
0 0 0 0 0  myogenin 100293 (myogenin) 43 N 9 AGGCAGCTC
TOO152 CP2 R00444 0 78 N 7 AGCCACT
TO 1470 Ik-2 M00087 (V$IK2_01) 21 R 12 CTGTTCCCTACC
TO1944 NF-ATp T01948 NF-ATp R05082 () 106 N 6 GGAGCC
_00000 RXR-alpha 100038 (RXR-alpha) 60 N 11 CCCTCAGCCCT
_00000 Sn 100250 (Sn) 19 N 7 ACCTGTT
T02450 GKLF M00286 (V$GKLF_01) 26 R 14 CCCTACCTTCTTTT
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T00395 Hb _00000 Hunchback
J00049 (MA0049) M00022 
(I$HB_01) 33 R 10 TTCTTTTCTC
_00000 Papl 100045 (Papl) 49 N 8 CTCACTCA
TO 1591 P (sh ortform ) TO 1590 
P (lo n g fo rm ) M00226 (P$P_01) 15 N 9 CCTTACCTG
T00697 PR Q00145 (-) 51 N 12 CACTCAGTCCCC
T00759 Spl M00008 (V$SP1_01) 25 R 10 TCCCTACCTT
T00032 AP-1 Q00006 (-) 50 R 7 TCACTCA
TOO123 c-Fos Q00027 (-) 49 R 9 CTCACTCAG
_00000 GR/PR 100104 (GR/PR) 22 N 6 TGTTCC
00000 RUSHl-alfa J00109 (MA0109) 16 N 8 CTTACCTG
00000 T3R-alpha 100033 (T3R-alpha) 93 R 6 AGGGCA
T00788 T-Ag Q00168 (-) 11 R 5 GCCTC
_00000 fl-fll 100222  (fl-fll) 31 N 8 CCTTCTTT
T00333 GR Q00075 (-) 47 R 12 AGCTCACTCAGT
T00036 AP-4 MOO 175 (V$AP4_Q5) 44 N 10 GGCAGCTCAC
_00000 GR/PR 100104 (GR/PR) 115 R 6 AGAAAA
_00000 F$STRE_01 MOO 154 (F$STRE_01) 58 R 8 TCCCCTCA
_00000 NF-X 100067 (NF-X) 69 N 8 CTGGAAAC
_00000 LVa 100193 (LVa) 21 R 6 CTGTTC
_00000 LBP-1 100191 (LBP-1) 68 N 5 CCTGG
_00000 MafB J00117 (M A0117) 42 R 8 CAGGCAGC
TOO 123 c-Fos Q00027 (-) 49 N 9 CTCACTCAG
T00625 AREB6 M00415 (V$AREB6_04) 70 R 9 TGGAAACCA
T00529 MZF-1 M00083 (V$MZF1_01) 58 R 8 TCCCCTCA
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00000 MalT 100377 (MalT) 61 R 10 CCTCAGCCCT
TO 1059 M NBla M00352 (P$DOF1_01) 32 R 11 CTTCTTTTCTC
T00035 AP-2 Q00008 (-) 59 R 11 CCCCTCAGCCC
_00000 Klf4 J00039 (MA0039) 27 R 10 CCTACCTTCT
T00306 GATA-1 Q00069 (-) 36 R 7 TTTTCTC
_00000 CP2 100132 (CP2) 80 N 5 CCACT
T02855 CDC5 M00361 (P$CDC5_01) 60 N 11 CCCT CAGCCCT
_00000 GR/PR 100104 (GR/PR) 36 N 6 TTTTCT
00000 TEF 100026 (TEF) 99 R 6 GCATGA
_00000 V$CAP_01 M00253 (V$CAP_01) 54 N 8 TCAGTCCC
T00997 T00996 SRY MOO 148 (V$SRY_01) 32 R 7 CTTCTTT
0 0 0 0 0  zeste 100263 (zeste) 51 R 6 CACTCA
_00000 HMG-1 J00044 (MA0044) 32 N 9 CTTCTTTTC
_00000 T3R-beta 100031 (T3R-beta) 57 R 9 GTCCCCTCA
_00000 LBP-1 100191 (LBP-1) 83 R 5 CTAGG
T00011 ADR1 M00048 (F$ADR1_01) 12 R 6 CCTCCT
00000 E l2 100274 (El 2) 61 R 7 CCTCAGC
T00372 HNF-4alphal M00411 (V$HNF4_01_B) 85 N 15 AGGGCCAAAGGGCAG
T00036 AP-4 Q00009 (-) 46 N 6 CAGCTC
00000 Bapxl J00122 (MAO 122) 79 R 9 GCCACTAGG
T00479 LyF-1 M00141 (V$LYF1_01) 12 R 9 CCTCCTTAC
_00000 MNB1A J00053 (MA0053) 34 R 5 TCTTT
_00000 TEF 100026 (TEF) 41 N 6 TCAGGC
T00550 TO 1944 NF-ATx 
NF-ATc TO 1946 TO 1947 
TO 1948 NFAT-1 T01949
T01945
NF-ATc3
NF-ATp M00302 (V$NFAT_Q6 ) 67 N 12 CCCTGGAAACCA
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T02462 NF-AT3 T00549 NF-AT
T02690 Dof2 M00353 (P$DOF2_01) 32 R 11 CTTCTTTTCTC
T00385 HSF1 M00029 (F$HSF_01) 32 R 5 CTTCT
00000 RXR-alpha 100038 (RXR-alpha) 19 N 11 ACCTGTTCCCT
T00872 USF-1 T00874 T00875 
T00876 USF1 T00877 T00870 USF MOO 187 (V$USF_Q6 ) 79 N 10 GCCACTAGGG
_00000 ENKTF1 100116 (ENKTF1) 85 R 7 AGGGCCA
_00000 V$CAAT_01 M00254 (VSCAAT Ol) 75 N 12 ACCAGCCACTAG
00000 DTF-1 100235 (DTF-1) 96 R 8 GCAGCATG
00000 V$CAP_01 M00253 (V$CAP_01) 63 N 8 TCAGCCCT
T02100 T 00918 Zeste M00283 (I$ZESTE_Q2) 46 R 16 CAGCTCACTCAGTCCC
T00386 HSTF M00028 (I$HSF_01) 32 R 5 CTTCT
_00000 V$CAAT_01 M00254 (V$CAAT_01) 84 N 12 T AGGGCCAAAGG
T00278 delta factor T00915 YY1 R04142 0 31 N 11 CCWTNTTNNNW
_00000 HNF4 J00114 (M A0114) 86 N 13 GGGCCAAAGGGCA
_00000 AP-1 100224 (AP-1) 50 R 7 TCACTCA
_00000 C/EBP 100034 (C/EBP) 111 R 10 CTTGAGAAAA
_00000 PEB1 100052 (PEB1) 91 R 8 AAAGGGCA
_00000 AF-1 100144 (AF-1) 90 R 8 CAAAGGGC
_00000 TCF-1 100029 (TCF-1) 34 R 6 TCTTTT
T00386 HSTF M00028 (I$HSF_01) 37 R 5 TTTCT
TO1542 E2F-1 Q00230 (-) 84 R 10 TAGGGCCAAA
_00000 TFAP2A J00003 (MA0003) 88 N 9 GCCAAAGGG
TO 1806 T00671 p53 M00272 (V$P53_02) 73 R 10 AAACCAGCCA
TO 1476 Abd-B M00090 (I$ABDB_01) 3 N 14 CTCTTGATGCCTCC
369
Appendices
TOO 123 c-Fos Q00027 (-) 9 R 9 ATGCCTCCT
_00000 IUF-1 100392 (IUF-1) 7 R 8 TGATGCCT
TOO 123 c-Fos Q00027 (-) 101 N 9 ATGAGGGAG
T00036 AP-4 Q00009 (-) 46 R 6 CAGCTC
T02841 FACB R08603 () 58 N 16 TCCNNNNNNNNNNGGA
_00000 MafB J00117 (M A0117) 60 R 8 CCCTCAGC
_00000 AP-3 100150 (AP-3) 36 R 8 TTTTCTCA
T00535 NF-1 Q 00112 (-) 88 R 6 GCCAAA
_00000 Gatal J00035 (MA0035) 7 N 6 TGATGC
00000 Nuclear J00127 (MF0004) 17 R 6 TTACCT
T00322 GCR1 M00046 (F$GCR1_01) 103 R 9 GAGGGAGCC
_00000 NFBK 100208 (NFBK) 70 N 13 TGGAAACCAGCCA
T00305 GATA-1 M00075 (V$GATA1_01) 5 N 10 CTTGATGCCT
T00076 CAC-binding_protein Q00018 (-) 75 R 7 ACCAGCC
_00000 R2 100041 (R2) 1 R 7 CCCTCTT
_00000 Zen 100262 (Zen) 46 N 8 CAGCTCAC
_00000 X2BP 100015 (X2BP) 54 R 8 TCAGTCCC
T00625 AREB6 R09394 () 16 N 9 CTTACCTGT
TO 1467 deltaEFl M00073 (VSDELTAEF1 _ 0 1) 15 N 11 CCTTACCTGTT
T00017 C/EBPbeta R02170 () 69 N 7 CTGGRAA
_00000 TTF-1 100022 (TTF-1) 111 R 8 CTTGAGAA
T 02691D ofi M00354 (P$DOF3_01) 32 R 11 CTTCTTTTCTC
TO 1591 P_(short_form) TO 1590 
P_(long_form) M00226 (PSP_01) 26 N 9 CCCTACCTT
T00373 HNF-4alpha2 T00372 HNF- MOO 134 (V$HNF4_01) 83 N 19 CTAGGGCCAAAGGGCAGC
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4alphal A
_00000 Dof3 J00021 (MA0021) 91 N 6 AAAGGG
T00385 HSF1 M00029 (F$HSF_01) 23 R 5 GTTCC
_00000 TCF-1 100029 (TCF-1) 2 R 6 CCTCTT
00000 RAR-gamma 100404 (RAR-gamma) 58 N 7 TCCCCTC
_00000 EIIaE-A 100143 (EIIaE-A) 104 R 7 AGGGAGC
T00045 ARP-1 Q 00011 (-) 90 N 9 CAAAGGGCA
T00642 POU2Fla T00643 T00644 
T00959 TO1031 TO1157 TO1466 
T00641 P0U2F1 MOO 137 (V$OCT1_03) 11 R 13 GCCT CCTT ACCTG
_00000 Klf4 J00039 (MA0039) 31 R 10 CCTTCTTTTC
_00000 Spl 100295(Spl) 12 R 6 CCTCCT
T00321 GCN4 T00918 Zeste T02100 
Zeste
R00830 () R04938 () R04941 () 
R04954 () 51 R 6 CACTCA
T02637 RAVI M00344 (PSR A V 102) 16 N 12 CTTACCTGTTCC
_00000 Eve 100241 (Eve) 54 N 9 TCAGTCCCC
T02692 PBF M00355 (P$PBF_01) 32 R 11 CTTCTTTTCTC
_00000 PH02 100324 (PH 02) 73 R 8 AAACCAGC
_00000 IL-6 .RE-BP 100218 (IL-6 .RE-BP) 69 N 7 CTGGAAA
_00000 T-Ag 100215 (T-Ag) 11 R 5 GCCTC
_00000 Nkx2-5 J00063 (MA0063) 3 R 7 CTCTTGA
_00000 TFAP2A J00003 (MA0003) 81 R 9 CACTAGGGC
TOO 123 c-Fos Q00027 (-) 9 N 9 ATGCCTCCT
T02450 GKLF M00286 (V$GKLF_01) 27 R 14 CCTACCTTCTTTTC
_00000 YY1 100012 (YY1) 68 R 9 CCTGGAAAC
_00000 cEBP J00102 (MAO 102) 108 R 12 AGCCTT GAG AAA
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T00378 HOXA3 M00395 (V$HOXA3_01) 79 R 9 GCCACTAGG
T00386 HSTF M00028 (I$HSF_01) 115 N 5 AGAAA
_00000 Ftz.2 100243 (Ftz.2) 7 N 7 TGATGCC
T00918 Zeste T02100 Zeste
R01518 0  R01519 () R04939 () 
R04942 0  R04943 () R04944 () 
R04945 () R04953 () R04955 () 51 N 6 CACTCA
_00000 AP-3 100150 (AP-3) 113 N 8 TGAGAAAA
00000 IUF-1 100392 (IUF-1) 78 N 8 AGCCACTA
00000 H-APF-1 100175 (H-APF-1) 69 N 7 CTGGAAA
00000 PR 100288 (PR) 36 N 6 TTTTCT
T00385 HSF1 M00029 (F$HSF_01) 115 N 5 AGAAA
T00385 HSF1 M00029 (F$HSF_01) 37 R 5 TTTCT
_00000 USF 100368 (USF) 99 R 7 GCATGAG
_00000 ABF-2 100389 (ABF-2) 108 N 8 AGCCTTGA
_00000 R2 100041 (R2) 28 R 7 CTACCTT
00000 El 2 100274 (El 2) 39 N 7 TCTCAGG
T00475 LVa R01134 () R01135 () 21 R 6 CTGTTC
Schug, J. 2003. Current protocols in Bioinformatics. J. Wiley and Sons.
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TFSearch (Heinemeyer et al. 1998)
** TFSEARCH ver.1.3 ** (c)1995 Yutaka Akiyama (Kyoto Univ.)
This simple routine searches highly correlated sequence fragments 
versus TFMATRIX transcription factor binding site profile database 
by E.Wingender, R.Knueppel, P.Dietze, H.Karas (GBF-Braunschweig).
<Warning> Scoring scheme is so straightforward in this version.
score = 100.0 * ('weighted sum' - min) / (max - min)
The score does not properly reflect statistical significance!
Database: TRANSFAC MATRIX TABLE, Rel.3.3 06-01-1998 
Query: Rebecca Promoter_sequencel (120 bases)
Taxonomy: Vertebrate
Threshold: 70.0 point
TFMATRIX entries with High-scoring:
GCCTCCTTAC CTGTTCCCTA CCTTCTTTTC TCAGGCAGCT entry score
----- > M00075 GATA-1 86.5
---- M00173 AP-1 84.5
< - M00199 AP-1 84.1
M00240 Nkx-2. 83.7
<--------------------- M00128 GATA-1 83 .6
M00199 AP-1 83.4
<-------------------- M00087 Ik-2 82 .9
- > M00100 CdxA 82 .1
--------------------> M00131 HNF-3b 81.5
<--------- M00148 SRY 80.9
c------------- M00083 MZF1 80.9
M00137 Oct-1 80.7
<------------------ M00173 AP-1 80.4
------> M00076 GATA-2 78.7
<--------- M00237 AhR/Ar 78.3
c-------------- M00077 GATA-3 78.1
----> M00106 CDP CR 77 .6
------------------ > M00073 deltaE 77 . 6
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 <-----------  M00001 MyoD 76.7
  M00037 NF-E2 76.5
------> M00101 CdxA 76.4
<-- M00173 AP-1 75.3 
-------> M00101 CdxA 75.0
 <............  M00128 GATA-1 74.8
<  M00096 Pbx-1 74.5
<  M00147 HSF2 74.4
 <---------  M00076 GATA-2 74.3
-----------> M00173 AP-1 74.2
 <----------------  M00065 Tal-lb 74.2
<  M00128 GATA-1 74.2
 <----------  M00203 GATA-X 74.2
c---------------  M00081 Evi-1 74.1
<----------  M00203 GATA-X 73.9
<-------------  M00126 GATA-1 73.9
-----------> M00073 deltaE 73.7
<------------  M00128 GATA-1 73.6
<  M00162 Oct-1 73.5
 ------> M00073 deltaE 73.2
-------> M00100 CdxA 73.1
<- M00037 NF-E2 72.8
 <-------  M00141 Lyf-1 72.7
 <-----  M00148 SRY 72.7
 <  M00075 GATA-1 72.7
<.........  M00008 Spl 72.6
 <  M00066 Tal-la 72.6
---------> M00032 C-Ets- 72.5
 <  M00126 GATA-1 72.5
 <  M00077 GATA-3 72.5
---------> M00199 AP-1 72.4
<----------  M00203 GATA-X 72.3
 <  M00070 Tal-lb 72.3
 <  M00146 HSF1 72.1
 <...   M00079 Evi-1 72.0
 > M00217 USF 71.9
<-------------  M00086 Ik-1 71.5
--------- > M00162 Oct-1 71.4
<-- M00033 p300 71.3
<----- M00192 GR 71.1
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<-------------  M00127 GATA-1 71.1
 <----------  M00082 Evi-1 71.0
 <  M00082 Evi-1 71.0
<--------  M00077 GATA-3 70.9
<   M00072 CP2 70.8
 ........> M00159 C/EBP 70.8
<-------------  M00088 Ik-3 70.6
<---- M00205 GR 70.6
--------> M00241 Nkx-2. 70.6
<---------  M00147 HSF2 70.5
---------> M00199 AP-1 70.5
 <--------------  M00269 XFD-3 70.5
--------------------> M00192 GR 70.5
 <    M00079 Evi-1 70.5
<--- M00271 AML-la 70.4
----------> M00228 VBP 70.3
<---.....- M00011 Evi-1 70.3
  M00205 GR 70.2
 <    M00078 Evi-1 70.1
  M00035 v-Maf 70.0
<  M00242 PPARal 70.0
 <  M00267 XFD-1 70.0
51 CACTCAGTCC CCTCAGCCCT GGAAACCAGC CACTAGGGCC AAAGGGCAGC entry score
<  M00083 MZF1 90.4
---  M00134 HNF-4 88.0
<  M00158 COUP-T 87.9
<  M00050 E2F 86.2
-------> M00173 AP-1 84.5
  M00199 AP-1 84.1
 > M00199 AP-1 83.4
<  M00033 p300 83.2
<  M00173 AP-1 81.4
< M00085 ZID 80.4
<- M00008 Spl 79.5
 > M00032 C-Ets- 78.4
  Mq0 2 3 7  AhR/Ar 78.3
-------------> M00074 c-Ets- 78.3
 > M00155 ARP-1 78.2
----- > M00148 SRY 78.2
Appendices
<- M00217 USF 76.9
-> M00037 NF-E2 76.5
M00173 AP-1 75.3
<------------  M00084 MZF1 75.0
 > M00227 v-Myb 74.3
---------> M00227 v-Myb 74.3
--------------> M00025 Elk-1 73.9
....... > M00073 deltaE 73.5
M00162 Oct-1 73.5 
<-- M00055 N-Myc 73.1
 <---------  M00075 GATA-1 73.1
  M00037 NF-E2 72.8
<--------  M00053 c-Rel 72.7
<------------  M00084 MZF1 72.6
--------------------- > M00264 Staf 72.4
<-----  M00240 Nkx-2. 72.1
------> M00148 SRY 71.8
<---------------  M00222 Thl/E4 71.8
  > M00087 Ik-2 71.5
<-----  M00271 AML-la 71.4
<--- M00075 GATA-1 71.4
- M00075 GATA-1 71.4
  M00123 c-Myc/ 71.4
-------> M00083 MZF1 71.3
----- M00033 p300 71.3
<--------  M00008 Spl 71.2
-------  M00Q08 Spl 71.2
--------- M00192 GR 71.1
---....... > M00072 CP2 70.8
------- M00205 GR 70.6
<-----------  M00131 HNF-3b 70.5
 <-----------  M00113 CREB 70.5
M00271 AML-la 70.4
 > M00037 NF-E2 70.4
<--------------  M00004 c-Myb 70.4
--------------> M00084 MZF1 70.2
------- > M00035 v-Maf 70.0
<------  M00101 CdxA 70.0
101 ATGAGGGAGC CTTGAGAAAA entry score
Appendices
M00134 HNF-4 88.0 
M00085 ZID 80.4 
M00217 USF 76.9 
M00101 CdxA 75.0 
M00055 N-Myc 73.1 
M00100 CdxA 73.1 
M00141 Lyf-1 72.7 
M00199 AP-1 72.4 
M00083 MZF1 72.2 
M00075 GATA-1 71.4 
M00075 GATA-1 71.4 
M00141 Lyf-1 71.4 
M00271 AML-la 71.4
-------> M00123 c-Myc/ 71.4
-> M00008 Spl 71.2
  M00004 c-Myb 70.4
 ....... > M00087 Ik-2 70.2
Total 129 high-scoring sites found. Max score: 90.4 point, Min score: 70.0 point
Heinemeyer, T. et al. 1998. Databases on Transcriptional Regulation: TRANSFAC, TRRD, and COMPEL. Nucleic Acids Research 26, pp. 364- 
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Matlnspector by Genomatix (Cartharius et al. 2005)
Inspecting sequence dbj|AB039835.1 [dbj|AB039835.1] (1 -120):
[dbj|AB039835.1|:217-336 Homo sapiens ADAM-TS4 gene, promoter region]
Family Detailed Information Opt. thresh. Start pos. End pos. Strand Sequence
V$PAX6 PAX-4/PAX-6 paired domain binding sites 0.76 22 tcttgATGCctccttacct
V$NR2F Nuclear receptor subfamily 2 factors 0.75 11 35 gaaggtAGGGaacaggtaaggaggc
V$RXRF RXR heterodimer binding sites 0.78 13 37 aagaaggtagggaac AGGT aaggag
V$PERO Peroxisome proliferator-activated receptor 0.76 14 36 agaaggtagggaac AGGT aagga
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V$ZFHX Two-handed zinc finger homeodomain transcription factors 0.93 14 26 + tccttACCTgttc
VSGKLF Gut-enriched Krueppel like binding factor 0 .86 26 38 - aaagaaggtAGGG
V$STAT Signal transducer and activator o f transcription 0.84 33 51 - gagcTGCCtgagaaaagaa
V$AHRR AHR-amt heterodimers and AHR-related factors 0.77 41 65 - tgaggggactG AGT gagctgcctga
V$AP1R MAF and API related factors 0.82 44 64 + ggcaGCT Cactcagtcccctc
V$SORY SOX/SRY-sex/testis determinig and related HMG box factors 0 .86 46 62 - ggggactgAGTGagctg
V$AP1F API, Activating protein 1 0.87 48 58 - actGAGTgagc
V$NOLF Neuron-specific-olfactory factor 0.88 52 74 + actcagT CCCctcagccctggaa
V$MZF1 Myeloid zinc finger 1 factors 0.99 54 64 - gaGGGGactga
VSGCMF Chorion-specific transcription factors with a GCM DNA binding domain 0.85 58 68 + tcCCCTcagcc
VSPAX6 PAX-4/PAX-6 paired domain binding sites 0.87 63 81 - ggctggtttCCAGggctga
V$NF1F Nuclear factor 1 0.82 66 86 - ctaGT GGctggtttccagggc
V$RXRF RXR heterodimer binding sites 0.78 78 102 + agccactagggccaaAGGGcagcat
VSSTAF Selenocysteine tRNA activating factor 0.76 78 100 - gctgCCCTttggccctagtggct
V$PERO Peroxisome proliferator-activated receptor 0.76 79 101 + gccactagggccaaAGGGcagca
V$NR2F Nuclear receptor subfamily 2 factors 0.82 80 104 + ccactagggcCAAAgggcagcatga
V$E2FF E2F-myc activator/cell cycle regulator 0.84 81 97 + cactagggcCAAAgggc
VSMOKF Mouse Krueppel like factor 0.98 97 117 + cagcatgagggagCCTT gaga
VSGCMF Chorion-specific transcription factors with a GCM DNA binding domain 0.85 99 109 - ctCCCTcatgc
VSCHRE Carbohydrate response elements, consist o f two E box motifs separated by 5 bp 0.82 100 116 + CAT Gagggagccttgag
A total of 24 matches were found in 1 sequences. Sequences searched: 1 (120 bp).
Cartharius, K. et al. 2005. Matlnspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, pp. 2933-2942.
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